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Introduction 11
  rheumAToID ArThrITIs
Rheumatoid arthritis (RA) is a disease characterized by arthritis of mainly the small joints 
of the hands and feet, which is thought to be the result of an autoimmune response. It is 
the most common inflammatory arthritis with a prevalence of 0.5-1.0% in European and 
North-American populations 1. There is substantial geographic variation in the occurrence 
of RA with very high prevalences reported in native American-Indian populations 2, and 
very low prevalences in populations from South-East Asia 3. The disease is approximately 
three times more frequent in women than in men, and the prevalence increases with 
age. Besides the potentially destructive arthritis, patients can be affected by various extra-
articular features such as secondary Sjögren’s syndrome, interstitial lung disease, pericar-
ditis and pleuritis. Fortunately, the advent of tumor necrosis factor (TNF) inhibitors and 
other biological agents have led to a therapeutic revolution for patients with rheumatoid 
arthritis 4. Instead of having to resign to an inevitably progressive and debilitating disease 
course, modern-day treatment aims at achieving the lowest possible disease activity and 
ultimately remission. Nonetheless, rheumatoid arthritis continues to be a major cause of 
(partial) disability and of loss of productivity, and is associated with substantial economic 
costs 5.
Classification criteria for the disease were first phrased in 1956 6 after Sir Alfred Garrod 
had introduced the term rheumatoid arthritis in 1876 in an attempt to counteract the 
unsatisfactory use of designations such as “chronic rheumatism” and “rheumatic gout” 7. 
The purpose of the classification criteria was to facilitate both clinical diagnosis and sci-
entific research. For many years since, the 1987 American College of Rheumatology (ACR) 
classification criteria have been used to this end, despite the fact that the incorporation 
of items such as erosive radiographic changes led to limited diagnostic value of these 
criteria for patients with early arthritis 8. In order to facilitate the study of persons with 
earlier stages of disease, the ACR and the European League Against Rheumatism (EULAR) 
have recently developed the 2010 classification criteria for RA as shown in Table 1 9. It 
is worthwhile to note that these criteria are based on patient characteristics which were 
associated with the decision by the physician to start treatment with methotrexate. These 
criteria are a reflection of the shift towards increasingly earlier diagnosis and treatment of 
rheumatoid arthritis.
AuToAnTIboDIes In generAl AnD AnTI-CITrullInATeD ProTeIn 
AnTIboDIes (ACPA) In PArTICulAr In rheumAToID ArThrITIs
Rheumatoid factor (RF) is the classic autoantibody associated with RA. It has long been 
known to be a marker of future RA development 10. However, the predictive ability of 
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immunoglobulin M (IgM)-RF is limited by its relatively modest specificity (85%), which 
entails that many patients who are IgM-RF-positive will not develop RA 11. Recently, a bet-
ter diagnostic and predictive marker has emerged in the form of anti-citrullinated protein 
antibodies (ACPA). 
ACPA bind to proteins or peptides containing citrulline, which is a post-translational 
modification of the naturally occurring amino acid arginine. By an enzymatic process 
called deimination or citrullination which is mediated by a series of enzymes known as 
peptidyl arginine deiminases (PADs), the positively charged peptidylarginine is converted 
into the neutral peptidylcitrulline (Figure 1) 12. The activity of PAD enzymes is dependent 
on high concentrations of calcium, and deimination can occur both intracellularly con-
current with apoptosis, and extracellularly provided the calcium concentration is high 
enough 13, 14. Besides the occurrence of endogenous citrullination, recent reports have 
drawn attention to the possible role of the oral bacterium Porphyromonas gingivalis (P. 
gingivalis) which also posses PAD 15. This pathogen is the major etiologic agent associated 
with periodontitis; a condition which is significantly increased in patients with longstand-
ing active RA 16. These associations raise the possibility that citrullination of bacterial and 
host proteins by P. gingivalis may be a mechanism by which citrullinated antigens in RA 
are generated.
Table 1. The 2010 ACr/eulAr classification criteria for rheumatoid arthritis
Target population: patients 
1) who have at least one joint with definite clinical synovitis (swelling)
2) whose synovitis is not better explained by another disease.
Criteria score
A. Joint involvement:
     - 1 large joint
     - 2-10 large joints
     - 1-3 small joints (with or without involvement of large joints)
     - 4-10 small joints (with or without involvement of large joints)






b. serology (at least one test result is needed for classification):
     - Negative RF and negative ACPA
     - Low-positive RF or low-positive ACPA




C. Acute-phase reactants (at least one test result is needed for classification):
     - Normal CRP and normal ESR
     - Abnormal CRP or abnormal ESR
0
1
D. Duration of symptoms:
      - < 6 weeks
      - ≥ 6 weeks
0
1
A score of ≥ 6/10 is needed for classification of a patient as having definite RA.
Joint involvement refers to any swollen or tender joint on examination. Distal interphalangeal joints, first 
carpometacarpal joints and first metatarsophalangeal joints are excluded from assessment. RF: rheumatoid 
factor. ACPA: anti-citrullinated protein antibody (tested as anti-cyclic citrullinated peptide (anti-CCP), CRP: 
C-reactive protein, ESR: erythrocyte sedimentation rate.
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The exact function of citrullination is not fully known although it has been described to 
make proteins more prone to degradation by proteolytic enzymes 14. The discovery that 
proteins undergoing processing in antigen-presenting cells (APCs) can be citrullinated 
before presentation of their peptides to T cells is immunologically interesting, although 
the exact consequences for the immune response remain unclear 17. Citrullinated proteins 
have been detected in a variety of inflamed tissues, such as in inflamed joints in several 
different forms of arthritis, in lungs and other organs 18. Furthermore, citrullination has 
been shown to take place in lining and sublining cells in the joints of patients with RA 13. 
ACPA were first described as anti-perinuclear factor and anti-keratin antibodies, both 
of which bind to filaggrin 19-21. It was not until several years later that recognition of this 
antigen was found to be exclusively dependent on the presence of citrulline residues 22. 
The same was the case for citrullinated vimentin, which was discovered to be the target of 
the RA-specific anti-Sa antibodies that had been described many years before 23, 24. Based 
on these findings, several commercial assays that test for the presence of antibodies to 
cyclic citrullinated proteins (CCP) have been developed and successfully introduced into 
clinical practice 25. The commercial ACPA tests have been designed to detect most, if not 
all, ACPA epitope reactivities found in vivo. The test which is currently most widely used 
in clinical practice is the second generation anti-CCP test, although other targets such as 










figure 1. The enzymatic process of citrullination.
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DIAgnosTIC AnD PrognosTIC vAlue of ACPA
A comprehensive overview of the diagnostic utility of the anti-CCP and RF tests in RA 
has been provided by a meta-analysis 11, 27. The most important difference between the 
two tests was the increased specificity of the anti-CCP assays versus IgM-RF (95% vs. 
85%). The sensitivity of anti-CCP2 was similar to that of IgM-RF (67% in patients with 
established rheumatoid arthritis). In patients with early rheumatoid arthritis (<2 years of 
disease) the summary sensitivity was 57% 28. The diagnostic characteristics of IgG-RF and 
IgA-RF, which had previously been reported to be more accurate than IgM-RF, proved to 
be similar to IgM-RF; thus, these measurements do not provide additional information. 
With regard to other rheumatologic diseases, ACPA have been detected in 5-15% of 
patients with psoriatic arthritis 29, 30 and in patients with juvenile idiopathic arthritis, in 
whom IgG-anti-CCP was most often present in IgM RF-positive polyarthritis which most 
closely resembles adult RA 31. Anti-CCP antibodies have also been reported in patients 
with non-rheumatologic diseases such as pulmonary TB 32. However, follow-up studies 
have revealed that sera from these patients also frequently react with unmodified arginine-
containing peptide, suggesting that these antibodies are not citrulline-specific 33. Of 
healthy controls, 1% tests positive for anti-CCP2-antibodies as was shown in an overview 
of 144 independent studies 34. It is unclear how many of these people may develop RA in 
the future.
In view of these data, it is necessary to re-examine how serological markers can be used 
most effectively in the diagnostic strategy for RA. Determination of anti-CCP2 antibodies, 
which have a high specificity and a reasonable sensitivity, is a good first option in patients 
presenting with inflammatory arthritis. However, anti-CCP-assays are still considerably 
more expensive than measurements of RF in most countries. Whether it is worthwhile to 
also determine IgM-RF depends on the interpretation of the results. Requiring a positive 
result on both tests leads to a loss of sensitivity, because fewer patients have both antibod-
ies than either RF or anti-CCP alone. On the other hand, considering a positive result 
on one test as sufficient for a diagnosis of RA would lead to a considerable reduction 
in specificity (especially when only using the RF test) in exchange for a small gain in 
sensitivity. This balance between sensitivity and specificity needs to be kept in mind when 
deciding whether to measure IgM-RF in addition to anti-CCP2. 
The 2010 ACR/EULAR classification criteria for RA have included an extra level of com-
plexity by discerning between low-positive and high-positive IgM RF and ACPA results, 
where low-positive refers to positive values ≤ 3 times the upper limit of normal (ULN), 
while high-positive refers to values >3 times the ULN (Table 1). Although it has previ-
ously been reported that the presence of high levels of IgM RF would lead to increased 
sensitivity for RA 35, a recent study showed that a high level of RF has very limited additive 
prognostic value compared to ACPA-positivity 36. The 2010 criteria for RA therefore could 
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be improved by omitting the RF level criterion. There are no clear results with regard to 
the value of anti-CCP levels in this respect 37, 38. 
During the disease course of RA, anti-CCP levels generally decline from the baseline 
value 39. In a study investigating intensive treatment in early RA, anti-CCP levels were 
even reported to decrease by 50% 40. In contrast to IgM-RF however, there is hardly any 
seroconversion, meaning that despite declining levels, patients who once tested anti-CCP-
positive hardly ever become anti-CCP-negative 39, 40. Conflicting results have been reported 
with regard to the association between anti-CCP levels and disease activity 41, although 
the majority of publications have described that a higher level of anti-CCP antibodies at 
baseline is associated with a higher level of disease activity, a less favorable response to 
treatment with methotrexate and increased joint destruction 42-44. Two small longitudinal 
studies have investigated whether anti-CCP levels fluctuate in parallel with disease activ-
ity and were not able to draw definitive conclusions 45, 46. Larger scale investigations of 
whether anti-CCP level fluctuations may occur prior to or concomitantly with an increase 
in disease activity are lacking.
In addition to their function as a diagnostic marker for RA, ACPA have also been ex-
tensively investigated with regards to their long-term predictive abilities. The presence 
of ACPA is currently the best predictive marker for the progression of undifferentiated 
arthritis (UA) to rheumatoid arthritis (RA). In multivariate logistic regression analysis that 
also accounted for other predictive variables, anti-CCP2 positivity was associated with an 
odds ratio of 8.1 (95% confidence interval 4.2–15.8; p<0.001) for the development of RA 
in UA patients 47. ACPA-positive RA patients also have a more severe disease course than 
ACPA-negative RA patients, with more joint destruction and extra-articular manifestations 
of disease 43, 48, 49. 
Several studies have investigated the time-point at which patients develop ACPA. By 
making use of pre-disease samples from blood-bank donors who later developed RA, 
these reports were able to demonstrate that ACPA can be detected many years before 
disease manifestation 50, 51 and that ACPA titers increase up to the point of disease 
onset. 
The fact that ACPA appear during the preclinical phase of RA, together with the find-
ing that ACPA can exacerbate arthritis in mice, suggest that anti-citrullinated protein 
immunity may play a role in the pathogenesis of the disease 52. This has prompted 
investigations into which risk factors are associated with the emergence of the anti-
citrullinated protein immune response. 
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geneTIC rIsk fACTors for rheumAToID ArThrITIs
The risk of developing RA is known to be influenced by several genetic risk factors, of 
which the Human Leucocyte Antigens (HLA) are the most important. The association 
between RA and the HLA region was originally described more than 30 years ago 53, 
and subsequent studies revealed that several of the HLA-DR alleles are associated with 
RA, which led to the formulation of the Shared Epitope (SE)-hypothesis in 1987 54. This 
hypothesis provided a theoretical background for the observed associations between the 
HLA region and RA based on the fact that all HLA-DR alleles which predispose to RA 
have the same or a similar amino acid sequence (shared epitope) at positions 70-74 of 
the HLA-DRB1 molecule. This sequence is located in the peptide-binding groove of the 
HLA alleles and may therefore be directly involved in the presentation of peptides to 
arthritogenic T cells.
After the first descriptions of ACPA, it soon became clear that the SE alleles were solely 
associated with, and thus only predisposed to, ACPA-positive RA 55. Several reports show-
ing that certain HLA SE alleles can bind and present citrullinated peptides 56, 57, have 
provided a possible biological explanation for the association between ACPA and the 
SE alleles. A chemical analysis of an induced murine immune response to citrullinated 
collagen type II demonstrated that the conformational change in the antigen induced 
by citrulline was critical for recognition by antibodies 58, again suggesting that citrulline 
plays an essential role in the initiation of the immune response. Intriguingly, further re-
search has now shown that the SE alleles mainly predispose to the development of ACPA, 
rather than to the development of RA 59. This suggests a pathophysiological sequence 
of events detailed below in which genetic predisposition results in the development of 
anti-peptidylcitrulline immunity prior to the onset of RA. 
After these seminal findings with regards to the association between the HLA SE alleles 
and RA, many of the genetic risk factors for RA have now been found to be specific for 
either ACPA-positive or ACPA-negative RA. The majority of genetic risk factors, such as 
PTPN22, the TRAF1-C5 locus, the OLIG3-AIP3-locus and STAT4, are preferentially associ-
ated with ACPA-positive RA 60, 61. Conversely, there are other genetic risk factors that have 
been described to be exclusively associated with ACPA-negative RA, such as HLA-DR3 
and interferon regulatory factor (IRF) haplotypes 62. As there are no markers available 
that are specific for this disease subset, it is impossible to determine at present whether 
these genetic risk factors predispose to ACPA-negative RA or to specific immunological 
alterations in these patients.
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envIronmenTAl rIsk fACTors
In addition to genetic aspects, environmental risk factors are known to contribute to 
the etiology of RA. Many epidemiological studies have shown an association between 
cigarette smoking and the development of RA 63, 64. Smoking was found to interact with 
the HLA SE alleles in the predisposition to RF-positive RA 65. However, recent data have 
shown a striking interaction between smoking and the SE alleles in conferring risk for 
ACPA-positive, rather than for RF-positive RA 66. They also demonstrated an association 
between smoking and the development of citrullinated antigens in bronchoalveolar lavage 
fluid cells, thereby providing a possible pathogenetic link between smoking and the de-
velopment of ACPA-positive RA.
PAThoPhysIologICAl moDel of rheumAToID ArThrITIs
The recent findings that have elucidated the differences in risk factors for ACPA-positive 
versus ACPA-negative RA have important consequences for the understanding of the 




































figure 2: A multi-stage model of the clinical and pathophysiological development of rA.
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In the first stage, a genetic predisposition along with environmental factors results in 
an adaptive immune response with antigen-dependent T and B cell activation. In the case 
of ACPA-positive RA, the SE alleles together with smoking may lead to the development 
of an anti-citrullinated protein immune response. A nonspecific environmental trigger 
could function as a secondary event leading to joint inflammation, which manifests itself 
as undifferentiated arthritis (UA). Other genetic risk factors involved in, for example, 
cytokine regulation, play a role in determining the extent and duration of joint inflam-
mation. The inflammatory process itself can subsequently further stimulate the adaptive 
immune response through the generation of new epitopes by, amongst other processes, 
citrullination, which has been shown to occur more readily in inflamed joints. In indi-
viduals who have previously developed an adaptive immune response (possibly with 
production of ACPA), the immune cells that now gain access to the joints can enhance 
the inflammation and lead to the increased production of cytokines and soluble inflam-
matory mediators. Large numbers of activated CD4-positive T cells accumulate in the 
joints of patients with RA. The abundant presence of these activated T cells in the joints 
has several different effects. Through production of cytokines and through cell-surface 
interactions, the activated T cells stimulate monocytes, macrophages, and synovial 
fibroblasts to produce other cytokines such as TNFα and to secrete matrix metallopro-
teinases 67. Furthermore, the activated T cells stimulate osteoclastogenesis 68. Finally, the 
autoreactive T cells are capable of providing help to autoreactive B cells, which can lead 
to the production of autoantibodies. B cells can also function as antigen-presenting cells 
and thus can promote T cell activation and perpetuation of the autoimmune response 69. 
Activated B cells and autoantibody-producing plasma cells are present in RA synovium, 
although it is not completely clear if the original B cell activation occurs in the joint or 
elsewhere. ACPA bound to citrullinated antigens have also been detected in the joints 
of RA patients 70, 71. 
Autoantibodies may play a pathogenic role by fixing complement in the joint leading 
to the release of chemotactic factors such as C5a and the subsequent recruitment of 
inflammatory cells. Another mechanism by which immune complexes can contribute 
to joint damage is through the activation of monocytes and macrophages by binding to 
Fc-receptors on the surface of these cells. This could cause perpetuation of the synovial 
inflammation and progression of UA to RA and erosive disease. This pathophysiological 
model, based on the activation of adaptive immunity, currently seems most applicable 
to ACPA-positive RA. 
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ouTlIne of ThIs ThesIs
There were three main aims of this thesis:
1. to quantify the heritability of ACPA-positive and ACPA-negative RA, and to elucidate 
the association of distinct genetic and environmental risk factors with both subsets of 
disease.
2. to characterize the immunological properties of ACPA and to investigate the associa-
tion between ACPA characteristics and disease progression.
3. to identify predictive factors for the most favorable outcome of RA: sustained remission 
after discontinuation of disease-modifying anti-rheumatic drugs (DMARDs).
The thesis is divided into three parts corresponding to the three main aims.
Part 1 is dedicated to the investigation of the heritability of RA, and to the exact as-
sociation of specific genetic risk factors (the HLA-DRB1 alleles) and an environmental risk 
factor (alcohol) with ACPA-positive and ACPA-negative RA. 
As described above, it has been known for many years that the most prominent ge-
netic risk factor for RA is situated at the HLA locus. The HLA-DRB1 alleles that confer 
the strongest predisposition for RA are also known as the shared epitope (SE) alleles 
and have been found to selectively predispose to ACPA-positive RA. Other HLA-DRB1 
alleles confer protection against disease although, due to conflicting results, it was unclear 
exactly which alleles are protective 72-74. It was also unknown whether these protective 
effects might be limited to ACPA-positive or ACPA-negative RA. We therefore performed 
a meta-analysis of four European populations to investigate precisely which HLA-DRB1 
alleles are associated with protection in ACPA-positive and ACPA-negative RA (chapter 2).
In addition to the HLA alleles, multiple other genetic risk factors have been described 
which predispose to RA. It is remarkable that the majority of these genetic risk factors have 
been found to preferentially confer risk to autoantibody-positive disease. This suggests 
that the extent to which genetic factors contribute to disease development may differ 
between ACPA-positive and ACPA-negative RA. In chapter 3, we therefore determined 
the heritability of ACPA-positive and ACPA-negative RA by applying quantitative genetic 
methods to data from a large twin cohort. Furthermore, we assessed the contribution of 
the predisposing HLA-DRB1 shared epitope (SE) alleles to the genetic variance of both 
groups.
Surprisingly, these studies described in chapter 3 revealed that that the heritability of 
ACPA-positive and ACPA-negative disease does not differ, and is 66% for both subsets of 
disease. The effect of the HLA SE alleles explained a relatively modest 18% of the genetic 
variance of ACPA-positive RA, raising the question which other genetic risk factors could 
account for the remaining 82% of “missing heritability”. In light of the findings of chapter 
2, which revealed a strong protective effect of HLA-DRB1*13 alleles for ACPA-positive 
disease, we investigated to what extent these protective HLA effects contribute to the 
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genetic variance of RA in chapter 4. Since a multitude of new genetic risk factors for RA 
in the form of single nucleotide polymorphisms (SNPs) has been described in the past few 
years, the effect of 12 well-replicated SNPs was also taken into account.
Besides genetic risk factors, there are also environmental risk factors which are known 
to predispose to RA, such as smoking. A recent case-control study proposed that another 
environmental risk factor: alcohol intake, may be associated with a lower risk of develop-
ing RA 75. This is in line with findings from experimental studies showing a downregulatory 
effect of alcohol on both innate and adaptive immune responses 76-78. In chapter 5 we 
evaluated whether the protective effect of alcohol is specific for RA, or may extend to 
other forms of inflammatory arthritis as well. Furthermore, we assessed if the protective 
effect differed between the ACPA-positive and ACPA-negative subset of disease.
Part 2 focuses on the immunological characteristics of ACPA, the influence of genetic 
and environmental risk factors on the shaping of the ACPA response, and the clinical value 
of the various commercially available ACPA tests.
Different parts of human antibodies have different functions. While the antigen specific-
ity is determined by the Fab (Fragment antigen binding) region, the Fc (Fragment crystalliz-
able) region is responsible for immune effector functions such as complement activation, 
antibody-dependent cellular cytotoxicity and binding to cellular Fc-receptors. These Fc-
mediated effects are influenced by Fc-linked carbohydrate structures known as glycans. By 
glycosylation, a posttranslational modification process, different kinds of glycan structures 
can be attached to the Fc-parts of the antibodies, resulting in several different glycoforms 
in human serum 79. Interestingly, early studies have demonstrated a predominance of IgG-
G0 (meaning without galactose) glycoforms in sera of RA patients which correlated with 
disease activity and reverted to normal levels in patients who achieved (spontaneous) 
remission 80, 81. To investigate whether ACPA, which are hypothesized to play a crucial 
role in the pathogenesis of RA, carry a different glycosylation pattern than other human 
antibodies, we developed a technique that allowed analysis of Fc-linked glycans in an 
antigen specific manner 82. Chapter 6 describes the results of the analysis of the ACPA 
glycan profile from serum and synovial fluid.
Human antibodies consist of four polypeptide chains: two heavy chains and two light 
chains. There are five different types of heavy chains that determine the isotype of the 
antibody: IgM, IgD, IgG1-4, IgA and IgE. The isotypes differ substantially with regard to their 
ability to mediate effector mechanisms, such as complement activation and binding to Fc- 
receptors. The ACPA response has been shown to consist of various isotypes, and the fact 
that ACPA of the IgM isotype could be detected at various stages of the disease indicated 
that the anti-citrullinated protein immune response is constantly being (re)activated 83-
86. It was unclear however, if during this process of continuous reactivation throughout 
disease progression, there was also further maturation of the ACPA response in the sense 
of isotype switching. In addition, the finding that the ACPA isotype use differed between 
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patients 86, raised the question whether changes in isotype use are associated with disease 
progression. In chapter 7, we therefore examined the relationship between ACPA isotypes 
and disease development and progression. The use of two large, independent cohorts 
with long-term follow-up data enabled us to investigate the association between the ACPA 
isotype profile and progression of radiographic damage.
Another antibody characteristic which is crucial for the pathogenicity of autoantibodies, 
is the fine specificity of antigen recognition 87. The important pathophysiological conse-
quences of an increase or shift in antigen recognition during the course of an immune 
response (a phenomenon known as epitope spreading), have been described in for ex-
ample systemic lupus erythematosus (SLE) 88. Knowing that ACPA can be detected before 
the clinical diagnosis of RA, we hypothesized that similar to SLE, epitope spreading of the 
ACPA response may play a role in the evolution of the disease. We therefore investigated 
the reactivity pattern of ACPA before disease onset and during disease progression, as 
described in chapter 8. Making use of several different cohorts, which cover the entire 
spectrum of the disease course ranging from ACPA-positive healthy individuals to long-
standing RA, this study provides an overview of the ACPA fine specificity development 
over time. The clinical effects of individual differences in ACPA fine specificity repertoire 
were examined in more detail in chapter 9. Based on the known association between 
the HLA SE alleles and some ACPA fine specificities as described below, this association 
was now investigated with regard to several more citrullinated epitopes. Moreover, an 
in-depth analysis of the effect of SE gene dose was performed. In order to investigate the 
clinical outcome of differences in the ACPA fine specificity repertoire, we investigated 
whether certain ACPA fine specificities were associated with the extent of radiographic 
joint damage. 
As mentioned in the first part of this introduction, the HLA SE alleles and smoking are 
known to predispose to the development of ACPA-positive RA. The combined effect of 
HLA SE alleles and smoking has been shown to exceed the sum of their single effects: a 
phenomenon known as biological interaction 89-91. Furthermore, a previous study on ACPA 
fine specificity reported that the HLA SE alleles may also determine the fine specificity 
of the ACPA response, since they predisposed to the development of antibodies against 
citrullinated vimentin but not against citrullinated fibrinogen 92. Based on these results, 
we wondered whether genetic and environmental risk factors might also interact with 
regard to their effect on the fine specificity of ACPA. If interaction were to be found in 
association with ACPA-reactivity to a particular citrullinated protein, this may indicate that 
the protein under investigation is of etiologic importance as an autoantigen in RA. Partly 
in response to a publication postulating a specific interaction between genotype, smoking 
and autoimmunity to citrullinated α-enolase peptide (CEP-1) 93, we analyzed the effects of 
HLA SE alleles and smoking on the ACPA reactivity profile in chapter 10. The results of this 
analysis revealed that the interaction between genotype, smoking and autoimmunity to 
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citrullinated antigens was not confined to citrullinated α-enolase, but extended to several 
other citrullinated antigens as well. 
Chapter 11 provides additional essential information with regard to these results. We 
hypothesized that the gene-environment interaction between the HLA SE alleles and smok-
ing affected the development of ACPA-positive RA in general, rather than the development 
of specific ACPA fine specificities. When the analysis was performed within ACPA-positive 
patients, the interaction was no longer present, which argues in favor of our hypothesis, 
and against an effect of the gene-environment interaction on shaping the reactivity of the 
ACPA response.
While the ACPA fine specificity studies mentioned above were all performed with in-
house assays specifically developed for this purpose, we also examined the clinical utility 
of the ACPA tests which are commercially available in chapter 12. The aim of this inves-
tigation was to compare the predictive ability of anti-CCP2-, anti-CCP3-, anti-modified 
citrullinated vimentin (anti-MCV-) and RF-tests with regard to three outcome measures: 
progression from UA to RA, the rate of joint destruction and achieving sustained DMARD-
free remission in RA. 
Part 3 of this thesis describes the results of two studies concerning remission in rheu-
matoid arthritis.
RA patients vary considerably in terms of their disease course and outcome. The spec-
trum extends from debilitating, destructive joint disease on one side, to remission, the 
most favorable outcome, on the other side 94. These days, remission is increasingly becom-
ing an attainable goal of RA treatment, especially since the introduction of biological 
anti-rheumatic therapy. The potent suppression of disease activity which can be achieved 
with these novel treatment agents, together with the finding that early aggressive therapy 
leads to better long-term outcomes, has resulted in new treatment goals striving to achieve 
remission in as many patients as possible 95, 96.
Remission rates after treatment with new therapeutic agents are now often reported, 
but there are few data on remission after treatment with conventional therapy, such as 
non-steroidal anti-inflammatory drugs (NSAIDs) and non-biological disease modifying 
anti-rheumatic drug (DMARD) therapy. These figures are however required for a fair 
comparison of the remission rates reported in clinical trials of novel agents. Moreover, 
the investigation of remission as a definitive disease outcome resembling cure is very 
important from a pathophysiological point of view. Data on patient characteristics as-
sociated with remission could lead to new hypotheses about the biological pathways 
involved in disease persistence and resolution. In chapter 13, we therefore used two 
large independent cohorts of patients treated with conventional therapy to examine the 
prevalence and predictive factors for disease modifying anti-rheumatic drug (DMARD)-
free sustained remission.
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The results of this study were extended in a subsequent investigation in which we com-
pared the prevalence and predictive factors for remission in two different patient cohorts. 
Conventional therapy as mentioned above, was used in one of the cohorts, while the other 
cohort was treated according to a tight control strategy. Tight control entails a treatment 
strategy aiming at a predefined goal of minimal disease activity. This strategy has been 
shown to lead to improved functional status and high remission percentages, irrespective 
of the exact initial choice of therapy 97. In chapter 14, we investigated whether this tight 
control strategy aiming at a low disease activity score (DAS < 1.6) resulted in more drug-
free remission, or led to drug-free remission in patients who were more difficult to treat.
Chapter 15 provides a summary of the results and a discussion of the implications of the 
studies described in this thesis.
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AbsTrACT
objective The protective effect of HLA-DRB1 alleles on the development of rheumatoid 
arthritis (RA) is poorly understood. We performed a meta-analysis of four European 
populations to investigate which HLA-DRB1 alleles are associated with protection in anti-
citrullinated protein antibody (ACPA)-positive and ACPA-negative RA.
methods More than 2800 patients and 3000 controls with information on HLA-DRB1 
typing and ACPA-status were collected from four European countries: Norway, Sweden, 
the Netherlands and Spain. The odds ratio’s (ORs) and 95% confidence intervals (CI) as-
sociated with the different HLA-DRB1 alleles were analyzed in a combined meta-analysis, 
focused on protective alleles and classifications. The analysis of ACPA-positive RA was 
stratified for the shared epitope (SE) alleles to correct for skewing due to this association.
results In ACPA-positive RA, the only alleles which conveyed protection after stratifica-
tion for SE, were HLA-DRB1*13 alleles (OR (95%CI): 0.54 (0.38-0.77)). The protective 
effect of the allele classifications based on the DERAA and D70 sequence was no longer 
present after exclusion of DRB1*13 (OR (95%CI) D70: 0.97 (0.75-1.25)), indicating that 
DRB1*13, rather than the DERAA or D70 sequence as such is associated with protec-
tion. Within the DRB1*13 alleles only DRB1*1301 was associated with protection (OR 
(95%CI): 0.24 (0.09-0.59)). Protection appeared to follow a North-South gradient with the 
strongest association in Northern countries. In ACPA-negative RA, there were no robust 
associations with HLA-DRB1 alleles.
Conclusion Our data do not support any of the classifications of protective alleles and 
indicate that protection against ACPA-positive RA is predominantly associated with HLA-
DRB1*1301.
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InTroDuCTIon
The Human Leucocyte Antigens (HLA) are the most prominent genetic risk factor for 
Rheumatoid Arthritis (RA). The association between RA and the HLA region was originally 
discovered based on the observation that lymphocytes from RA patients were not reactive 
against cells from other RA patients in mixed lymphocyte cultures 1, 2. This meant that 
RA patients had certain HLA alleles in common, which were less prevalent in control 
populations. Serological testing subsequently revealed that the HLA-D-Related (DR)w4 
alloantigen, but not HLA-A, B or C antigens were associated with RA 3. Later studies 
demonstrated that several of the HLA-DR alleles were associated with RA, which led to 
the formulation of the Shared Epitope (SE)-hypothesis in 1987 4. This hypothesis provided 
a theoretical background for the observed associations between the HLA region and 
RA based on the fact that all HLA-DR alleles which predispose to RA have the same 
or a similar amino acid sequence (shared epitope) at positions 70-74 of the HLA-DRB1 
molecule. This sequence is located in the peptide-binding groove of the HLA alleles and 
may therefore be directly involved in the presentation of peptides to arthritogenic T cells. 
However, due to the complexity of the HLA region, the association between the HLA 
region and RA is multifaceted and it is now known that not all HLA SE alleles contribute 
to RA to the same extent 5, 6. Nonetheless, the formulation of the HLA SE hypothesis has 
provided a rationale for combining several HLA molecules in analyses and has thereby 
enabled further well-powered investigations of the contribution of the HLA region to the 
risk of RA 7.
The discovery of anti-citrullinated protein antibodies (ACPA) has led to a paradigm shift 
in the investigation of genetic risk factors for RA. The HLA SE alleles were found to not 
predispose to RA as such, but rather to ACPA-positive disease, which is present in approxi-
mately two-thirds of patients with RA according to the ACR criteria 8. These observations 
are very important for the pathophysiological concept of disease development, since they 
indicate that the HLA SE alleles may be involved in the induction of the ACPA-response 
9. Several SNPs known to be associated with RA, such as PTPN22, were also discovered 
to be specifically associated with ACPA-positive RA 10, 11. In contrast, DRB1*03 has been 
reported to be associated with ACPA-negative disease 12, 13, although not all studies have 
confirmed this association 14. These differences in underlying risk factors indicate that 
ACPA-positive and ACPA-negative RA may constitute distinct disease entities with a differ-
ent underlying pathogenetic background.
In addition to the HLA-DRB1 alleles which contribute to RA susceptibility, other HLA-
DRB1 alleles confer protection against disease 15-17. These protective HLA-DRB1 alleles 
have been categorized according to several different classifications, analogous to the 
shared epitope classification of susceptibility alleles. The three best-known classifications 
postulate that HLA-DRB1 alleles with a protective effect harbor the “shared sequence” 
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DERAA at position 70-74 18, or an aspartic acid (D) at position 70 16, or an isoleucine (I) at 
position 67 of the HLA-DRB1 molecule 15. The DERAA and D70 alleles have been shown 
to be protective both in the presence and the absence of SE alleles 19, 20, which demon-
strates that their protective effect is not solely due to the absence of SE alleles 21, 22. A 
new classification of HLA-DRB1 alleles has recently been put forward which incorporates 
both predisposing and protective effects 23, 24. Although this has provided some interesting 
nuances with regard to the predisposing effect of the different shared epitope alleles, it is 
unclear if this classification accurately describes the protective HLA effects 7. 
The multitude of classifications of protective HLA alleles illustrates that a protective 
effect of HLA alleles in RA is now well-accepted. However, it is still unclear which HLA 
alleles exactly are protective. Geographical differences in the prevalence of HLA alleles 
have led to conflicting results, which have been further complicated by the use of different 
classifications. Furthermore, it is as yet unclear whether protective effects are present in 
ACPA-positive as well as in ACPA-negative disease. 
For these reasons, we wished to determine the contribution of individual HLA-DRB1 
alleles to RA, both with respect to susceptibility and protection in a meta-analysis across 
European populations. Using data from four different populations, being from Norway, 
Sweden, The Netherlands and Spain, we investigated the HLA-DRB1 associations with 
ACPA-positive and ACPA-negative RA in more than 2800 patients and 3000 controls. A 
significant protective effect of HLA-DRB1*13 was found which remained present after 
stratification for the SE effect. Moreover, the protective effect of HLA-DRB1*13 was only 
observed for ACPA-positive and not for ACPA-negative disease. An in-depth analysis of 
the protective classifications revealed that the protective effect of DERAA and D70 alleles 
was limited to the HLA-DRB1*13 alleles and was in fact only observed for DRB1*1301. 
Together, our data do not support any of the classifications described above and indicate 
that protection is mainly associated with DRB1*1301.
mATerIAls AnD meThoDs
Populations
Data on cases and controls were contributed by cohorts from four different European 
countries: Norway, Sweden, the Netherlands and Spain. The protocol of each cohort was 
approved by the relevant local ethics committee and all participants provided informed 
consent. More than 97% of cases and controls in all four cohorts was of Caucasian descent.
The Norwegian dataset consisted of RA patients who participated in the Oslo RA 
registry (ORAR) or the European Research on Incapacitating Disease and Social Support 
(EURIDISS) cohort. For the ORAR, which was initiated in 1992, inclusion criteria were a 
diagnosis of RA according to the 1987 ACR classification criteria and a residential address 
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in Oslo. The EURIDISS, which commenced in 1991, enrolled consecutive RA patients 
with a maximum disease duration of 4 years at baseline. Both RA cohorts have been 
described in detail elsewhere 25, 26. Controls were randomly selected from the Norwegian 
Bone Marrow Registry and cases and controls were matched for gender at a group level. 
The Swedish Epidemiological Investigation of RA (EIRA) cohort recruited cases and 
controls aged 18-70 from May 1996 to December 2003 from a geographically defined 
area in the south and central regions of Sweden. Patients were seen by rheumatologists at 
private as well as general health care units and were eligible for inclusion if they fulfilled 
the 1987 ACR criteria for RA. Controls were randomly selected from a national population 
register and were matched to the cases for age, sex and residential area. More details on 
the EIRA have been described in previous publications 27.
Data on Dutch cases were provided by two inception cohorts of early arthritis patients, 
the Leiden Early Arthritis Clinic (EAC) and the BehandelStrategieën (BeSt) trial. The Leiden 
EAC was initiated in 1993 and included patients with recent-onset arthritis (less than 2 
years of complaints) treated at the Leiden University Medical Center (LUMC). For the BeSt 
study, patients with arthritis with a maximum disease duration of 2 years and active disease 
were recruited at 20 centers in the western part of the Netherlands from 2000 to 2002. 
Only patients with a diagnosis of RA were included in the present study. These cohorts 
are described in further detail elsewhere 28, 29. Dutch controls were randomly selected by 
the section Immunogenetics and Transplantation Immunology (ITI) of the Department of 
Immunohematology and Blood Transfusion, LUMC. 
The Spanish dataset consisted of RA patients fulfilling the ACR criteria for RA, who were 
recruited from 4 Spanish hospitals in Granada, Seville, Lugo and Madrid. Blood donors 
and bone marrow donors from the same cities were included as healthy controls. Controls 
were matched to patients by age and sex. More characteristics of the Spanish dataset have 
been presented in previous reports 30. 
Genotyping 
The genotyping procedures of the HLA-DRB1 alleles have been described in previous 
publications 14, 20, 30, 31. High-resolution, 4-digit typing was available for the entire Norwe-
gian and Spanish cohorts. For the Dutch cohort, low-resolution typing was complemented 
by 4-digit typing of the DRB1*04 alleles, and by specific probes to detect the presence 
of the SE or DERAA sequence in individuals carrying DRB1*01, DRB1*10, DRB1*11 or 
DRB1*13 alleles. DRB1*1301 and *1302 were differentiated in part by 4-digit typing, 
and in part on the basis of their known, specific associations with HLA-DRB3 and -DQB1 
alleles which were determined in the entire dataset.
Similarly, for the Swedish dataset high-resolution typing of all DRB1*04 alleles was 
performed. All alleles containing a DERAA sequence in the Swedish cohort were identi-
fied by help of an interpretation table for the HLA-DRB1 low resolution kit. This allowed 
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the ascertainment of the following allelic groups in this cohort: DRB1*0103, DRB1*0402, 
DRB1*11-DERAA (*1102 or *1103) and DRB1*13-DERAA (*1301 or *1302). Unfortu-
nately, this did not allow the differentiation of DRB1*1301 from DRB1*1302. 
Shared epitope alleles and protective classifications were defined according to Table 1. 
Serological measurements
ACPA were determined by the measurement of antibodies against cyclic citrullinated 
peptides by a second-generation ELISA (anti-CCP2) (for the ORAR: DIASTAT; Axis-Shield 
Diagnostics, Dundee, UK. For the EURIDISS: INOVA, San Diego, CA, USA. For the 
Swedish, Dutch and Spanish cohorts: Immunoscan RA Mark 2; Eurodiagnostica, Malmö/
Arnhem, Sweden/The Netherlands). These different anti-CCP2-assays have been shown to 
provide very similar results 32. Samples with a value above the cut-off as specified by the 
manufacturer were considered positive. 
Statistical analysis
For each of the cohorts, we used logistic regression analysis to calculate the odds ratio’s 
(ORs) and 95% confidence intervals of developing ACPA-positive and ACPA-negative RA 
in association with the different HLA-DRB1 alleles. To take into account the matching of 
cases and controls in the study design, the analyses in the Swedish cohort were corrected 
for residential area, since age and gender have been shown to have no effect on the 
distribution of HLA alleles 33. A dominant genetic model which estimates the effect of 
the presence of a certain allele, irrespective of the presence of 1 or 2 copies, was used 
for all analyses. This model provided a better fit of the data than an additive allele model 
which assumes the effect in homozygotes to be considerably larger than the effect in 
heterozygote individuals. 
Due to the strong predominance of SE alleles among ACPA-positive patients, all other 
alleles are inherently less prevalent in patients than in controls. This results in seemingly 
protective effects of these alleles, which are in fact merely caused by skewing due to the 
large difference in the prevalence of SE alleles. In order to obtain an accurate estimate 
of the effect of the non-SE alleles, the analyses for these alleles in ACPA-positive patients 
were therefore stratified for the presence of SE in the following manner. For each non-SE 
allele (e.g. DRB1*03) the six possible combinations of this allele with SE alleles were 
investigated:
A) DRB1*03/DRB1*03 B) DRB1*03/x C) x/x 
D) SE/SE  E) SE/x  F) SE/DRB1*03
For the SE-negative stratum, the presence of DRB1*03 was compared to the absence 
of DRB1*03, hence the effect in group A and B was investigated using group C as the 
reference category. This corresponds to the dominant genetic model as described above. 
For the SE-positive stratum, the risk associated with the genotype F (SE/DRB1*03) was 
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analyzed using group E (SE/x) as the reference category, to adjust for the risk associated 
with the presence of 1 SE allele. 
Subsequently, we performed a meta-analysis using the effect sizes (β) and standard 
errors of the different cohorts. To account for the fact that there was significant statistical 
heterogeneity (Q-statistic, p-value<0.10) in a small number of the analyses, a random 
effect approach 34 was applied for all comparisons. This method allows between-study 
heterogeneity and incorporates it in the calculations. The data were analyzed per cohort 
with the Statistical Package for the Social Sciences (SPSS) 16.0. For the meta-analysis, we 
used the freely available software environment for statistical computing R.
resulTs
The study cohort consisted of 2806 RA patients and 3772 controls from four different 
European populations. The distribution of cases and controls across the cohorts was: Nor-
way: 788 cases and 898 controls, Sweden: 827 cases and 934 controls, the Netherlands: 
844 cases and 1213 controls, and Spain: 347 cases and 727 controls. All patients fulfilled 
the 1987 ACR criteria for RA. The proportion of patients which was ACPA-positive was 
very similar in all cohorts and ranged from 58% to 62%. 
The classifications of predisposing and protective HLA-DRB1 alleles, which have been 
described to be associated with RA, are listed in Table 1. The Shared Epitope (SE) classifi-
cation incorporates several HLA-DRB1 alleles which confer a high risk for ACPA-positive 
disease, with reported odds ratio’s (ORs) ranging from 4.6 to 11.3 30, 35. 
The DERAA, D70 and I67 alleles have been claimed to be associated with protection 
from RA, with ORs of 0.50, 0.23 and 0.14 (for DERAA presence 20, D70 homozygosity 16 
and I67 homozygosity respectively 15). As shown in Table 1 there is considerable overlap 
between the protective classifications. The frequencies of the presence of the separate 
HLA-DRB1 alleles in the four control populations are also presented in Table 1, as well as 
the frequencies of the allele-classifications.
Associations between HLA-DRB1 alleles and ACPA-negative RA
Table 2 shows the results of the meta-analysis for ACPA-negative RA. Although the data 
show a predisposing effect of DRB1*03 and DRB1*04, as well as a possible protective 
effect of DRB1*07 and DRB1*15 on ACPA-negative RA, these associations were only 
weakly significant. With regard to the effects of DRB1*03 and DRB1*07 there were 
marked geographical differences. The previously reported association between DRB1*03 
and susceptibility was present in the two Scandinavian cohorts and in the Dutch cohort, 
but was absent in Spain. However, a recent extensive study in Sweden 14 did not reveal a 
predisposing effect of DRB1*03 on ACPA-negative RA, indicating that more studies will be 
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Table 1. frequencies and classifications of hlA-Drb1 alleles according to predisposition and protection in rA
Allele shared epitope DerAA D70 I67 frequency in 
controls in %*




































































*07 X X 17 16 20 27
*08 X 8.5 9.0 7.0 5.4
*09 - - - - 2.7 3.2 2.0 2.1














































*1454 - - - - 3.1 4.1 7.0 4.1
*15 X 29 29 27 19




no sw nl sp no sw nl sp no sw nl sp no sw nl sp
53 49 44 37 26 30 26 27 56 60 66 75 67 67 66 63
Rare alleles with a median prevalence in controls < 0.5% were not listed. 
No = Norway, Sw = Sweden, Nl = Netherlands, Sp = Spain.
* In the Swedish and Dutch cohorts, four-digit typing was not available for all alleles as described in the 
Methods section. The frequencies were therefore listed in the following manner: sum of DRB1*0101 and 
DRB1*0102, sum of all DRB1*10 alleles (in the row of *1001), sum of DRB1*1101 and DRB1*1104 (in 
the row of *1101), sum of DRB1*1102 and DRB1*1103, (for the Swedish cohort: sum of DRB1*1301 and 
DRB1*1302) and sum of all DRB1*14 alleles (in the row of *1454). 
It has recently been shown that the majority of individuals previously genotyped as DRB1*1401 in fact 
carry the genotype DRB1*1454 44. In anticipation of probable genotyping revisions we have therefore listed 
DRB1*1454 as the most common DRB1*14 allele.
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required in order to draw definitive conclusions about this association. With regard to the 
protection conferred by DRB1*07, there appeared to be a North-to-South gradient with 
the strongest protective effect in Norway and no observable effect in Spain.
To perform a more detailed analysis of possible protective alleles, we also investigated 
the effects of the three classifications proposed to be associated with protection: the 
DERAA-, D70- and I67- alleles .The DERAA alleles did not convey a protective effect 
for ACPA-negative RA, while both the D70- and I67- alleles showed a modest protective 
effect (OR (95%CI) 0.75 (0.59-0.96) and 0.70 (0.53-0.94) respectively).
Associations between HLA-DRB1 alleles and ACPA-positive RA
Table 3 displays the results of the meta-analysis for ACPA-positive RA. Since our aim 
was to specifically investigate protective effects, the table only lists the four-digit subtype 
analysis of alleles which have been reported to be associated with protection. Due to the 
preponderance of SE alleles among ACPA-positive patients, all other alleles are inherently 
less prevalent in patients than in controls. This leads to seemingly protective effects of 
these alleles, which are in fact merely the result of skewing caused by the large difference 
in the prevalence of SE alleles. In order to obtain an accurate estimate of the effect of the 
non-SE alleles, the analyses for these alleles were therefore stratified for the presence of SE. 
The well-known association between SE alleles and susceptibility to ACPA-positive RA 
is confirmed by our data, as well as the hierarchy in the strength of this association, being 
DRB1*04>*10>*01. We also observed predisposing effects of DRB1*09, *15 and *16 , 
although the effect of *09 and *16 alleles was limited to SE-negative individuals. Despite 
the fact that some of these associations were relatively weak, they nonetheless suggest that 
Table 2. hlA-Drb1 associations with ACPA-negative rA, meta-analysis results
hlA-Drb1 allele ACPA-negative patients
or (95% CI)
p-value
*01 1.06 (0.90-1.25) 0.46
*03 1.39 (1.01-1.93) 0.05
*04 1.17 (1.00-1.37) 0.05
*07 0.67 (0.48-0.95) 0.03
*08 0.97 (0.59-1.60) 0.90
*09 0.90 (0.54-1.50) 0.68
*10 1.04 (0.67-1.60) 0.86
*11 1.01 (0.79-1.29) 0.95
*12 0.84 (0.59-1.20) 0.34
*13 0.87 (0.73-1.03) 0.10
*14 1.09 (0.80-1.48) 0.58
*15 0.78 (0.65-0.94) 0.01
*16 1.04 (0.42-2.58) 0.94
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Table 3. hlA-Drb1 associations with ACPA-positive rA, meta-analysis results
hlA-Drb1 allele or (95% CI) p-value stratification, or (95% CI) p-value
*01
   *0101 and *0102







*03 0.64 (0.55-0.75) <0.001 SE neg: 1.05 (0.80-1.38) 0.71
SE pos: 1.18 (0.95-1.46) 0.14
*04
   *0402








*07 0.56 (0.47-0.67) <0.001 SE neg: 1.04 (0.79-1.38) 0.76
SE pos: 0.89 (0.69-1.14) 0.35
*08 0.50 (0.36-0.70) <0.001 SE neg: 0.73 (0.46-1.14) 0.17
SE pos: 1.00 (0.50-1.98) 0.99
*09 1.43 (0.94-2.16) 0.10 se neg: 3.25 (2.06-5.12) <0.001
SE pos: 1.76 (1.00-3.11) 0.05
*10 2.37 (1.56-3.60) <0.001
*11 0.56 (0.46-0.68) <0.001 SE neg: 0.93 (0.64-1.36) 0.72
SE pos: 0.90 (0.67-1.19) 0.45
   *1102 and *1103 1.01 (0.61-1.67) 0.97 SE neg: 1.46 (0.63-3.37)* 0.38
SE pos:1.53 (0.75-3.12) 0.24
    other *11 0.49 (0.39-0.62) <0.001 SE neg: 0.80 (0.49-1.29) 0.36
SE pos: 0.70 (0.51-0.97) 0.03
*12 0.60 (0.42-0.84) 0.003 SE neg: 0.76 (0.37-1.54) 0.44
SE pos: 1.10 (0.69-1.77) 0.68
*13
   *1301 and *1302







se neg: 0.54 (0.38-0.77)
se pos: 0.57 (0.41-0.81)
se neg: 0.45 (0.27-0.74)
se pos: 0.54 (0.34-0.83)
SE neg: 2.35 (0.63-8.72)







*14 0.48 (0.34-0.68) <0.001 SE neg: 0.52 (0.28-0.98)##
SE pos: 1.02 (0.46-2.24)##
0.04
0.96
*15 0.69 (0.57-0.82) <0.001 se neg: 1.51 (1.17-1.95)
SE pos: 1.25 (1.02-1.55)
0.001
0.04
*16 1.21 (0.73-1.99) 0.46 SE neg: 2.91 (1.12-7.56)
SE pos: 1.51 (0.69-3.27)
0.03
0.30
Printed in bold are effects with a p-value below 0.01. For the non-SE alleles, only those associations with a 
p-value ≤ 0.005 after stratification for SE, are printed bold.
* No cases in Leiden cohort.
# Stratification for SE led to absence of cases or controls in the different strata in two of the four cohorts, 
therefore not performed.
** No cases in Norwegian cohort.
## HLA-DRB1*1402 alleles have a SE motif and were exceedingly rare in all cohorts (prevalence below 0.3% 
in controls). Therefore the HLA-DRB1*14 effect was also stratified for SE, after exclusion of individuals with 
DRB1*1402 alleles.
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the effect of HLA-DRB1 alleles on susceptibility to ACPA-positive RA may extend beyond 
the SE alleles.
Intriguingly, the DRB1*13 alleles appeared to be the only alleles associated with protec-
tion (Table 3). In both the SE-negative and SE-positive stratum, the protective effect of 
DRB1*13 not only remained present, but was also associated with a considerable effect 
size (OR 0.54 and 0.57 respectively) (Figure 1). 
In the subtype analysis of some of the protective alleles, e.g. in the case of DRB1*0103 
and DRB1*0402, stratification resulted in a lack of cases or controls in several cohorts, Figure 1A
OR= 0.33 (0.25-0.44) 
p < 0.001
Figure 1B
OR= 0.54 (0.38-0.77) 
p < 0.001
















OR= 0.33 (0.25-0.44) 
p < 0.001
Figure 1B
OR= 0.54 (0.38-0.77) 
p < 0.001

















figure 1: The effect of Drb1*13 on ACPA-positive rA.
Forest plots depicting the ORs and 95% CIs of the four separate cohorts and the combined estimate of the 
random effects meta-analysis.
Figure 1A: Unstratified analysis.
Figure 1B: SE-negative stratum.
Figure 1C: SE-positive stratum.
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rendering a meta-analysis ineffective. We can therefore not formally exclude that these 
alleles may be associated with a protective effect, although in the case of *0402 this is 
unlikely based on the result of the non-stratified analysis.
The protective effect of DRB1*13 and protective classifications on ACPA-positive RA
All protective classifications described for RA include DRB1*13 or some of the DRB1*13 
suballeles (Table 1). When analyzed according to the different protective classifications, 
the protective effect of the I67 alleles did not remain significant after stratification for 
SE. Both the D70 and the DERAA alleles were associated with a protective effect, which 
OR = 0.60 (0.41-0.88) 
p = 0.009
OR = 0.69 (0.57-0.84) 
p = 0.0002
OR = 0.97 (0.75-1.25) 
p = 0.82























OR = 0.60 (0.41-0.88) 
p = 0.009
OR = 0.69 (0.57-0.84) 
p = 0.0002
OR = 0.97 (0.75-1.25) 
p = 0.82























figure 2: The effect of D70 alleles with and without Drb1*13 alleles in ACPA-positive rA. 
Forest plots depicting the ORs and 95% CIs of the four separate cohorts and the combined estimate of the 
random effects meta-analysis.
Figure 2A: Effect of all D70 alleles, SE-negative stratum.
Figure 2B: Effect of all D70 alleles, SE-positive stratum.
Figure 2C: Effect of D70 alleles after exclusion of DRB1*13, SE-negative stratum.
Figure 2D: Effect of D70 alleles after exclusion of DRB1*13, SE-positive stratum.
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remained present after stratification for SE (Figure 2A and 2B), yet it was remarkable that, 
apart from DRB1*13, none of the alleles with a D at position 70 or a DERAA-motif appeared 
to confer protection by themselves (Table 3). We therefore investigated if the protection 
associated with the group of D70 or DERAA alleles as a whole, could be explained solely 
by the protective effect of the DRB1*13 alleles. To this end, we excluded the DRB1*13 
alleles from the analysis and re-analyzed the effect of all alleles with a D at position 70 on 
ACPA-positive RA. As can be seen in Figure 2C and 2D, these alleles were not protective, 
despite the fact that they had a D at position 70. The same was the case for the DERAA 
alleles (data not shown). These data indicate that the presence of a D at position 70 or of 
OR = 0.50 (0.33-0.76) 
p = 0.001
OR = 0.85 (0.54-1.33) 
p = 0.48
OR = 0.91 (0.48-1.75) 
p = 0.78
Figure 3BFigure 3A
Figure 3C Figure 3D














OR = 0.24 (0.09-0.59) 
p = 0.0 2
OR = 0.50 (0.33-0.76) 
p = 0.001
OR = 0.85 (0.54-1.33) 
p = 0.48
OR = 0.91 (0.48-1.75) 
p = 0.78
Figure 3BFigure 3A
Figure 3C Figure 3D














OR = 0.24 (0.09-0.59) 
p = 0.0 2
A b
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figure 3: The effect of Drb1*1301 and *1302 in ACPA-positive patients. 
Forest plots depicting the ORs and 95% CIs of the three separate cohorts with high-resolution typing of the 
DRB1*13 alleles, and the combined estimate of the random effects meta-analysis.
Figure 3A: Effect of DRB1*1301, SE-negative stratum.
Figure 3B: Effect of DRB1*1301, SE-positive stratum.
Figure 3C: Effect of DRB1*1302, SE-negative stratum.
Figure 3D: Effect of DRB1*1302, SE-positive stratum.
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the DERAA sequence as such does not result in protection from ACPA-positive RA, but 
rather, that DRB1*13 appears to be associated with protection.
In light of the strong protective effect conveyed by DRB1*13, we investigated if the pres-
ence of a DRB1*13 allele could annul the predisposition associated with a SE allele. The 
risk of SE/DRB1*13 heterozygote individuals compared to the risk of individuals carrying 
neither SE nor DRB1*13 alleles, was however still increased (OR (95%CI): 2.14 (1.64-
2.80)). Although this effect will vary according to the difference in risk associated with the 
different SE alleles and in different cohorts, the presence of one DRB1*13 allele does not 
compensate the risk associated with the presence of one SE allele in meta-analysis.
Next, we analyzed whether the DRB1*13 association was confined to DRB1*13 alleles 
which contain a DERAA-sequence: DRB1*1301 and*1302 (DRB1*1304 was not present 
in the study populations). As can be seen in Table 3, the protective effect was limited to 
the DRB1*1301 and*1302 alleles, although the analysis for the other DRB1*13 alleles 
was possibly hampered by relatively small numbers of cases and controls. Complete 
four-digit typing of DRB1*13 was available for three of the four populations included 
in this meta-analysis (Norway, Netherlands and Spain). Subtype analysis revealed that 
the protective effect of DRB1*1302 was no longer present after stratification for the SE 
(Figure 3). DRB1*1301 therefore was the only allele which was consistently associated 
with protection from ACPA-positive RA.
DIsCussIon
HLA alleles contribute to the susceptibility of RA in various ways. As a consequence of 
the highly polymorphic nature of the HLA-region in the population, it has been difficult to 
dissect the contribution of the various HLA alleles to RA-susceptibility. Previously, several 
different classifications have been developed in order to summarize the predisposing and 
protective effects of the HLA alleles with regards to RA. Our data confirm the predisposing 
effect of the SE alleles and also corroborate the differential effect sizes with which different 
HLA SE alleles predispose to ACPA-positive disease 5, 6. Furthermore, our results indicate 
a contribution of DRB1*09 and DRB1*15 to ACPA-positive disease. The relatively modest 
effect of DRB1*15 requires replication in further studies, before any firm conclusions can 
be drawn. The predisposing effect of DRB1*09 to ACPA-positive RA on the other hand, has 
been described in other populations as well 36. Therefore, it may be appropriate to include 
DRB1*09 in the list of susceptibility genes for ACPA-positive RA. 
More importantly, however, our results confirm the association of HLA-DRB1 alleles with 
protection and considerably refine the definition of protective alleles. Our data indicate 
that the protective effect is only apparent for the DRB1*13 allelic group. Analysis of the 
different allele-classifications which have been developed to capture the protective effects 
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of HLA-DRB1 alleles in RA 15, 16, 18 revealed that the protective effect of the DERAA and 
D70 classification could largely be attributed to the DRB1*13 alleles. This underscores the 
relative importance of the protective effect mediated by DRB1*13 in comparison to other 
alleles, and also raises the question whether the classifications of protective effects may 
need to be reconsidered.
Further analysis of the DRB1*13 alleles showed that protection was only apparent 
for the DRB1*1301 allele. Although our study included over 2700 patients and 3000 
controls from four large data-sets from four different European populations, we cannot 
exclude that smaller protective effects may also be present for other alleles than DRB1* 
1301 which could not be detected in the present investigation. Previous studies in other 
ethnicities have also reported protective effects of other HLA alleles such as DRB1*1302 
and DRB1*14 for RA, although not all of these results were stratified for ACPA-status or 
corrected for the effect of the HLA SE alleles 37, 38. It would be interesting to know to what 
extent the protective effects differ among different populations.
The present study clearly confirms that the SE alleles are only associated with ACPA-pos-
itive RA. The same is true for the association between DRB1*13 or *1301 and protection. 
The present study thus demonstrates once more that the associations between HLA-DRB1 
alleles and ACPA-positive versus ACPA-negative RA are very different both quantitatively 
and qualitatively. Regarding protective effects of HLA-DRB1 alleles in ACPA-negative RA, 
a recent study in a limited number of patients has reported that the DERAA alleles may be 
protective in this subset as well 39. We could not confirm this finding in the present study, 
although the weak protective effects we observed for DRB1*07 and DRB1*15 in ACPA-
negative RA do not exclude the presence of HLA-mediated protection in ACPA-negative 
disease. 
In the current investigation, the effect of the presence of the different HLA-DRB1 alleles 
was investigated separately. The risk for ACPA-positive RA in individuals heterozygous 
for the SE was assessed as part of the stratified analysis, but we cannot make conclusions 
about the risk associated with heterozygosity for the various other HLA-DRB1 alleles. It is 
conceivable that combinations of certain alleles may confer susceptibility or protection, 
as was described in a recent report, in which the combination of DRB1*03 and DRB1*13 
alleles was found to be associated with an increased risk of ACPA-negative disease 14. A 
meta-analysis of heterozygosity effects may therefore yield very interesting results in the 
future. 
For the statistical analysis, a dominant allele model was applied in the present study. An 
alternative would have been to use an additive allele model, which assumes substantially 
larger effects in homozygous versus heterozygous individuals. Although the dominant 
allele model provided the best fit to the data in the current analysis, other reports have 
favored an additive model 7. Discrepancies between publications may therefore be partly 
attributable to differences in statistical methods. A meta-analysis such as presented here is 
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helpful in this respect because it overcomes these statistical differences and provides an 
overview of the results of four cohorts analyzed in the same way.
As can be seen from Figures 1A and 3B, there was a tendency towards a North-South 
gradient in the strength of the associations of several HLA-DRB1 alleles. Associations were 
often the strongest in Norway and Sweden, slightly less strong in the Netherlands and the 
weakest or sometimes even absent in Spain. This was the case for both predisposing and 
protective alleles in both ACPA-positive and ACPA-negative disease. For HLA-associated 
susceptibility, these same geographical differences can be observed in previous publica-
tions 40, 41, but they have not been described for the protective effects of HLA in RA. If 
the existence of this gradient proves to be real, it may be a factor which needs to be 
taken into account when comparing data from different populations. It may also serve to 
reconcile some of the seemingly conflicting data which have been reported in different 
populations. Furthermore and perhaps most importantly, it may provide clues to candidate 
environmental factors that may be involved in the pathogenesis of the disease.
The main reason to perform studies such as the current meta-analysis, is to obtain 
mechanistic insight into the contribution of the HLA-region to RA. This has provided 
important new insights in the past, such as the realization that the HLA SE alleles do 
not contribute to RA as such, but rather to ACPA-positive disease 8. More recently it was 
also shown that the presence of the HLA SE alleles influences both the magnitude and 
specificity of the ACPA-response 9, 42. Together, these observations indicate that the HLA 
SE alleles are primarily involved in shaping of the ACPA-response presumably by facilitat-
ing T-cell help to ACPA-producing B-cells. Intriguingly, our data show that the protective 
effects associated with the presence of DRB1*13 are also most prominent in the ACPA-
positive group of RA patients. These observations would be in line with the notion that the 
predisposing effect of the HLA SE alleles and the protective effect of DRB1*13 act within 
the same biological pathway. Indeed, the presence of DRB1*13 considerably lowered the 
predisposing effects of the HLA SE alleles in individuals heterozygote for both, although 
the predisposing effect of the HLA SE alleles was not annulled. In case these effects target 
the same biological pathway, the presence of DRB1*13 may perhaps also influence the 
specificity and magnitude of the ACPA-response.
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AbsTrACT
objective The majority of genetic risk factors for rheumatoid arthritis (RA) are associated 
with anti-citrullinated protein antibody (ACPA)-positive RA, while far fewer genetic risk 
factors have been identified for ACPA-negative RA. To quantify the contribution of genetic 
risk factors in general and of the predisposing HLA-DRB1 shared epitope (SE) alleles 
in particular to these two subsets of RA, we computed the heritability and assessed the 
contribution of HLA SE alleles.
methods 148 RA twin pairs, of which at least one twin had RA, were tested for ACPA 
and typed for HLA-DRB1 genotypes. Heritability was assessed by including a bivariate 
normally distributed random effect representing the contribution of unobserved genetic 
factors to RA susceptibility in a logistic regression model with the correlation between 
the random effects fixed according to twin zygosity. The contribution of HLA SE alleles to 
the genetic variance was assessed by a similar model using genotype-specific population 
prevalences.
results The heritability of RA was 66% (95% confidence interval (CI) 44-75%). For 
ACPA-positive RA the heritability was 68% (CI: 55-79%) and for ACPA-negative RA 66% 
(CI: 21-82%). The HLA SE alleles explained 18% (CI: 16-19%) of the genetic variance of 
ACPA-positive RA, and only 2.4% (CI: 1.6-10%) of ACPA-negative RA. 
Conclusion The heritability of ACPA-positive and ACPA-negative RA is comparable. These 
data indicate that genetic predisposition plays an important role in the pathogenesis of 
ACPA-negative RA, for which most individual genetic risk factors remain to be identified. 
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InTroDuCTIon
Several new genetic risk factors for rheumatoid arthritis (RA) have been identified in the 
past few years. Candidate gene studies and new techniques such as whole genome scans 
have led to the discovery of various new genetic variants which predispose to RA, in for 
example the genomic regions encoding PTPN22, STAT4 and TRAF1/C5 1-3. Interestingly, 
the majority of the genetic factors which predispose for RA have been found to pref-
erentially confer risk to autoantibody-positive disease. The importance of distinguishing 
autoantibody-positive from autoantibody-negative RA is increasingly being recognized 
due to the recent findings concerning anti-citrullinated protein antibodies (ACPA). 
ACPA were first described as anti-perinuclear factor and anti-keratin antibodies, that 
both bind to citrullinated fillagrin 4-7. Since then, ACPA have been found to be the most 
predictive factor for the future development of RA 8-10. Due to its superior specificity and 
predictive characteristics as compared to IgM RF, ACPA are increasingly being used for 
diagnostic purposes 11. Approximately two-thirds of patients with established RA are 
ACPA-positive, and these patients are characterized by a destructive phenotype with 
higher rates of joint destruction as compared to ACPA-negative RA patients 12. 
ACPA-positive and ACPA-negative disease differ not only with regard to clinical dis-
ease phenotype, but are also associated with different genetic and environmental risk 
factors 13, 14. The HLA-DRB1 shared epitope (SE) alleles for example, which confer the 
highest risk of all known genetic risk factors, predispose specifically to the development 
of an anti-citrullinated protein immune response, rather than to the development of RA 15. 
PTPN22 gene variants, as well as the C5-TRAF locus, have been found to be predomi-
nantly associated with ACPA-positive RA, although an association with ACPA-negative 
RA cannot be excluded 2, 16. It is possible that studies which include a larger number of 
ACPA-negative patients will also find an association between these genetic risk factors and 
ACPA-negative RA, such as has been shown for STAT4 17. At this moment however, the 
number of genetic risk factors which has been described to be predominantly associated 
with ACPA-negative RA is more limited, and includes HLA-DR3 haplotypes and interferon 
regulatory factor 5 (IRF5) 14, 18. 
Not only genetic, but also environmental risk factors differ between ACPA-positive and 
ACPA-negative RA. Recent data have shown an interaction between smoking and the SE 
alleles in conferring risk for ACPA-positive RA 19, 20. The differences in clinical phenotype 
and underlying risk factors have lead to the concept that ACPA-positive and ACPA-negative 
RA constitute distinct entities with different pathophysiological mechanisms of disease 21. 
The extent to which genetic factors contribute to disease development may differ between 
these two subsets, and thus far, more genetic factors have been found to be associated 
with ACPA-positive than with ACPA-negative RA.
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To investigate the contribution of genetic factors to disease development, twins are 
a valuable source of information. Twin studies provide two measures for the influence 
of genetic factors on disease development: the concordance and the heritability. The 
concordance represents the frequency with which the twin brothers or sisters of diseased 
individuals are also affected. While the concordance is influenced by the prevalence of 
the disease (or disease subset), heritability is not. The heritability supplies a quantitative 
measure for the amount of variation in disease susceptibility which can be explained 
by genetic factors. Another advantage of heritability estimates compared to concordance 
rates, is that the heritability is based on the combined data of both mono- and dizygotic 
twins. This makes heritability modeling a more powerful method, especially when using 
small populations such as RA twin cohorts. For RA, the heritability has been assessed 
at approximately 60% 22. There are no data available however for the heritability of 
autoantibody-positive versus autoantibody-negative RA. 
In this study, we determined the heritability of ACPA-positive and ACPA-negative RA by 
applying quantitative genetic methods to data from a large twin cohort. In addition, we 
assessed the contribution of the predisposing HLA-DRB1 shared epitope (SE) alleles to the 
genetic variance of both groups.
meThoDs
Study population
A nationwide study of twin pairs of which one or both had RA was performed in the 
United Kingdom in 1989 23. Twin pairs were recruited by two parallel strategies. All UK 
rheumatologists were contacted and requested to ask all patients with RA whether they 
were a twin. Secondly, there was a simultaneous multi-media campaign, inviting patients 
who had been diagnosed with RA and who had a living twin to contact a study centre. 
Both members of each twin pair were visited at home by trained research nurses who 
recorded detailed history and demographic characteristics and performed joint examina-
tions. Blood samples were collected of which serum was stored and lymphocytes were 
separated for HLA typing. High resolution HLA-DRB1 genotyping was performed enabling 
the assignment of RA-associated HLA SE alleles 24.
RA was diagnosed according to the 1987 revised ACR criteria 25. Twin pairs were only 
eligible for inclusion if at least one twin satisfied these criteria. Zygosity status was verified 
by DNA fingerprinting on all same-sexed pairs using non-radioactive Southern blotting 
with a multilocus probe 26. 
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ACPA (Anti-CCP2) assays 
Total IgG anti-CCP2 was measured in serum samples by enzyme-linked immunosorbent 
assay (ELISA) (Immunoscan RA Mark 2; Eurodiagnostica, Arnhem, The Netherlands). 
Samples with a value above 25 units/ml were considered positive according to the manu-
facturer’s instructions. 
Statistical analysis
Summary statistics were generated to investigate the prevalence of ACPA-positive and 
ACPA-negative RA and the occurrence of the HLA SE alleles. Concordance figures were 
calculated by dividing the number of pairs in which both twins were affected by the total 
number of twin pairs. 
To calculate the heritability of RA, as well as of ACPA-positive RA and ACPA-negative 
RA, we used a logistic regression model with a normally distributed random effect 27-29. In 
this case, the normally distributed random effect represents the contribution of unobserved 
genetic factors to RA susceptibility. The correlation between the outcomes of twins due to 
genetic factors is modeled according to the extent to which a twin pair shares this random 
effect. Monozygotic twin pairs share all their genome and therefore they also share all 
their random effect. Dizygotic twins share half of their genome, hence they also share half 
of the random effect in the model. The variance of the random effect (genetic variance) is 
a measurement for the total contribution of genetic factors to the outcome. The heritabil-
ity is defined as the genetic variance divided by the total variance of the outcome. The 
variance of the random effect with 95% confidence intervals was estimated using profile 
likelihood, i.e. for a grid of genetic variances the likelihood was computed and the value 
for which the likelihood curve obtained its maximum is the maximum likelihood estimate 
of the genetic variance. Since the twin pairs were selected for having at least one affected 
twin, the prevalences of RA, ACPA-positive RA and ACPA-negative RA were fixed to their 
population prevalences (see Table 3 for the values used) (see Appendix A for further details 
of the heritability modeling approach).
Subsequently, we computed the contribution of SE to the total genetic variance of RA, 
as well as of ACPA-positive RA and of ACPA negative RA. This measure can be obtained 
by using a method similar to the method for computing the heritability. Instead of using 
the general population prevalence, now the genotypic specific population prevalences 
are used (see Table 3). For this model the variance of the random effect represents the 
genetic factors other than the genotype under study (see Appendix B for further details of 
the calculation of the contribution of SE to the genetic variance). 
All computations were performed in the freely available software environment for 
statistical computing R.




The characteristics of the study cohort, which consisted of 64 monozygotic and 84 dizy-
gotic twin pairs as described previously 22, are displayed in Table 1. The patient character-
istics of the monozygotic and dizygotic twins are comparable with regard to demographic 
factors, autoantibody status and radiographic severity of RA.
The concordance of RA, which represents the frequency with which the twin brothers or 
sisters of RA patients are also affected, was calculated for the monozygotic and dizygotic 
twin pairs (Table 2). For monozygotic twins the concordance is 15.6% versus 3.6% for 
dizygotic twins. Based on the results of the anti-CCP2 measurements, the concordance of 
the ACPA-positive and ACPA-negative subsets was also determined. In this cohort, twins 
who were concordant for RA all had the same ACPA status, meaning that there was no 
twin pair consisting of two affected individuals in which one individual had ACPA-positive 
disease and one individual had ACPA-negative disease. The concordance of ACPA-positive 
RA is comparable to the concordance of RA, while the concordance of ACPA-negative RA 
is lower than that of RA and ACPA-positive disease. 
Table 1. Patient characteristics
Patient characteristic † monozygotic twins
(64 pairs with 
74 rA patients)
Dizygotic twins 
(84 pairs with 
87 rA patients)
Age in years, mean (SD) 41 (14) 37 (13)
Female gender, n (%) 65 (88%) 71 (82%)
Rheumatoid factor IgM positive, n (%) 58 (78%) 74 (85%)
Anti-CCP2 positive, n (%) 54 (73%) 71 (82%)
Erosive disease, n (%) 55 (74%) 69 (79%)
† For dichotomous variables, the number and the percentage of patients are listed, relative to the total 
number of RA patients for whom information about the characteristic under investigation was available. 





concordant discordant concordance (%) concordant discordant concordance (%)
RA 10 54 15.6 3 81 3.6
ACPA+ RA 8 38 17.4 3 65 4.4
ACPA- RA 2 16 11.1 0 16 0
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Heritability 
Heritabilities were estimated to quantify the extent to which genetic variation contributes 
to the development of disease, independent of the disease prevalence. For the logistic 
regression model as described in appendix A, the population prevalence of the disease or 
disease subsets was fixed to the specific population prevalence as reported in the United 
Kingdom 30, 31 or, if not available, in studies from other Caucasian populations 11, 32, 33 (Table 
3).
The overall heritability of RA is 66% with a 95% confidence interval (CI) of 44-75%. The 
same approach was used to model the outcome of ACPA-positive and ACPA-negative RA. 
As shown in Table 4, the heritability estimates for ACPA-positive and ACPA-negative RA 
are similar to the heritability of total RA. The heritability of ACPA-positive RA is 68% (95% 
CI: 55-79) and the heritability of ACPA-negative RA 66% (95% CI: 21-82%).
Contribution of HLA SE alleles
The HLA SE alleles have recently been shown to be specifically associated with ACPA-
positive RA 34. Therefore we set out to investigate if there is a difference in the extent 
to which the HLA SE alleles contribute to the genetic variance of ACPA-positive versus 
ACPA-negative RA. 
HLA-DRB1 typing was available for 142 twin pairs (96%). The HLA SE alleles were 
found to be preferentially associated with ACPA-positive RA. Specifically, 109 (109/123 
Table 4. heritability
Disease (subset)                    twin pairs (n) heritability
Total RA                                   148 66% (95% CI: 44-75%)
ACPA-positive RA                    114 68% (95% CI: 55-79%)
ACPA-negative RA                     34 66% (95% CI: 21-82%)
Table 3. Population prevalences used for heritability modeling
Characteristic Prevalence reference
Prevalence of RA 1% 32
Prevalence of ACPA-positive RA 0.67% 11
Prevalence of ACPA-negative RA 0.33% 11
Prevalence of ACPA in healthy controls 1% 33
Prevalence of SE in ACPA-positive RA patients 84% 30
Prevalence of SE in ACPA-negative RA patients 59%* *
Prevalence of SE in healthy controls 44% 31
The prevalence for each genotype was fixed to the specific population prevalence as reported in the United 
Kingdom 30,31 or, if not available from the UK, in studies from other Caucasian populations 11,32,33. * personal 
communication from the Welcome Trust Case Control Consortium, Jane Worthington
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= 89%) of patients with ACPA-positive RA carried one or two SE alleles, compared to 15 
(15/32 = 47%) of patients with ACPA-negative RA. The contribution of the HLA SE to RA in 
general, as well as to ACPA-positive and to ACPA-negative RA was estimated by including 
this genetic risk factor in the logistic regression model. The prevalence for each genotype 
was fixed to the specific population prevalence as reported in the United Kingdom 30, 31 or, 
if not available, in studies from other Caucasian populations 11, 32, 33 (Table 3). 
This analysis revealed that the contribution of HLA SE alleles to the total genetic vari-
ance of RA is 11% (CI 10-12%) (Table 5). In the ACPA-positive disease subset the HLA SE 
alleles contribute 18% (CI 16-19%), whereas they only contribute 2.4% (CI: 1.6-10%) to 
the heritability of ACPA-negative RA. 
DIsCussIon
The present study investigated the heritability of ACPA-positive and ACPA-negative RA. 
Data from a large RA twin cohort revealed a heritability for both disease subsets of ap-
proximately 66%. Furthermore, the contribution of the predisposing HLA SE alleles to 
ACPA-positive and ACPA-negative RA was assessed. While the HLA SE alleles contribute 
18% to the genetic variance of ACPA-positive RA, they contribute only 2.4% to the genetic 
variance of ACPA-negative RA. 
The heritability of ACPA-positive and ACPA-negative RA is similar despite the fact that 
the concordance of these two disease subsets differs. Both among mono- and dizygotic 
twins the concordance of ACPA-negative RA is lower than that of ACPA-positive RA. This 
can be explained by the fact that the concordance, which indicates how often a twin 
brother or sister of a patient is affected as well, is influenced by the prevalence of the 
disease in the population, whereas heritability is not. Concordance therefore reflects the 
prevalence of the disease in the population. Due to the fact that ACPA-negative RA is less 
prevalent than ACPA-positive RA the concordance of this disease subset is lower, despite 
similar heritability. 
The fact that the prevalence of the disease affects the concordance but not the heri-
tability also serves to explain the seeming discrepancy between the apparently modest 
monozygotic concordance of 16% and the heritability of 66% for RA. The concordance 
figure of 16% needs to be interpreted in light of the prevalence of RA which is only 1% 32. 
Table 5. Contribution of hlA se alleles to genetic variance
Disease (subset) twin pairs (n) Contribution of hlA se  alleles
Total RA 142 11% (95% CI: 10-12%)
ACPA-positive RA 113 18% (95% CI: 16-19%)
ACPA-negative RA 29 2.4% (95% CI: 1.6-10%)
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This indicates that genetic factors are important determinants for disease development and 
is compatible with a high heritability. 
The estimate of 66% (95% CI: 44-75%) for the overall heritability of RA is consistent with 
the results of a previous study that reported an overall heritability of 65% (95% CI: 50-77%) 
22. The previous report used the same twin cohort but a different modeling approach. Both 
models quantify the genetic and environmental contribution to a dichotomous variable 
by assuming that there is a continuous underlying liability to disease and that a threshold 
of liability divides subjects in affected with RA and unaffected. The previous study used a 
normal distribution for the liability while we used a logistic distribution. The advantage of 
a logistic distribution is that this model corresponds to the logistic regression model which 
is most commonly used for binary outcomes in epidemiology.
In twin studies, the variance of continuous traits, such as the underlying liability to dis-
ease, is often divided into variance due to environmental and due to genetic effects. In this 
paper, we estimated only additive genetic variances. Variance components for dominance 
genetic effects or for shared environmental effects can be added to this model, though 
it must be kept in mind that in twins these two effects are statistically confounded and 
cannot be added simultaneously to the same model. When a dominance genetic effect or 
a shared environmental effect was added to the model, we found that this determined less 
than 1% of the total variance of RA and of the ACPA-positive and ACPA-negative disease 
subsets. According to these data, dominance genetic effects or shared environmental fac-
tors do not appear to have a substantial effect on the development of RA. 
The modeling approach employed in this study uses the population prevalences of the 
genetic risk factors of interest to estimate their contribution to the genetic variance. To 
ensure the validity of our estimates we therefore used prevalence figures of the HLA SE 
alleles reported in large studies of RA patients. While the prevalence of HLA SE alleles in 
ACPA-positive RA as reported in the literature (84%) was in line with the number observed 
in the twin study population (89%), the prevalence of HLA SE alleles in the ACPA-negative 
twins was found to be lower than the figure observed in a large UK RA study (47% versus 
59%). To assess the impact of this discrepancy, the modeling was also performed with other 
assumed population prevalences, all of which consistently revealed a minor contribution 
of the HLA SE alleles to ACPA-negative RA. The results provided by the current modeling 
approach therefore appear to be valid irrespective of small uncertainties of prevalence 
figures. 
The HLA SE alleles are, to our current knowledge, the genetic risk factors which confer 
the highest risk for disease development 13. In the past, HLA genes have been estimated 
to contribute 37% to the overall inherited risk of developing RA 35. Our result that the 
contribution of the HLA SE alleles to the genetic variance is only 11% (95% CI: 10-12%) 
for RA and 18% (95% CI: 16-19%) for ACPA-positive RA may therefore be considered 
surprising. This difference may be due to the fact that the methods used to calculate the 
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contribution of the HLA SE alleles may not be completely comparable. Assuming that they 
are measuring similar parameters, a possible explanation for the difference could be that 
the contribution of SE was overestimated in the past due to the use of selected literature 
data for the calculation and weaknesses of the method of Rotter & Landaw, as indicated by 
Deighton et al. in the original publication 35. On the other hand, we cannot exclude that 
our figure of 11% contribution of HLA SE alleles to RA may represent an underestimate 
of the true value, due to the fact that the genotype-specific population prevalences which 
were required for our modeling, may vary among populations as discussed in the previous 
paragraph. Probably the most important explanation is however, the fact that a substantial 
part of the contribution of HLA to the genetic variance could be due to protective genetic 
factors 36 in addition to the predisposing SE alleles. While we deliberately only considered 
the predisposing SE alleles, Deighton et al used HLA haplotype sharing for their calcula-
tion, and thereby included the effect of protective HLA alleles, which may have resulted 
in a higher estimate. It is likely that further characterization of genetic risk factors, in 
particular the protective HLA-DRB1 alleles, and elucidation of interactions will be neces-
sary to fully understand the role of genetic risk factors in disease development. 
Recent genome wide association studies and candidate gene approaches have identified 
several new genetic risk factors for RA 2, 3. The majority of these genetic risk factors, such 
as PTPN22 and C5-TRAF1 have been shown to be predominantly associated with ACPA-
positive RA just like the HLA SE alleles 34, 37. This may partly be due to the fact that some of 
the larger studies have included mainly ACPA-positive patients. One cannot exclude that 
newer studies which incorporate a more extensive investigation of ACPA-negative RA will 
show that these risk factors also predispose to ACPA-negative RA 17.
At this moment however, the number of risk factors described to be preferentially asso-
ciated with ACPA-negative RA is smaller and to our knowledge restricted to the HLA-DR3 
haplotype and IRF5 14, 18. The latter risk factors however do not confer as high a risk 
for disease development as the HLA SE alleles. The observation that the heritability of 
ACPA-negative RA is similar to the heritability of ACPA-positive RA is therefore intrigu-
ing. This suggests that most genetic risk factors for ACPA-negative RA are still unknown 
and remain to be discovered. One reason why the description of genetic risk factors for 
ACPA-negative RA has not advanced at the same pace as for ACPA-positive RA, could be 
that ACPA-negative RA may be a more heterogeneous disease entity than ACPA-positive 
RA, with different phenotypes being associated with different genetic risk factors. Another 
explanation is that many of the cohorts which have been used for large-scale genetics 
studies have consisted solely of patients with ACPA-positive RA. Because ACPA-negative 
disease is less prevalent, it is also more challenging to find sufficient numbers of patients 
to perform a well-powered study. 
For the current study, the limited number of ACPA-negative twins also presented a statis-
tical restriction. This resulted in a larger confidence interval for the heritability estimate of 
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ACPA-negative RA as compared to that of ACPA-positive RA. Confirmation of these results 
would therefore be helpful to reach a definitive conclusion regarding the heritability of 
ACPA-negative RA.
In conclusion, ACPA-positive and ACPA-negative RA have a similar heritability of ap-
proximately 66%. This means that genetic predisposition also plays an important role 
in the pathogenesis of ACPA-negative RA, for which most individual genetic risk factors 
remain to be identified. 
APPenDIX A
Logistic regression model used to compute heritability.
We used a logistic regression model with a random effect to model the outcomes of twin 
pairs. With u corresponding to the random effect which represents all genetic factors that 
contribute to the outcome and y being 1 if a twin is affected and 0 if it is healthy, the 




Given the population prevalence p of the outcome and the genetic variance t2 (= the vari-
ance of the random effect u), the parameter α can be derived from the following equation :
p=∫ exp (α+u)  dFt2 (u)1+ exp (α+u)
 (2)
with F the normal distribution of u with mean zero and variance t2. Since u is not observed 
we integrate over its distribution F. Note that due to the non-linear relationship between 
the prevalence p and the genetic variance t2, the absolute value of the parameter α in-
creases with the genetic variance t2. This attenuation effect is well known from regression 
models which take into account errors in variables 28. 
Now given t2 and α, the log likelihood of the data is computed. Here (y1,y2) and (u1, 
u2) represent the pairs of outcomes and of random effects of a twin pair. The correlation 
of the random effects (u1,u2) is fixed at 1 if the twins are monozygotic and 1/2 if they are 
dizygotic. The log likelihood is then given by
l(y1y2 | α,t
2)=log ∫
exp(y1(α+u1)) exp(y2(α+u2))  dFt2 (u1,u2),1+ exp (α+u1) 1+ exp(α+u2)
 (3)
with F the bivariate normal distribution of (u1,u2). The above steps are carried out for a 
grid of values of t2 and the value t2 for which the curve has its maximum is the maximum 
likelihood estimate of the genetic variance. The heritability is now given by the genetic 
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variance (t2) divided by the total variance of the outcome (t2 +3). Here the value 3 cor-
responds to the variance of the logistic distribution 38.
APPenDIX b
Model used to compute the contribution of HLA SE to the total genetic variance.
The contribution of the HLA SE alleles to the total genetic variance of RA, of ACPA-
positive RA and of ACPA-negative RA is computed as follows. In an extension of the 
approach explained in appendix A, we used a logistic regression model which now 
not only estimates the genetic variance but also the amount of this variance which is 
explained by the HLA SE alleles. To take into account that the risk provided by the HLA 
SE alleles differs for the development of RA, ACPA-positive RA, and ACPA-negative RA, 
these varying genotype specific population prevalences were derived from Table 3 using 
Bayes’ theorem. The prevalences were subsequently entered into equation 2 to obtain the 
genotype specific α (αSE+ and α SE-) of the regression model. The variance of the contribu-
tion of SE to the outcome equals (αSE+-α SE-)
2 PSE (1-PSE), and this variance was then included 
in the logistic regression model alongside with the parameter for the genetic variance. In 
the logistic regression model including HLA SE, the variance of the random effect (n2) now 
measures the contribution of all remaining genetic factors besides HLA SE. Hence the part 
of the genetic variance explained by SE is given by the variance of the contribution of SE 
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AbsTrACT
objective Genetic factors explain 66% of susceptibility to rheumatoid arthritis, but it 
is unclear how much of this genetic risk can be explained by the genetic risk factors 
known to date. In addition to the contribution of the HLA shared epitope (SE) alleles 
which we have quantified previously, we now investigated the contribution of the protec-
tive HLA-DRB1*13 alleles and of 12 replicated single nucleotide polymorphisms (SNPs), 
to the genetic variance of total, anti-citrullinated protein antibody (ACPA)-positive and 
ACPA-negative RA. 
methods A cohort of 148 twin pairs, of which at least one twin had RA, were tested for 
ACPA. The contribution of the HLA-DRB1 alleles and SNPs to the genetic variance was 
assessed by a logistic regression model with genotype-specific parameters and a random 
effect model representing the contribution of unobserved genetic factors. 
results In the ACPA-positive subset, the HLA SE alleles contributed 19.2% to the genetic 
variance, while the contribution of the protective HLA-DRB1*13 alleles was very small: 
0.13%. Both SE and DRB1*13 alleles hardly contributed to ACPA-negative RA (1.52%). 
The contributions of the separate SNPs to the different subsets of RA were small with an 
average of below 1%. 
Conclusion A modest amount of the genetic variance of ACPA-positive, but not ACPA-
negative RA can be explained by the HLA SE alleles, while the contribution of the protec-
tive HLA-DRB1*13 alleles and non-HLA loci is very small. These results indicate that the 
largest part of the genetic contribution to RA remains unexplained.
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InTroDuCTIon
Rheumatoid arthritis (RA) affects approximately 0.5-1% of the population in western civi-
lizations 1 and investigations of factors which determine a person’s risk of developing RA 
have been ongoing since decades. Several risk factors for RA are now known, and these 
can be broadly classified as genetic or environmental risk factors. The relative importance 
of genetic and environmental risk factors can be investigated by estimating the heritability: 
the amount of disease variance which can be explained by genetic factors. The heritability 
of RA has consistently been reported to be approximately 66% 2, 3.
The hypotheses concerning how risk factors determine the development of RA have 
changed dramatically since the discovery of anti-citrullinated protein antibodies (ACPA) 4. 
Many of the risk factors for RA have now been found to be specific for either ACPA-positive 
or ACPA-negative RA. For example, the genetic risk factors which confer the highest risk 
of disease, the human leucocyte antigen (HLA) DRB1 shared epitope (SE) alleles, have 
been described to specifically predispose to autoantibody-positive, and most prominently 
ACPA-positive, disease 5, 6. This predilection for ACPA-positive RA has also been reported 
for the majority of the other genetic risk factors known to date 7. It was therefore surprising 
to discover that the heritability of ACPA-positive and ACPA-negative disease does not dif-
fer, and is 66% for both subsets of disease, as we have recently described 3. This suggests 
that many genetic risk factors for ACPA-negative RA remain to be discovered. Furthermore, 
the effect of the HLA SE alleles explained a relatively modest 18% of the genetic variance 
of ACPA-positive RA, raising the question which other genetic risk factors could account 
for the  “missing” 82% of the heritability.
A possible answer to this question may lie in genes which confer protection from de-
veloping RA. In a recent meta-analysis of HLA-DRB1 associations in 2800 RA patients 
and 3000 controls, the presence of HLA-DRB1*13 alleles was associated with a markedly 
lower risk of ACPA-positive disease 8. This protective effect was present in both SE-positive 
and SE-negative individuals, demonstrating that protection was not just due to the absence 
of predisposing effects, but was an independent phenomenon. Furthermore, the DRB1*13 
alleles were the only alleles with a significant protective effect, and the protection which 
had in the past been ascribed to alleles harboring a DERAA or D70, could be explained 
solely by the protective effect of the DRB1*13 alleles. Within the DRB1*13 alleles, es-
pecially DRB1*1301 was associated with protection and in light of the strength of this 
protective effect (OR= 0.24 - 0.50), it seems plausible that these protective alleles may 
contribute considerably to the heritability.
Another factor which may play a role in explaining the remaining genetic variance 
of RA, is the effect of non-HLA genes associated with single nucleotide polymorphisms 
(SNPs). As a result of recent genome-wide association studies (GWAS), several new SNPs 
have been described to be associated with RA 9 and although the effects of these SNPs by 
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themselves tend to be limited, the combined effect of several SNPs may nonetheless be 
substantial with regard to the genetic variance of the disease.
For these reasons, we wished to investigate to what extent protective HLA effects, in 
the form of DRB1*13, and the effect of 12 well-replicated SNPs associated with RA, 
contribute to the genetic variance of RA. Using genotype frequencies reported in large 
case-control studies, we applied quantitative genetic methods to data from a relatively 
large twin cohort to assess the effect of these genetic risk factors for RA in general, as well 
as for ACPA-positive and ACPA-negative disease. 
meThoDs
Study population
A nationwide study of twin pairs of which one or both had RA was performed in the 
United Kingdom in 1989 10. Twin pairs were eligible for inclusion if at least one twin 
fulfilled the 1987 revised ACR criteria 11. Blood samples were collected and zygosity 
status was verified by DNA fingerprinting on all same-sexed pairs using non-radioactive 
Southern blotting with a multilocus probe 12. SNP genotyping was not available for this 
twin cohort.
ACPA (Anti-CCP2) assays 
Total IgG anti-CCP2 was measured in serum samples by enzyme-linked immunosorbent 
assay (ELISA) (Immunoscan RA Mark 2; Eurodiagnostica, Arnhem, The Netherlands). 
Samples with a value above 25 units/ml were considered positive according to the manu-
facturer’s instructions. 
Statistical analysis
The contribution of the HLA genotypes and the 12 SNPs to the total genetic variance of RA, 
ACPA-positive and ACPA-negative RA was computed from the genotype frequencies avail-
able for Dutch and UK cohorts and the total genetic variance (t2) estimated previously 3. 
When investigating the genetic contribution of DRB1*13, it is important to take both 
DBR1*13 and SE alleles into account because these alleles are mutually exclusive at the 
HLA-DRB1 locus. All six possible genotype combinations of DRB1*13 (denoted as DR13) 
and SE therefore need to be taken into consideration (SE/SE, SE/x, x/x, DR13/x, DR13/
DR13 and SE/DR13, where x denotes genotypes which are neither SE nor DR13). In order 
to quantify the effect of SE and DRB1*13 alleles separately, the following dummy variables 
were defined:
X1 to measure the effect of 1 SE allele (assuming the value 1 for genotypes SE/x and SE/
DR13 and 0 for the other four genotypes),
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X2 measuring the effect of 2 SE alleles (value=1 for genotype SE/SE and 0 for the other 
five genotypes),
X3 measuring the effect of 1 DRB1*13 allele (value=1 for genotypes DR13/x and SE/
DR13 and 0 for the other four genotypes),
X4 measuring the effect of 2 DRB1*13 alleles (value=1 for genotype DR13/DR13 and 0 
for the other five genotypes).
We assumed the following logistic regression model for the relationship between the 















With Y = 1 for RA patients and Y=0 for controls, and ur is a Gausian random effect with 
zero mean and variance t2r
 which represents unmeasured genetic factors.
Previously we estimated the total genetic variance t2 by using model (1) without the 
genotypes (assuming β1, β2, β3, β4 = 03). t2  equals the sum of the genetic variance 
explained by HLA (var(G)) and the genetic variance explained by other genetic risk factors 
(t2r):
t2 = var(G)+ tr
2 (2)






For the genetic effect of HLA we considered the effect of the six genotypes on RA as 

























The variance terms in this equation can be computed from the genotype frequencies. The 
β* are the parameters of the random effects model (1) and they are related to the β of a 
standard logistic regression model without random effects (marginal model) by
β ≈ (0.346tr
2 +1)-½β* (4)
13. The β can be computed from the genotype frequencies in cases and controls and from 
the prevalence of RA.
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Given β and t2 and using the two equations given by formula (2) and (4), we can com-
pute t2r, β* and hence var(G). Note that var(G) in formula (2) is a function of β* as given 
by formula (3).
















The calculation of the genetic contribution of the separate SNPs was performed in a simi-
lar manner with the logistic regression formula (1) containing only 1 β and 1 X. Now X 
assumed the value 1 for genotypes containing 1 or 2 minor alleles.
All computations were performed in the freely available software environment for 
statistical computing R.
resulTs
Contribution of HLA-DRB1*13 and *1301 to the genetic variance
The study cohort consisted of 64 monozygotic and 84 dizygotic twin pairs from the United 
Kingdom (UK). The heritability modeling using twin pairs with at least one affected requires 
that the prevalence for each genotype be fixed to the specific population prevalence, in 
this case from the UK. Genotype data from 2914 RA patients, (1470 ACPA-positive, 723 
ACPA-negative RA patients and 721 RA patients without ACPA-status) and 1348 controls 
were used to calculate the HLA population prevalences listed in Table 1 (unpublished 
data received from Ann Morgan). Since four-digit HLA typing was not available for British 
controls, the effect of the HLA-DRB1*1301 alleles, which have been shown to be associ-
ated with the strongest protective effect, could not be assessed. The analysis was therefore 
Table 1. hlA population prevalences from the united kingdom used for modeling.
Prevalence of Population
All RA patients ACPA-positive ACPA-negative Controls
ACPA 67% 100% 0% 1%
HLA-DRB1
      SE/SE
      SE/x
      x/x
      *13/x
      *13/*13
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performed for the HLA-DRB1*13 alleles, which in meta-analysis were also associated 
with a significant protective effect.
Before performing the heritability analysis, we first investigated whether the protective 
effect of HLA-DRB1*13 on the risk of ACPA-positive RA was also present in the UK, 
based on the prevalences shown in Table 1. In order to correct for skewing due to the 
association between ACPA-positive RA and the SE alleles, the analysis was stratified for the 
SE alleles as described previously 8. There was no effect of DRB1*13 on the development 
of ACPA-positive RA in the SE-negative stratum (OR: 1.08, 95% CI: 0.74-1.58), while in 
the SE-positive stratum there was a trend towards a protective effect (OR: 0.72, 95% CI: 
0.50-1.04). As expected, there was no effect of DRB1*13 on the risk of developing ACPA-
negative RA (OR: 1.15, 95% CI: 0.90-1.47).
Although the effect of HLA-DRB1*13 in the UK was smaller than observed in a large 
European meta-analysis, this did not exclude a contribution of the HLA-DRB1*13 alleles 
to the genetic variance of RA. Using the genotype frequencies from the UK listed in Table 
1, we estimated the contribution of HLA-DRB1*13 to the genetic variance, while also 
taking into account the effect of the SE alleles. As shown in Table 2, the contribution of the 
HLA-DRB1*13 alleles to the genetic variance of total, ACPA-positive and ACPA-negative 
RA was very limited.
The fact that the combined contribution of SE and DRB1*13 is not equal to the sum 
of their separate contributions can be explained by the existence of covariance between 
the various genotypes, as described by the covariance term in formulas (4) and (5) in 
the Methods section. The figures for the contribution of the SE alleles differed slightly 
from the previously reported estimates 3, which is most likely due several factors: the 
statistical methods differed as described in the methods section, the current approach took 
both heterozygote and homozygote effects into account, used another reference category 
(no carriers of SE or DRB1*13 alleles) and was based on slightly different population 
prevalences.
The observation that the DRB1*13 alleles were not associated with a significant protec-
tive effect with regard to the risk of ACPA-positive RA in the UK, raised the question 
whether the contribution of the DRB1*13 alleles might have been larger in a population in 
which there was a strong effect of these alleles. To test this hypothesis, the contribution of 
DRB1*13 to the genetic variance of ACPA-positive RA was also assessed using population 
Table 2. Contribution of hlA se alleles and hlA-Drb1*13 alleles to the genetic variance.
se Drb1*13 Combined se and Drb1*13
Total rA 12.9% 0.1% 12.8%
ACPA-positive rA 19.2% 0.1% 19.6%
ACPA-negative rA 1.4% 0.4% 1.5%
Diana vd Woude BW.indd   75 19-01-12   11:37
76 Chapter 4
prevalences from the Netherlands where there is a strong protective effect of DRB1*13. 
Genotype prevalences shown in Table 3 were extracted from the Leiden Early Arthritis 
Clinic (EAC) and the BeSt trial, which together consisted of 844 RA patients, (492 ACPA-
positive and 352 ACPA-negative RA patients), as well as from a cohort of 1213 random 
healthy controls 8.
This however did not result in a larger contribution of DRB1*13 to the genetic variance. 
As shown in Table 4, the DRB1*13 alleles contributed merely 1.46% to the genetic variance 
of ACPA-positive RA. The increase in the combined estimate of the contribution of SE and 
DRB1*13 over the two separate contributions is due to the positive covariance inherently 
present between a predisposing (SE) effect and protective (DRB1*13) effect. For ACPA-
negative RA, the amount of explained genetic variance by the HLA alleles was very small 
and hardly increased by taking the effect of DRB1*13 into account. Since DRB1*1301 is 
the allele which is mainly responsible for the protective effect of DRB1*13, the analysis 
was repeated using the population prevalences of DRB1*1301 from the Netherlands. The 
resulting estimates were similar (data not shown), demonstrating that neither the DRB1*13 
nor the DRB1*1301 alleles explain a large part of the genetic variance of RA.
Contribution of SNPs to the genetic variance
Recent GWAS and meta-analyses of GWAS have revealed numerous SNPs to be associ-
ated with RA 7. For the current analysis, we assessed the effect of 12 SNPs which have been 
Table 3. Population prevalences from the netherlands (ref. 8) used for modeling.
Prevalence of Population
All RA patients ACPA-positive ACPA-negative Controls
































Table 4. Contribution of hlA se alleles and hlA-Drb1*13 alleles to the genetic variance assuming 
population prevalences from the netherlands.
se Drb1*13 Combined se and 
Drb1*13
Total rA 8.9% 0.9% 11.1%
ACPA-positive rA 13.5% 1.5% 17.0%
ACPA-negative rA 0.5% 0.3% 0.9%
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well-replicated, and of which data on the prevalence in the UK in RA patients and controls 
was available. The prevalence figures in the population of the United Kingdom which were 
used for the logistic regression model are listed in Table 5. If the prevalence figures were 
not directly reported in the literature, they were determined based on the reported odds 
ratio’s and patient numbers for the different RA subsets. For some of the SNPs (e.g. TRAF1-
C5, STAT4, IL2RB), the prevalence in the total RA patient population was not completely 
in line with the prevalence in the ACPA-positive and ACPA-negative subgroups. This is 
most likely due to the fact that the patient population used to determine the prevalence in 
all RA patients was much larger than the groups of ACPA-positive and ACPA-negative RA 
patients combined, thereby causing small discrepancies in the SNP prevalences.
Table 6 shows the calculated contribution of the SNPs to the genetic variance. The contri-
butions associated with the separate SNPs were small and, with the exception of PTPN22, 
were all well below 1%. If the effects of these SNPs were to be completely independent 
without interaction, then the addition of the contribution of the separate SNPs would give 
an impression of the total contribution of these SNPs. Assuming this to be the case, the 
12 SNPs would together explain 3.4% of the genetic variance of total RA. Although this 
calculation is not possible for the ACPA-positive and ACPA-negative subset due to the lack 
of subset-specific prevalences for some of the SNPs, it appears unlikely, based on Table 3, 
that these estimates would exceed 5% of the explained genetic variance of total RA. 
Table 5. minor allele frequencies reported in studies from the united kingdom used for modeling.
gene region of snP 
(uk reference)
Population
All RA patients ACPA-positive ACPA-negative Controls
PTPn22 (T allele) 23 15.0% 16.7% 12.1% 10.3%
TrAf1-C5 24 45.6% 45.5% 45.0% 43.8%
sTAT4 24 24.2% 24.7% 25.0% 21.7%
TnfAIP3-olIg3 25 25.1% 26.6% 23.2% 21.5%
CTlA4 26 43% - - 43.8%
CD40 27 22.6% 21.5% 24.5% 25.2%
mmel1-Tnfrsf14 17 29.4% - - 33.2%
kIf5A 28 34.2% 34.4% 33.9% 37.1%
PrkCQ 28 17.1% 16.6% 17.7% 19.5%
CCl21 27 36.5% 37.0% 33.6% 34.8%
Il2rA 29 24.4% - - 28.6%
Il2rb 28 28.4% 29.2% 29.1% 26.1%
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DIsCussIon
In the present study, we investigated to what extent the effects of protective HLA alleles 
and non-HLA SNPs contribute to the, thus far largely unexplained, genetic variance of RA. 
The DRB1*13 and *1301 alleles had only a small contribution  to ACPA-positive RA, and 
together with the HLA SE alleles explained 19.6% of the genetic variance of this subset 
of disease. Neither the HLA SE alleles nor the DRB1*13 alleles contributed substantially 
to the genetic variance of ACPA-negative RA, which was to be expected based on the fact 
that these alleles have not been found to confer a strong predisposing or protective effect 
for ACPA-negative RA 8. The effects of 12 well-replicated SNPs on the genetic variance of 
RA were very modest. Most SNPs explained far less than 1% of the genetic variance, and 
assuming independent effects, all SNPs combined would explain less than 5%.
The HLA-DRB1*13 alleles were not significantly associated with protection from ACPA-
positive RA in the UK, in contrast to the findings of a recent meta-analysis of case-control 
cohorts from Norway, Sweden, the Netherlands and Spain. While the allele frequency of 
DRB1*13 was similar in RA patients in the UK and the four populations contributing to 
the meta-analysis, the prevalence of these alleles in the UK controls used in the current 
report was 8%, compared to at least 14% in the controls from the other cohorts. The lack 
of effect in the UK may thus be due to a difference in population structure and distribution 
of HLA alleles in the general British population.
In light of the non-significant effect of the HLA-DRB1*13 alleles in the UK, it was not 
surprising that this did not result in a large contribution of DRB1*13 to the genetic vari-
Table 6. Contribution of snPs to the genetic variance.
Prevalence of Population
All RA patients ACPA-positive ACPA-negative
PTPn22 (T allele) 1.1% 1.5% 0.2%
TrAf1-C5 0.1% 0.1% 0.0%
sTAT4 0.2% 0.2% 0.3%
TnfAIP3-olIg3 0.4% 0.7% 0.1%
CTlA4 0.0% - -
CD40 0.2% 0.4% 0.0%
mmel1-Tnfrsf14 0.4% - -
kIf5A 0.2% 0.1% 0.2%
PrkCQ 0.2% 0.3% 0.1%
CCl21 0.1% 0.1% 0.0%
Il2rA 0.5% - -
Il2rb 0.2% 0.2% 0.2%
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ance. To investigate whether the DRB1*13 alleles might explain a larger part of the genetic 
variance of RA if they were associated with a stronger protective effect, the analysis was 
repeated in a hypothetical fashion assuming the Dutch prevalences for DRB1*13. Unex-
pectedly, this also did not result in a marked contribution of the HLA-DRB1*13 alleles to 
the genetic variance of ACPA-positive RA. 
The most likely explanation for the limited contribution of HLA-DRB1*13 is the low 
prevalence of these alleles. Despite the fact that the HLA-DRB1*13 alleles are more 
prevalent in the Netherlands than in the UK, an allele frequency of 14.8% in the healthy 
controls used in this study still places a considerable limit on the maximally achievable 
effect. The explanatory value of a genetic risk factor is ultimately dependent on both the 
associated effect size and the prevalence in the general population. In case of the other 
type of genetic risk factor investigated in the current study: the SNPs, the contribution to 
the genetic variance is most likely constrained by the modest effect sizes with which they 
are associated.
It is remarkable that there is a historic estimate of 37% contribution of HLA genes to 
the overall inherited risk of developing RA, as described by Deighton et al 14. Due to the 
haplotype sharing approach which was used in the study by Deighton, protective HLA 
effects were also taken into account and the resulting 37% reflects far more than the 
contribution of solely the SE alleles. A possible reason for the fact that this estimate is 
much larger than our figure could be that, besides the effect of SE and DRB1*1301 alleles, 
other effects may remain within the MHC region 15, 16, which were, perhaps unconsciously, 
also taken into account by the haplotype sharing approach.
The observation that 12 well-replicated SNPs had a relatively minor contribution to 
the genetic variance is in line with the results of a previous study which estimated that 
all non-MHC genetic variants (known at the end of 2008) would explain just 3.6% of the 
total disease variance 17. These results justify the conclusion that SNPs associated with 
moderate odds ratio’s probably have a very limited contribution to the genetic variance.
In order to calculate the contribution of the 12 SNPs to the total genetic variance, we 
used the genotypic specific population prevalences reported in the largest number of total 
RA, ACPA-positive and ACPA-negative patients. This resulted in slightly deviant estimates 
for STAT4 and IL2RB, since the reported prevalences for ACPA-positive and ACPA-negative 
RA patients were higher than for the total RA population. This inconsistency can be re-
solved as soon as data on larger cohorts become available, but the contribution of these 
SNPs to the genetic variance will nonetheless remain small.
The results of the current study improve our understanding of the relative importance of 
distinct genetic factors in developing RA. However, most of the genetic variance remains 
unexplained, and RA therefore still suffers from “missing heritability”, as do many other 
diseases 18. Where should one look for this missing heritability? It appears unlikely that 
other common variants (SNPs) with increasingly smaller odds ratio’s will have a large con-
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tribution, although one cannot exclude that the true causal genetic variants, which may 
be incompletely tagged by the current SNPs, may have a much stronger effect. Another 
possibility is that rare variants, with a low minor allele frequency precluding identification 
by the GWAS, could play an important role 19, 20. Such rare variants could very well have 
considerable odds ratio’s (> 2), and if in addition some of these variants were found to be 
inherited in a Mendelian fashion, a small number of families could thereby explain a large 
part of the genetic component of RA 21. 
Structural genomic variation, such as copy number variants (CNV), may contribute to 
the heritability, although recent data indicate that the SNP genotyping arrays used for the 
GWAS have captured most of the variability due to this trait 22. Another possibility is that 
interaction between different genetic factors may play an important role, although the 
latest reports indicate that there is no gene-gene interaction between the known genetic 
risk factors and the most recently identified SNPs 17. Similarly, gene-environment interac-
tion could be a contributing factor to the heritability, although it is unclear to what extent 
this would be reflected in the current heritability estimates. All of the factors listed above 
may play a part in determining an individual’s risk for RA. Future studies including large 
numbers of patients and controls, and using increasingly advanced techniques to study 
genetic variation will be required to shed more light on the causes of missing heritability.
In conclusion, the current data show that the HLA-DRB1*13 alleles do not substan-
tially contribute to the genetic variance of this RA subset. Similarly, the effect of 12 well-
replicated SNPs on the genetic variance of RA is small. Despite a substantial contribution 
of HLA, the largest part of the genetic risk for both ACPA-positive and ACPA-negative RA 
remains unexplained. 
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AbsTrACT
objective To evaluate the association between alcohol consumption and the risk of devel-
oping rheumatoid arthritis (RA) and other forms of arthritis.
methods Included were patients participating in the Leiden Early Arthritis Cohort with RA 
(n=651), other forms of arthritis (reactive arthritis, spondylarthropathy or psoriatic arthri 
tis, n=273), osteoarthritis (OA, n=73), as well as 5877 general population controls. Odds 
ratios were calculated by logistic regression analysis. Subgroup analysis was performed, 
stratified for antibodies to citrullinated peptide antigens (ACPA) status (n=257) compared 
to patients with other forms of arthritis (n=273). Subset analyses were performed on remis-
sion data and radiographic progression.
results Alcohol consumption was associated with a reduced risk of RA (OR 0.27 (95%CI 
0.22-0.34)), of other forms of arthritis (OR 0.34 (95%CI 0.24-0.48)) and OA (OR 0.31 
(95%CI 0.16-0.62)). The degree of systemic inflammation, reflected by the level of eryth-
rocyte sedimentation rate (ESR), was inversely associated with alcohol consumption. There 
was no dose-response relationship between the amount of alcohol consumed and the risk 
of arthritis. ACPA-positive RA patients reported less alcohol consumption than patients 
with other forms of arthritis (OR 0.59 (95%CI 0.36-0.99)). Adjustment for the ESR-level 
slightly changed this risk (OR 0.63 (95%CI 0.38-1.07)). No association between alcohol 
consumption and rate of joint destruction or remission was seen. 
Conclusion Arthritis patients report less alcohol consumption than controls, regardless of 
the type of arthritis. The largest part of this association is not specific for RA, but subgroup 
analysis shows that there may a particularly protective effect of alcohol consumption 
towards ACPA-positive RA. 
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InTroDuCTIon
Rheumatoid arthritis (RA) is a chronic, inflammatory disease which is characterized by 
persistent inflammation and joint destruction. It has previously been shown that envi-
ronmental risk factors such as smoking may interact with genetic factors in predisposing 
to the development of RA characterized by the presence of antibodies to citrullinated 
peptide antigens 1-5. Smoking habits and drinking habits are associated. It is of interest to 
evaluate the possible effect of alcohol consumption on the risk of developing RA. 
Several reports have suggested a compromising effect of ethanol on both innate and 
adaptive immunity 6, 7 with downregulation of proinflammatory cytokines and increase of 
anti-inflammatory cytokines 8-11. Moreover, experimental studies with collagen-induced 
arthritis in mice have shown an anti-inflammatory and anti-destructive effect of ethanol 
consumption by interaction with innate immune responsiveness 12.
The association between alcohol consumption and RA has been evaluated in several 
previous reports 13-17, but no definite conclusions could be drawn. Recently, a report 
comprising Swedish and Danish data on alcohol consumption in reference to develop-
ment of RA indicated that there may be a dose-dependent protective effect of alcohol 18. 
Our objective was to evaluate whether there is an inverse association between alcohol 
consumption and the risk of developing arthritis, and more specifically in relationship to 
the presence of RA with antibodies to citrullinated peptide antigens (ACPA). By inclusion 
of several arthritic case groups, we investigated whether the effect of alcohol is specific for 
RA. The latter has never been evaluated in previous studies. 
meThoDs
Patient and control population
We performed a case-control analysis in which cases were participants in the early 
arthritis cohort (EAC) from the Leiden University Medical Center, the Netherlands. This 
cohort consists of patients presenting with arthritis to the outpatient clinic, who were sub-
sequently diagnosed with various different forms of arthritis. Cases that were included in 
the analyses were recruited between February 1993 and December 2008 and were older 
than 18 years of age. Patients were diagnosed with RA according to the 1987 criteria of the 
American College of Rheumatology 19. Patients with other forms of arthritis were selected 
from the EAC cohort based on a definite diagnosis of reactive arthritis, spondylarthropathy, 
psoriatic arthritis or osteoarthritis (OA).
A total of 5877 non-arthritic controls were selected from the Multiple Environmental 
and Genetic Assessment of risk factors for venous thrombosis study (MEGA trial). This 
group consisted of patients with a first diagnosis of venous thrombosis. Between March 
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1999 and September 2004 patients were selected from files of the anticoagulation clinics 
in Amsterdam, Amersfoort, the Hague, Leiden, Rotterdam and Utrecht. This group has 
been described in detail elsewhere 20. A group of 3297 partners of patients with venous 
thrombosis were included in our study. From January 2002 to September 2004 an ad-
ditional number of 3000 random control subjects were recruited in the MEGA study and 
used in our study. Only control subjects with no recent history of venous thrombosis were 
included. Patients with severe psychiatric problems or those unable to speak Dutch were 
considered ineligible. All control subjects selected were older than 18 years of age. Both 
cohorts were approved by the medical ethical committee.
Data collection
Alcohol consumption was recorded at baseline, at first presentation to the outpatient 
clinic. In the EAC cohort, information on alcohol and smoking was initially obtained 
by means of an interview by a trained research nurse when patients first presented to 
the outpatient clinic. After December 2002, data were collected by self-administered 
questionnaires. A modified Stanford Health Assessment Questionnaire (HAQ) was filled in 
and the disease activity score in 44 joints was assessed (DAS44) 21.The control subjects in 
the MEGA trial were sent questionnaires to fill in at home. Cases and controls with missing 
data on alcohol consumption where excluded in our analyses. 
The questions asked about alcohol- and smoking habits in both cases and controls were 
comparable. Data on alcohol consumption were dichotomized as current or non-drinker. 
Additionally, the amount of alcohol consumption was categorized into four groups, based 
on the quartiles of percentages in the control population: non-drinkers; low consumption; 
moderate consumption and high consumption. The data on smoking were divided in cur-
rent/previous or non-smokers.
Statistical analysis
Statistical analysis was performed using SPSS version 16.0 (SPSS Inc, Chicago, Ill). To 
compare the distribution of baseline characteristics in the groups, Kruskal-Wallis-, 
Chi-square- and t-tests were performed. The effect of alcohol consumption on the risk 
of developing disease was analyzed by univariate and multivariate logistic regression. 
Relative risks are expressed as odds ratios with 95% confidence intervals based on the 
standard errors derived from the model. The latter analysis was adjusted for age, sex and 
body mass index (BMI) and smoking since these were possible confounders. Separate 
analyses were executed based on diagnosis, ACPA-status and the type of healthy con-
trol (partners vs random controls). Pearson’s chi-square test was used for analyzing the 
association between alcohol consumption and the level of erythrocyte sedimentation rate 
(ESR). P-values less than 0.05 were considered significant for all statistical tests. Subset 
analyses were performed on remission data and radiographic progression. Sustained 
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DMARD-free remission was defined as fulfilling the following criteria for at least one year: 
1) no current DMARD-use, 2) no swollen joints and 3) classification as remission by the 
patient’s rheumatologist 22. For remission data a Cox-regression analysis was performed. 
Data on radiographic progression with a follow-up duration of 7 years, were evaluated 
using a repeated measurement (linear multivariate regression) model 23, 24 corrected for 
smoking, ACPA-status, sex, age, HAQ, DAS44, delay (time between onset of symptoms 
and first visit to the outpatient clinic) and baseline Sharp-van der Heijde score. 
resulTs
Alcohol consumption and risk of RA and other forms of arthritis
A total of 651 RA patients, 346 patients with other forms of arthritis (273 patients with 
reactive arthritis, spondylarthropathy or psoriatic arthritis, 73 patients with osteoarthritis 
(OA)) and 5877 healthy controls were included. The baseline characteristics are shown 
in Table 1. Patients with RA or OA were older and more often female than patients with 
other forms of arthritis and the healthy controls. The BMI differed between the group of 













Age (in yrs), mean (sD) 56.5 (16) 64.0 (12) 44.4 (15) 47.3 (13) <0.001 
female gender, n (%) 435 (67) 56 (77) 123 (45) 3158 (54) <0.001 
bmI (in kg/m2), mean (sD) 25.9 (4) 26.4 (4) 25.7 (4) 25.6 (4) 0.018 
symptom duration (in months), 
mean (sD) 
6.8 (10) 9.1 (17) 5.8 (11) ---- <0.001 
esr (in mm/h), mean (sD) 39 (26) 22 (21) 34 (31) ---- <0.001 
ACPA-positive, n (%) 257 (54%) 3 (7%) # 15 (10%) # ---- <0.001 
* Spondylarthropathy, psoriatic arthritis, reactive arthritis: P-values are listed for the comparison between 
two cohorts, using t-tests for normally distributed continuous variables and Chi-square tests for dichotomous 
variables.
Age of RA patients vs healthy controls: p-value <0.001
Age of osteoarthritis patients vs healthy controls: p-value <0.001
Age of other arthritis patients vs healthy controls: p-value <0.001
Sex of RA patients vs healthy controls: p-value <0.001
Sex of osteoarthritis patients vs healthy controls: p-value <0.001
Sex of other arthritis patients vs healthy controls: p-value 0.005
BMI of RA patients vs healthy controls: p-value 0.058
BMI of osteoarthritis patients vs healthy controls: p-value 0.230
BMI of other arthritis patients vs healthy controls: p-value 0.650
# ACPA was measured in 43 of 73 osteoarthritis patients and 157 of the 273 “other arthritis” patients. 
Abbreviations: RA: rheumatoid arthritis, OA: osteoarthritis, BMI: body mass index.
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OA patients and the group of healthy subjects, therefore these possible confounders were 
included in subsequent multivariate analyses. 
Table 2 lists the number of patients and controls that reported drinking alcohol. Odds 
ratios (OR) were adjusted for age, sex, BMI and smoking due to the known association 
between smoking and drinking habits. This analysis shows a substantially reduced risk 
of all forms of arthritis associated with alcohol consumption. A subanalysis performed 
within in the group of cases included after December 2002 (when patients where given 
self-administered questionnaires), showed that the cited amount of alcohol consumption 
was not influenced by how the data on alcohol consumption were collected.
Dose-response relationship 
When alcohol consumption was stratified into different categories (non-drinkers; low 
consumption (more than 0 but less than 2 alcoholic beverages per week); moderate con-
sumption (2-14 alcoholic beverages per week); high consumption (more than 14 alcoholic 
beverages per week)) no dose-response relationship in the odds ratios related to the amount 
of alcohol consumption was found. For rheumatoid arthritis, odds ratios by amount of 
alcohol consumption relative to non-drinkers, were: low consumption: OR 0.12 (95%CI 
0.08-0.18), moderate OR 0.46 (95%CI 0.36-0.59), and high OR 0.17 (95%CI 0.12-0.25). 
For the other forms of arthritis the analyses yielded similar results (data not shown).
Effect of symptom duration on alcohol consumption
To investigate if a long symptom duration of arthritis prior to presentation might result in 
decreased alcohol consumption, we evaluated whether there was an association between 
symptom duration and alcohol consumption. To this end, the symptom duration at first 
presentation was divided into three categories based on cumulative tertiles (short (0-2.0 
months), medium (2.1-6.0 months), and long (>6.0 months)). For this analysis, patients 
with all different forms of arthritis were combined. There was no association between 




n = 5877, n (%)
or * 95% CI * p
rA, n=651 362 (56) 4901 (83) 0.27 0.22-0.34 <0.001
Total other arthritis n=273 175 (64) 4901 (83) 0.34 0.24-0.48 <0.001
• spA, n= 76 44 (58) 4901 (83) 0.34 0.17-0.67 0.002
• Arthr.Ps., n=130 89 (69) 4901 (83) 0.38 0.23-0.62 <0.001
• react. Arthr, n=67 42 (63) 4901 (83) 0.27 0.14-0.52 <0.001
osteoarthritis, n=73 39 (53) 4901 (83) 0.31 0.16-0.62 0.001
* 95% Confidence interval adjusted for age, sex, BMI, smoking
RA= rheumatoid arthritis, SpA= spondylarthropathy, Arthr. Ps.= psoriatic arthritis, React. Arthr.= reactive 
arthritis, BMI= body mass index, OR= odds ratio.
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sympton duration and the percentage of arthritis patients that reported drinking alcohol 
(short 62%, medium 53%, and long 60%)
Systemic inflammation and alcohol consumption
To examine if the inverse association between alcohol consumption and arthritis was 
related to the degree of inflammation, the presence of alcohol consumption was related 
to the level of systemic inflammation, as reflected by the level of the ESR (within the 
group of cases), and ESR was stratified into four groups. The level of the ESR was inversely 
correlated with alcohol consumption (p = <0.001) (Figure 1). 
We also evaluated whether there was an association between a subjective marker 
for disease activity, in the form of the visual analogue scale on general health and the 
reporting of drinking alcohol. In contrast to our findings with regard to ESR, there was no 
association between the level of general health and reporting of drinking alcohol. 
Reported alcohol consumption in ACPA-positive RA patients compared to other 
forms of arthritis
A recent population based case-control study of two Scandinavian cohorts showed that 
alcohol consumption is associated with attenuation of the effect of established risk factors 
for RA; smoking and HLA-DRB1 shared epitope with regard to ACPA-positive RA 18.
To investigate whether reported alcohol consumption may be particularly negatively 
associated with the development of RA compared to other arthritides, a subgroup analysis 
was performed comparing the RA patients stratified for ACPA-status, with the patients 
with other forms of arthritis (n=273). This revealed a particularly negative association in 
figure 1: Alcohol consumption by esr category.
Pearson test over all four categories <0.001
Comparison of ESR 2-16 vs ESR 17-31: p-value 0.090
ESR 2-16  vs ESR 32-53: p-value <0.001
ESR 2-16 vs ESR >54: p-value <0.001
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ACPA-positive RA patients (n=257) (OR 0.59, 95% CI: 0.36-0.99), compared to other 
forms of arthritis. Correction for the ESR-level slightly changed this risk (OR 0.63, 95% CI: 
0.38-1.07). No differences were observed between alcohol consumption and the risk of 
ACPA-negative RA relative to the other forms of arthritis (data not shown). 
Effect of alcohol consumption on radiographic progression and remission
To further investigate the negative association between the reported alcohol consumption and 
RA, we analyzed the effect of alcohol consumption on remission and radiographic progression. 
An increase in remission or decrease in radiographic progression would support the notion 
that alcohol might have an immunomodulatory effect in the process of inflammatory arthritis. 
To compare the progression in radiographic destruction over 7 years, the rate of progres-
sion was plotted within the four alcohol consumption categories (none, low/little, moder-
ate, high/substantial) (Figure 2). No significant association between alcohol consumption 
and rate of joint destruction over 7 years follow-up was found. 
With regard to remission, there was no association between alcohol consumption and 
the frequency with which RA patients achieved remission (data not shown).
DIsCussIon
This study shows that patients presenting with arthritis report less alcohol consumption 
than population controls, regardless of the type of arthritis. This may indicate a protective 
effect of alcohol on the development of arthritis, which is not specific for RA. Alternatively, 
it may be that patients stop drinking due to the presence of disease. 
There was no dose-response relationship with the amount of alcohol consumed. Other 
studies reported varying dose-response relationships within categories with low or moder-
figure 2: median joint destruction over 7 years in rA patients in four alcohol categories.
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ate25, 26 respectively high18 alcohol consumption. Thus it is at present difficult to draw any 
definitive conclusions about a possible dose-effect of alcohol consumption on the risk of RA. 
The inverse association between the ESR level and alcohol consumption shows that 
patients with more severe systemic inflammation report drinking less alcohol, or alterna-
tively, that alcohol may protect against the development of more systemic inflammation. 
This last hypothesis is supported by reports that have shown a suppressive effect of alcohol 
on the level of systemic inflammation 27, 28. Reports on alcohol use in other diseases with 
an inflammatory background have also shown a protective effect of alcohol consumption, 
which supports a more general role of alcohol in suppressing systemic inflammation 29, 30. 
Thus, the association between alcohol consumption and arthritis might be due to a more 
general effect of alcohol on systemic inflammation rather than a specific protective effect 
in RA. It could be postulated that patients suffering from any illness tend to drink less due 
to compromised general health. We evaluated the visual analogue scale on general health, 
as a subjective marker for disease activity, in relationship to alcohol consumption. There 
was no correlation between the level of general health and reporting of drinking alcohol. 
In the subgroup analysis investigating the association of ACPA with alcohol consump-
tion, there was an inverse association, suggesting that alcohol consumption may be 
particularly negatively associated with ACPA-positive RA. In order to further analyze the 
effect of alcohol consumption specifically for ACPA-positive RA, we performed a com-
bined analysis of our data and of previously published data from Sweden (the EIRA cohort) 
and Denmark (the COCORA cohort) comparing ACPA-positive to ACPA-negative patients.
This small “meta”-analysis yielded an OR 0.31 (95% CI 0.23-0.40), with a consistent 
protective effect seen in all cohorts. The analysis of all available data showed that the 
effect of alcohol was consistent in both the Dutch, the Swedish and the Danish cohort 
when controls were used that suffered from arthritis but that do not harbour antibodies 
to citrullinated antigens. These data are very relevant because they provide evidence 
that in addition to smoking, alcohol consumption is a risk factor that differs between 
ACPA-positive and ACPA-negative RA. These data support the concept that ACPA-positive 
disease is a different disease than ACPA-negative disease 31.
Källberg et al showed a more pronounced risk reduction with alcohol consumption 
among carriers of HLA-DRB1 shared epitope alleles than among non-carriers 18. In our 
study no association was found between the effect of alcohol consumption and the pres-
ence of the shared epitope within the ACPA-positive RA patients. 
If there was to be a real immunomodulatory effect of alcohol this would have effect 
on long-term phenotype such as rate of joint destruction or ability to achieve remission. 
Nissen et al 26 previously showed a J-shape relation between alcohol consumption and 
radiological progression; low alcohol consumption was most beneficial compared to no- 
and heavy consumption. We repeated this analysis (with similar adjustment variables) in 
our study, but did not find a significant association between alcohol consumption and rate 
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of joint destruction over 7 years of follow up. Although this could be due to lack of power 
in our analyses, no tendency toward reduced radiographic progression was observed. In 
our study merely baseline data on alcohol consumption were used in analyses addressing 
this topic, due to the strict advice to stop drinking alcohol in combination with the use 
of some DMARDs, such as methotrexate, thereby causing bias. In the study performed by 
Nissen et al both baseline and follow-up data on alcohol consumption where used in the 
analyses and subsequently have influenced the data on radiographic progression. 
It is unknown how long and in what way the immunomodulatory effect of alcohol will 
affect disease manifestation and the long-term disease course. Jonsson et al 12 showed that 
collagen induced arthritis remained non-destructive in mice that were provided with 10% 
ethanol in drinking water over a period of 6 weeks. The beneficial effects of ethanol might 
be mediated by up-regulation of testosterone production which in turn inhibits NF-κB 
activation leading to decreased cytokine/chemokine production (IL-6, MIP-1α, TNF-α) 
and decreased chemotactic activity of leukocytes. 
In contrast to the inhibitory effects of acute alcohol, prolonged alcohol treatment in mice 
results in augmentation of macrophage TNF-α production 32, and in increased expression 
of co-stimulatory molecules CD80 and CD86 on TLR9-activated CD11b-positive spleno-
cytes thereby contributing to systemic immunodysregulation including T-cell activation 33, 
34. Overall therefore, it is difficult to determine the immunomodulatory role of alcohol in 
the course of arthritis, based on the different outcomes of in vivo experiments in mice. 
One of the main comments on our study could be that the effect seen is being caused 
by recall bias. This means that cases might not actually have been drinking less alcohol 
but reported to be drinking less when faced with a questionnaire in the outpatient clinic, 
while the drinking behaviour was in fact unchanged. The questions asked in cases and 
general population controls were similar therefore minimising a major effect of recall bias 
35. The assumption that drinking behaviour may be influenced by the disease duration was 
not confirmed by our data.
In summary, this study suggests that patients presenting with arthritis report less alcohol 
consumption, regardless of the form of arthritis. This observation could be due to the fact 
that compromised general health leads to decreased alcohol consumption. The inverse 
association between alcohol and ESR might be related to the effect of alcohol on systemic 
inflammation rather than a protective effect specific for RA although our data also suggest 
that alcohol consumption may be particularly protective against ACPA-positive RA.
Diana vd Woude BW.indd   92 19-01-12   11:37
Protective effect of alcohol on RA development 93
referenCes
 1.  Kallberg H, Padyukov L, Plenge RM et al. Gene-gene and gene-environment interactions 
involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum 
Genet 2007;80(5):867-875.
 2.  Klareskog L, Stolt P, Lundberg K et al. A new model for an etiology of rheumatoid arthritis: 
smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens 
modified by citrullination. Arthritis Rheum 2006;54(1):38-46.
 3.  Linn-Rasker SP, van der Helm-van Mil AH, van Gaalen FA et al. Smoking is a risk factor 
for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared 
epitope alleles. Ann Rheum Dis 2006;65(3):366-371.
 4.  Lundstrom E, Kallberg H, Alfredsson L et al. Gene-environment interaction between the DRB1 
shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheuma-
toid arthritis: all alleles are important. Arthritis Rheum 2009;60(6):1597-1603.
 5.  Pedersen M, Jacobsen S, Garred P et al. Strong combined gene-environment effects in anti-
cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in 
Denmark. Arthritis Rheum 2007;56(5):1446-1453.
 6.  Szabo G, Mandrekar P. A recent perspective on alcohol, immunity, and host defense. Alcohol 
Clin Exp Res 2009;33(2):220-232.
 7.  Waldschmidt TJ, Cook RT, Kovacs EJ. Alcohol and inflammation and immune responses: sum-
mary of the 2006 Alcohol and Immunology Research Interest Group (AIRIG) meeting. Alcohol 
2008;42(2):137-142.
 8.  Mandrekar P, Catalano D, Szabo G. Inhibition of lipopolysaccharide-mediated NFkappaB 
activation by ethanol in human monocytes. Int Immunol 1999;11(11):1781-1790.
 9.  Mandrekar P, Catalano D, Dolganiuc A et al. Inhibition of myeloid dendritic cell accessory cell 
function and induction of T cell anergy by alcohol correlates with decreased IL-12 production. 
J Immunol 2004;173(5):3398-3407.
 10.  Pruett SB, Zheng Q, Fan R et al. Acute exposure to ethanol affects Toll-like receptor signaling 
and subsequent responses: an overview of recent studies. Alcohol 2004;33(3):235-239.
 11.  Verma BK, Fogarasi M, Szabo G. Down-regulation of tumor necrosis factor alpha activity by 
acute ethanol treatment in human peripheral blood monocytes. J Clin Immunol 1993;13(1):8-
22.
 12.  Jonsson IM, Verdrengh M, Brisslert M et al. Ethanol prevents development of destructive 
arthritis. Proc Natl Acad Sci U S A 2007;104(1):258-263.
 13.  Bergstrom U, Jacobsson L, Nilsson A et al. Smoking, low level of formal education, and 
infrequent alcohol consumption are independent predictors of rheumatoid arthritis. Arthritis 
Rheum. 56 (Suppl), S192. 2007. Abstract
 14.  Cerhan JR, Saag KG, Criswell LA et al. Blood transfusion, alcohol use, and anthropometric risk 
factors for rheumatoid arthritis in older women. J Rheumatol 2002;29(2):246-254.
 15.  Hazes JM, Dijkmans BA, Vandenbroucke JP et al. Lifestyle and the risk of rheumatoid arthritis: 
cigarette smoking and alcohol consumption. Ann Rheum Dis 1990;49(12):980-982.
 16.  Pedersen M, Jacobsen S, Klarlund M et al. Environmental risk factors differ between rheuma-
toid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis 
Res Ther 2006;8(4):R133.
 17.  Voigt LF, Koepsell TD, Nelson JL et al. Smoking, obesity, alcohol consumption, and the risk of 
rheumatoid arthritis. Epidemiology 1994;5(5):525-532.
Diana vd Woude BW.indd   93 19-01-12   11:37
94 Chapter 5
 18.  Kallberg H, Jacobsen S, Bengtsson C et al. Alcohol consumption is associated with decreased 
risk of rheumatoid arthritis: results from two Scandinavian case-control studies. Ann Rheum 
Dis 2009;68(2):222-227.
 19.  Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised 
criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31(3):315-324.
 20.  Pomp ER, le Cessie S, Rosendaal FR et al. Risk of venous thrombosis: obesity and its joint effect 
with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007;139(2):289-
296.
 21.  van der Heijde DM, van ‘t Hof MA, Van Riel PL et al. Judging disease activity in clinical 
practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann 
Rheum Dis 1990;49(11):916-920.
 22.  van der Woude D, Young A, Jayakumar K et al. Prevalence of and predictive factors for sus-
tained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results 
from two large early arthritis cohorts. Arthritis Rheum 2009;60(8):2262-2271.
 23.  Fitmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. Chapter 3. John Wiley & 
Sons; New York 2004.
 24.  Knevel R, Tsonaka R, le Cessie S. Comparison of methodology to analyze progression of joint 
destruction in rheumatoid arthritis. Submitted 2011.
 25.  Maxwell JR, Gowers IR, Moore DJ et al. Alcohol consumption is inversely associated with risk 
and severity of rheumatoid arthritis. Rheumatology (Oxford) 2010;49(11):2140-2146.
 26.  Nissen MJ, Gabay C, Scherer A et al. The effect of alcohol on radiographic progression in 
rheumatoid arthritis. Arthritis Rheum 2010;62(5):1265-1272.
 27.  Imhof A, Froehlich M, Brenner H et al. Effect of alcohol consumption on systemic markers of 
inflammation. Lancet 2001;357(9258):763-767.
 28.  Imhof A, Woodward M, Doering A et al. Overall alcohol intake, beer, wine, and systemic 
markers of inflammation in western Europe: results from three MONICA samples (Augsburg, 
Glasgow, Lille). Eur Heart J 2004;25(23):2092-2100.
 29.  Boyko EJ, Perera DR, Koepsell TD et al. Coffee and alcohol use and the risk of ulcerative 
colitis. Am J Gastroenterol 1989;84(5):530-534.
 30.  Nakamura Y, Labarthe DR. A case-control study of ulcerative colitis with relation to smoking 
habits and alcohol consumption in Japan. Am J Epidemiol 1994;140(10):902-911.
 31.  van der Helm-van Mil AH, Huizinga TW, de Vries RR et al. Emerging patterns of risk factor 
make-up enable subclassification of rheumatoid arthritis. Arthritis Rheum 2007;56(6):1728-
1735.
 32.  Kishore R, McMullen MR, Cocuzzi E et al. Lipopolysaccharide-mediated signal transduction: 
Stabilization of TNF-alpha mRNA contributes to increased lipopolysaccharide-stimulated 
TNF-alpha production by Kupffer cells after chronic ethanol feeding. Comp Hepatol 2004;3 
Suppl 1:S31.
 33.  Cook RT, Zhu X, Coleman RA et al. T-cell activation after chronic ethanol ingestion in mice. 
Alcohol 2004;33(3):175-181.
 34.  Zhu X, Coleman RA, Alber C et al. Chronic ethanol ingestion by mice increases expression of 
CD80 and CD86 by activated macrophages. Alcohol 2004;32(2):91-100.
 35.  Embree BG, Whitehead PC. Validity and reliability of self-reported drinking behavior: dealing 
with the problem of response bias. J Stud Alcohol 1993;54(3):334-344.
Diana vd Woude BW.indd   94 19-01-12   11:37
Diana vd Woude BW.indd   95 19-01-12   11:37
Diana vd Woude BW.indd   96 19-01-12   11:37
Part II
Characteristics of ACPA
Diana vd Woude BW.indd   97 19-01-12   11:37
Diana vd Woude BW.indd   98 19-01-12   11:37
 Chapter 6
glycan profi ling of anti-
citrullinated protein antibodies 
isolated from human 
serum and synovial fl uid
Hans U. Scherer, Diane van der Woude, Andreea 
Ioan-Facsinay, Hanane el Bannoudi, Leendert 
A. Trouw, Carolien A.M. Koeleman, Jun Wang, 
Thomas Häupl, Gerd-R. Burmester, André M. 
Deelder, Tom W.J. Huizinga, Manfred Wuhrer 
and René E.M. Toes
Arthritis and Rheumatism. 2010 June; 62(6): 1620-9
Diana vd Woude BW.indd   99 19-01-12   11:37
100 Chapter 6
AbsTrACT
objective Anti-citrullinated protein antibodies (ACPA) exhibit unique specificity for RA. 
Whether and how ACPA contribute to disease pathogenesis, however, is incompletely 
understood. The Fc part of human IgG carries two N-linked glycan moieties which are 
crucial for the structural stability of the antibody and modulate its binding affinity to Fcγ 
receptors and its ability to activate complement. We have purified ACPA from serum and 
synovial fluid and analyzed Fc glycosylation profiles in a specific manner.
methods ACPA were isolated by affinity purification using cyclic citrullinated peptides as 
antigen. IgG1 Fc glycosylation was analyzed by mass spectrometry. ACPA glycan profiles 
were compared to glycan profiles of total serum IgG1 obtained from 85 well-characterised 
patients. Glycan profiles of paired synovial fluid and serum samples were available from 
11 additional patients.
results Compared to the pool of serum IgG1, ACPA IgG1 lack terminal sialic acid residues. 
In synovial fluid, ACPA are highly agalactosylated and lack sialic acid residues, a feature 
that was not detected for total IgG1 in synovial fluid. Moreover, differential ACPA glycan 
profiles were detected in RF-positive versus -negative patients.
Conclusion ACPA IgG1 exhibit a specific Fc-linked glycan profile which is distinct from 
total serum IgG1. Moreover, Fc glycosylation of ACPA differs markedly between synovial 
fluid and serum. As Fc glycosylation directly affects the recruitment of Fc-mediated effec-
tor mechanisms, these data could further our understanding of the contribution of ACPA 
to disease pathogenesis.
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InTroDuCTIon
Antibodies relevant to tissue pathology in autoimmune diseases are identified based on 
antigen binding specificity of the variable region. Only very few autoantibodies, however, 
mediate pathology by direct interaction with the antigen. In most other cases, the constant 
region (Fc part) determines antibody-mediated effector functions such as complement 
activation, antibody-dependent cellular cytotoxicity (ADCC) and engagement of activat-
ing or inhibitory Fc receptors. These Fc-mediated effects are influenced by the Fc part’s 
amino acid sequence (i.e. antibody isotype and sub-class) and by Fc-linked carbohydrate 
structures. The latter are located in the Cγ2 domain of the heavy chain in close vicinity 
to amino acids that interact with Fc receptors and the complement system. Accordingly, 
Fc-linked carbohydrate structures have recently received increasing attention, as modifi-
cation of Fc-linked glycan residues of therapeutic antibodies has been shown to strongly 
influence the antibodies’ therapeutic potential 1-6. 
The Fc part of human immunoglobulin G (IgG) carries two N-linked, highly heteroge-
neous glycan moieties interposed between the heavy chains. These carbohydrate structures 
are crucial for the stability of the antibody and influence its biological activity 7-9. Attached 
to amino acid Asn297 of each heavy chain is a conserved, biantennary glycan backbone of 
N-acetylglucosamine (GlcNAc) and mannose residues, which is modified by core fucose, 
additional N-acetylglucosamine, galactose and terminating sialic acid residues to yield a 
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figure 1A: Schematic depiction of a monosialylated glycan chain linked to Asn297 of the IgG heavy chain and 
legend for symbols used in this manuscript.
The dotted line indicates the conserved sequence of glycan residues. An additional sialic acid residue can be 
attached to the second galactose residue, and an additional N-acetylglucosamine residue (‘bisecting GlcNAc’) 
to the central mannose (not depicted). 
figure 1b, 1C: Typical mass-spectrometry profiles of IgG1 tryptic glycopeptides obtained after isolation of 
ACPA from serum (B) and synovial fluid (C). Sum mass spectra of the elution range of the IgG1 glycopeptides 
with neutral glycans are shown 34. pep = peptide moiety; m/z = mass/charge.
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presence or absence of galactoses, so called G0 (no galactose), G1 (one galactose) and 
G2 (two galactoses) glycoforms, which make up around 20-35%, 35% and 16% of all IgG 
Fc-linked glycoforms in healthy subjects, respectively 7. Lack of galactose residues results 
in a concomitant lack of terminal sialic acid residues and increases the affinity for activat-
ing Fcgamma receptors (FcγR) 10, 11. In contrast, presence of the fully processed glycan 
structure terminating in sialic acid residues has anti-inflammatory effects 1, 3. Presence of 
an additional, bisecting GlcNAc residue and absence of core fucose residues was found 
to enhance ADCC through high-avidity interaction with FcγRIIIa 5, 12-14. Hydrolysis of the 
entire glycan backbone by glycosidase treatment or mutational deletion of the entire 
Asn297 N-linked glycosylation site leads to a change of the Fc part’s quartenary structure. 
This yields a non-immunogenic antibody unable to interact with FcγR and, consequently, 
to elicit significant cytokine release 2, 6, 8. Of interest, immune complexes containing such 
aglycosylated IgG fail to be eliminated rapidly from the circulation 15.
In line with these structural observations, both human and murine studies indicate a 
strong impact of Fc-linked glycan variants on the pathogenic potential of IgG antibodies 
in inflammatory disorders such as rheumatoid arthritis. Early studies have demonstrated 
a predominance of IgG-G0 glycoforms in sera of RA patients that correlates with disease 
activity and reverses to normal levels in patients who undergo (spontaneous) remission 
16-19. Removal of galactose residues from murine IgG by β-galactosidase treatment resulted 
in increased arthritogenicity of transferred IgG in a murine arthritis serum transfer model 
20. Likewise, pregnancy-induced remission in the pristane-induced arthritis model was 
paralleled by a decrease of IgG-G0 glycoforms, while the postpartum period was accom-
panied by a respective increase in agalactosylated glycoforms 21. While these studies have 
narrowed the focus on the presence or absence of galactose residues, more recent studies 
indicate that not a lack of galactose residues itself, but rather the concomitant absence of 
terminal sialic acid residues may be responsible for the enhanced inflammatory activity 
exerted by G0 glycoforms 1, 3. Indeed, a receptor specifically recognizing IgG Fc-linked 
sialic acid residues has newly been described on a population of murine regulatory 
splenic macrophages, a cellular subset that may be involved in downregulation of inflam-
matory responses 22. While these latter findings await confirmation in the human system, 
relevance of sialic acid residues for modulating immune responses is demonstrated by the 
finding that intravenous immunoglobulin preparations (IVIG) completely lose their immu-
nosuppressive capacity upon removal of sialic acid residues by neuraminidase treatment 1, 
3. Together, these findings underline the importance of IgG Fc-linked glycan structures for 
antibody-mediated inflammatory responses.
Anti-citrullinated protein antibodies (ACPA) are highly specific autoantibodies for a 
subgroup of rheumatoid arthritis patients that suffer from severe erosive disease. A body 
of evidence points to a crucial role for ACPA in disease pathogenesis, but the pathogenic 
potential of ACPA and the mechanism by which ACPA could cause tissue pathology are 
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ill-defined. ACPA are present in serum years before the onset of clinical symptoms, ACPA 
production has been detected in synovial membrane explants, and increased ACPA levels 
were found in synovial fluid as compared to serum 23-25. ACPA-positive RA patients suffer 
from more severe disease than patients without a citrulline-specific immune response, 
and presence of ACPA favours the development of overt RA in patients with undifferenti-
ated arthritis 26-29. Intriguingly, however, ACPA levels do not or only moderately correlate 
with disease activity, and depletion of CD20+ B cells improves clinical symptoms while 
ACPA levels are only moderately affected 30, 31. The observation that ACPA can be present 
without signs of inflammation, both before and during disease, raises the possibility that 
the quality rather than the quantity of the ACPA immune response influences disease. So 
far, studies have focussed on ACPA fine specificity and isotype usage, but data on ACPA 
Fc-linked glycan residues have not been obtained. In light of the strong influence of Fc-
linked glycans on the inflammatory potential of antibodies, we have recently developed 
a technique that allows analysis of Fc-linked glycans in an antigen specific manner 32. 
We have now used this technique to analyze Fc glycosylation of IgG1-ACPA in serum 
and synovial fluid of early arthritis patients in order to further characterize the immune 
response to citrullinated antigens.
PATIenTs AnD meThoDs
Serum and synovial fluid samples
Serum samples of 85 clinically well-defined, ACPA-positive arthritis patients participating 
in the Leiden Early Arthritis Clinic (EAC) were collected following informed consent of 
study participants and study-approval by the local institutional review board. The Leiden 
EAC is a population-based inception cohort that includes patients with self-reported 
symptom duration of ≤ 2 years 33.
Paired serum and synovial fluid samples were collected from 11 additional ACPA-
positive rheumatoid arthritis patients. 7 samples originated from the outpatient clinic of 
the Department of Rheumatology and Clinical Immunology at Charité Hospital in Berlin 
(Germany), 4 samples were collected at the respective outpatient clinic of the Department 
of Rheumatology of Leiden University Medical Center (The Netherlands). 
ACPA positivity was determined based on reactivity of sera against a second genera-
tion cyclic citrullinated peptide (CCP2) in a commercially available ELISA system (Im-
munoscan RA Mark 2; Euro-Diagnostica, Arnhem, The Netherlands). Serum and synovial 
fluid samples were aliquoted and stored at -80°C until further use.
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Isolation of ACPA and total IgG from serum and synovial fluid samples
ACPA were isolated from total human serum and synovial fluid as previously described 
32. In brief, sera and synovial fluid samples were incubated in CCP2-coated ELISA plates 
(Immunoscan RA Mark 2; Euro-Diagnostica, Arnhem, The Netherlands) for 1 hour at 37°C. 
Supernatants were discarded and plates were washed thoroughly. Bound antibodies were 
eluted from the plates by adding 100mM formic acid (pro analysi for mass spectroscopy; 
Merck Darmstadt, Germany) for 15 minutes at room temperature. Eluates were collected 
in 96-well V-bottom plates, dried in a vacuum centrifuge and subjected to tryptic digest 
by adding 200ng trypsin (sequencing grade; Promega, Leiden, The Netherlands) in 40µl 
ammonium bicarbonate to each well followed by incubation at 37°C overnight. Digested 
samples were stored at -20°C until further use. Purity of eluted ACPA was verified by 
subjecting ACPA-negative control sera to the same isolation procedure. Non-trypsinized 
eluates of ACPA-negative samples were tested for the presence of human IgG by ELISA. 
None of the ACPA-negative eluates contained detectable amounts of IgG, indicating that 
only citrulline-specific IgG-molecules were eluted from the CCP2-plates (data not shown; 
for methodological details see 32).
Purification of total IgG was achieved by incubating serum or synovial fluid samples 
with Protein A-sepharose beads (GE Healthcare, Eindhoven, The Netherlands) in 96-well 
filter plates (Multiscreen Solvinert, 0.45 µm pore-size low-binding hydrophilic PTFE; Mil-
lipore, Billerica, MA) on a shaker for 1 hour. Beads were thoroughly washed and bound 
IgG-molecules (IgG1, IgG2 and IgG4) were eluted into a 96-well V-bottom plate using 
100mM formic acid. Samples were dried by vacuum centrifugation, digested with trypsin 
and stored at -20°C until further use 32, 34. 
Fc glycoslylation analysis
Analysis of Fc-linked N-glycans was performed as previously described 32, 34. In brief, 
trypsinized samples obtained from the ACPA and total serum IgG isolation procedures 
were applied to an RP column (C18 PepMap 100 Å, 3 µm, 75 µm x 150 mm; Dionex/
LC Packings, Amsterdam, The Netherlands) using an Ultimate3000 nanoLC (Dionex/
LC Packings). The LC system was coupled via an online nanospray source to an Esquire 
HCTultra ESI-IT-mass spectrometer (Bruker Daltonics, Bremen, Germany) equipped with 
an electron transfer dissociation module (PTM Discovery System™) and was operated 
in the positive ion mode. Ions from mass/charge (m/z) 600 to m/z 1800 were registered. 
The high-performance liquid chromatography method resulted in resolution of the glyco-
peptides based on the peptide moiety, with IgG1 glycopeptides eluting first, followed by 
IgG4 and IgG2 glycopeptides. Glycopeptides with neutral glycan moieties tended to elute 
earlier than glycopeptides with antenna sialylation. Average mass spectra were generated 
over a 1-minute elution range for both the neutral and the acidic glycopeptides of each 
IgG subclass. 
Diana vd Woude BW.indd   104 19-01-12   11:37
Glycan profiling of ACPA 105
As the most frequent isotype in ACPA-positive RA patients is IgG1, only IgG1 Fc-linked 
N-glycans were analyzed in this study. Furthermore, it is important to note that also the 
Fab-fragment of IgG-molecules can carry N-glycans 35. Most previous studies have ana-
lyzed N-glycans released enzymatically from total human serum IgG, which results in 
a mixture of both Fc-linked and Fab-linked N-glycans. However, Fab-linked glycoforms 
can differ considerably from Fc-linked N-glycans, and vary between IgG subclasses 
36. In our approach, the specific mass of the Fc peptide portion obtained after tryptic 
cleavage of the IgG molecule allows to exclusively analyze Fc-linked N-glycans, whilst 
Fab-linked glycopeptides exhibit a heterogeneous group of signals that do not interfere 
with Fc glycosylation analysis at the glycopeptide level. Due to the exclusive analysis 
of Fc-linked N-glycans, the total number of glycoforms detected was lower than that of 
previous reports, and some glycoforms were not detected at all.
Statistical analysis
In order to account for measurement variability, the relative peak intensity of the glycoform 
containing one galactose residue (G1) identified by mass spectrometry was deliberately set 
at 1, and peak intensities of all other glycoforms were normalized accordingly. Frequen-
cies of individual glycoforms are reported as percent of the total number of detectable 
glycoforms based on this normalization procedure. Differences in frequencies of glyco-
forms obtained from different samples were evaluated for statistical significance using 
the non-parametric Kruskal-Wallis test (in case of unpaired samples) followed by Dunn’s 
post hoc test to adjust for errors introduced by multiple testing. Dunn’s test generalizes 
the Bonferroni adjustment procedure for multiple testing to maintain the probability of a 
type-I error at ≤ 5%. For glycoforms of paired serum/synovial fluid samples, groups were 
compared using the non-parametric Mann-Whitney rank-sum test. This is indicated where 
appropriate. P-values <0.05 were considered statistically significant. Data were analyzed 
using SPSS version 16.0.2 and GraphPad Prism Software 4.0.
resulTs
Fc-linked galactosylation of ACPA IgG1 isolated from human serum
Specific Fc glycosylation profiles of ACPA IgG1 and respective profiles of total serum IgG1 
were obtained from 85 ACPA-positive Dutch early arthritis patients (mean age 52.6 ± 14.4 
years; 69.4% female). Based on previous observations reporting a predominance of aga-
lactosylated glycoforms in patients with rheumatoid arthritis, we first analyzed frequen-
cies of IgG1 Fc-linked galactose residues (Figure 2). A median of 25.4% (IQR 19.8-32.3) 
of serum IgG1 molecules were found to lack galactose residues, consistent with previous 
reports (Figure 2A) 17. ACPA IgG1 contained slightly higher frequencies of G0-glycoforms 
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as compared to total serum IgG1 (29.8% (IQR 20.9-38.8)), a nominal difference that did 
not remain significant after correction for multiple testing. Almost two thirds (62.4%) of 
patients carried ACPA IgG1 that exhibited higher G0-frequencies than their respective 
serum IgG1. Patients of whom these ACPA were isolated did not differ significantly in age 
(data not shown), but did have slightly higher ESR than those with ACPA G0-frequencies 
below those of serum IgG1 (median ESR 32.0 mm/1h (IQR 21.5 - 65.0) vs. 24.5 (IQR 
15.5 - 40), p = 0.06). This is in line with a linear correlation between the frequency 
of ACPA G0-glycoforms and ESR (Spearman ρ = 0.54; p<0.0001; Figure 2B). A similar 
correlation, although weaker, was found for G0-glycoforms of serum IgG1 (Spearman ρ = 
0.38; p<0.0003) and has been reported previously 18. Importantly, the frequency of ACPA 
G0-glycoforms did not correlate with ACPA-titres (p = 0.28; data not shown). Furthermore, 
no significant difference was noted between ACPA IgG1 and total serum IgG1 with respect 
to the presence of G1- or G2-glycoforms. Taken together, we observed a trend towards 
more agalactosylated glycoforms on ACPA IgG1 than on serum IgG1 that did not reach 
statistical significance at the available sample size.
ACPA-specific Fc-linked sialylation and fucosylation patterns
Given the reported impact of sialic acid and core fucose residues on the biological activity 
of antibodies, we next determined the frequency of IgG1 Fc-linked terminal sialic acid and 
core fucose residues (Figures 3 & 4). Absence of sialic acid residues increases the affinity 
for activating FcγR, while presence of sialic acid accounts for anti-inflammatory effects, as 
has been shown for IVIG 3, 11. The frequency of sialic acid residues attached to ACPA IgG1 
was found to be significantly reduced as compared to serum IgG1 for both G1- (Figure 3A; 
ACPA median 1.73% (IQR 1.36-2.16), serum median 2.16% (IQR 1.94-2.53); p<0.001) 
and G2-glycoforms (Figure 3B; ACPA median 5.47% (IQR 3.94-8.96), serum median 
Figure 2
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figure 2: fc galactosylation of ACPA Igg1 and serum Igg1. 
figure 2A: Frequencies of G0 (no galactose), G1 (1 galactose) and G2 (2 galactoses) glycoforms for ACPA 
IgG1 and serum IgG1 as the percentage of all detected glycoforms. Horizontal lines indicate the medians.
figure 2b: Correlation between the frequency of ACPA-G0 glycoforms and erythrocyte sedimentation rate 
(ESR). Dashed lines represent the 95% confidence interval of the linear regression (solid line). ns = not 
significant.
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7.43% (5.82-10.44); p<0.001). As terminal sialic acid residues require galactose residues 
for linkage, sialic acid can only be detected on G1- or G2-, but not on G0-glycoforms. We 
did not detect glycoforms carrying two sialic acid residues in our samples. 
Fucosylation strongly influences ADCC by modulating the Fc part’s binding avidity to 
FcγRIIIa. In the absence of core fucose residues ADCC is significantly increased 13, 14, 37. 
The vast majority of IgG1-antibodies analyzed here contained core fucose residues with 
no significant overall difference between ACPA IgG1 and total serum IgG1 (Figure 4; ACPA 
median 93.9% (IQR 92.5-95.3); serum median 94.0% (IQR 92.1-94.9), p=0.66).
Overall, these data indicate that the glycosylation profile of ACPA IgG1 differs consider-
ably from total serum IgG1 in the degree of sialylation. 
Fc-linked glycosylation of ACPA isolated from synovial fluid
RA is primarily characterized by synovial inflammation and progressive joint destruction. 
ACPA are thought to be involved in this process. However, the origin of ACPA circulating 
in serum is still unknown, and it remains to be determined to what extent serum ACPA 
contribute to synovial inflammation in the joint. In fact, ACPA titres in synovial fluid (SF) 

























figure 3: ACPA-specific fc-linked sialylation patterns. Frequencies of monosialylated G1- (A) and G2-
glycoforms (B) for both ACPA IgG1 and serum IgG1. No Fc-linked disialylated glycoforms were detected. 










figure 4: ACPA-specific fc-linked fucosylation patterns. Overall frequency of fucosylated ACPA IgG1 
glycoforms (G0+G1+G2) versus fucosylated serum IgG1 glycoforms (G0+G1+G2). Horizontal lines indicate 
the medians.
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ated locally by plasma cells within the synovial membrane 24. So far, however, qualitative 
differences between serum ACPA and ACPA in SF have not been determined. In order to 
investigate whether Fc glycosylation differs between ACPA in SF and ACPA circulating in 
serum, we isolated ACPA from serum and synovial fluid of 11 paired samples. ACPA IgG1 
glycosylation profiles were compared to profiles of total IgG1 isolated from the same com-
partments. In contrast to ACPA in serum, ACPA isolated from SF were found to be highly 
agalactosylated (Figure 5A; serum-ACPA: G0 median 27.4% (IQR 21.7-37.6), SF-ACPA: 
G0 median 47.0% (IQR 34.9-60.1), Mann-Whitney p = 0.008). This finding was specific 
for ACPA IgG1, as no such predominance of G0-glycoforms was observed for the pool 
of total synovial fluid IgG1 (Figure 5B; serum IgG1: G0 median 27.5% (IQR 15.6-35.0); 
SF-IgG1: G0 median 31.4% (IQR 17.6-43.2), Mann-Whitney p = 0.5). Increased frequen-
































































































































































figure 5: ACPA-specific fc glycosylation in serum versus synovial fluid. 
figure 5A and 5b: G0-, G1- and G2-glycoforms of ACPA IgG1 (A) and total serum IgG1 (B) isolated from 11 
paired samples of serum and synovial fluid of. Horizontal lines indicate the medians.
figure 5C: ACPA IgG1 and total serum IgG1 G0-frequencies in serum and synovial fluid from each individual 
patient. Significance levels were determined by comparing individual groups using the non-parametric 
Mann-Whitney rank sum test. 
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all 11 patients analyzed (Figure 5C). In contrast, G0-frequencies of total synovial fluid 
IgG1 were higher than in serum for some patients, but lower in others. Due to the lack of 
galactose residues, SF-ACPA also exhibited a significantly lower degree of sialylation (data 
not shown). All glycoforms examined in SF exhibited a high degree of fucosylation (up 
to 100%) with no significant difference between ACPA and total IgG1 (data not shown). 
In summary, ACPA IgG1 in synovial fluid differ from ACPA IgG1 in serum in terms of 
Fc glycosylation. Synovial fluid ACPA are highly agalactosylated and lack terminal sialic 
acid residues. This differential glycan profile appears to be a specific feature of ACPA, as 
no significant difference in Fc glycosylation was observed for total IgG1 isolated from the 
same compartments. 
Differential ACPA IgG1 Fc glycosylation profile in RF-positive and -negative patients
Previous studies indicate that the specificity and positive predictive value of ACPA for RA 
are increased in the presence of rheumatoid factors (RF) 25. Individuals with both ACPA 
and IgM-RF are significantly more likely to develop RA than those who test positive for 
ACPA only, suggesting that ACPA and RF directly or indirectly interact 38, 39. Intriguingly, 
RF binding sites include the Cγ2 domain of the Fc part of human IgG which is in close 
proximity to amino acid Asn297 to which the carbohydrate chains are attached. Therefore, 
it has been suggested that Fc glycosylation could influence RF-binding to IgG-Fc, and 
indeed fractions of RF exhibiting high affinity for agalactosyl IgG have been identified in 
RA patients 40, 41. Based on these observations, we were interested in investigating whether 
ACPA Fc glycosylation differs between IgM-RF-positive and -negative patients (Figure 6). 
We observed a significant predominance of ACPA IgG1 G0-glycoforms in RF-positive (n 
= 61; G0 median 31.6% (IQR 24.4-39.3)) as compared to RF-negative patients (n = 24; 
G0 median 19.1% (IQR 13.7-31.3), Figure 6A). This RF-dependent difference was only 
observed for ACPA, but not for total serum IgG1 (Figure 6B). In order to exclude that the 



























figure 6: Differential ACPA fc glycosylation in rheumatoid factor (rf)-positive and rf-negative patients. 
Galactosylation profiles for ACPA IgG1 (A) and total serum IgG1 (B) molecules in IgM-RF-positive and 
-negative patients. Horizontal lines indicate the medians.
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observed difference could be due to the co-elution of agalactosylated RF bound to ACPA 
during the ACPA isolation procedure, we also isolated ACPA from RF-negative/ACPA-
positive sera after mixing them with RF-positive/ACPA-negative sera. Fc glycan profiles 
of ACPA isolated from these mixing experiments did not differ from the profiles obtained 
without additional RF (data not shown), making it unlikely that our results are confounded 
by RF bound to ACPA.
We also noted a significant lack of the sialylated ACPA-linked G2-glycoform in RF-
positive patients (RF-positive: median 5.2% (IQR 3.6-6.5), RF-negative: median 8.6% 
(4.4-11.1), p = 0.038), while the sialylated G1-glycoform was equally frequent in both 
subgroups (data not shown). No difference within these subgroups was observed for core 
fucosylation. Of note, RF-positive and -negative subgroups did not differ significantly in 
age or the degree of ESR-/C-reactive protein elevation (data not shown). 
DIsCussIon
N-glycans are crucial determinants of IgG Fc-mediated antibody effector functions. 
Modification of the Fc-linked carbohydrate backbone by addition of galactose, sialic 
acid, fucose and N-acetylglucosamine residues has a differential impact on Fc-mediated 
immune responses both in-vivo and in-vitro 10-14, 20. Serum IgG molecules of RA patients 
have long been known to lack Fc-linked galactose residues when compared to serum 
IgG molecules of age-matched healthy controls, but whether antibodies of defined an-
tigenic specificity differ in their degree of Fc glycosylation remained undetermined in 
these patients. Given recent insights in RA pathogenesis based on the identification of 
anti-citrullinated protein antibodies, we sought to determine whether these RA-specific 
autoantibodies exhibit specific Fc glycosylation profiles that would help to elucidate their 
role in disease pathogenesis.
Comparing Fc-linked glycosylation profiles of ACPA IgG1 to the pool of total serum IgG1 
in early arthritis patients, we found a significant lack of sialic acid residues on ACPA IgG1 
molecules. Furthermore, we observed a non-significant trend towards a lower degree of 
ACPA-galactosylation which could result in an additional reduction in sialic acid residues. 
This finding points to an increased inflammatory potential of ACPA IgG1 and is in line with 
the recent observation that sialic acid residues rather than galactose residues determine 
the anti-inflammatory activity of human IgG 3. Sialylated IgG molecules have reduced 
affinity to activating FcγR and, at least in the mouse, have been described to bind to a 
specific receptor on regulatory macrophages in the spleen 22. Likewise, a complete lack of 
Fc-linked sialic acid residues favours the pathogenic potential of IgG as demonstrated by 
the loss of anti-inflammatory activity of IVIG upon treatment with neuraminidase 3. Thus, 
ACPA IgG1 circulating in human serum exhibit, based on functional data from murine 
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studies, a more pro-inflammatory Fc glycosylation profile than the pool of total serum 
IgG1. 
With regard to core-fucosylation, we found that ACPA IgG1 G0-glycoforms were highly 
fucosylated, an observation previously reported for total serum IgG G0-glycoforms of RA 
patients when compared to healthy controls 42, 43. Based on in-vitro studies this high core 
fucose content is associated with a low potential to induce ADCC 13, but the functional 
relevance for RA pathogenesis is currently unclear and warrants further study. 
Extending our ACPA-specific glycan analysis to synovial fluid we observed both a re-
duction in ACPA IgG1-linked galactose residues as well as a concomitant absence of sialic 
acid residues. This lack of galactose and sialic acid residues was specific for ACPA, as no 
such difference in Fc glycosylation was observed for the pool of total IgG1. Although this 
finding is suggestive of an increased inflammatory potential of SF-ACPA as compared to 
serum ACPA, we cannot conclude that this ACPA Fc glycosylation profile is cause rather 
than consequence of inflammation. Despite this limitation, our observations demonstrate 
for the first time that ACPA in serum and in synovial fluid are not only quantitatively but 
also qualitatively different. Fc-linked glycan residues are unlikely to be enzymatically 
modified post-secretion in SF, as such modifications would be independent of antigen 
specificity and also affect the pool of total IgG in SF. Therefore, differential ACPA Fc 
glycosylation in SF as compared to serum suggests that SF-ACPA originate predominantly 
from specific B cell subsets in synovial tissue. Such ACPA-specific B cells could be under 
the influence of local cytokines that regulate glycan processing in plasma cells susceptible 
to the respective cytokine signal. Local ACPA-production has been postulated previously 
and is in line with the histological presence of germinal centers in synovial tissue of RA 
patients 23, 24, 44. RA B and T cells are known to exhibit reduced enzymatic activity of β1,
4-galactosyltransferase, the enzyme responsible for adding galactose residues to terminal 
GlcNAc residues in N-glycans 45, 46. Whether even more complex differences in N-glycan 
processing exist among B cell subsets in different compartments in RA is unknown. In 
the context of RA and other autoimmune disorders such as SLE, it would be of particular 
interest to investigate whether newly generated and long-lived plasma cells differentially 
process Fc-linked N-glycans. 
We noted differential ACPA Fc glycosylation profiles in IgM-RF-positive versus -negative 
patients. Serum-ACPA of RF-positive patients lacked galactose residues when compared to 
ACPA isolated from RF-negative patients. This differential Fc glycosylation profile was only 
observed for ACPA but not for total serum IgG, the latter being in line with previous results 
47. Our finding is intriguing, as it fuels the hypothesis of an interaction between ACPA and 
RF. ACPA associate with RA independently of RF, but the risk to develop RA increases 
markedly (>30 fold) if RF are additionally present. In contrast, IgM-RF alone do not seem 
to associate with RA in the absence of ACPA 39. RF binding sites have been mapped 
to the Cγ2 and Cγ3 domains of human IgG. Not all RF recognize the same antigenic 
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determinant, but at least one binding site involves Asn297 which carries the Fc-linked 
N-glycans 41. Thus, it has been postulated that Fc glycosylation can influence RF-binding 
affinity, and indeed RF with high affinity for agalactosylated IgG were repeatedly identi-
fied in RA patients 40, 41. Moreover, IgG aggregrates in synovial fluid of RA patients were 
found to contain high amounts of agalactosylated IgG, suggesting that a lack of galactoses 
facilitates association of IgG molecules 48. It is conceivable that lack of galactose residues 
leads to a conformational change in IgG-Fc structure 9 which could favour high affinity RF 
binding and even reveal novel epitopes that promote the generation of high affinity RF. So 
far, binding activity of IgG-RF was found to increase with decreasing RF Fc galactosylation 
(and -sialylation), compatible with the idea that Fc-glycosylation influences “antigenicity” 
of the Fc-tail 49. Whether RF directly or even preferentially also bind to ACPA that lack 
galactose residues cannot be concluded from our data, but our data suggest that the IgG 
recognized by RF exhibits a similar glycosylation profile to the one detected on ACPA. 
Thus, it is intriguing to speculate that ACPA G0-glycoforms help in the generation of RF 
with high affinity for agalactosylated IgG, thereby facilitating immune complex formation 
and complement activation. 
Finally, as others before, we observed a strong correlation between the frequency of 
serum IgG-G0 glycoforms and ESR as well as age (data not shown). This association was 
even more pronounced for ACPA-G0 glycoforms (Figure 2). Of note, we accounted for 
these correlations in our subgroup analyses, rendering it unlikely that our results are 
influenced by these confounding factors.
In summary, we describe a detailed analysis of Fc-linked glycosylation profiles spe-
cific for ACPA. Fc glycosylation profiles differ between antibodies of different antigenic 
specifities and between antibodies isolated from different compartments. These data en-
hance our understanding of the citrulline-specific immune response and may open up 
novel strategies for therapeutic interventions.
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AbsTrACT
objectives The presence of anti-citrullinated protein antibodies (ACPA) is a powerful 
predictive factor for the development and progression of rheumatoid arthritis (RA). The 
ACPA response has been shown to consist of various isotypes, but the consequences of 
differences in isotype-distribution have not been extensively investigated. In this study, we 
investigated the relationship between ACPA isotypes, disease progression and radiological 
outcome. 
methods ACPA isotypes were determined in sera of anti-CCP2-positive patients by 
enzyme-linked immunosorbent assay (ELISA). To investigate if the ACPA response con-
tinues to evolve during disease development, we studied the ACPA isotype profile during 
progression of undifferentiated arthritis (UA) to RA. The association of disease progression 
with ACPA isotype use was assessed using long-term radiographic follow-up data from RA 
patients in two independent cohorts. 
results The ACPA isotype distribution did not expand during disease progression from UA 
to RA, but was relatively stable over time. In both RA cohorts, the baseline ACPA isotype 
profile was a significant predictor of disease severity, with more isotypes indicating a 
higher risk of radiographic damage (odds ratio for every additional isotype: 1.4 (95% CI: 
1.1-1.9) p<0.001). ACPA isotypes supplied additional prognostic information to ACPA-
status alone, even after correction for other predictive factors.
Conclusions The magnitude of the ACPA isotype profile at baseline reflects the risk of 
future radiographic damage. These results indicate that not only the presence, but also the 
constitution of the ACPA response, is relevant for the disease course of RA. 
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InTroDuCTIon
Anti-citrullinated protein antibodies (ACPA) have emerged as a very distinctive feature 
of rheumatoid arthritis (RA) patients. The presence of these antibodies, which is com-
monly assessed by reactivity against cyclic citrullinated peptides (CCP), has been shown 
to potently predict both the development of RA and the extent of associated joint destruc-
tion 1-3. Recent evidence indicates that well-known risk factors for RA such as the HLA-
DRB1 shared epitope alleles and smoking predominantly predispose to ACPA-positive 
RA 4, 5. These differences in clinical phenotype and underlying risk factors have led to 
the concept that ACPA-positive and ACPA-negative RA constitute distinct entities with 
different pathophysiological mechanisms of disease 6, 7. 
Studies using animal models to investigate the biologic processes underlying RA have 
shown that ACPA can exacerbate arthritis in mice 8, 9. These findings suggest that anti-
citrulline immunity may play a role in the pathogenesis of autoantibody-positive RA. Pos-
sibly, isotype switching may be one of the events required in order for autoantibodies to 
contribute to disease pathogenesis.
Isotype switching during the maturation of an immune response leads to an increased 
diversity of antibody structure. The generated antibody isotypes differ substantially with 
regard to their ability to mediate effector mechanisms. For example, IgM and IgG3 are 
much more potent activators of the complement system than other isotypes. Furthermore, 
the various isotypes can bind to specific Fc receptors on the surface of different cell-
types, which in the case of IgG1 and IgG3 can lead to the activation of macrophages 
with concomitant cytokine production. In light of these well-known differences between 
antibody isotypes, a detailed investigation of the isotype distribution of an autoantibody 
response such as ACPA may provide important clues about the role of these antibodies in 
the pathogenesis of the disease 10.
The isotype use of the ACPA response has been studied using several tests, some of 
which were derived from the commercially available CCP2 assays, which were modified 
in order to be able to measure IgG subclass antibodies, as well as IgM and IgA ACPA 11-14. 
The fact that ACPA of the IgM isotype could be detected at various stages of the disease 
indicates that new B cells are continuously being recruited into the ACPA response 14. This 
means that the anti-citrullinated protein immune response is constantly being (re)activated 
during the course of ACPA-positive arthritis. It is unclear however, if during this process of 
continuous reactivation throughout disease progression, there is also further maturation of 
the ACPA response in the sense of isotype switching. In addition, the reported findings of 
the differences in ACPA isotype use between patients 13, raise the question to what extent 
the exact features of the ACPA response, such as isotype use, are associated with disease 
progression.
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In this study, we examined the relationship between ACPA isotypes and disease de-
velopment and progression. The use of two large, independent cohorts with long-term 
follow-up data enabled us to investigate the association between the ACPA isotype profile 
and progression of radiographic damage.
meThoDs
Patient populations
The Leiden EAC is an inception cohort of patients with recent-onset arthritis (less than 
2 years of complaints) that was initiated in 1993 15. At standardized follow-up visits two 
weeks after the first presentation and yearly thereafter, diagnoses were recorded for all 
patients. Patients were classified as having RA when they fulfilled the 1987 revised ACR 
criteria. 
In order to investigate the association of ACPA isotypes with radiographic damage, base-
line serum samples of all ACPA-positive RA patients in the EAC (n= 171) were analyzed for 
ACPA isotypes. Annual radiographs of hands and feet of all RA patients were assessed for 
radiographic damage according to the Sharp-van der Heijde score (SHS) 16.
To determine if the findings in the Leiden EAC cohort could be replicated in a second 
cohort, ACPA isotypes were measured in a Norwegian cohort which was part of the Euro-
pean Research on Incapacitating Disease and Social Support (EURIDISS) project 17. Con-
secutive RA patients (n=238) with a maximum disease duration of 4 years at baseline were 
enrolled in this study and followed longitudinally for 10 years. 125 patients had X-rays of 
the hands available at baseline and after 5 and 10 years of follow-up for scoring with the 
SHS method. There were no significant differences between the patients with X-rays avail-
able at follow-up (n=125) and the whole cohort (n=238) 1. ACPA isotype measurements 
were performed on baseline serum samples. The protocols of both cohorts were approved 
by the local ethics committees and all participants provided written informed consent.
Anti-CCP2 assays 
Total IgG anti-CCP2 was measured in baseline serum samples from patients with UA or RA 
by a second-generation ELISA (for the EAC cohort: Immunoscan RA Mark 2; Eurodiagnos-
tica, Arnhem, The Netherlands, for the EURIDISS cohort: INOVA diagnostics, San Diego, 
CA, USA). Samples with a value above the cut-off as specified by the manufacturer were 
considered positive.
Measurement of ACPA isotypes
ACPA IgG1, IgG2, IgG3, IgG4, IgA and IgM were determined using a sandwich ELISA 
technique as described previously 14. Briefly, assays were performed using anti-CCP2 
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ELISA plates (Eurodiagnostica) with isotype-specific detection antibodies. A series of suc-
cessive dilutions of pooled patient sera that were positive for all isotypes was included as a 
standard on all plates, along with a positive control to verify comparability between plates. 
Sera from 8 representative healthy controls were included on each plate to determine the 
cut-off for positivity. Cut-off values were defined as the mean plus 2 standard deviations 
of the measurements of the healthy control sera. 
Statistical analysis
To assess changes in ACPA isotype usage between baseline and follow-up patients who 
presented with undifferentiated arthritis (UA) and subsequently developed RA, McNemar’s 
test was used. Changes in the levels of ACPA isotypes between baseline and follow-up 
samples were evaluated using Wilcoxon signed ranks test. Correlation between changes 
in the levels of the various ACPA-isotypes were investigated using Spearman’s rank cor-
relation coefficient, due to the non-normal distribution of the data.
To investigate the association between ACPA isotypes and radiographic progression, 
differences in radiographic damage between groups were assessed using Mann-Whitney 
U-tests and logistic regression analysis. The radiographic progression (dependent vari-
able) was calculated as the difference in SHS between baseline and the last time point 
of follow-up (4 years in the EAC, 10 years in the EURIDISS). This value was subsequently 
dichotomized into minor and major radiographic progression based on the median values 
per cohort (10 in the EAC, 17 (hands only) in the EURIDISS). Patients with a change in 
SHS greater than or equal to the median were classified as having major progression, 
while the other patients were classified as having minor progression. Multivariate logistic 
regression analysis was performed to adjust for additional variables (age, gender, CRP, 
IgM rheumatoid factor and SHS at baseline). The positive likelihood ratio was calculated 
as the sensitivity divided by (1- specificity). Likewise, the negative likelihood ratio was 
calculated as (1- sensitivity) divided by the specificity. All analyses were performed us-
ing the Statistical Package for the Social Sciences (SPSS) 16. P-values below 0.05 were 
considered to be statistically significant.
resulTs
The ACPA isotype distribution does not expand during disease progression
Previously, we have shown that in patients with longstanding RA, the ACPA isotype profile 
at baseline did not markedly differ from the ACPA isotype use after 7 years of follow-up on 
the population level 14. In order to extend these findings to an earlier stage of the disease, 
and to investigate if the ACPA response continues to evolve during disease progression, 
we studied the ACPA isotype profile in baseline and follow-up serum samples of 67 ACPA-
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positive patients from the Leiden EAC. All patients had undifferentiated arthritis (UA) at 
baseline, meaning they did not fulfill the ACR criteria for RA and their clinical presentation 
was not compatible with any other well-defined rheumatologic disease. For the present 
study 579 UA patients were analyzed of whom 142 were ACPA-positive as measured by 
the CCP2 ELISA. Of all anti-CCP2-positive UA patients who had developed RA after one 
year, serum samples collected at baseline and after one year of follow-up were examined 
(n=67 samples available). Measurements of isotypes were restricted to patients who were 
positive for ACPA, since the occurrence of ACPA isotypes has been shown to be confined 
to ACPA-positive patients 13, 14. 
As shown in Figure 1, ACPA isotype levels varied considerably during disease progres-
sion, with some patients showing an increase and others showing a decrease in levels. 
Most of the changes in the levels of the different isotypes were significantly correlated 
with each other. Especially changes in IgG3- and IgA-ACPA-levels were accompanied by 
similar changes in levels of the other isotypes (correlation coefficient: 0.23-0.66). 
figure 1: ACPA isotype levels at baseline and after 1 year of follow-up of 67 uA-rA patients. All patients had 
UA at baseline and had developed RA at the time of follow-up. Dots depict the levels of individual patients 
in arbitrary units per milliliter (AU/ml) at baseline and follow-up. The number of arbitrary units/ml for one 
isotype is not comparable to the number of arbitrary units /ml for another isotype. Differences in the levels of 
ACPA isotypes between baseline and follow-up samples were assessed using Wilcoxon signed ranks test.
Table 1. ACPA isotype use in patients who experienced disease progression from undifferentiated arthritis 
(uA) to rA






Igg1 67 (100%) 66 (99%) 1 0 1
Igg2 51 (76%) 44 (66%) 12 5 0.14
Igg3 34 (51%) 35 (52%) 7 8 1
Igg4 64 (96%) 65 (97%) 0 1 1
IgA 45 (67%) 41 (61%) 9 5 0.42
Igm 39 (58%) 40 (60%) 7 8 1
The isotype profile at baseline (BL (UA)) compared to the isotype profile after 1 year of follow-up (FU (RA)).
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Both the paired-samples analysis and the comparison of the median levels at baseline 
and follow-up revealed that there was no significant difference between baseline and 
follow-up levels for any of the isotypes. Despite the fluctuation in levels, most patients 
remained either positive or negative for a certain isotype at both baseline and follow-up. 
Thus, the number of patients which was positive for a certain ACPA isotype did not change 
(Table 1). Although some patients lost or acquired certain ACPA isotypes, there was no 
overall trend towards an increase in ACPA isotype use. The median number of ACPA 
isotypes present at baseline and follow-up was also the same: 5.
On the basis of these results, we can conclude that despite a worsening of the clinical 
phenotype, the ACPA isotype use does not expand during disease progression from UA 
to RA.
figure 2: effect of ACPA isotypes on radiographic damage in eAC and eurIDIss.
Depicted are the median Sharp-van der Heijde radiographic scores (SHS) over time. 
Panels A and B present the results of the EAC and contain information on 251 RA patients of whom 113 were 
ACPA-positive with ACPA isotype data. 
Panels C and D depict the results of the EURIDISS cohort and contain information on 125 RA patients of 
whom 74 were ACPA-positive with ACPA isotype data. 
Due to the non-normal distribution of SHS, medians were compared by Mann-Whitney U-test. 
* in panels A and C indicates a significant difference with a p-value < 0.05 between ACPA-positive and 
ACPA-negative patients. 
*  in panels B and D indicates a significant difference with a p-value < 0.05 between the upper two groups: 
patients with less than 5 ACPA isotypes and patients with 5 or more ACPA isotypes. 
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ACPA isotypes at baseline predict future radiographic progression in patients with 
ACPA-positive RA
In view of the finding that the presence of ACPA isotypes in individual patients is relatively 
constant over time, we next investigated if the baseline ACPA isotype profile is associated 
with radiographic progression in the two independent cohorts: the Leiden EAC and in 
the Norwegian EURIDISS cohort. As has been described previously 1, 2, 18, ACPA-positive 
patients had substantially more radiographic damage than ACPA-negative patients in both 
cohorts (Figure 2A and 2C).
Within the ACPA-positive patients, a high number of ACPA isotypes present at baseline 
was associated with significantly more radiographic damage during the disease course 
(Figure 2B and D).
A more detailed investigation of the effect of the ACPA isotype profile on radiographic 
progression was performed using logistic regression analysis. As shown in Table 2 for 
the EAC and in Table 3 for the EURIDISS, several ACPA isotypes were significantly more 
prevalent in patients with major as compared to minor radiographic progression. By logis-
tic regression analysis, these isotypes, which were more prevalent in patient with major 
radiographic progression, were significant predictors of radiographic progression within 
the ACPA-positive group of patients (Tables 2 and 3). The significant odds ratio (p ≤ 0.02) 
for every additional ACPA isotype which was present, reflects the effect of the number of 
ACPA isotypes (Tables 2 and 3). 
The predictive effect of ACPA isotypes remained significant even after adjustment in 
multivariate logistic regression analysis for other variables known to influence radiographic 
progression (age, gender, disease activity, RF status and SHS at baseline) (Tables 2 and 3). 
The presence of five or more isotypes increased the odds of progression by 3.53 (95% 
CI 1.4-9.3) and 6.76 (95%CI 1.60, 28.7) in the EAC and EURIDISS cohorts, respectively.
Patients who used a total of 5 ACPA isotypes or more, also had significantly higher levels 
of total IgG anti-CCP2 (p<0.01) which is known to be associated with radiographic pro-
gression 1. Due to this strong correlation, the level of anti-CCP2 and the number of ACPA 
isotypes cannot be entered into the same multivariate model as explanatory variables, as 
this results in annulment of the effect. We therefore used a matching approach to assess 
the effect of ACPA isotypes independently of the effect of anti-CCP2 level. Patients with 
≤4 and with ≥5 ACPA isotypes were matched for anti-CCP2 levels, resulting in 18 pairs 
in the EAC and 15 pairs in the EURIDISS (Figure 3A and 3C). The median SHS over time 
among these pairs with equivalent anti-CCP2 levels is depicted in Figure 3B and 3D. In 
the EAC, patients positive for 5 or more ACPA isotypes had significantly more radiographic 
damage at the first four timepoints, and in the EURIDISS, there was a trend towards more 
radiographic damage in patients using 5 or more ACPA isotypes (p=0.10 after 10 years of 
follow-up). These findings suggest that ACPA isotypes and the total anti-CCP2 IgG level 
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are not interchangeable, and that determination of ACPA isotypes may supply additional 
information to the total ACPA IgG level.
In summary, these results demonstrate that in addition to the presence of ACPA, the 
constitution of the anti-citrullinated protein autoantibody response is significantly associ-
ated with the disease course of RA. Within ACPA-positive patients, an expanded ACPA 
isotype profile indicates a high risk for severe radiographic damage.
DIsCussIon
In this study, we investigated the relationship between the ACPA isotype distribution and 
the progression and severity of RA. A more extensive use of ACPA isotypes at baseline 
was associated with more radiographic damage in RA patients in both cohorts. However, 
disease development from UA to RA was not accompanied by an expansion of the ACPA 
isotype profile.
figure 3: effect of ACPA isotypes after matching for total anti-CCP2 levels.
Patients with ≤ 4 ACPA isotypes were matched to patients with ≥ 5 ACPA isotypes with equivalent anti-CCP2 
levels. 
Panel A depicts the anti-CCP2 levels of the 18 matched patient pairs in the EAC.
Panel B shows the median Sharp-van der Heijde radiographic scores (SHS) over time for the 18 patients with 
≥ 5 ACPA isotypes compared to the 18 matched patients with ≤ 4 ACPA isotypes in the EAC.
*  indicates a significant difference with a p-value < 0.05.
Panel C depicts the anti-CCP2 levels of the 15 matched patient pairs in the EURIDISS.
Panel D shows the median Sharp-van der Heijde radiographic scores (SHS) over time for the 15 patients with 
≥ 5 ACPA isotypes compared to the 15 matched patients with ≤ 4 ACPA isotypes in the EURIDISS.
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The continued presence of IgM ACPA in patients with longstanding RA is an especially 
noteworthy feature of the ACPA response. IgM antibodies have a half-life of approximately 
1 day 19 and since long-lived plasma cells producing IgM antibodies against T cell-depen-
dent antigens have not been described, the presence of IgM most likely indicates that the 
ACPA response is continuously reactivated during the course of the disease.
In previous studies, patients who were positive for IgA ACPA were found to have higher 
disease activity scores (DAS), even after taking into account the higher total ACPA-levels 
in this group of patients 13. We have shown here that the presence of IgA ACPA and other 
isotypes also affects radiographic progression. The measurement of one solitary ACPA 
isotype (e.g. IgA) in addition to the standard anti-CCP assay, may not have a very high 
diagnostic yield, in view of the relatively modest likelihood ratio statistics associated 
with the single isotypes. However, the risk of radiological damage increased with every 
additional isotype, demonstrating that the breadth of the isotype response (i.e. the total 
number of isotypes present) may be of particular importance.
Previous reports have revealed that ACPA can be detected years before disease mani-
festation 20-22 and that they tend to persist in the vast majority of patients in whom they 
have developed 23. The fact that most patients are ACPA-positive for a certain period of 
time before they develop disease, indicates that not all ACPA are pathogenic. A potential 
underlying mechanism could be that the anti-citrullinated protein immune response may 
need to fully evolve and develop certain characteristics which then enable ACPA to cause 
tissue damage. Possibly, isotype switching and a resulting larger number of antibody 
isotypes, may be one of the features required for autoantibodies to contribute to disease 
pathogenesis. 
The current study does not allow us to draw any conclusions about the events taking 
place before disease onset, when isotype switching could perhaps be involved in disease 
development. We therefore decided to study isotype switching in a very early phase after 
the onset of arthritis: during disease progression from UA to RA. Although UA-RA patients 
have been shown to have more ACPA isotypes at baseline than UA-nonRA patients14, the 
size of the ACPA isotype profile did not increase during the first year of follow-up, despite 
the development of RA in these patients during that period. Previous studies examin-
ing the ACPA response at baseline and follow-up in RA patients without overt disease 
progression, have reported that anti-CCP2-titers and levels of ACPA isotypes can even 
decrease with time 14, 23. A possible explanation for these observations could be the effect 
of immunosuppressive treatment. The current first-line treatment for patients with RA and 
patients with severe, progressive UA 24 consists of disease-modifying antirheumatic drugs 
(DMARDs), which all have more or less immunosuppressive functions. This makes it dif-
ficult to discern if the previously reported decrease in ACPA isotype levels is due to the 
natural course of the immune response or to the influence of medication. 
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Another possible reason why disease progression from UA to RA is not accompanied 
by a further expansion of the ACPA isotype use, could be that the clinical phenotype 
may lag behind the features of the autoantibody response. Analogous to observations in 
systemic lupus erythematosus (SLE), where a rise in anti-dsDNA antibodies is followed by 
a disease flare 25, 26, the extended isotype distribution of UA-RA patients at baseline may 
be reflected by the disease course throughout the first year of the disease. The elucidation 
of the precise temporal relationship between changes in ACPA characteristics and disease 
phenotype will require further comprehensive follow-up studies.
The presence of 5 or more ACPA isotypes was significantly associated with higher 
levels of total IgG anti-CCP2 (p<0.01) which is known to be associated with radiographic 
progression 1. Nonetheless, when patients were matched for anti-CCP2-levels, the pres-
ence of 5 or more ACPA isotypes was still associated with more radiographic progression, 
indicating that the presence of ACPA isotypes supplies additional information compared 
to the total anti-CCP2 IgG level. However, the number of matched patient pairs in which 
the independent effect of ACPA isotypes could be determined was limited, and more data 
will be required to validate these observations.
These findings are particularly important for our comprehension of the development 
of the ACPA response. As the anti-citrullinated protein immune response evolves and 
matures, it is conceivable that all features of the ACPA response, including the antibody 
level and the isotype use, will expand. Despite the fact that both total ACPA IgG level and 
the breadth of the ACPA isotype profile may, in this respect, be reflections of the same 
underlying immunological process, they can independently affect disease outcome. The 
association of radiographic outcome with these markers of ACPA maturity supports the 
theory that within ACPA-positive patients, the evolution of the ACPA response may be of 
pathophysiological importance.
A possible pathway by which differences in the ACPA isotype distribution may influ-
ence disease severity is through selective activation of the complement system. ACPA can 
activate the complement system in vitro and it is conceivable that a more diverse isotype 
profile would lead to an increase in complement activation. Furthermore, the differential 
effects of ACPA isotypes on disease severity may also be due to the recruitment of other 
effector mechanisms such as binding to Fc receptors. Ligation of Fc receptors by in vitro 
generated fibrinogen-ACPA immune complexes has been shown to result in cell activation 
and cytokine secretion 27, both of which are of prime importance for tissue damage in RA.
The hypothesis that the nature and characteristics of the ACPA response may determine 
disease development and progression can certainly not be proven by the current study 
which was designed to investigate associations. Nonetheless, the present findings are 
consistent with this hypothesis and add to a growing body of evidence for the role of ACPA 
in the pathogenesis of the disease. 
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AbsTrACT
objective Antibodies against citrullinated proteins (ACPA) are the most predictive fac-
tor for the development of rheumatoid arthritis (RA). To investigate if the recognition of 
citrullinated epitopes changes during disease onset or progression, we studied the fine 
specificity of ACPA in serum samples collected throughout the disease course, from before 
the onset of arthritis to long-standing RA.
methods Antibodies recognizing five distinct citrullinated antigens were determined by 
enzyme-linked immunosorbent assay. Sera from 36 individuals who had donated blood 
before and after disease manifestation were used to investigate the development of citrul-
linated antigen recognition before disease onset. The association of ACPA reactivities with 
disease outcome was studied using sera of anti-cyclic citrullinated peptide 2 (CCP)-positive 
patients with undifferentiated arthritis (UA) who did or did not progress to RA (UA-RA 
n=81, or UA-UA n=35). To investigate the ACPA recognition profile in RA patients over a 
prolonged period of time, baseline serum samples from 68 RA patients were compared to 
samples obtained 7 years later.
results The number of recognized citrullinated peptides increased in the period preceding 
disease onset. At the time of disease manifestation, UA patients who later developed RA 
recognized significantly more peptides than UA-UA patients. At later stages of the disease 
course, the ACPA fine specificity did not change. 
Conclusion Epitope spreading with an increase in the recognition of citrullinated antigens 
occurs before onset of RA. Immunological differences in ACPA fine specificity are present 
at baseline between UA-UA patients and UA-RA patients and are associated with the 
future disease course. 
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InTroDuCTIon
Anti-citrullinated protein antibodies (ACPA) are a very distinctive feature of rheumatoid 
arthritis (RA) patients. The presence of these antibodies, which is most commonly assessed 
by reactivity against cyclic citrullinated peptide-2 (CCP), has been shown to be highly 
predictive for both the development of RA and the extent of associated joint destruction 1, 
2. Recent evidence indicates that well-known genetic risk factors for RA: the HLA-DRB1 
shared epitope (SE) alleles and the PTPN22 T-allele are predominantly associated with 
ACPA-positive RA 3, 4. These reports, together with the finding that ACPA can exacerbate 
arthritis in mice 5-7, suggest that anti-peptidylcitrulline immunity plays an important role 
in the pathogenesis of the disease. To elucidate the biological mechanisms underlying RA, 
and possibly identify targets for intervention, it is therefore very important to gain more 
insight into the development of ACPA. 
Studies investigating at which point in time ACPA first appear, have revealed that these 
antibodies can often be detected several years before disease onset 8-10. The mere presence 
of ACPA therefore does not appear to be sufficient to precipitate disease. An explanation 
for this observation could be that the anti-citrullinated protein immune response first needs 
to mature more fully, in the course of which, ACPA could acquire distinct characteristics 
which are instrumental in mediating tissue damage. 
An antibody characteristic which has been shown to be crucial for the pathogenicity 
of autoantibodies, is the fine specificity of antigen recognition 11. An increase or shift in 
antigen recognition during the course of an immune response (a phenomenon known 
as epitope spreading), can have very important pathophysiological consequences as has 
been described in, for example, systemic lupus erythematosus (SLE) 12. 
Taking into consideration that ACPA can be detected before the clinical diagnosis of 
RA, and that the presence of ACPA is strongly associated with disease progression, we 
hypothesized that epitope spreading of the ACPA response may play a role in the evolution 
of the disease. In the present study we therefore investigated the reactivity pattern of ACPA 
before disease onset and during disease progression. In order to cover the entire spectrum 
of the disease course ranging from ACPA-positive healthy individuals to patients with 
long-standing RA, we made use of several different cohorts, which together provide an 
overview of the ACPA fine specificity development over time. 




In a previous study, individuals who had donated blood before the onset of arthritis were 
identified among RA patients treated at the Department of Rheumatology of the Umeå 
University Hospital 8. The time period between collection of the pre-disease sera and 
disease onset ranged from 43 days to 10.8 years with a median of 2.5 years. 
Patients with UA or RA were selected from the Leiden Early Arthritis Clinic (EAC), an 
inception cohort of patients with recent-onset arthritis (less than 2 years of complaints) 
that was initiated at the Department of Rheumatology of the Leiden University Medical 
Center in 1993 13. Diagnoses were recorded for all patients at annual follow-up visits 
and RA was diagnosed according to the 1987 revised ACR criteria. Patients who did not 
fulfill the diagnosis criteria and whose clinical presentation was not compatible with any 
other well-defined rheumatologic disease entity, were classified as having UA. For the 
present study we analyzed 116 anti-CCP positive UA patients and 68 anti-CCP-positive 
RA patients. 
Informed consent was obtained and the study was approved by the local medical ethics 
review board. 
Anti-CCP2 assays 
Total IgG anti-CCP2 was measured by enzyme-linked immunosorbent assay (ELISA) (Im-
munoscan RA Mark 2; Eurodiagnostica, Arnhem, The Netherlands). Samples with a value 
above 25 units/ml were considered positive according to the manufacturer’s instructions. 
Anti-citrullinated peptide assays
ELISA assays were developed against peptides derived from vimentin, fibrinogen and 
alpha-enolase. Although there are also other targets for ACPA 14, 15, we chose to primarily 
investigate epitopes from these proteins because they have been most consistently identi-
fied as citrullinated autoantigens 16-18.
Antibodies against both the citrullinated (Cit) and the uncitrullinated form of 2 linear 
peptides derived from vimentin (Vim 1-16: STCitS VSSS SYCitCit MFGG and Vim 59-74: 
VYAT CitSSA VCitLCit SSVP), 2 linear peptides derived from fibrinogen (Fibα 27-43: FLAE 
GGGV CitGPR VVER H and Fibβ 36-52: NEEG FFSA CitGHR PLDK K) and 1 linear peptide 
derived from alpha-enolase (Eno 5-20: KIHA CitEIF DSCitG NPTV) were determined by 
ELISA. All peptides were sythesized with a C-terminal spacer and biotin tag. The vimentin 
and fibrinogen epitopes which were used for the present study were selected based on 
the fact that they were most frequently recognized by sera from ACPA-positive patients 
with long-standing RA. A linear alpha-enolase peptide was used with a small difference in 
sequence compared with the peptide used by Lundberg et al 19. Because antibodies from 
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different RA patients have been shown to recognize distinct epitopes of the same protein, 
an approach using citrullinated peptides rather than whole proteins was used in order to 
attain optimal discriminative ability 20. 
Fine specificity ELISA assays were performed as described previously 21. Briefly, 
streptavidin-coated pre-blocked microtiter plates were coated with the different peptides, 
followed by incubation with the serum samples. After washing, antibodies were detected 
with a rabbit anti-human IgG HRP-conjugated antibody and tetramethylbenzidine (TMB) 
as the coloring substrate. Baseline and follow-up samples were always analyzed on the 
same day and on the same plate. The inter-assay variability of the assays was very low (≤ 
2% of samples with conflicting positive/negative results). 
Definition of cut-off values and citrulline-specificity
Cut-off values on the citrullinated and arginine-containing peptides were defined as the 
mean plus two times the standard deviation of the values of 30 control subjects. A patient 
sample was considered to recognize a particular peptide in a citrulline-specific manner 
when it fulfilled all three of the following requirements: 1) an OD value on the citrul-
linated peptide above the citrulline cut-off and 2) an OD value on the arginine-variant 
below the arginine cut-off and 3) an OD difference (=OD for citrullinated peptide – OD 
for arginine-containing peptide) of at least 0.1. The number of patients that recognized 
both the citrullinated and the arginine-containing peptide above cut-off levels and thus 
did not bind to the peptide in a citrulline-specific way was small (approximately 3%). 
Statistical analysis
To assess changes in the frequency of recognition of the citrullinated peptides between 
baseline and follow-up samples, McNemar’s test was used. Differences in the number of 
epitopes recognized, and in the levels of antibody reactivity between baseline and follow-
up samples were evaluated using Wilcoxon signed ranks test. When two independent 
patient groups were compared (UA-UA versus UA-RA patients), Mann Whitney U tests 
were used to analyze differences between median optical density (OD-)values and the 
median number of recognized peptides. Relative risks (RR) with 95% confidence intervals 
were calculated for the development of RA from UA, based on the presence of a certain 
fine specificity. Logistic regression analysis was performed to calculate the risk associated 
with recognizing one additional citrullinated peptide for the outcome UA or RA after one 
year of follow-up. All analyses were performed using the Statistical Package for the Social 
Sciences (SPSS) 14.0 and StatCalc 2.0. 
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resulTs
Epitope spreading occurs before disease onset
In order to assess the recognition of citrullinated epitopes before disease onset, we made 
use of a unique serum collection of 36 individuals who had donated blood before the 
onset of RA and shortly after disease manifestation (on average 7.5 months post-disease 
onset) 8. As shown in Figure 1A, the sera collected before disease onset (pre-RA) had a 
figure 1: reactivity of sera collected before disease onset (pre-rA) and after disease onset (rA).
figure 1A: The number of units/ml against CCP2 and the raw optical density (OD-) values against the five 
fine specificity peptides are shown for the 36 individuals of whom serum was collected before and after 
disease onset. Differences between the median levels at the pre-RA and RA timepoints against each of the 
five peptides were investigated by Wilcoxon signed rank tests. 
figure 1b: Differences in peptide recognition between samples obtained before disease onset (pre-RA) 
and after disease onset (RA). Shown are the percentages of pre-RA and RA sera (n=36) that bound to the 
indicated number of peptides. 
figure 1C: Development of epitope recognition prior to the onset of arthritis. Depicted is the median number 
of peptides recognized by serum samples available from the specified time period antedating the symptoms 
of RA (n=36) and at the time RA was diagnosed (n=36). 
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significantly lower reactivity against all of the peptides, except for vimentin 1-16, than the 
sera collected after disease manifestation. For individual patients, the changes in reactivity 
to the different peptides over time were often correlated, but this correlation was not 
absolute. 
Most peptides, with the exception of vimentin 1-16, were recognized substantially more 
frequently by the RA samples than by the pre-RA sera as listed in Table 1. The presence 
of (one or more isotypes of) RF also increased in the period before disease onset (data 
not shown). While many of the sera demonstrating reactivity to one of the fine specificity 
peptides also contained IgA- or IgM-RF, this was not always the case. Recognition of the 
fine specificity peptides was limited to the 29 individuals who were anti-CCP2-positive 
after disease onset.
The overall gain in peptide recognition resulted in a significant increase in the number 
of patients who recognized 1 or more peptides (38% versus 66%, p= 0.01) (Figure 1B). 
The median number of recognized peptides was 0 before disease development compared 
to 1 in the RA samples (p=0.08). As the period between pre-RA sample collection and 
disease manifestation varied among patients, the expansion of epitope recognition over 
time is shown in more detail in Figure 1C. This figure illustrates that the recognition of 
citrullinated epitopes increases before disease onset. 
Taken as a whole, the analysis of the ACPA fine specificity profile before and after 
disease onset reveals that there is epitope spreading prior to the onset of RA.
The baseline ACPA reactivity profile differs between UA patients who progress to 
RA (UA-RA) and those who do not (UA-UA)
To investigate if a distinct recognition pattern of citrullinated peptides is associated with 
disease progression, we made use of serum samples from a different cohort: the Leiden 
EAC. ACPA reactivities were determined in baseline serum samples from UA patients 
who had not been treated with disease modifying antirheumatic drugs (DMARDs). Of 











CCP2 21 (58%) 29 (81%) 2 10 0.039
vimentin 1-16 3 (8.1%) 1 (2.7%) 3 1 0.63
vimentin 59-74 10 (27%) 14 (38%) 4 8 0.39
fibrinogen α 27-43 2 (5.6%) 7 (19%) 0 5 0.062
fibrinogen β 36-52 9 (25%) 15 (42%) 4 10 0.18
enolase 5-20 4 (11%) 9 (25%) 1 6 0.13
recognition of ≥1 
peptide
14 (38%) 24 (66%) 2 12 0.013
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116 anti-CCP2 positive UA patients, 81 fulfilled the ACR criteria for RA after one year of 
follow-up (UA-RA), whereas the remaining 35 patients did not develop RA (UA-UA). In 
Figure 2A, the baseline reactivity is depicted in the form of the raw optical density (OD-)
values. At baseline, the reactivity of the UA-RA sera was significantly higher than that of 
the UA-UA sera against two of the five peptides. When the OD-values were translated 
into negative/positive recognition by applying cut-off values based on 30 control subjects, 
figure 2: baseline reactivity of uA-uA versus uA-rA sera. 
figure 2A: Depicted are the raw optical density (OD-) values for each of the UA-UA (n=35) and UA-RA 
(n=81) patients. Lines indicate the median OD. Differences between the median OD-values of the UA-UA 
and UA-RA patients for each of the five peptides were investigated by Mann-Whitney U tests. 
figure 2b: Recognition of individual citrullinated peptides at baseline by UA-UA and UA-RA patients. 
Depicted are the percentages of patients per group that recognized the different peptides in a citrulline-
specific manner. Relative risks (RR) with 95% confidence intervals were calculated for the development of 
RA from UA, based on the presence of a certain fine specificity.
figure 2C: Number of peptides recognized by UA-UA and UA-RA patients. Error bars indicate the minimum 
and maximum number of peptides recognized per patient. Boxes designate the 25th and 75th percentile, 
while the lines in the boxes indicate the median number of recognized peptides.
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the prevalence of recognition of both vimentin peptides and fibrinogen β 36-52 was 
significantly higher among UA-RA than among UA-UA patients (Figure 2B). As shown in 
Figure 2C, the median number of recognized peptides per patient was larger in UA-RA 
patients (2 peptides) than in UA-UA patients (1 peptide) (p=0.02). Regression analysis 
revealed that for every additional epitope which was recognized, the risk of developing 
RA increased by a factor of 1.55 (p=0.02). 
In summary, these results indicate that ACPA-positive UA-UA and UA-RA patients are 
immunologically distinct at baseline with regards to their ACPA reactivity profile. The 
UA-RA patients displayed reactivity against a significantly larger number of citrullinated 
epitopes. 
Recognition of citrullinated peptides does not change during disease progression
To investigate whether the reactivity against citrullinated antigens would further increase 
during disease development from UA to RA, we performed fine specificity assays with 
serum samples obtained at baseline and after approximately 1.5 year of follow-up of the 
same UA-RA patients as described above. All patients had progressed to RA at this point 
in time. Serum samples were available for 67 of the previously tested 81 patients. As 
shown in Figure 3A, the recognition of all five fine specificity peptides did not markedly 
change. At follow-up, a smaller number of patients recognized the individual peptides, 
but the difference was not statistically significant. The number of citrullinated peptides 
recognized per patient was also lower at follow-up as compared to baseline (Figure 3B).
On the basis of these results, we can conclude that the ACPA reactivity with regard to 
the five fine specificity peptides we measured, did not further increase during the progres-
sion of UA to RA. 
figure 3: recognition of individual citrullinated peptides by uA-rA patients at baseline and after 1.5 years 
of follow-up. figure 3A: Depicted are the percentages of patients (n=67) which recognized the peptides in a 
citrulline-specific manner at baseline (when all patients had UA), and after 1.5 years of follow-up when all 
patients had developed RA. 
figure 3b: Number of peptides recognized by UA-RA patients at baseline and after 1.5 years of follow-up. 
Error bars indicate the minimum and maximum number of peptides recognized per patient. Boxes designate 
the 25th and 75th percentile, while the lines in the boxes indicate the median number of recognized peptides.
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No changes in recognition of anti-citrullinated peptides by RA patients after seven 
years of follow-up
To further substantiate the finding that the ACPA recognition pattern does not change dur-
ing the course of the disease, we examined a group of 68 patients who presented with RA 
and of whom serum samples were available at baseline and after a median follow-up time 
of 7 years (interquartile range: 6.2-7.9 years). As depicted in Figure 4A, the percentage of 
patients that recognized the five peptides did not change after 7 years of follow-up. With 
regard to the absolute number of peptides that was recognized per patient, the findings 
were similar to the observations described above for UA-RA patients. The number of 
recognized peptides was slightly lower at the time of follow-up, as can be seen in Figure 
4B, but this differences was not statistically significant (p=0.25). 
Overall, these results reveal that with regard to these five fine specificity peptides, the 
ACPA recognition pattern does not change during the course of RA and that the reactivity 
profile does not expand after disease onset.
DIsCussIon
In this study, we analyzed the recognition pattern of ACPA throughout the disease course 
of RA. The results reveal that the recognition of citrullinated epitopes expands before 
disease onset. Furthermore, at the time of disease onset, an extensive recognition pattern 
of citrullinated peptides by patients who present with UA, is associated with rapid disease 
progression to RA in the first year of follow-up. After disease development, we could not 
detect a further increase in reactivity to the five fine specificity peptides used in this study. 
figure 4: Citrulline-specific recognition of the different peptides at baseline and after seven years of follow-
up in 68 rA patients. figure 4A: The graph shows the percentage of patient samples which bound to the 
selected peptides citrulline-specifically at baseline and after a median of seven years of follow-up. 
figure 4b: Number of peptides recognized by 68 RA patients at baseline and after seven years of follow-up. 
Error bars indicate the minimum and maximum number of peptides recognized per patient. Boxes designate 
the 25th and 75th percentile, while the lines in the boxes indicate the median number of recognized peptides.
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The accumulation of autoantibody reactivities before disease manifestation which we 
observed in RA patients, has also been reported in other studies of human disease, such as 
SLE 12 and pemphigus 22, as well as in animal models such as the collagen-induced arthritis 
model (CIA) 23. Together, these findings suggest that epitope spreading before disease onset 
may be a commonly occurring phenomenon which, as shown for the first time by the data 
presented here, may also take place before the onset of RA.
It is intriguing that at the time of disease onset, ACPA-positive UA patients who will 
subsequently develop RA and those who will not, are already immunologically distinct 
with regards to their ACPA response. The fact that none of the tested fine specificity pep-
tides was exclusively recognized by UA-RA patients, indicates that the measurement of 
these ACPA reactivities may not have immediate clinical utility for individual patients. 
Rather, the results indicate that on the population level, the “footprint” of past epitope 
spreading (being an expanded epitope recognition repertoire) is associated with disease 
progression. These differences in the ACPA fine specificity repertoire are not an isolated 
immunological phenomenon, since UA patients who rapidly progress to RA also exhibit a 
broader use of ACPA isotypes 24. The characteristics of the ACPA response at baseline thus 
reflect the progression of the disease in UA patients. These findings are consistent with the 
hypothesis that the nature and characteristics of the ACPA response may determine disease 
development and progression, but additional studies will be required to fully elucidate the 
role of ACPA in the pathogenesis of the disease.
Although baseline sera from UA-RA patients recognized more peptides than sera from 
UA-UA patients, we could not detect a further increase in reactivity after disease onset. 
A very similar observation has been reported in SLE, where the accrual of new types of 
autoantibodies gradually increased up to the time of diagnosis and then virtually stopped 
12. These findings are also in line with previous reports which have shown that anti-CCP2-
titers and levels of ACPA isotypes decrease with time 24, 25. A possible explanation for 
these observations is the effect of immunosuppressive treatment such as DMARDs, which 
are commonly prescribed once the diagnosis of RA has been established. This makes it 
difficult to discern if the observed decrease in ACPA reactivities over time is due to the 
natural course of the immune response or to the influence of medication. 
The patients studied in the current investigation were generally treated with mono-
therapy with conventional DMARDs. Consistent with the severe phenotype known to be 
associated with ACPA-positive disease, medication was frequently changed in all patients, 
which hampered a thorough analysis of clinical subgroups stratified for treatment. Further 
studies will be required to definitively answer the question whether specific therapies do 
or do not affect epitope recognition profiles.
Although we could not observe a further expansion of the ACPA reactivity profile after 
disease manifestation, it should be noted that the number of citrullinated epitopes investi-
gated in the current study is limited. Therefore, one cannot rule out that epitope spreading 
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after disease onset was in fact present, but could not be detected. However, the data of 
the cohort of individuals who had donated blood before disease onset, reveal that there 
is clearly epitope spreading of the ACPA response before disease onset, suggesting that 
the five peptides had enough discriminative potential to allow the detection of diversifica-
tion of epitope recognition. Nonetheless, further studies using a larger set of citrullinated 
antigens will be required to fully explore the possibility of epitope spreading after disease 
onset in RA.
When investigating epitope spreading, two other immunological phenomena must be 
taken into account: antibody cross-reactivity and affinity maturation. With regard to the 
peptides used in the current study, a previous report described that the HLA SE alleles 
are strongly associated with the recognition of citrullinated vimentin 59-74, but not with 
the recognition of citrullinated fibrinogen β 36-52, indicating that there was little cross-
reactivity between the different epitopes 21. The fine specificity of the ACPA response as 
investigated in the current study, was also associated with the presence of HLA SE alleles 
(data not shown). Furthermore, in the current study several patients were single-positive for 
each specific peptide, which rules out a large extent of antibody cross-reactivity. Affinity 
maturation, which leads to a higher antibody binding affinity and thus makes antibodies 
easier to detect by ELISA, could in this manner, have contributed to the increase in epitope 
recognition which we measured using this method. With regard to our understanding of 
the immune response in vivo, however, the distinction between epitope spreading and 
affinity maturation is, in this case, largely inconsequential, as the effect would be the 
same: increased antibody reactivity to a certain citrullinated epitope. 
The in vitro methodology employed in this study cannot mimic the way in which antigen 
is presented in vivo and was therefore not intended as a technique by which to identify 
a specific ACPA fine specificity as the culprit of disease onset or exacerbation. Instead, 
the study was designed to assess the extent to which epitope spreading occurs in associa-
tion with disease progression by using a selected set of peptides as a model for ACPA 
diversification. It was not possible to discern clusters of peptides which were preferentially 
recognized together, nor was it possible to identify a specific sequence in which the ACPA 
reactivities developed over time. 
In summary, our findings indicate that the recognition of citrullinated epitopes expands 
before the development of arthritis. Furthermore, at the time of clinical presentation, UA 
patients who will later develop RA already recognize more citrullinated antigens than UA 
patients who will not develop RA. During disease progression from UA to RA, as well as 
during the further disease course of RA, we did not observe additional changes in anti-
citrulline reactivity. Together, these data indicate that an important part of the evolution of 
the ACPA response may take place before disease onset.
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AbsTrACT 
objectives HLA shared epitope (SE) alleles are associated with joint destruction, the 
presence of anti-citrullinated protein antibodies (ACPA) and the ACPA fine specificity 
repertoire in rheumatoid arthritis (RA). A large variation in joint destruction is seen within 
the ACPA-positive patient population, and it is conceivable that certain ACPA reactivities 
contribute to radiological damage. Here, we investigated whether ACPA fine specificities, 
which are formed under the influence of SE alleles, associate with the extent of radio-
graphic joint damage. 
methods Antibodies recognizing six citrullinated epitopes were determined in sera of 330 
ACPA-positive RA patients genotyped for SE alleles. The association between SE alleles, 
ACPA fine specificity and radiographic joint damage was assessed using radiographic 
follow-up data. A second cohort of 154 RA patients with 5- and 10-year radiographic 
follow-up was used for replication.
results SE alleles predisposed to the recognition of certain citrullinated epitopes. How-
ever, none of the ACPA fine specificities studied influenced radiographic joint damage. 
Importantly, although SE alleles associated with radiographic damage in the total RA 
population, this association was no longer detectable after stratification for the presence 
of ACPA.
Conclusions SE alleles are instrumental in shaping the ACPA repertoire. However, ACPA 
fine- specificities formed under the influence of SE alleles do not seem to affect joint 
destruction.
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InTroDuCTIon
HLA shared epitope (SE) encoding genes are the most prominent genetic risk factor 
for rheumatoid arthritis (RA). SE alleles exert their risk effect by predisposing for anti-
citrullinated protein antibody (ACPA)-positive RA 1. This and other findings have led to 
the concept that RA represents at least two distinct disease entities (ACPA-positive and 
–negative RA) with different pathogenetic mechanisms 2, 3.
The strength of the SE effect on susceptibility to ACPA-positive disease depends on the 
number of SE alleles present, with two alleles conferring a higher risk of disease than one 
allele. The fact that ACPA are also found in SE-negative patients, albeit in lower frequency, 
indicates that SE alleles are not absolutely required for the development of ACPA 1. It 
has been postulated that SE alleles primarily facilitate priming and activation of T helper 
cells, which can then provide help to ACPA-producing B cells. Such help is required for 
isotype switching and generation of a potent and long-lasting antibody response. 
It is conceivable that certain citrullinated antigens are more potent than others in acti-
vating T cells in the context of SE alleles. Only very few T-cell epitopes have so far been 
found, and no skewing of T-cell responses has been described. However, SE alleles were 
found to associate with antibodies targeting peptides from citrullinated vimentin, but not 
with the presence of antibodies recognizing citrullinated fibrinogen 4. This differential 
modulation of the ACPA response by SE alleles, and the fact that disease phenotypes 
vary greatly among ACPA-positive patients, has raised the question whether certain ACPA 
fine specificities might associate with a more severe disease phenotype. If so, designing 
assays that test for these specificities would be of prognostic value and could influence 
treatment decisions in clinic. 
In the present study, we analysed the relation between SE alleles, different ACPA 
fine specificities and their independent effects on disease outcome. 
meThoDs
Patients and Radiographs
ACPA fine specificity was determined on baseline serum samples of RA patients participat-
ing in the Leiden Early Arthritis Clinic (EAC) 5. The present study included patients who 
presented between March 1993 and November 2006 and who fulfilled the 1987 revised 
ACR criteria for RA within the first year of follow-up. Annual radiographs of hands and feet 
were assessed as previously described 6.
Replication of the association between SE alleles and radiographic progression in rela-
tion to ACPA status was performed using data of Norwegian RA patients with a maximum 
disease duration of 4 years included in 1992-1993 in the European Research on Incapaci-
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tating Disease and Social Support (EURIDISS) project 7, 8. Radiographs of the hands were 
available for 154 patients at baseline and assessed according to the Sharp-van der Heijde 
method 9 by one experienced reader with known time order.
Anti-CCP2 assays 
Anti-CCP2 antibody levels were measured by ELISA (EAC: Immunoscan RA Mark 2; Eu-
rodiagnostica, Arnhem, The Netherlands; EURIDISS: INOVA Diagnostics, San Diego, CA, 
USA).
ACPA fine specificity assays
Antibodies against the citrullinated (Cit) and the arginine-containing form of two peptides 
derived from vimentin (Vim1-16; Vim59-74), two peptides derived from fibrinogen (Fibα 
27-43; Fibβ 36-52), one peptide derived from alpha-enolase (Eno 5-20) and against citrul-
linated myelin basic protein (MBP) were determined by in-house ELISA as previously 
described 4, 10.
Cut-off values were defined as the mean plus three times the standard deviation of 
the values of 30 control subjects (anti-CCP-negative EAC patients diagnosed with gout). 
Recognition was deemed to be citrulline-specific when the following requirements were 
met: 1) OD value citrullinated peptide > cut-off, and 2) OD difference (=OD citrullinated 
peptide – OD arginine-containing peptide) ≥ 0.1. The number of patients recognizing both 
the citrullinated and the arginine-variant above cut-off levels was small (~ 3%).
Statistical analysis
Association between fine specificity recognition and SE alleles was assessed using chi-
square tests. Association of fine specificities with the rate of joint destruction was assessed 
using a repeated measurement analysis on log-transformed radiological data. Adjust-
ments were made for age, gender and treatment strategy used at the time of inclusion 
as previously described 5, 6. No association between inclusion period and recognition of 
separate ACPA fine specificities was found (data not shown). For the EURIDISS cohort, 
non-parametric Mann-Whitney U test was used because of non-normal distribution of the 
data despite log-transformation. For comparison, Mann-Whitney U test was also applied 
to the Leiden EAC where indicated.
resulTs
HLA SE alleles associate with several ACPA fine specificities
SE alleles associate with the presence of certain ACPA fine specificities 4. We first extended 
these findings by analyzing reactivity to more citrullinated epitopes, by increasing the 
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number of patients studied, and by analyzing the effect of the SE gene dose on ACPA fine-
specificity. Three out of six citrullinated epitopes studied associated with the presence of 
SE alleles (Table 1). Reactivity to citrullinated vimentin 59-74, citrullinated alpha-enolase 
5-20 and citrullinated MBP was found in significantly increased frequency in SE-positive 
patients, whereas no such effect was observed for the other three antigens. The effect was 
independent of the number of SE alleles, as patients with one or two SE alleles displayed 
a comparable profile of ACPA epitope recognition. These data indicate that one SE allele 
is sufficient to facilitate the development of certain ACPA fine specificities, and that pres-
ence of a second SE allele does not further skew the ACPA profile towards more frequent 
recognition of a specific epitope. 
The ACPA fine specificity repertoire does not predict future radiographic progression
ACPA-positive patients suffer from more severe disease than ACPA-negative patients. 
However, it is unknown whether distinct ACPA fine specificities are pathogenetically driv-
ing the inflammatory process and thus lead to a more severe disease outcome. Consider-
ing radiographic joint damage as the most objective sign of disease severity in RA, we 
analyzed the association between baseline recognition of specific citrullinated antigens 
and progression of radiographic joint damage in ACPA-positive patients over the course 
of 5 years (Figure 1, panels A and B). The ACPA fine specificity repertoire in individual 
patients did not change during this time period 11. We did not detect a difference in 
radiographic outcome in patients who harbour ACPA of one of the fine specificities tested. 
Also, patients with ACPA that recognized more citrullinated peptides did not suffer from a 
higher degree of progression of joint damage than patients with a limited ACPA repertoire 
(Figure 1, panel C). These data indicate that harbouring ACPA of any of the specificities 
tested has no direct influence on the progression of radiographic joint damage. 
Table 1: Association of hlA se alleles with ACPA fine specificity.









vimentin 1-16 8/63 (13%) 25/188 (13%) 8/73 (11%) 41/324 (13%)
vimentin 59-74 16/64 (25%) 100/190 (53%) 46/73 (63%) 162/327 (50%)
fibrinogen-α 27-43 20/64 (31%) 51/190 (27%) 15/73 (21%) 86/327 (26%)
fibrinogen-β 36-52 43/63 (68%) 128/181 (71%) 52/73 (71%) 223/317 (70%)
α –enolase 5-20 12/64 (19%) 70/190 (37%) 27/73 (37%) 109/327 (33%)
mbP 30/64 (47%) 128/190 (67%) 51/73 (64%) 209/327 (64%)
Displayed is the number of patients within the ACPA-positive patient population who harbor ACPA 
recognizing defined citrullinated antigens. Chi-squared test over all 3 allelic groups (Vim 1-16:  p = 0.88; 
Vim 59-74: p < 0.001; Fib-α: p = 0.35; Fib-β: p = 0.92; α-enolase: p = 0.022; MBP: p = 0.006).
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figure 1: Association between different ACPA fine specificities and radiographic progression. 
figure 1A, b: Median Sharp-van der Heijde scores (SHS) during 5 year follow-up of ACPA-positive patients 
from the Leiden EAC testing positive or negative for six different ACPA fine specificities at baseline. 
figure 1C: Median SHS in ACPA-positive patients grouped by the number of ACPA fine specificities 
recognized. All statistical comparisons (repeated measurement analysis) were non-significant (p>0.05). 
Numbers of patients in each group are given in the table below each figure. The line representing the group 
of patients recognizing six fine specificities diverts from the rest due to the low number of patients in this 
group. In order to highlight this, this group is depicted with a dotted line. Radiographic data was available 
for n=292 ACPA-positive patients at baseline and n=142 at year 5.
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Stratification for ACPA status abolishes the effect of HLA SE alleles on 
radiographic joint damage
None of the fine specificities tested was found to associate with radiographic progres-
sion. A drawback of this analysis is that lack of association does not exclude that the 
investigation of other citrullinated peptides would have revealed a positive association 
with long-term joint damage. As this limitation can persist in case more (non-associating) 
reactivities would be analyzed, we reasoned that an additional way to investigate the 
relationship between the ACPA recognition profile and radiographic outcome is to study 
the effect of SE alleles on joint damage in ACPA-positive disease only. Since SE alleles af-
fect the recognition of certain citrullinated epitopes (Table 1), SE alleles can be interpreted 
as a surrogate marker for the constitution of the ACPA response. 
figure 2: shared epitope (se) alleles exert no effect on radiographic progression after stratification for ACPA. 
Median Sharp-van der Heijde scores (SHS) in relation to SE positivity in the entire RA population and after 
stratification for ACPA-positive disease in patients of the Leiden Early Arthritis Clinic (panels A and B) and of 
the EURIDISS cohort (panels C and D). 
For the Leiden EAC: radiographic data was available for n=481 patients at baseline and n=214 at year 5, of 
which n=266 were ACPA-positive (data for n=132 available at year 5). Figure 2A: Repeated measurement 
analysis: p = 0.013; Mann-Whitney U test p < 0.001 at year 1, p < 0.001 at year 2, p = 0.007 at year 3, p = 
0.005 at year 4, p = 0.012 at year 5; Figure 2B: Repeated measurement analysis: p > 0.05; all Mann-Whitney 
U test p-values > 0.05. 
For the EURIDISS cohort: radiographic data was available for n=154 patients at baseline and n=142 at year 
10, of which n=94 were ACPA-positive (data for n=83 available at year 10). Figure 2C: Mann-Whitney U test 
p = 0.029 at baseline, p < 0.001 at year 5, p < 0.001 at year 10; Figure 2D: Mann-Whitney U test p = 0.36 at 
baseline, p = 0.93 at year 5, p = 0.97 at year 10.
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While SE alleles associated with the degree of radiographic joint damage in the total RA 
population (Figure 2A), they no longer contributed to radiographic joint damage in ACPA-
positive disease (Figure 2B). We sought replication of this observation in the Norwegian 
EURIDISS cohort. The findings in this cohort with 5- and 10-year radiographic follow-up 
confirmed our results: there was no association between the presence of SE alleles and 
radiographic damage in ACPA-positive disease (Figure 2C and D).
DIsCussIon
Recent findings on ACPA fine specificity and its association with SE alleles have fuelled 
a hypothesis in which (a) ACPA are pathogenetically driving the disease and in which (b) 
certain ACPA fine specificities (developing preferentially under the influence of SE alleles) 
could be more pathogenic than others, leading to more severe joint destruction over time 
4, 12. Further insights into which ACPA fine specificities might be associated with disease 
severity could therefore have prognostic value and contribute to our understanding of 
disease pathogenesis. 
Here, we could not detect an association between ACPA fine specificities and radio-
graphic joint damage. An anti-peptidylcitrulline immune response to 3 out of 6 of the 
epitopes studied developed preferentially in patients harboring SE alleles, but this did 
not translate into more severe radiographic outcome. Also, the number of citrullinated 
epitopes recognized by an individual patient did not influence the degree of joint destruc-
tion. Although we accounted for baseline treatment strategy in this analysis, and although 
no association between year of inclusion and recognition of the separate ACPA fine 
specificities was found, we cannot fully exclude that treatment effects later in the disease 
course could have influenced our results. The number of citrullinated epitopes also limits 
our study, and it cannot be excluded that other epitopes would have been more useful for 
this purpose. We addressed this issue by using SE alleles as a surrogate marker for those 
ACPA fine specificities that develop under the influence of SE alleles. After stratification for 
ACPA, SE alleles no longer contributed to joint damage. Based on this finding, we consider 
it unlikely that a SE-associated ACPA fine specificity can be identified that predicts disease 
course in RA. If such a predictive recognition profile exists, antibodies recognizing this 
epitope are likely to be generated independent of SE alleles. 
Our findings are relevant for strategies aimed at identifying patients that are at risk for 
rapidly progressive disease and provide evidence that the recognition profile of the ACPA 
response is unlikely to have a relevant impact on radiographic progression. 
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In a recent publication in Nature Genetics 1, Mahdi et al. investigated gene-environment 
interactions and the specific association with autoantibodies to citrullinated α-enolase, in 
order to get an impression of the etiologic importance of this antigen in susceptibility to 
rheumatoid arthritis (RA). Mahdi et al report that a specific interaction is present between 
genotype, smoking and autoimmunity to a citrullinated α-enolase peptide (CEP-1), sug-
gesting that the major genetic and environmental susceptibility factors for rheumatoid 
arthritis are associated mainly with the development of anti-CEP1-positive disease. 
As referenced by Mahdi et al 1, pivotal pathophysiological insight has been obtained 
in the past decade by the identification of anti-citrullinated protein antibodies (ACPA). 
ACPA are highly specific for RA and have been implicated in disease etiology 2, 3. It has 
now become clear that RA represents two main syndromes, ACPA-positive- and ACPA-
negative disease. These are most likely etiologically distinct as the most prominent genetic 
risk factor, the HLA-DRB1 shared epitope alleles (HLA-DRB1 SE alleles), as well as the 
most important environmental risk factor, smoking, are predominantly restricted to ACPA-
positive RA 4, 5. 
figure 1: risk of autoantibody-positive disease conferred by hlA-Drb1 se alleles, smoking and their 
interaction.
Bars are colored black from OR 0 to 1, light-grey to indicate the risk conferred by the presence (1 or 2 
alleles) of HLA-DRB1 SE alleles, white for the risk conferred by smoking, and dark-grey for the interaction. 
The effect the HLA-DRB1 SE alleles was corrected for the effect of smoking and vice versa, therefore the 
depicted numbers differ slightly from the figures listed in Table 1.
Anti-CCP-negative RA patients were used as the reference category for all comparisons.
figure 1A: Odds ratio’s for anti-CCP-positive RA patients who were either negative of positive for the 
citrullinated fibrinogen peptide (cFib- and cFib). 
figure 1b: Odds ratio’s for anti-CCP-positive RA patients who were either negative of positive for the 
citrullinated vimentin peptide (cVim- and cVim+).
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Previously, we have shown that the HLA-DRB1 SE alleles influence the specificity of the 
antibody response against citrullinated antigens, using peptides derived from citrullinated 
fibrinogen (cFib) and citrullinated vimentin (cVim) 6. These observations indicated that at 
least part of the associations reported by Mahdi et al. may also exist for other citrullinated 
antigens. We have therefore performed further studies to investigate whether similar inter-
actions between genetic and environmental risk factors could also be found for reactivity 
against other citrullinated peptides.
Samples from 701 patients participating in the Leiden Early Arthritis Clinic (EAC) were 
investigated in this case-only analysis 7. All patients fulfilled the 1987 criteria for RA of the 
American College of Rheumatology. Anti-CCP2-antibodies were determined by enzyme-
linked immunosorbent assay (ELISA) (Immunoscan RA Mark 2; Eurodiagnostica, Arnhem, 
The Netherlands). Antibodies against both the citrullinated and the uncitrullinated form 
(arginine-variant) of linear peptides derived from vimentin (vimentin 59-74) and fibrino-
gen (fibrinogen β 36-52) were determined by ELISA as described previously 6. 361 RA 
patients were anti-CCP-negative and of the 340 anti-CCP-positive RA patients, 247 (73%) 
recognized cFib, and 167 (49%) recognized cVim. 
For all analyses, a case-only study design was used with ACPA-negative rheumatoid 
arthritis patients from the EAC as the reference group. Logistic regression analysis was 
used to determine the separate effects of the HLA-DRB1 SE alleles and smoking on the 
specificity of the ACPA response in individuals with rheumatoid arthritis. The association 
of HLA-DRB1 SE alleles was the strongest in the subset of individuals who were anti-cVim-
positive (Table 1 and Figure 1)
Interaction analyses were performed investigating both departure from additivity and 
departure from multiplicativity using logistic regression analysis 8. The combined effect 
of the HLA-DRB1 SE alleles and smoking in susceptibility to rheumatoid arthritis was the 
largest in the anti-cVim-positive subset (Figure 1). For this subset, a very high OR of 58 
(95%CI 19.6-174.9) was present for smokers who were homozygous for the HLA-DRB1 
SE alleles, compared to an OR of 5.4 (95% CI 2.1-14.2) for the anti-cVim-negative subset 
(Table 1). This OR of 58 is very similar to the OR of 53 reported by Mahdi et al. in the anti-
CEP1-positive patients with the same combination of risk factors (homozygous HLA-DRB1 
SE alleles and smoking). 
Biological interaction, defined as departure from additivity, can be quantified using 
three measures: the relative excess risk due to interaction (RERI); the attributable propor-
tion (AP) due to interaction; and the synergy index (S). While all measures of biological 
and multiplicative interaction were significant for anti-CCP-positive RA patients who also 
recognized cFib, there was no significant biological interaction for anti-CCP-positive pa-
tients who did not recognize cFib (Table 1). With regard to the recognition of citrullinated 
vimentin, the interaction analysis revealed even larger differences. While the RERI and the 
AP indicated some degree of biological interaction for the anti-CCP-positive anti-cVim-
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Table 1, Part 2: The effect of the hlA-Drb1 se alleles, smoking and the interaction between these two risk 
factors on the specificity of the ACPA response.
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Listed are the number of patients per group which were positive for HLA-DRB1 SE alleles, smoking or both 
of these risk factors. The odds ratios (OR) are the result of univariate analysis. The interaction between the 
HLA-DBR1 SE alleles and smoking is quantified by the additive and multiplicative measures of interaction.
The assay for citrullinated fibrinogen yielded ambiguous results in 2 patients, therefore the table contains 
the results of 340 anti-CCP2-positive patients tested for anti-citrullinated vimentin (cVim)-reactivity, and 338 
anti-CCP2-positive patients tested for anti-citrullinated fibrinogen (cFib)-reactivity. Smoking information was 
available for 44 anti-CCP2-negative patients of whom HLA SE information was lacking, and for a total of 330 
anti-CC2-positive patients.
Table 1, Part 1: The effect of the hlA-Drb1 se alleles, smoking and the interaction between these two risk 
factors on the specificity of the ACPA response.
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negative subgroup, all three measures were significant for the anti-cVim-positive cases. 
The multiplicative interaction measure showed borderline significance in the anti-CCP-
positive anti-cVim-negative subgroup, resembling the significant multiplicative interaction 
Mahdi et al. found in the anti-CCP-positive anti-CEP-1-negative subgroup. In agreement 
with Mahdi et al., we considered departure from additivity as the more appropriate statisti-
cal method for these analyses.
Our data show that the presence of established genetic and environmental risk factors 
predispose to the recognition of cVim and to a lesser extend cFib, autoantigens which 
have also been implicated in rheumatoid arthritis 9. These data complement the findings 
reported by Mahdi et al. 1 by demonstrating that the interaction between genotype, smok-
ing and autoimmunity to citrullinated antigens is not confined to citrullinated α-enolase. 
Together, these observations imply that the combination of genetic and environmental 
risk factors predispose to a broader citrullinated epitope recognition profile, possibly by 
influencing the magnitude of the anti-citrullinated protein response. 
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AbsTrACT
objective Recent data suggest that a gene-environment interaction exists between smoking 
and the HLA SE alleles in shaping the autoimmune reaction towards specific citrullinated 
antigens. Here, we determined the effects of HLA SE alleles and TE (Tobacco Exposure) 
on the immune response against various citrullinated antigens. These associations were 
analyzed in the ACPA-positive stratum to control for the possibility that found associations 
are explained by the known interaction between HLA SE alleles and TE with regard to 
ACPA status. 
methods The reactivity of 661 RA patients against several citrullinated antigens from 
vimentin, fibrinogen, enolase and myelin basic protein was determined by ELISA. The 
effects of the HLA SE alleles and TE were assessed by logistic regression analysis. Biologic 
interaction was analyzed by investigating if the effects of the risk factors combined exhib-
ited departure from additivity.
results A significant interaction between TE and HLA SE alleles was present for the pres-
ence of ACPA as reported previously. When these interaction effects were studied for 
several ACPA fine specificities, significant interactions were noted for several citrullinated 
peptides. However these interactions were not present after stratification for ACPA status, 
indicating that the interaction between TE and HLA SE alleles does not influence autoim-
munity towards specific citrullinated antigens, but rather to ACPA development. 
Conclusion Our data indicate that the gene-environment interaction between HLA SE 
alleles and smoking does not appear to shape the reactivity of the ACPA response. These 
data suggest that smoking promotes non-specific citrullination rather than citrullination 
of specific antigens.
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InTroDuCTIon
Rheumatoid arthritis (RA) is a systemic autoimmune disease involving inflammation of the 
joints. The detection of anti-citrullinated protein antibodies (ACPA), often measured by 
an anti-citrullinated antibodies assay (anti-CCP2), is an accepted diagnostic tool for RA 1. 
Anti-CCP antibodies are highly specific for RA, can be detected years before the first clini-
cal manifestation of RA 2,3 and are reported to be a good predictor for the development of 
RA 4. Anti-CCP antibodies recognise multiple citrullinated peptides and proteins and are 
thus a collection of ACPA 5. Likewise ACPA have been shown to be able to initiate and 
enhance arthritis in murine models of arthritis 6,7 and human ACPA are able to activate 
both FcR-positive cells 8,9 and the complement system arguing that they could play a role 
in disease pathogenesis 10.
ACPA-positive and ACPA-negative disease have been shown to be associated with dif-
ferent genetic and environmental risk factors, fuelling the hypothesis that different patho-
physiological mechanisms are underlying these two separate disease subsets 11,12. Some 
types of human leukocyte antigens (HLA alleles), particularly HLA-DRB1 alleles encoding 
an amino acid sequence named Shared Epitope (SE), are known to be associated with RA 
susceptibility 13, more specifically susceptibility to ACPA-positive RA 14. 
It has been shown that ACPAs can recognize a variety of citrullinated antigens, includ-
ing citrullinated fibrinogen (cFib) and citrullinated vimentin (cVim), which is also known 
as the Sa antigen 15. However not all ACPA-positive sera will recognize all citrullinated an-
tigens, as has been shown by analyzing the reactivity against different citrullinated peptide 
antigens 5,16. In ACPA-positive patients, HLA SE alleles have been shown to predispose for 
the development of antibodies against a peptide from cVim, but not for the development 
of antibodies recognizing a peptide from cFib. These data indicate that HLA SE alleles 
influence not only the magnitude, but also the specificity of the ACPA response 17. 
Like the HLA SE alleles, the environmental factor Tobacco Exposure (TE) is also known 
to predispose mainly to autoantibody-positive disease 18. The combined effect of HLA SE 
alleles and TE has been shown to exceed the sum of their single effects: a phenomenon 
known as biological interaction 19-21. A gene-environment interaction thus exists between 
the HLA SE alleles and TE with regard to the development of ACPA-positive RA. This inter-
action is displaying a dose-dependent effect as there is an even stronger gene-environment 
interaction present for heavy cigarette smoking 22.
Recently, it has been reported that a specific interaction exists between the presence 
of HLA-DRB1*04, TE and the specific recognition of a peptide derived from citrullinated 
enolase (CEP1) 23. Such epidemiological studies might be of relevance as they link estab-
lished genetic and environmental risk factors to an autoimmune response against specific 
citrullinated antigens that are expressed in the inflamed joint of RA patients. Therefore, 
such findings might provide relevant clues to aid the understanding of the pathological 
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mechanism underlying RA-development and progression. More recently however, we 
have reported a similar interaction for two peptides derived from two other citrullinated 
proteins, cVim and cFib 24. These latter data indicate that the observed interaction might 
not be confined to an autoimmune response against a specific citrullinated antigen. 
Rather, these findings indicate that these interaction effects extend to several citrullinated 
autoantigens, which might even be explained by a ‘general’ predisposition for ACPA 
development. Here, we wished to analyze in greater detail the extent of the interaction 
between HLA SE alleles and TE on the antigen-recognition profile of ACPA, especially in 
ACPA-positive individuals to exclude the possibility that the association is caused by the 
presence of ACPA rather then by the presence of an autoimmune reaction towards specific 
citrullinated epitopes.
mATerIAls AnD meThoDs 
Patient population
The patients who were analyzed in this study were derived from the Leiden Early Arthri-
tis clinic (EAC) cohort (n=661). The Leiden EAC is an inception cohort of patients with 
recent-onset arthritis (symptoms duration <2 years) that was started at the Department of 
Rheumatology of the Leiden University Medical Center in 1993 and is described in detail 
by de Rooy et al 25. All patients fulfilled the American College of Rheumatology (formerly 
the American Rheumatism Association) 1987 revised criteria for the classification of RA 
26 within 1 year of follow up (EAC cohort). At baseline, patients were asked by trained 
research nurses if they had ever or never smoked. Cumulative smoking data were not 
included in these analyses due to insufficient power. The protocols were approved by the 
relevant local ethics committee and all participants provided informed consent. 
Genotyping
DNA was collected at baseline for genotyping of the HLA-DRB1 region by polymerase 
chain reaction and hybridization to sequence-specific oligonucleotides as described 
previously 27. The HLA-DRB1*01:01, *01:02, *04:01, *04:04, *04:05, *04:08, *10:01 and 
*14:02 alleles were classified as the SE alleles. 
Anti-CCP2 assays
Total IgG anti-CCP2 was measured in sera collected at baseline by enzyme-linked im-
munosorbent assay (ELISA) (Immunoscan RA Mark 2; Eurodiagnostica, Arnhem, The Neth-
erlands). Samples with a value above 25 units/ml were considered positive according to 
the manufacturer’s instructions. Individuals with antibodies against CCP2 were considered 
ACPA-positive. 
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ACPA fine specificity assays
ELISA assays were developed, as previously described 17, against peptides derived from 
cVim, cFib and citrullinated α-enolase 5-20 (cEno5-20). Antibody reactivity against both 
citrullinated (Cit) and the uncitrullinated form of two linear peptides derived from vimentin 
(Vim 1-16: STCitS VSSS SYCitCit MFGG and Vim 59-74: VYAT CitSSA VCitLCit SSVP), two 
linear peptides derived from fibrinogen (Fibα 27-43: FLAE GGGV Cit GPR VVER H and 
Fibβ 36-52: NEEG FFSA CitGHR PLDK K) and one linear peptide derived from α-enolase 
(Eno 5-20: KIHA CitEIF DSCitG NPTV) were determined by ELISA 28. 
Briefly, streptavidin-coated pre-blocked microtiter plates (Thermo Scientific) were 
coated with the different Fib, Vim and Eno peptides, followed by incubation with the 
serum samples. After washing, antibodies were detected with a rabbit anti-human IgG 
HRP-conjugated antibody (P0214; DAKO, the Netherlands) and 2,2’-Azinobis [3-eth-
ylbenzothiazoline-6-sulfonic acid]-diammonium salt (ABTS) as the coloring substrate, 
according to the recommendations of the manufacturer (Sigma-Aldrich). 
Citrullination of MBP (Sigma-Aldrich) and the specific ELISA was performed as previ-
ously described 29. Antibodies reactive with citrullinated MBP were determined in 1:100 
diluted sera.
Although there are also other targets for ACPA 30,31 we chose primarily to investigate 
epitopes from these proteins because they have been most consistently identified as citrul-
linated autoantigens 15,32,33. We elected to use citrullinated myelin basic protein (MBP) 
as a citrullinated protein antigen as its ELISA has been previously standardized to be the 
clinical equivalent (positive versus negative) of the original anti-Sa (cit-Vimentin) western 
blot assay 29. 
Cut-off values for the citrulline-specific responses were calculated as previously de-
scribed in each assay and were defined as 3 standard deviations above the value of the 
mean concentration of the serum samples obtained from 41 gout controls. In fine specific-
ity studies, citrulline-specific signals were defined as a positive signal, above the cut-off 
based on gout, against the citrullinated antigen and a minimum difference of 0.1 in delta 
OD values compared to the non-citrullinated antigen 34.
The fine specificity reactivity was confined to the ACPA-positive subset. More than 98% of 
the individuals recognizing a specific fine specificity epitope were also CCP2-positive; there-
fore we did not analyze all the CCP2-negative patients for their fine specificity repertoire. 
IgM-RF was determined by enzyme-linked immunosorbent assay (ELISA). Anti-CCP3 auto-
antibodies (IgA and IgG subforms) and anti-MCV autoantibodies were also measured by ELISA 
(Quanta Lite CCP version 3.1 for IgG/IgA from Inova Diagnostics San Diego, USA as well as 
ELISAs from Orgentec Diagnostika, Mainz, Germany). The cutoff level for both the anti-CCP3 
test and the anti-MCV test was 20 arbitrary units, according to the manufacturers’ instructions
Sera were tested for ANF (anti-nuclear factor) using indirect immunofluorescence at a 
1:40 dilution on Hep-2000 cells (Biomedical diagnostics). 
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Statistical analysis
Logistic regression analysis was performed to determine the odds ratio’s (ORs) and 95% 
confidence intervals (95% CI) of developing autoantibody-positive relative to autoanti-
body-negative RA for the risk factors HLA SE alleles and smoking. The association between 
the recognition of different citrullinated epitopes and a gene-environment interaction was 
analysed using the same method. To take into account the effect of the known association 
of HLA SE alleles and TE with ACPA status, stratified analyses were performed within the 
ACPA-positive stratum. 
Biological interaction, defined as the deviation from additivity, was evaluated by three 
measures: RERI, relative excess risk due to interaction; AP, the attributable proportion due 
to interaction; and S, the synergy index. These measures indicate significant biological 
interaction if they differ from 0 (RERI and AP) or 1 (S). RERI can be interpreted as the 
excess risk due to interaction relative to the risk without exposure. AP is interpreted as the 
attributable proportion of disease which is due to interaction among persons with both 
exposures. The synergy index can be interpreted as the excess risk from exposures (to both 
exposures) when there is interaction relative to the excess risk from exposure (to both 
exposures) without interaction 35. For a more detailed definition of these measures please 
refer to Rothman 36. To obtain the parameter estimates needed for calculating these three 
measures, a logistic regression model was fitted 21. Data were analyzed using the Statisti-
cal Package for the Social Sciences (SPSS) 17.0 and p-values below 0.05 were considered 
to be statistically significant.
resulTs
Effect of single risk factors on ACPA fine specificity
To investigate whether HLA SE alleles and TE are associated with specific reactivities 
within the total ACPA response, the CCP2 status was determined in 661 RA patients, of 
whom 348 were found to be anti-CCP2-positive (Table 1). In baseline sera of these 348 
ACPA-positive as well as in 90 ACPA-negative RA patients we determined the reactivity 







gender (female) 450/661 (68.1%) 228/348 (65.5%) 222/313 (70.9%)
mean age at inclusion 
(mean ± sD)
55.8± 16 54.7± 15 57.1± 16
Anti-CCP2-positive 348/661 (52.6%) 348/348 (100%) 0/313 (0%)
rf-positive 321/537 (59.8%) 267/305 (87.5%) 54/232 (23.3%)
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against two citrullinated vimentin peptides (cVim1-15 and cVim59-74), two citrullinated 
fibrinogen peptides (cFibα and cFibβ), citrullinated α-enolase peptide and cMBP. Over 
98% of the individuals positive for a specific citrullinated epitope, were also ACPA-positive 
(Table 2). Among ACPA-positive RA patients, 50% displayed antibodies against cVim 59-
74 and 12% against cVim1-15. The highest percentage of reactivity was found for cFibβ, 
for which 70% of the ACPA-positive RA patients displayed reactivity. The cEno peptide 
was recognized by 34% of the patients and cMBP by 65%. Almost all ACPA-positive 
individuals were also positive for MCV and CCP3 as described before 37.
An association between the presence of HLA SE alleles and the recognition of virtually 
all citrullinated peptides was found when analyzing all RA patients, ACPA-positive and 
ACPA-negative (Table 3). The strongest association for HLA SE alleles was found for the 
recognition of the Vim59-74 peptide (OR=8.4 (95% CI 4.8-14.8)). Similar associations 
were found for other citrullinated reactivities. To determine whether the presence of the 
HLA SE alleles influences the recognition of specific citrullinated epitopes, we performed 
similar analyses in the ACPA-positive stratum only. In doing so, we control for the pos-
sibility that the results described above are explained by the known association between 
HLA SE alleles and ACPA status, rather than by an influence of the HLA SE alleles on 
specific epitope recognition. Within the ACPA-positive subset we still found a significant 
association between HLA SE alleles and some, but not all citrullinated epitopes (Table 4). 
This suggests that HLA SE alleles are involved in shaping the immune response against 
specific citrullinated antigens. 
Likewise, we performed a similar analysis to investigate the association between TE 
and the recognition of citrullinated peptides. This analysis revealed smaller, but similar 
associations (Table 3). The strongest association was found between cEno-recognition 
and TE, with an OR of 3.0 (95% CI 1.9-4.9). To analyze whether the observed associa-
tion between TE and the recognition of citrullinated epitopes was also specific for the 
Table 2. Percentage of individuals positive for different fine specificity epitopes.
        rA
  (max n=658)
    Anti-CCP2-positive
  (max n=345)
   Anti-CCP2-negative








0-3 cit reactivities #
4-8 cit reactivities #
  42/652    (6%)
172/658  (26%)







  42/342  (12%)
171/345  (50%)





 84/284   (30%)
200/284  (70%)
  0/89  (0%) 
  1/92  (1%)
  0/92  (0%)
  1/89  (1%)
  2/92  (2%)
  1/92  (1%)
 42/88 (48%)
 91/92 (99%)
  1/92    (1%)
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recognition of certain epitopes rather than the known association between TE and ACPA 
status, we analyzed the association within the ACPA-positive stratum. Only an association 
remained between TE and cEno-recognition (OR = 1.7 (95% CI 1.1-2.8)), while the other 
citrullinated epitopes were no longer significantly associated with TE (Table 4). This may 
indicate that TE might play a modest role in broadening of the immune response against 
some, but not all, citrullinated antigens. 
Effect of risk factor interaction on ACPA fine specificity
Next we wished to investigate the effect of biological interaction between HLA SE alleles 
and smoking with regard to ACPA fine specificity. The recognition of most fine specificity 
peptides indicated biological interaction between those two risk factors when using the 
ACPA-negative patients as reference (Table 5). Significant interaction was present in the 
recognition of cVim59-74, cFibβ and cMBP. The interaction effects were most prominent 
in the subset of people recognizing cEno (OR=16 (95% CI 6.1-42.7), RERI=9.8 (95% 
CI -0.5-20.1)) and cVim59-74 molecules (OR=14 (95% CI 6.3-31.5) RERI=7.8 (95% CI 
0.5-15.1)) (Figure 1A). Even stronger effects were observed when individuals carrying two 
HLA SE alleles were analyzed for recognition of cVim59-74, yielding an OR of 32.0 ((95% 
CI 10.9-94.1), RERI=19.7 (95% CI -10.3-49.7)) as depicted in Figure 2. 
Intriguingly, interaction effects were also noted in the subset of ACPA-positive subjects 
that did not react with for example, cVim1-16. This observation indicated that the interac-
tions detected are mainly explained by the known effects between HLA SE alleles and 
TE on ACPA status. To control for this possibility we next performed similar analyses after 
stratifying for ACPA status, in the ACPA-positive subjects only. We reasoned that if the inter-
action would only affect specific reactivities the interaction should be detectable in the total 
ACPA-positive subset as well. Remarkably no significant effects were observed anymore 
after stratification for ACPA status (Table 6). For example HLA SE alleles and TE no longer 
showed a significant interaction on the recognition of cVim59-74 with a combined effect 
OR of 4.0 (95% CI 1.7-9.6) (RERI=0.3 (95% CI -0.5-0.7)), which is comparable to the as-
sociation found for HLA SE alleles and cVim59-74 recognition only (i.e.: OR = 3.7 (95% CI 
2.0-6.8)). Similar effects were observed for the other fine specificity reactivities (Figure 1B).
In agreement with the results presented above, the AP due to interaction was compa-
rable among all the citrullinated reactivities and ACPA (Figure 3). As the AP was calculated 
before stratification for ACPA, these results indicate that the interaction effects between 
TE and HLA SE alleles did not affect the fine specificity, but rather the ACPA status. Only 
cVim1-16 displayed a slightly higher AP, but this might be a spurious finding due to 
the small number of RA patients recognizing cVim1-16 (6%). Analyzing the interaction 
between TE and only HLA DRB1*04 SE alleles resulted in similar findings with strong 
interactive effects disappearing after stratification for ACPA status (data not shown). 
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Moreover, the interaction effects between HLA SE status and TE observed in the un-
stratified analysis for recognition of more than 3 citrullinated epitopes (OR 9.7 (95% 
CI 4.9-19.1), RERI=5.1 (95% CI 0.7-9.4)) also became smaller and non significant after 
stratification for ACPA (OR 3.1 (95% CI 1.3-7.3), RERI=-0.4 (95% CI -3.0-2.2)). Similarly, 
the subset of patients carrying two HLA SE alleles recognizing for example cVim59-74 did 
figure 1: risk of autoantibody-positive disease conferred by hlA se positivity, Te and their interaction. 
Bars are colored black from OR 0 to 1, light grey to indicate the risk conferred by the presence (1 or 2 
alleles) of HLA SE alleles, white for the risk conferred by TE and dark grey for the interaction. Analyses were 
performed using the ACPA-negative individuals as reference group (1A) and the same analysis was performed 
within the ACPA-positive stratum (1B). 
figure 2: risk of autoantibody-positive disease conferred by hlA se homozygosity (sese), Te and their 
interaction. 
Bars are colored black from OR 0 to 1, light grey to indicate the risk conferred by the presence of two HLA 
SE alleles, white for the risk conferred by TE and dark grey for the interaction. Analyses were performed using 
the ACPA-negative individuals as reference group (bars 1 and 2) and the same analysis was performed within 
the ACPA-positive stratum (bar 3). 
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figure 3: Attributable proportion due to interaction between hlA se alleles and Te. 
Attributable proportion due to interaction was calculated by dividing the relative excess risk due to 
interaction by the total risk of autoantibody positive disease in patients with 1 or 2 HLA SE alleles and TE 
(AP=RERI/R11) for the different fine specificity reactivities. All the reactivities show a similar attributable 
proportion compared to anti-CCP2 positive individuals. ACPA-negative individuals were used as reference 
group. 
figure 4: risk of autoantibody-positive disease with recognition of a limited or extended number of 
citrullinated epitopes conferred by hlA se-alleles, Te and their interaction. 
Bars are colored black from OR 0 to 1, light grey to indicate the risk conferred by the presence of (1 or 
2) HLA SE alleles or HLA SE homozygosity (SESE), white for the risk conferred by TE and dark grey for the 
interaction. Analyses were performed using the ACPA-negative individuals as reference group (bars 1 and 2) 
and the same analysis was performed within the ACPA-positive stratum (bar 3). Recognising 0-3 citrullinated 
epitopes was considered limited recognition and recognising 4-8 citrullinated peptides as extended 
recognition. Eight epitopes were included in this analysis (cVim1-16, cVim59-74, cFibα, cFibβ, cEno5-20, 
cMBP, CCP3 and MCV). 
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not show signs of interaction anymore after stratification (Figure 4). Together these data 
indicate that an interaction between HLA SE alleles and TE contributes to ACPA status, but 
is not likely to contribute to the recognition of specific citrullinated antigens. 
DIsCussIon
Our results show that the apparent interaction between HLA SE alleles and TE for ACPA 
fine specificity disappears after stratification for ACPA status, indicating that this interac-
tion does not greatly affect the fine specificity of the ACPA-response.
Recently it has been suggested that a gene-environment interaction is present between 
HLA SE alleles and TE in shaping an autoimmune response specifically directed against a 
peptide derived from enolase 23. Upon further experimentation similar results were found 
with regard to the recognition of other citrullinated epitopes that were derived from vi-
mentin and fibrinogen 24. Nonetheless, these findings could be of relevance as interactions 
between genotype, smoking and autoimmunity to certain citrullinated antigens could 
further expand our understanding of RA pathogenesis.
However, in these cases no stratification for ACPA status was performed, allowing the 
possibility that the interaction effects were not explained through their influence on the 
formation of auto-immune reactions against specific citrullinated antigens, but rather on 
the formation of ACPA. In this manuscript we specifically analyzed this possibility. Careful 
analyses of these original data published by us and Mahdi et al 23,24, suggested that no 
such interaction effects were present as, for example, the AP was similar for ACPA-positive 
disease in the presence but importantly also in the absence of a specific ACPA reactivity. 
Therefore, we reasoned that if such interaction effects would only shape the response 
to certain specific, but not to other citrullinated epitopes, these effects should still be 
observed in the ACPA-positive stratum as well. We now show that this is not the case as 
the OR’s observed in the interaction analysis were similar to the OR’s observed for the 
presence of HLA SE alleles only after stratification for ACPA status. Together, these data 
thus indicate that the gene-environment interaction between TE and HLA SE alleles does 
not seem to influence the reactivity of the ACPA response. Rather, the presence of the 
HLA SE alleles seems to be the main factor in shaping the antigen recognition of the ACPA 
response as the association between HLA SE alleles and certain fine specificities like 
cVim59-74 and cEno remained, even after stratification for ACPA status, as has been re-
ported before 17. Thus, these data indicate that ACPA fine specificity recognition is mainly 
dependent on HLA SE status, and that TE and the interaction between HLA SE alleles and 
TE have a relatively minor contribution. These data also suggest that smoking promotes 
non-specific citrullination rather than citrullination of specific antigens.
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The findings presented in this manuscript add to the discussion on the role of TE and 
possibly other environmental triggers such as infection with certain pathogens, in the 
pathogenesis of RA. For example, it has been postulated that the fact that immunity to 
some citrullinated antigens associates strongly with both TE and SE alleles argues in favor 
of the hypothesis that smoking may induce citrullination of certain proteins in the lungs 
and that immunity to these post-translationally modified proteins may be determined by 
certain HLA alleles 38. This hypothesis is intriguing and warrants further investigation, 
also because it would incriminate certain citrullinated proteins and/or epitopes in the 
break of tolerance against citrullinated antigens. However, our data now indicate that 
the presumed interaction effects described by us and by Mahdi et al 23,24 should not be 
taken as an argument to support this hypothesis, but rather that the main driver of ACPA 
fine specificity is found in the HLA SE alleles. In contrast, the interaction effects between 
HLA SE alleles and smoking are more likely to be confined to the predisposition to ACPA-
positive disease. 
A potential limitation of our study is that the results are not corrected for multiple test-
ing, allowing the possibility that some associations are false-positive. However, the (large) 
OR’s found are in line with previously published data 17,23. Likewise we cannot formally 
exclude the presence of interaction between HLA SE alleles and TE for the peptides ana-
lyzed, due to insufficient power. The observed RERI for e.g. cVim59-74 (i.e.: 0.29 (95% CI 
-2.02 – 2.59) is statistically non-significant 39. Clearly a large number of patients would be 
required to obtain significant RERI values. The confidence interval surrounding this RERI 
further indicates that it is unlikely that a RERI above 2.6 is or will be found in larger stud-
ies. Thus even if such an interaction would exist, it is modest compared to the previous 
analyses and does not have a very strong influence on the constitution of the fine specific-
ity repertoire. In contrast, our data indicate that the HLA SE status is mainly driving the 
observations. Although our data indicate that no clear link exists between environmental 
and genetic risk factors in the development of autoimmunity against specific citrullinated 
antigens, other potential citrullinated autoantigens will be awaiting further investigation 
and clearly we cannot exclude that such an interaction is involved in the development 
of antibodies against other citrullinated antigens. This would especially be the case when 
the analyses are focused on ‘heavy smoking’ as cumulative smoking exposure might affect 
such a presumed specific interaction. We did not perform such an analysis because of 
insufficient power. 
All together our findings indicate that gene-environment interactions play no major 
role in shaping the reactivity of the ACPA response by broadening the ACPA recognition 
profile, but rather that the HLA SE alleles do have a significant contribution to the ACPA 
recognition profile.
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AbsTrACT
objective Autoantibodies such as rheumatoid factor (RF) and the second generation anti-
cyclic citrullinated peptide autoantibodies (anti-CCP2) are frequently measured in clinical 
practice because of their association with disease outcome in undifferentiated arthritis 
(UA) and rheumatoid arthritis (RA). Recently two new tests were developed: anti-CCP3 
and anti-modified citrullinated vimentin autoantibodies (anti-MCV). To facilitate the deci-
sion of which autoantibody to test in daily practice, this study evaluates aforementioned 
autoantibodies and combinations of them for predicting three outcome measures: pro-
gression from UA to RA, the rate of joint destruction and achieving sustained DMARD-free 
remission in RA.
methods 625 UA patients were studied for the progression to RA after 1 year. 687 RA 
patients were studied for achieving sustained DMARD-free remission and the rate of joint 
destruction during a median follow-up of 5 years. Positive predictive values (PPVs) for RA 
development and the associations with the disease course in RA were compared for single 
tests (anti-CCP2, anti-CCP3, anti-MCV, RF) and for combinations.
results Using a single test in UA patients revealed that anti-CCP2 tended to have the 
highest PPV for RA development (67.1%), but the 95% confidence intervals of the other 
tests overlapped. Using a single test in RA, all tests showed comparable associations with 
the rate of joint destruction and achievement of remission. In ACPA-positive and ACPA-
negative RA, RF-presence did not associate with more joint destruction. For all outcome 
measures, combining two autoantibody tests did not increase the predictive accuracy 
compared to performing one test. 
Conclusion For clinical practice, a single autoantibody test is sufficient for risk estimation 
in UA and RA. 
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InTroDuCTIon
Rheumatoid arthritis (RA) is considered to have an autoimmune origin because of the 
presence of self-reactive autoantibodies. In addition to rheumatoid factor (RF), which is to 
date the only serologic measure included in the 1987 American College of Rheumatology 
criteria for RA, several other autoantibodies have been described in recent years.1 The 
discovery of anti-citrullinated protein autoantibodies (ACPA) has led to the development 
of various new tests for autoantibodies in RA. The first generation anti-cyclic citrullinated-
peptide (anti-CCP) test, directed against a synthetic citrullinated peptide, revealed a higher 
specificity than RF (91-96% vs. 74-91%).2-6 Subsequently, a commercially available second 
generation anti-CCP test (anti-CCP2) was developed, showing an even better specificity 
(90-97%).3-8 RF and anti-CCP2 autoantibodies can also be present in the preclinical phase 
and are associated with future RA development.9,10 Consequently, tests for anti-CCP2 and 
RF are nowadays widespread used as diagnostic tools in clinical practice.
Recently two other serological tests emerged, anti-CCP3 and anti-MCV. The anti-CCP3 
test has been reported to have sensitivities and specificities comparable to anti-CCP2 (69-
83% and 93-95% respectively).8,11 The second novel autoantibody test targets modified 
citrullinated vimentin (MCV). This test has its origin in the older anti-Sa autoantibody test 
that has been shown to target citrullinated vimentin.12 Compared to anti-CCP2, studies 
reported somewhat lower specificities and higher sensitivities for anti-MCV (79-92% and 
70-84%).3-5,13 
The aforementioned data were obtained by case-control studies comparing RA patients 
with non-RA patients or healthy individuals and the resulting test characteristics quantify 
the proportion of patients that are identified as positive by the test (sensitivity) or the 
proportion of healthy individuals that are identified as negative (specificity). As such, these 
measures, as well as the likelihood ratio of a test, provide information on the quality of 
the test. In clinical practice, the value of determining ACPA or RF relates to their ability to 
predict the disease course. The chance for an individual patient to have a certain disease 
course is expressed by the positive predictive value (PPV) and negative predictive value 
(NPV). A clinical state in which knowledge on the presence of RF and ACPA can be 
particularly helpful is undifferentiated arthritis (UA). In this subgroup of early arthritis 
patients no diagnosis can be established according to existing classification criteria and 
the presence of RF or anti-CCP2 indicates an increased risk for RA development.14,15 
Thus far the PPV and NPV for the risk to develop RA in UA have not been studied for 
anti-CCP3 and anti-MCV and the four autoantibodies have not been subjected to a head-
to-head comparison. Furthermore, the additive value of testing several combinations of 
autoantibodies for the prediction of RA development in individual UA patients has not 
been addressed. Therefore, the first aim of this study is to compare anti-CCP2, anti-CCP3, 
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anti-MCV and RF in the prediction of the RA development in patients with UA and to 
explore whether testing combinations of autoantibodies increases the predictive accuracy.
RF and anti-CCP2 are not only important predictors for RA development, but are also 
some of the most potent predictors for the outcome of RA, as measured by the rate of 
radiological joint destruction.16-18 Thus far, only one study compared radiological progres-
sion for anti-MCV and anti-CCP2 in 273 RA patients and provided suggestive evidence 
that anti-MCV is a better predictor than anti-CCP2.19 The effect of testing combinations of 
all four autoantibodies however was not studied. Thus, the second aim of the present study 
is to compare anti-CCP2, anti-CCP3, anti-MCV and RF in the prediction of the rate of 
joint destruction and to explore whether combinations of autoantibodies can increase the 
predictive ability, making use of a longitudinal cohort of 687 RA patients with a median 
follow-up of 5 years. 
A second disease outcome of RA is the achievement of remission which with the in-
troduction of new aggressive treatment modalities has increasingly become an attainable 
goal. We chose a strict definition and defined sustained disease-modifying antirheumatic 
drugs (DMARD)-free remission as the persistent absence of synovitis for at least 1 year 
after cessation of DMARD-therapy.20 Since the predictive value of the four autoantibodies 
in relation to remission is scarcely explored, the present study compares the four tests 
for their ability to predict sustained DMARD-free remission in RA patients treated with 
conventional DMARDs.
In summary, to support the choice on which autoantibody to test in daily practice, this 
study uses a large longitudinal cohort to evaluate the value of determining anti-CCP2, 
anti-CCP3, anti-MCV and RF for predicting three outcome measures: progression from UA 
to RA, the rate of joint destruction and the chance of achieving sustained DMARD-free re-
mission in RA. In addition, the predictive value of combining several tests is investigated.
PATIenTs AnD meThoDs
Patients
All patients included in this study are selected from the Leiden Early Arthritis Clinic (EAC) 
cohort that was started in 1993.21 Patients were referred by general practitioners when 
arthritis was suspected. Inclusion took place when arthritis was confirmed at physical 
examination and symptom duration was less than 2 years. Written informed consent was 
obtained from all participants. The study was approved by the local Medical Ethical Com-
mittee. 
At inclusion, patients were asked about their joint symptoms and subjected to a physi-
cal examination. Blood samples were taken for routine diagnostic laboratory screening 
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(including IgM-RF) and stored to determine other autoantibodies at a later time. Follow-up 
visits were performed on a yearly basis and included radiographs of hands and feet.
Since the start of the EAC treatment strategies for RA have changed; four different 
strategies were applied depending on the inclusion period. Patients included between 
1993 and 1995 were treated initially with analgesics and subsequently with chloroquine 
or salazopyrin if they had persistent active disease (delayed treatment).22 From 1996 to 
1998 RA patients were promptly treated with either chloroquine or salazopyrin (early 
treatment).21,22 From 1998 to 2002 patients were promptly treated with either salazopyrin 
or methotrexate (early treatment) and patients included in 2002 or later were promptly 
treated with either salazopyrin or methotrexate combined with treatment adjustments 
based on the disease activity (early and disease activity based treatment). Treatment of 
UA patients was not protocollized. 
UA was defined as not fulfilling one of the existing classification criteria for rheumato-
logic diagnoses two weeks after the first presentation.23 Thus other rheumatic diseases like 
Sjögren’s syndrom, psoriatic arthritis, spondylarthropathies, etc. that were established at 
baseline were excluded (Figure 1). 625 patients with UA, consecutively included between 
1993 and 2006, were studied. After 1 year of follow-up, 201 patients (32.2%) had pro-
gressed to RA, fulfilling the 1987 ACR criteria for RA. In addition, 687 patients with RA 
included between 1993 and 2006 were studied for their disease outcome; 486 patients 
fulfilled the ACR criteria for RA already at inclusion and 201 patients were initially diag-
nosed with UA and developed RA within the first year of follow-up (Figure 1). 
Leiden  
EAC 
Diagnosis at  
2 weeks 
RA 
N = 486 
UA 
N = 625 
Other diagnoses 
N ≥ 1100 
RA 
N = 687 
RA 
N = 201 
Other diagnosis  
N = 424 
Diagnosis at  
1 year 
 Median follow-up 5 years 
figure 1: flowchart of the study. 
Of the 687 RA patients, 579 had radiographic data available and for 635 patients information on sustained 
DMARD-free remission was available. Of all UA patients RF, anti-CCP2, anti-CCP3 and anti-MCV were 
determined in 623, 624, 597 and 597 patients respectively. Of all RA patients with radiographs available RF, 
anti-CCP2, anti-CCP3 and anti-MCV were determined in 572, 565, 544 and 544 patients respectively. Of all 
RA patients with data on sustained DMARD-free remission, RF, anti-CCP2, anti-CCP3 and anti-MCV were 
determined in 615, 603, 579 and 579 patients respectively
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Autoantibodies
IgM–RF was determined by enzyme-linked immunosorbent assay (ELISA). Anti-CCP2 
autoantibodies (total IgG) were measured by ELISA (Immunoscan RA Mark 2; Euro-Diag-
nostica, Arnhem, The Netherlands). The cutoff level for anti-CCP2 autoantibody-positivity 
was set at 25 arbitrary units, according to the manufacturer’s instructions. Anti-CCP3 
autoantibodies (IgA and IgG subforms) and anti-MCV autoantibodies were measured with 
ELISA as well (Quanta lite CCP 3.1 IgG/IgA, INOVA Diagnostics Inc., San Diego, CA, USA 
and Orgentec Diagnostika GmbH, Mainz, Germany respectively). According to the manu-
als, the cutoff level for both tests was 20 arbitrary units. The numbers of patients in which 
RF, anti-CCP2, anti-CCP3 and anti-MCV measurements were performed varied slightly 
(available data for RF, anti-CCP2, anti-CCP3 and anti-MCV were respectively 665, 653, 
629 and 629 out of 687 RA patients and 623, 624, 597 and 597 out of 625 UA patients). 
This is due to the difference in timing of performing the tests. RF was determined routinely 
at inclusion whereas the ACPA were determined using stored serum samples. The recently 
introduced anti-CCP3 and anti-MCV assays were performed on all available sera in 2008, 
whereas the anti-CCP2 assay was performed earlier. 
Radiographs
Radiographs of hands and feet were taken on consecutive years starting at baseline and 
were scored according to the Sharp-van der Heijde method.24 From all RA patients, 579 
had data on both autoantibodies and radiographs. To encompass a reliable sample size 
during follow-up, radiographic data were restricted to a maximum of 7 years of follow-
up. The number of available radiographs varied per time-point and declined from 552 
at baseline to 478 after 1 year, 426, 358, 299, 270, 207 and 156 after 2 until 7 years 
of follow-up respectively. Due to the study design (an inception cohort) not all patients 
had a similar duration of follow-up (median 5 years). All radiographs were scored by 
one experienced scorer (ML) who was blinded with respect to the patient’s autoantibody 
status, treatment and other clinical data. Scoring was performed with known time order, 
which is more sensitive to change compared to scoring with unknown time sequence.25 
From the total number of scored radiographs, 499 radiographs were rescored by the same 
reader, consisting of 149 baseline radiographs and 350 radiographs during follow-up 
belonging to 60 randomly selected RA patients. The intraobserver intraclass correlation 
coefficients were 0.91 for all scored radiographs, 0.84 for baseline radiographs and 0.97 
for the radiographic progression rate. 
Sustained DMARD-free remission in RA
Remission was defined in its most stringent form as the persistent absence of synovitis for 
at least one year after cessation of DMARD therapy and the identification of remission by 
the patient’s rheumatologist.26 The remission status could be reliably ascertained in 635 
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RA patients. Most patients who achieved remission were followed-up longer than the 
minimum requirement of 1 year; the median time of observation after discontinuation 
of DMARDs in the absence of swollen joints was 2.5 years. Patients who had a recur-
rence of their arthritis after discharge, could easily return to the Leiden University Medical 
Center, the only referral center for Rheumatology in a health care region of approximately 
400.000 inhabitants. The frequency of relapse was recorded and patients with relapse 
were included in the non-remission group (n=6).
Statistical analysis
The PPV (proportion of UA patients with a positive test that progressed to RA) and the NPV 
(proportion of UA patients that did not develop RA) were determined. 
As radiographic data are not normally distributed, non-parametric Mann-Whitney 
tests were used to compare the Sharp-van der Heijde scores at individual time points 
for patients with and without autoantibodies or for autoantibody combinations. In ad-
dition, to take advantage of the prospective character of the data consisting of repeated 
measurements, and to avoid multiple testing by performing statistical tests for each time 
point, a linear mixed model with an autoregressive correlation structure with heteroge-
neous variances was used. This model estimates the linear progression rate in radiological 
joint destruction using normalized, log-transformed Sharp-van der Heijde scores, taking 
missing observations into account. This means that it compares the progression rates for 
the different patient groups. In the mixed model analyses, corrections were applied for 
age, gender and inclusion period/treatment strategy. Correction for treatment strategy was 
performed by including the inclusion period in the linear mixed model. This was done 
because treatment modalities improved over time and an influence of the treatment strat-
egy (reflected by the inclusion period) on the progression of radiographic joint damage 
was observed previously as well as in the present study (data not shown). In addition, 
the available follow-up duration differed between patients and therefore the number of 
radiographs per time point decreased during follow-up. As the patients with the longest 
follow-up were included in the earliest inclusion period and thus have been treated with 
the least aggressive treatment strategy, correction for inclusion period was performed. In 
order to prevent overfitting of the data no corrections were applied for other variables. 
Analysis of sustained DMARD-free remission was performed by Cox regression analysis, 
to take into account the differences in follow-up times among patients. For patients that 
achieved remission the dependent variable is the “time-to-event”, indicating the time until 
reaching remission. For non-remission patients the time to last follow-up was used, with a 
maximum of 10 years. SPSS version 16.0 (SPSS Inc., Chicago, IL, USA) was used. P-values 
<0.05 were considered significant. All reported p-values are two-sided.
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resulTs
Progression from UA to RA
From the total EAC, consisting of >2,000 patients with early arthritis, UA patients (n=625) 
were selected and studied for progression to RA after 1 year of follow-up. At inclusion, the 
mean age was 50.9 (±17.0) years, 371 (59.1%) patients were female and the self-reported 
symptom duration was 5.5 (±8.5) months. Anti-CCP2, anti-CCP3, anti-MCV and RF were 
present in 149 (23.9%), 172 (28.7%), 199 (31.7%) and 155 (24.8%) patients respectively. 
The presence of autoantibodies overlapped; UA patients who tested positive for anti-CCP2 
were also frequently positive for other autoantibodies (Figure 2). 
The PPV was compared for the four autoantibodies (Table 1). Anti-CCP2 had the highest 
PPV, 67.1%, compared to 64.0%, 56.3% and 61.7% for anti-CCP3, anti-MCV and RF 




































































figure 2: Prevalence of other autoantibodies in case of a positive test result for anti-CCP2, anti-mCv or rf 
for both uA and rA. 
The prevalence of other autoantibodies given one positive autoantibody test is depicted. This figure was 
derived using 596 UA and 540 RA patients for whom data on all autoantibodies was present. None: no other 
autoantibodies present.
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antibody test is performed, a positive anti-CCP2 test tends to correlate with the highest risk 
of RA development, but overlapping 95%CI’s hamper a definite differentiation. 
Next it was determined whether performing two autoantibody tests results in a better 
estimation of the risk for RA than performing one test. Since anti-CCP2 and anti-CCP3 are 
related tests and anti-CCP2 positive patients were in 90% also positive for anti-CCP3, the 
possible combinations of anti-MCV, anti-CCP2 and RF were first assessed. The proportions 
of patients that developed RA in case of two positive test results (PPV) were: anti-CCP2+/
anti-MCV+ 69.9% (95%CI 62.1-77.7), anti-CCP2+/RF+ 74.1% (95%CI 65.8-82.3) and 
anti-MCV+/RF+ 70.6% (95%CI 62.1-79.2). Additional analyses using anti-CCP3 instead 
of anti-CCP2 yielded comparable results (data not shown). Altogether, these data show 
that when two tests are performed none of these combinations is clearly superior to the 
other. Furthermore, no additive value of performing two instead of one autoantibody test 
could be observed.
When performing a single autoantibody test, no information about the presence or ab-
sence of the other autoantibodies is obtained. However, the eventual coexisting presence 
of other unmeasured autoantibodies can affect the risk for RA. To determine the risk for 
RA as conferred to by the individual autoantibodies or by the number of autoantibodies, 
the PPVs for progression to RA were determined in the group of 587 UA patients for 
whom information on all three autoantibodies was available. The difference with above 
mentioned data is that the presence of two autoantibodies now indicates that the third is 
absent, whereas in above mentioned data only two tests were performed and the third 
autoantibody test could be positive as well as negative. The PPV for RA development in 
patients without autoantibodies was 17.9% (95%CI 13.9-22.0). In the presence of one 
autoantibody the PPV was 27.5% (95%CI 17.9-35.0) and increased significantly to 61.2% 














0 17.9 (13.9-22.0) 61/340 - - -
1 27.5 (18.8-36.1) 28/102 Anti-CCP2+/anti-MCV-/RF- 12.5 (-10.4-35.4) 1/8
Anti-CCP2-/anti-MCV+/RF- 29.3 (17.6-41.0) 17/58
Anti-CCP2-/anti-MCV-/RF+ 27.8 (13.2-42.4) 10/36
2 61.2 (47.6-74.9) 30/49 Anti-CCP2+/anti-MCV+/RF- 58.1 (40.7-75.4) 18/31
Anti-CCP2+/anti-MCV-/RF+ 83.3 (53.5-113.2) 5/6
Anti-CCP2-/anti-MCV+/RF+ 58.3 (30.4-86.2) 7/12
3 71.9 (62.9-80.9) 69/96 - - -
These data are based on the patients with data available for all three antibody-tests (anti-CCP2, anti-MCV 
and RF, n=587). UA: undifferentiated arthritis; PPV: positive predictive value; 95%CI: 95 % Confidence 
Interval; pos.: positive.
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(95%CI 47,6-74,9) in the presence of two autoantibodies (Table 2). The PPV was the 
highest in the presence of 3 autoantibodies (71.9%, 95%CI 62,9-80.9). 
In conclusion, when performing one autoantibody test in clinical practice, none of 
the four tests is clearly superior. Although the presence of 2 autoantibodies significantly 
increased the risk for RA compared to the presence of 1 autoantibody, for clinical use 
performing two tests does not significantly increase the predictive performance compared 
to performing one test. This finding is likely explained by the presence of other, non-
measured autoantibodies that affect the risk for RA.
Joint destruction in RA
Baseline characteristics of the 579 studied RA patients were: mean age 56.2 (±15.5) years, 
405 patients (69.9%) were female, anti-CCP2, anti-CCP3, anti-MCV and RF were present 
in 313 (55.4%), 322 (59.2%), 331 (60.8%) and 334 (58.4%) patients respectively. Anti-
CCP2 positive patients also tested positive for anti-MCV and RF in 93% and 87% of cases 
respectively (Figure 2).
First, the association between autoantibody-positivity and rate of joint destruction was 
assessed when performing only one autoantibody test. For all autoantibody tests (anti-
CCP2, anti-CCP3, anti-MCV and RF) a positive test result was associated with a higher 
Sharp-van der Heijde score at all time points except baseline (M-W, p<0.001) and a higher 
rate of joint destruction over a period of 7 years (mixed model, p<0.001) compared to a 
negative test result. Figure 3A shows that there is no difference among the four tests with 
regard to predictive ability for joint destruction. 
Next, it was investigated whether the addition of a second autoantibody test increased 
the predictive value for the rate of joint destruction. As depicted in Figure 3B no dif-







































































figure 3: mean sharp-van der heijde scores (±sem) for the different autoantibody tests (A) and for 
combinations of positive tests (b). 
The number of patients in Figure 3A for anti-CCP2-positive/negative, anti-CCP3-positive/negative, anti-
MCV-positive/negative and RF-positive/negative was respectively 313/252, 322/222, 331/213 and 334/238. 
*Mann-Whitney, p<0.001, for comparison of positive with negative test. For all four tests the p-value was 
<0.001 using mixed models analysis. 
In Figure 3B, for anti-CCP2+, RF+, anti-MCV+, anti-CCP2+/ RF+, anti-CCP2+/anti-MCV+, anti-MCV+/
RF+ and anti-CCP2+/anti-MCV+/RF+ the number of patients was 313, 334, 331, 271, 283, 259 and 244 
respectively.
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ferences were seen between testing positive for anti-CCP2, anti-MCV or RF alone and 
combinations of these autoantibodies. These results indicate that for clinical use, a posi-
tive test for one of these autoantibodies predicts a severe disease course, and a second or 
third autoantibody test does not increase the predictive accuracy. Testing for anti-CCP3 
instead of anti-CCP2 gave comparable results (data not shown).
To identify the contribution of the individual autoantibodies to the association with 
the rate of joint destruction, the effect of the number of positive autoantibodies (with the 
known absence of the other autoantibodies) was investigated using data on RF, anti-CCP2 
and anti-MCV. The presence of either 2 or 3 autoantibodies was associated with a higher 
rate of joint destruction compared to 0 or 1 autoantibody (Figure 4A) (mixed model, p 
<0.001 for both 2 and 3 compared to 0 as well as 1 autoantibody). No significant dif-
ference was observed between the presence of 2 or 3 autoantibodies or between 0 and 
1 autoantibody. It should be noted that the group with 1 autoantibody consisted almost 
exclusively of patients that were anti-MCV+ (n=33) or RF+ (n=39); only two patients were 
positive for anti-CCP2 and negative for anti-MCV and RF. 
To more specifically investigate the role of RF in relation to ACPA (anti-CCP2, anti-CCP3 
or anti-MCV) and the rate of joint destruction, the additional effect of RF in the presence 
or absence of ACPA was determined (Figure 4B). This revealed that in the presence of 
ACPA, but also in the absence of ACPA, RF did not significantly contribute to the rate of 
joint destruction. 





























































figure 4: mean sharp-van der heijde scores (±sem) for the number of positive autoantibody tests (A) and 
for the effect of rf in the presence or absence of ACPA (b). 
Figure 4A: depicted are the mean Sharp-van der Heijde scores for the number of positive autoantibody 
tests (with the other tests negative) using data for RF, anti-CCP2 and anti-MCV (total n=540). The number of 
patients positive for 0, 1, 2 or 3 autoantibodies was 152, 74, 70 and 244 respectively. Comparing 3 with 0, 3 
with 1, 2 with 1 and 2 with 0 autoantibodies revealed a p<0.05 at all time points except baseline (M-W) and 
a p<0.001 for the 7 year period (mixed model). 
Figure 4B: depicted are the mean Sharp-van der Heijde scores for the following groups ACPA-RF-, ACPA-
RF+, ACPA+RF- and ACPA+RF+. The patients numbers per group were 152, 39, 36 and 244. P=0.864 for 
comparison of ACPA-RF- with ACPA-RF+ and p=0.702 for comparison ACPA+RF- and ACPA+RF+ (both 
mixed model)
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Sustained DMARD-free remission in RA
From a total of 635 RA patients, 78 patients achieved sustained DMARD-free remission 
after a median follow-up of 39.5 months. These 78 patients had a mean age of 59.4 (±15.7) 
years and 57 patients (73.1%) were female. Anti-CCP2 autoantibodies were present in 
11.8% and anti-CCP3, anti-MCV autoantibodies and RF in 21.9%, 28.8% and 25.0%. 
The four autoantibody tests were compared for their association with the achievement 
of remission (Figure 5A). The Hazard Ratio (HR) of each of the four tests for not achieving 
sustained DMARD-free remission was 11.6 (95%CI 5.8-23.4) for anti-CCP2, 6.0 (95%CI 
3.4-10.4) for anti-CCP3, 4.9 (95%CI 3.0-8.2) for anti-MCV and 4.7 (95%CI 2.8-8.0) for RF.
Subsequently, the additive value of performing two autoantibody tests compared to 
one test was investigated. The HRs were 15.6 (95%CI 6.7-36.4), 14.0 (95%CI 6.4-31.0) 
and 11.5 (95%CI 5.4-24.5) for combinations of anti-CCP2 and RF, anti-CCP2 and anti-
MCV and anti-MCV and RF respectively. These data indicate that to predict the chance of 
remission, performing two tests has no additional value compared to anti-CCP2 alone.
To investigate whether the number of present autoantibodies affected the chance of 
achieving sustained DMARD-free remission, the HRs were determined for the presence of 
1, 2 or 3 positive autoantibodies (with the other autoantibodies known to be absent) using 
data on anti-CCP2, anti-MCV and RF (Figure 5B). The HRs for not achieving sustained 
DMARD-free remission were as follows, 3.7 (95%CI 1.1-12.3), 15.5 (95%CI 5.9-41.2) 
and 17.1 (95%CI 6.8-43.3) for the presence of, respectively, 1, 2, and 3 autoantibodies 
compared to no autoantibodies. Thus, however the 95%CIs were overlapping, the results 
suggestively indicate that the more autoantibodies are present, the lower the chance is to 
achieve sustained DMARD-free mission. 















































figure 5: effect of the presence of a positive autoantibody test (A) and the number of autoantibodies (b) on 
sustained DmArD-free remission.
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DIsCussIon
Among the autoantibodies tested in RA, only RF and ACPA are considered clinically use-
ful. In clinical practice a physician or patient is interested in the chance for the individual 
to progress to RA or not, given a positive or negative test result respectively. These risks 
are reflected by the PPV and NPV. In addition, in early arthritis the predictive value of 
these autoantibody tests is valued the most in patients in whom at presentation no definite 
diagnosis can be established (UA), as only one-third of these patients progress to RA after 
one year.14 Also in RA, the autoantibody tests form one of the most potent predictors 
of the severity of the future disease course. As such, information on the results of the 
autoantibody tests can influence treatment decision in individual patients with UA and 
RA.23 Nevertheless, it is thus far unknown which test, or which combination of tests, is 
most powerful in predicting the progression from UA to RA and the disease progression in 
RA and therefore the present study was undertaken. 
To evaluate the prediction from UA to RA using a single test, the PPVs of the four tests 
were compared. This revealed that a positive anti-CCP2 test tended to have the highest 
predictive value (PPV 67% compared to 62% and 56% for RF and anti-MCV), but due to 
overlapping 95%CIs a definite differentiation could not be made. In addition, performing 
a second test did show a tendency for a higher chance on RA development in case both 
tests were positive (highest risk for RA in anti-CCP2+, RF+ patients, PPV 74%), but also 
here the 95%CIs overlapped. To formally conclude whether the PPVs of 67% and 74% are 
statistically significantly different or not, >1800 UA-patients would be required (using a 
p-value of 5% and a power of 90%). Based on the present data it can be concluded that 
addition of a second test does not result in an increased predictive accuracy. Notably, 
UA patients who tested positive for anti-CCP2 were also frequently positive for other 
autoantibodies (Figure 2). Thus the finding of comparable prognostic performances of one 
or two tests is likely due to co-existing presence of autoantibodies that are unmeasured 
with a single test but that do affect the risk-estimation for RA. 
The development of RA was assessed after 1 year of follow-up. This time-point was 
chosen in order to have a similar duration of follow-up for all studied patients. However, 
this may have introduced misclassification as patients with UA may have progressed to 
RA after more than 1 year of follow-up. With all available follow-ups, 25 patients (4.4%) 
progressed to RA later than 1 year, indicating that the current PPVs may be marginally 
underestimated. Since this misclassification is present in the total group of UA patients this 
does not hamper a comparison of tests. 
Two measures were studied for the severity of the disease course in RA: achieving 
sustained DMARD-free remission and the level of radiological joint destruction during a 
median follow-up of 5 years. Although Figure 3A and 5A may lead to the impression that 
anti-CCP2 positive patients have a higher rate of joint destruction and achieve sustained 
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DMARD-free remission less frequently than patients positive for the other autoantibodies, 
these differences were not statistically significant. Similar to the data on RA development, 
performing a second test appeared not to result in a more accurate prediction for the 
disease outcome in RA. This observation, which is in contrast to an earlier report,27 can 
be explained by the presence of non-measured autoantibodies that are associated with a 
progressive course of RA. 
To obtain a more detailed comprehension of the current results, the contribution of 
the individual autoantibodies to disease progression (RA development, joint destruction 
and achievement of remission) was investigated. This showed that the presence of two 
autoantibodies indicated a significantly increased risk compared to the presence of one 
autoantibody. However, the group with one autoantibody present consisted mostly of 
anti-MCV or RF-positive patients. Patients that were positive only for anti-CCP2 were 
very rare. Therefore it cannot be excluded that the increased risk in the presence of two 
compared to one autoantibody is due to the effect of anti-CCP2 rather than to the effect of 
an additional autoantibody. Nevertheless, in general it was observed that a higher number 
of autoantibodies present resulted in a higher risk for RA or for progressive disease. This 
is in line with recent published data showing that a broader autoantibody response is 
associated with disease progression.28 
As the association of RF with the presence of RA is primarily explained by its asso-
ciation with ACPA,29 we investigated whether we could observe a similar effect for the 
progression of joint destruction in RA. Intriguingly, the rate of joint destruction both in the 
ACPA-positive and ACPA-negative groups was not affected by the presence or absence of 
RF. This finding further supports the notion that RF does not, by itself, contribute to disease 
progression. 
In order to get an impression of the effect of anti-MCV itself on the rate of joint de-
struction, RA patients that were positive only for anti-MCV (n=33) were studied. This 
revealed that the rate of joint destruction was comparable to that of the patients with no 
autoantibodies (data not shown), indicating that anti-MCV alone does not strongly affect 
the level of joint damage in RA.
In conclusion, our results indicate that for risk estimation of the disease course in clini-
cal practice, performing a single autoantibody test is sufficient, both in UA and RA. 
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AbsTrACT
objective Remission has become an attainable goal of rheumatoid arthritis (RA) treat-
ment, especially since the advent of biological anti-rheumatic therapy. Because little is 
known about patients who achieve remission with conventional treatment, we used two 
large independent inception cohorts to study the prevalence and predictive factors for 
disease modifying anti-rheumatic drug (DMARD)-free sustained remission after treatment 
with conventional therapy.
methods Remission was assessed in patients from the Leiden Early Arthritis Clinic (EAC, 
n=454) and the British Early RA study (ERAS, n=895) who fulfilled the 1987 ACR criteria 
for RA and were treated with conventional therapy. Sustained DMARD-free remission was 
defined as fulfilling the following criteria for at least one year: 1) no current DMARD-use, 
2) no swollen joints and 3) classification as remission by the patient’s rheumatologist. 
Predictive factors were identified by Cox regression analysis.
results Sustained DMARD-free remission was achieved by 68/454 (15%) of patients in the 
EAC and 84/895 (9.4%) in the ERAS. Five factors were associated with sustained DMARD-
free remission in both cohorts: acute onset, short symptom duration before inclusion, 
non-smoking, absence of IgM rheumatoid factor and of HLA shared epitope alleles. In 
the ERAS, low disease activity at baseline was also predictive of remission. Multivariate 
analyses revealed symptom duration and the absence of autoantibodies (anti-CCP2/RF) as 
independent predictors. 
Conclusion Sustained DMARD-free remission in RA patients treated with conventional 
therapy is not uncommon. Symptom duration at presentation and the absence of autoan-
tibodies are associated with sustained DMARD-free remission. 
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InTroDuCTIon
Patients with rheumatoid arthritis (RA) vary considerably in terms of their disease course 
and outcome. The spectrum of possible disease outcomes extends from debilitating, 
destructive joint disease on one side, to remission, the most favorable outcome, on the 
other side 1. Since the introduction of biological anti-rheumatic treatment, remission is 
increasingly being reported as a primary disease outcome of new therapeutic trials 2. In 
addition to the potent suppression of disease activity which can be achieved with these 
novel treatment agents, the recent insight that early initiation of anti-rheumatic therapy 
leads to better long-term outcomes 3, 4, has led to a shift in the current goals of RA treat-
ment towards aiming for remission.
When studying remission in RA, there are several aspects of remission which need to 
be taken into account and which are inconsistently defined and used in the literature. 
The first inconsistency involves the duration of the remission. Clinical trials frequently 
use a disease activity score (DAS)-based definition of remission which does not require a 
specified follow-up period, but can be fulfilled at one single point in time. 
The second factor which needs to be taken into account is the use of anti-rheumatic 
treatment. Remission can be interpreted as either a state of minimal disease activity while 
using anti-rheumatic treatment, or as persistent resolution of the disease after discon-
tinuation of therapy 5, 6. The DAS-based remission criteria do not require remission to be 
drug-free, because they were intended to monitor treatment response in clinical trials 7, 8. 
Remission rates as reported in clinical trials therefore often reflect the number of patients 
which achieve minimal disease activity while using novel therapeutic agents. Data on 
how often remission persists after discontinuation of treatment are scarce 9, though this 
may better reflect disease resolution.
A third aspect of remission studies is the type of treatment which was administered. 
Despite the fact that remission rates after treatment with new therapeutic agents are now 
often reported, there are few data on remission after treatment with conventional therapy 
such as non-steroidal anti-inflammatory drugs (NSAIDs) and non-biological disease modi-
fying antirheumatic drug (DMARD) therapy. Such studies would however, allow a better 
interpretation of the remission rates reported by clinical trials of novel agents. 
In this study, we investigated the prevalence and prognostic factors for sustained 
DMARD-free remission in two large, independent inception cohorts of RA patients treated 
with conventional therapy. In order to investigate remission as a definitive disease out-
come, stringent criteria were used to define remission: the sustained absence of synovitis 
for at least one year after the discontinuation of therapy with DMARDs. This definition is 
an approximation of a definitive cure of the disease, and as such, is close to the meaning 
of remission as it is used for other diseases such as malignancies. 
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Investigating remission as a definitive disease outcome, resembling cure, is very impor-
tant from a pathophysiological point of view. Knowledge of which clinical or immuno-
logical patient characteristics are associated with remission could fuel new hypotheses 
about the biological pathways involved in disease persistence and resolution, and would 
increase our understanding of the disease course of RA. 
meThoDs
Patient population
The study population consisted of two cohorts: the Leiden Early Arthritis Clinic (EAC) and 
the British Early RA Study (ERAS). 
The Leiden EAC is an inception cohort of patients with recent-onset arthritis (less than 
2 years of complaints) that was initiated at the department of rheumatology of the Leiden 
University Medical Center in 1993 10. The present study included patients who fulfilled the 
1987 revised ACR criteria for RA at baseline (n=369) or within the first year of follow-up 
(n=85), and who presented to the EAC between 1993 and 2002. The treatment strategy 
differed according to the inclusion period. Patients included between 1993 and 1995 
were initially treated with analgesics and subsequently with chloroquine or sulfasalazine 
if they had persistent active disease. Between 1996 and 1998, patients who were included 
were promptly treated with chloroquine or sulfasalazine, while after 1998 the initial 
treatment strategy consisted of either methotrexate or sulfasalazine. Patients included 
in the EAC after January 2003 were not part of the current study because, due to their 
limited duration of follow-up, they only had a short period of time to achieve sustained 
DMARD-free remission, and therefore had a high risk of misclassification. These patients 
who presented after January 2003 did not differ markedly from the patients who were 
included earlier with regard to the rate and the predictive factors of sustained DMARD-
free remission (data not shown), but they were not part of the present study because 
of the high risk of misclassification as mentioned above. Follow-up visits with standard 
clinical assessments were performed two weeks after the first presentation and yearly 
thereafter. Demographic characteristics, a 44 swollen joint count (SJC) and the modified 
Stanford Health Assessment Questionnaire (HAQ) were recorded at each visit. Laboratory 
evaluation consisted of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) 
measurements, determination of IgM rheumatoid factor (RF) and anti-cyclic citrullinated 
peptide 2 antibodies (anti-CCP2). Furthermore, genotyping of the HLA-DRB1 region 
was performed to determine the number of RA-associated Shared Epitope (SE) alleles 11. 
Radiographs of hand and feet were scored according to the Sharp-van der Heijde scoring 
method (SHS) 12.
Diana vd Woude BW.indd   206 19-01-12   11:38
Sustained DMARD-free remission 207
To determine if the prevalence and predictive factors which were identified in the 
Leiden EAC cohort could be replicated, a second inception cohort was used: the ERAS. 
This cohort consists of RA patients who were recruited from 9 rheumatology departments 
in the UK from 1986 until 1996. During this period, consecutive patients who presented 
with RA according to the ACR criteria were included in the ERAS if their symptoms of RA 
had lasted less than 2 years and no second-line antirheumatic medication had been used. 
ERAS patients were treated according to the rheumatologist’s preference, which generally 
entailed a short course of analgesics, followed by sequential monotherapy or combination 
therapy for more severe RA with methotrexate, sulfasalazine and hydroxychloroquine as 
favored drugs. 
Baseline and yearly assessments comprised of the Ritchie articular index, a 44 SJC, the 
HAQ and measurements of ESR and IgM RF. Disease activity scores (DAS) were calculated 
according to the original formula 13. In addition, HLA-DRB1 genotyping was performed. 
Radiographs of hand and feet were scored according to the Larsen scoring method 14. In 
contrast to the EAC, measurements of CRP and anti-CCP were not performed in the ERAS. 
Both in the ERAS and the EAC, a number of patients failed to complete follow-up: 
n=136 (23%) in the EAC and n=384 (30%) in the ERAS. The most common reasons in 
both cohorts were death, moving and withdrawal of consent. Because the definitive 
disease outcome (remission versus non-remission) could not be accurately determined for 
the deceased patients, the present report shows the results of the analyses without these 
patients. However, when the deceased patients were included in the non-remission group, 
the identified predictive factors did not change (data not shown). In total, 454 EAC patients 
and 895 ERAS patients were included in the present study. 
Definition of remission
Sustained DMARD-free remission was defined according to the following three criteria: 
1) no current use of DMARDs, 2) no swollen joints and 3) classification as DMARD-
free remission by the patient’s rheumatologist. Corticosteroids were considered to be 
equivalent to DMARDs for the present study, while NSAIDs did not qualify as DMARDs. 
Patients had to fulfill all three criteria in order to be diagnosed with remission. To ensure 
that remission was not temporary, but rather sustained and long-lasting, the absence of 
swollen joints had to have been observed by a rheumatologist for at least one year after 
discontinuation of DMARD-therapy. In both EAC and ERAS cohorts, all patients were seen 
approximately every four months by their rheumatologists, even when they had very low 
disease activity. In addition, standardized follow-up visits to collect data for the EAC and 
ERAS were performed annually. In the EAC, all patients with remission were discharged 
from the outpatient clinic after at least one year of observation after discontinuation of 
DMARDs in the absence of joint swelling. Most patients in the EAC who achieved remis-
sion were followed-up longer than the minimum requirement of one year; the median 
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time of observation after discontinuation of DMARDs in the absence of swollen joints 
was 2.5 years. Patients who had a recurrence of their arthritis after discharge, could easily 
return to the Leiden University Medical Center, the only referral center for Rheumatology 
in a health care region of approximately 400.000 inhabitants. The frequency of relapse 
was recorded and patients with relapse (n=6) were included in the non-remission group. 
In the ERAS, the majority of patients who had achieved remission continued to undergo 
their yearly assessments, which provided an opportunity to assess if there was continued 
absence of joint swelling. 
Statistical analysis
Summary statistics were generated to investigate the prevalence of sustained DMARD-
free remission and the baseline characteristics of remission and non-remission patients. 
Patients included in the ERAS had a longer average period of follow-up than patients in 
the EAC, due to the fact that the ERAS was initiated in 1986, while the EAC was started in 
1993. To avoid skewing of the results due to the difference in follow-up time, the present 
analysis used data from the first 10 years of follow-up for all patients. 
Baseline variables were assessed for their ability to predict remission by univariate and 
multivariate regression analysis. To take into account the difference in follow-up times 
among patients, analyses were performed by Cox regression analysis, after verification 
that the proportional hazards assumption was satisfied. In Cox regression models the 
dependent variable is the “time-to-event”, which consisted of the time to remission for 
the remission patients, and the time to last follow-up (with a maximum of 10 years) for 
the non-remission patients. The time of remission was defined in the EAC as the date at 
which DMARDs were discontinued due to remission, and in the ERAS as the date of the 
first annual study visit when patients were in DMARD-free remission. The analysis was 
also performed with a later date defined as the time of remission (date described above 
plus one year), which led to similar results. This indicates that the predictive factors were 
stable regardless of the exact date used to define remission.
In order to investigate the predictive ability of baseline characteristics in univariate 
analysis, each variable was included as a covariate in a separate non-conditional Cox 
regression analysis. The results of the univariate analyses were subjected to correction 
for multiple testing by the Holm method 15. Subsequently, multivariate Cox regression 
analysis was performed to identify significant independent predictors for achieving re-
mission. As possible explanatory variables, all baseline variables with a p-value below 
0.10 in univariate analysis were included in the model. A two-step modeling approach 
was performed which in the first step identified independent predictive variables by a 
backward step selection procedure that removed variables with a p-value greater than 
0.10. To verify that the identified predictive variables were indeed independent predictors 
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for the entire cohort, they were then entered as covariates into a second multivariate Cox 
regression analysis (enter model). 
If there is a highly significant correlation between two variables they cannot be entered 
into the same multivariate model, as this results in over-correction and annulment of 
the effect. In both cohorts, symptom duration and radiographic damage (as measured by 
SHS in the EAC and Larsen score in the ERAS) were highly correlated. Symptom duration 
was included in the multivariate models because a longer symptom duration most likely 
caused a higher radiological score and not vice versa. In the ERAS, the Ritchie articular 
index, SJC and DAS were highly correlated due to the fact that the DAS is a component 
measure consisting of amongst others, the Ritchie articular index and the SJC, and there-
fore the DAS was omitted from the multivariate model.
In the EAC, a number of cases (n<50) had missing values for baseline continuous vari-
ables, which would have resulted in their exclusion from the multivariate model. For these 
patients with missing values, multiple imputation analysis was performed using STATA 
with the ice and mim packages (StataCorp. 2007. Stata statistical software: Release 10. 
College Station, TX, USA). Multiple imputation was applied to the final Cox regression 
model identified through the preliminary variable selection step (predictive variables: 
symptom duration, CRP and anti-CCP). The full database was used to generate 25 imputa-
tions, each from 10 cycles and incorporating both survival and censoring information 
within the multiple imputation prediction equations. In the ERAS, the number of cases 
with missing variables was very limited and for that reason no imputation was performed. 
All analyses were performed using the Statistical Package for the Social Sciences (SPSS) 
14.0, except for the multiple imputation. P-values below 0.05 were considered to be 
statistically significant, except for the results of univariate analysis for which subsequent 
correction for multiple testing was performed. 
resulTs
Prevalence of sustained DMARD-free remission
The baseline characteristics of the RA patients in the EAC and ERAS are shown in Table 1. 
On average, ERAS patients had a longer disease duration and a higher number of swollen 
joints at baseline, and were more often IgM RF and HLA SE allele positive than EAC 
patients. 
Sustained DMARD-free remission was achieved by 68/454 = 15.0% of patients in the 
EAC and 84/895 = 9.4% of patients in the ERAS. The median time to remission was 43 
months in both cohorts (interquartile range (IQR) EAC: 24-67, ERAS: 18-60) (Figure 1A). 
A subgroup analysis was performed to investigate if the prevalence of remission in the 
EAC would have been different if only the 369 patients who presented with RA at baseline 
Diana vd Woude BW.indd   209 19-01-12   11:38
210 Chapter 13





Period of inclusion 1993-2003 1986-1996
Age in years, mean (sD) 56 (16) 52 (13)
female gender 69% 69%
symptom duration in months, mean (sD) 6.4 (9) 8.3 (6)
44 swollen joint count, median (IQr) 8 (4-14) 14 (7-25)
Igm rheumatoid factor positive 58% 63%
hlA se positive 66% 72%
sharp van der heijde score, mean (sD) 8.0 (11) NA
larsen score, mean (sD) NA 3.7 (9)
NA: not available
figure 1: kaplan-meijer curves of the percentage of patients with sustained DmArD-free remission.
Figure: 1A: The y-axis depicts the percentage of patients who achieved remission. The x-axis reflects the 
follow-up time in years. Indicated below the x-axis is the number of patients available for analysis at each 
timepoint.
Figure 1B: Kaplan-Meijer curves of the percentage of patients in the EAC with sustained DMARD-free 
remission, stratified for period of inclusion. Differences between the different strata are non-significant: 
p-value log rank test across all strata: 0.52. The line representing the patients included from 1999 until 2002 
terminates at 8 years of follow-up due to the fact that this was the maximum follow-up for patients in this 
stratum (data were collected in 2007). 
Diana vd Woude BW.indd   210 19-01-12   11:38
Sustained DMARD-free remission 211
had been included (leaving out the 85 patients who developed RA within the first year of 
follow-up). This revealed a similar prevalence of sustained DMARD-free remission as in 
the entire group: 14.9% (55/369). 
The prevalence of remission steadily increased in the first part of the follow-up period 
until approximately seven years after inclusion, after which it remained relatively stable. 
To investigate if patients who were included at a later point in time and who had therefore 
been treated with a different treatment strategy had a higher chance of achieving remis-
sion, or achieved remission faster, analyses in both cohorts were stratified for inclusion 
period. This revealed that the rate of achieving remission did not differ between patients 
who were included in different inclusion periods (log rank test: p-value: 0.52) as shown 
for the EAC in Figure 1B. The same was true for patients who were included in different 
time periods in the ERAS (data not shown).
Univariate analysis
In order to investigate which baseline patient characteristics can predict sustained 
DMARD-free remission, univariate Cox regression analysis was performed. The following 
variables were associated with sustained DMARD-free remission in the EAC: symptom 
duration at baseline, smoking, CRP, RF IgM, anti-CCP2 antibodies, radiographic damage 
as measured by SHS, and HLA SE alleles (Table 2). A subgroup analysis of the 369 patients 
who presented with RA at baseline (without the 85 patients who developed RA within the 
first year of follow-up) again led to the same results. Of these identified factors, symptom 
duration at baseline, acute start of complaints, the presence of RF IgM, HLA SE alleles, and 
radiographic damage could be replicated in the ERAS (Figure 2). 
In addition, univariate analysis in the ERAS revealed several other predictive variables 
(44 SJC, Ritchie articular index, HAQ and DAS4, Table 3). A sub-analysis in the ERAS on 
figure 2: Predictors for sustained DmArD-free remission identified in both cohorts. 
Depicted are the hazard ratio’s with 95% confidence intervals.
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Table 2. eAC univariate analysis: baseline characteristics of patients who did and did not achieve sustained 
DmArD-free remission.






95% CI # P *
Age in yrs, mean (sD) 59 (17) 56 (16) 1.02 0.99-1.03 0.067
female gender, n (%) 50 (74%) 262 (68%) 1.28 0.74-2.19 0.38
symptom duration at baseline in 
months, median (IQr)






smoking, n (%) 22 (33%) 175 (47%) 0.56 0.34-0.94 0.028
family history positive for rA, 
n (%) 12 (19%) 111 (31%) 0.55 0.30-1.04 0.064
Absence of comorbidities, n (%) 43 (64%) 233 (63%) 0.98 0.59-1.61 0.92
Acute start of complaints, n (%) 43 (64%) 192 (53%) 1.55 0.94-2.56 0.084
start of complaints in small 
joints, n (%) 38 (57%) 175 (47%) 1.48 0.91-2.40 0.11
symmetrical start of complaints, 
n (%) 46 (72%) 239 (67%) 1.24 0.72-2.14 0.44















esr in mm/h, mean (sD) 38 (25) 44 (28) 0.99 0.98-1.00 0.14
CrP in mg/l, median (IQr)






rf Igm positive, n (%) 14 (21%) 247 (64%) 0.17 0.10-0.31 <0.001*
Anti-CCP2 positive, n (%) 8 (13%) 236 (66%) 0.09 0.04-0.18 <0.001*
shs, median (IQr) ¶






hlA se positive, n (%) 33 (50%) 247 (69%) 0.46 0.29-0.75 0.002*
† For variables which were normally distributed, mean and standard deviation (SD) are reported. For non-
normally distributed variables, median and interquartile range (IQR) are reported and also the mean and 
standard deviation since Cox regression uses parametric analysis. For dichotomous variables, the number and 
the percentage of patients are listed, relative to the total number of patients for whom information about the 
characteristic under investigation was available. 
‡ The hazard ratio, which is the effect measure generated by Cox regression analysis, can be interpreted 
similar to an odds ratio, meaning that a higher hazard ratio signifies a higher chance of remission.
# 95% CI denotes the 95% confidence interval.
* p-values below 0.05 are printed in bold. Asterisks indicate p-values significant after correction for multiple 
testing by the Holm method.
§ Ritchie articular index and DAS were not reported in the EAC.
¶ SHS denotes the Sharp van der Heijde score for radiographic damage.
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the effect of current or past smoking as compared to never smoking as the reference group, 
revealed that current smoking was associated with the lowest chance of achieving remis-
sion (hazard ratio (HR) with 95% confidence interval (CI): 0.27 (0.08-0.87)), followed 
by past smoking (HR (95%CI): 0.78 (0.39-1.58)). In both EAC and ERAS, there was not a 
significant gene dose effect of the HLA SE alleles. 
To correct for multiple testing, the Holm method was applied which revealed that in 
both cohorts, autoantibody status, presence of the HLA SE alleles and, in the ERAS, the 
Ritchie articular index, 44 SJC, DAS and HAQ at baseline were significant predictors of 
remission. 








95% CI P *
Age in yrs, mean (sD) 51 (16) 52 (13) 1.00 0.98-1.01 0.58
female gender, n (%) 53 (63%) 560 (69%) 0.78 0.50-1.22 0.28
symptom duration at baseline in 
months, median (IQr)






smoking, n (%) 13 (28%) 268 (42%) 0.54 0.29-1.02 0.059
family history positive for rA, 
n (%) 20 (24%) 211 (26%) 0.87 0.53-1.44 0.59
bmI, mean (sD) 25 (4) 26 (5) 0.98 0.93-1.04 0.54
Acute start of complaints, n (%) 51 (61%) 383 (48%) 1.71 1.10-2.67 0.017*
start of complaints in small 
joints, n (%) 25 (30%) 204 (25%) 1.27 0.80-2.04 0.31
symmetrical start of complaints, 
n (%) 63 (81%) 615 (78%) 1.18 0.67-2.07 0.56























esr in mm/h, mean (sD) † 36 (30) 40 (27) 0.99 0.99-1.0 0.21
rf Igm positive, n (%) 29 (36%) 520 (66%) 0.31 0.20-0.50 <0.001*
DAs4, mean (sD) 3.3 (1) 4.3 (2) 0.65 0.55-0.76 <0.001*
larsen score, median (IQr)






hlA se positive, n (%) 34 (56%) 440 (74%) 0.47 0.28-0.78 0.003*
* p-values below 0.05 are printed in bold. Asterisks indicate p-values significant after correction for multiple 
testing by the Holm method.
† CRP and anti-CCP2 were not measured in the ERAS.
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Multivariate analysis
To investigate which of the patient characteristics were independent predictors for 
remission, multivariate Cox regression analysis was performed by a two-step modeling 
approach. Table 4 shows the results of the multivariate analysis for both cohorts. Three 
variables were found to be independent predictors of sustained DMARD-free remission 
in the EAC, two of which were significant (p<0.05): baseline CRP and anti-CCP status. In 
the ERAS, these two characteristics were not available but autoantibody status in the form 
of IgM RF was the most significant predictive variable. Symptom duration showed a trend 
towards significance in the EAC (p=0.07), while significantly associated with remission in 
the ERAS (p=0.029).
The fact that CRP and anti-CCP status were not available in the ERAS, made it difficult 
to assess to what extent the results of the ERAS replicated the findings in the EAC. The 
multivariate analysis of the EAC was therefore also performed after exclusion of these vari-
ables. This analysis revealed the following independent predictive variables (HR, 95%CI): 
symptom duration (0.96, 0.91-1.01), IgM RF (0.19, 0.11-0.35) and HLA SE alleles (0.59, 
0.36-0.96). These three factors were also identified as independent predictors in the ERAS 
cohort, which therefore provides a complete replication of the data of the EAC.
Radiological progression
Although the present study aimed to find baseline characteristics predictive of achieving 
sustained DMARD-free remission, the rate of joint destruction during follow-up was also 
compared in the remission versus the non-remission group in the EAC. The remission 
patients had a lower level of joint damage with a median SHS (with IQR) after 1, 3 and 5 
years of follow-up of 4 (1-9), 6 (1-14) and 6 (3-15), compared to the median SHS of the 
non-remission patients of 11 (5-24), 20 (9-39) and 26 (12-50).
Table 4. multivariate analysis: independent predictors for achieving sustained DmArD-free remission.
Cohort Patient characteristic hazard ratio 95% CI P
eAC Symptom duration in months 0.95 0.90-1.00 0.07
CRP in mg/l 0.99 0.98-1.0 0.040
Anti-CCP2 0.09 0.04-0.20 <0.001
erAs Symptom duration in months 0.94 0.89-0.99 0.029
Acute start of complaints 2.03 1.15-3.59 0.015
Ritchie articular index 0.92 0.88-0.97 0.001
HAQ 0.66 0.44-0.99 0.044
RF IgM 0.28 0.16-0.49 <0.001
HLA SE 0.44 0.26-0.73 0.002
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Remission defined according to the ACR criteria
To determine whether the results would have been different if remission had been defined 
as specified by the ACR criteria, this definition was also applied to the EAC. Remission 
according to the ACR criteria was achieved by 97/454 (21.4%) of patients, including 
all of the 68 patients who achieved sustained, DMARD-free remission. The additional 
29 patients were still using DMARDs at the time when they fulfilled the ACR remission 
criteria. Investigation of which baseline factors were predictive of achieving remission as 
defined by the ACR criteria revealed almost completely the same predictive factors (data 
not shown). 
DIsCussIon
The present study investigated the prevalence and predictive factors for sustained DMARD-
free remission in RA patients treated with conventional therapy. The long-term follow-up 
data from the Dutch EAC and the British ERAS cohorts revealed that sustained DMARD-free 
remission occurs in 9 to 15% of RA patients. Furthermore, sustained DMARD-free remis-
sion can be predicted by several clinical variables at first presentation which are routinely 
assessed in outpatient clinic. Most predictive characteristics which were identified in the 
EAC could be replicated in the ERAS. In this study, sustained DMARD-free was defined in 
its most stringent form which closely resembles a cure of the disease. The present findings 
therefore provide important new insights with regards to disease resolution and the factors 
underlying this process. 
Notably, the frequency of sustained DMARD-free remission was roughly comparable 
in the ERAS and the EAC cohort, being 9.4 and 15% respectively. The finding that the 
prevalence was somewhat lower in the ERAS may be due to the fact that patients in the 
ERAS had a longer symptom duration at presentation, higher 44 SJC and were more often 
IgM RF positive and HLA SE positive than patients included in the EAC. These factors were 
found to be independently associated with a smaller chance of achieving remission in 
both cohorts, and are known to be associated with a severe disease course. This indicates 
that the patients included in the ERAS were less prone to achieve sustained DMARD-free 
remission than patients in the EAC. 
Previous studies on remission in patients treated with conventional therapy have also 
reported remission rates between 10 and 20% 1, 16-19. However, remission was not defined 
as a sustained disease outcome in these previous investigations, but rather as an episodic 
phenomenon. In the present study, the long-term follow-up data from the EAC and ERAS 
cohorts enabled us to investigate remission as a definite disease outcome, which most 
closely resembles a cure of the disease. 
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The possibility that treatment differences between the EAC and the ERAS may have 
affected the prevalence of remission cannot be entirely excluded. However, in the EAC, 
stratification for inclusion period (reflecting different treatment strategies) showed compa-
rable remission rates for the three inclusion periods. This indicates that changes in treat-
ment strategy during the course of the study did not have a major effect on the prevalence 
of sustained DMARD-free remission. Furthermore, in order to exclude the possibility that 
patients who achieved remission had been treated more stringently, a detailed investiga-
tion of medication use was performed in both cohorts. This revealed that the patients 
who achieved remission had not been treated more stringently, but rather tended to have 
been treated less aggressively, e.g. with NSAIDs only (in approximately 25% of patients) 
or with less potent DMARDs (data not shown). In both cohorts, patients who had been 
treated with DMARDs had a significantly lower chance of ever achieving remission (EAC: 
HR (with 95% CI) =0.12 (0.07-0.21), ERAS: HR=0.08 (0.05-0.12)). This suggests that the 
rheumatologists deemed the remission patients to have less severe disease which did not 
need to be treated with DMARDs. This is in line with the other results of the univariate 
analysis, which reveal that remission patients had less radiological damage (in the EAC 
and ERAS) and lower swollen joint counts, Ritchie articular index and HAQ (in the ERAS) 
at baseline. The effect of ever using DMARDs was not included in the multivariate models 
because the aim of the analysis was to identify baseline characteristics of the patients 
which were predictive of remission.
One may consider the observed prevalence of remission (9-15%) to be surprisingly 
high, leading to the question whether these patients “really” had RA. However, all patients 
fulfilled the 1987 ACR criteria for RA; a set of criteria that is not perfect, but is nonetheless 
the most frequently applied. In addition, remission was achieved after a median of 3.5 
years, indicating that patients had a chronic polyarthritis for this lengthy period. Finally, 
the majority of remission patients had radiological joint destruction (although less severe 
than in the non-remission group); a hallmark which is considered characteristic for RA. 
The current study identified several predictive factors for sustained DMARD-free remis-
sion. Autoantibody status, HLA SE alleles, smoking, an acute onset of complaints and 
the symptom duration before inclusion, were found to be predictive in both cohorts. The 
findings on the association between the absence of autoantibodies and remission are in 
line with prior reports that have documented a strong association between autoantibody 
status (IgM RF and anti-CCP2) and the rate of joint destruction in RA 20-22. The current 
observations illustrate that these autoantibodies are also important persistency factors. 
The majority of predictive factors identified in the EAC could be replicated in the ERAS, 
particularly when the same baseline characteristics were included in the multivariate 
models. The ERAS then provided a perfect replication of the results of the EAC. There 
were also some differences between the two cohorts with regard to the predictive factors 
which were identified. In the ERAS, disease activity at baseline, as reflected by the Ritchie 
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articular index, 44 SJC, DAS and HAQ, was inversely associated with achieving remission, 
while in the EAC, the 44 SJC and HAQ were not associated with remission. Part of this 
difference may be attributable to the on average higher disease activity in the ERAS at 
baseline (as apparent from the higher 44 SJC) and accompanying larger range of values, 
which lends more power to the ERAS to find an association between disease activity at 
baseline and definite disease outcome. 
Interestingly, several factors which were recently described to predict remission after 
treatment with anti-TNF therapy such as age, gender and comorbidity could not be repli-
cated in the present study 23, 24. This could very well be the result of the different definitions 
of remission which were used. In these reports, remission was defined as a DAS below 
1.6 or DAS28 below 2.6 during treatment, and it is therefore conceivable that the factors 
which were identified predict treatment response, rather than long-term disease resolu-
tion 25. The difference in predictive factors emphasizes that low disease activity during 
treatment is different from remission which persists after discontinuation of anti-rheumatic 
therapy. 
In conclusion, 9-15% of RA patients treated with conventional therapy achieved sus-
tained DMARD-free remission. Several factors which can easily be determined in clinical 
practice such as symptom duration before presentation and the absence of IgM RF and 
anti-CCP antibodies are consistently associated with sustained DMARD-free remission. In 
light of our findings that RA can resolve in approximately one-tenth of patients, additional 
studies are warranted to further elucidate the underlying mechanisms. 
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AbsTrACT
objectives To compare the prevalence of and predictors for sustained drug-free remission 
in two cohorts of patients with recent-onset rheumatoid arthritis (RA) treated with disease 
activity score (DAS)-driven therapy or non-DAS-driven therapy. 
methods Sustained drug-free remission was assessed after 5 years of follow-up in 508 
patients treated with DAS-driven therapy (DAS<=2.4) in a randomized treatment cohort, 
and in 424 patients who received non-DAS-driven therapy in a prospective inception 
cohort. The design of the DAS-driven cohort required systematic joint assessments with 
DAS-driven restart of therapy. Predictors for remission were identified by univariable and 
multivariable logistic regression in each cohort separately and in a combined multivariate 
logistic regression analysis corrected for propensity scores, including a sensitivity analysis 
on patients receiving initial monotherapy. 
results Patients in the DAS-driven cohort had more active disease at baseline, but the 
prevalence of sustained drug-free remission was similar after DAS-driven (9.8%) and 
non-DAS-driven therapy (10.6%). Among patients with antibodies to citrullinated proteins 
(ACPA), drug-free remission was more frequently achieved after DAS-driven than after 
non-DAS-driven therapy (5.4% versus 2.1%, OR 2.68, 95%CI 0.97-7.43). Absence of 
ACPA and short symptom duration were independent predictors for sustained drug-free 
remission in both cohorts. Initial treatment choice and inclusion period were not predic-
tive. The sensitivity analysis yielded comparable results. 
Conclusions Retrospectively comparing a DAS-driven to a non-DAS-driven therapy co-
hort, the occurrence and predictors of sustained drug-free remission were similar. The 
DAS-driven cohort had a more unfavorable prognosis. DAS-driven therapy may improve 
the chance of sustained drug-free remission in ACPA-positive patients with recent-onset 
RA.
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InTroDuCTIon
In rheumatoid arthritis (RA), an early start of treatment, use of combination therapy with 
corticosteroids or tumor necrosis factor (TNF)-blockers, and a strategy of tight control have 
significantly improved the clinical and radiographic outcomes of patients. 1-6 Continued tight 
control aimed at a predefined goal of minimal disease activity has resulted in suppressed 
inflammation, improved functional status and high remission percentages, irrespective of 
the initial choice of therapy. 7, 8 Recently an international task force has reviewed and 
summarized all the evidence on tight control of RA and has formulated recommendations 
to enhance the implementation of ‘treating to target’ in clinical practice. 9, 10
According to these recommendations, the primary target of RA treatment should be a 
state of clinical remission, defined as the absence of signs and symptoms of inflammatory 
disease activity, assessed by a validated (composite) measure such as the disease activity 
score (DAS). 10, 11 Ideally, clinical remission is maintained even after discontinuation of 
treatment, resulting in what could be called ‘cure’. In the BeSt study, which combined an 
early start of treatment with DAS-driven therapy adjustments, the attainment of clinical re-
mission (DAS44<1.6) led to tapering and ultimately discontinuation of disease modifying 
anti-rheumatic drugs (DMARDs) according to the prespecified treatment protocol.  After 
five years, 10-19% of the patients in the four strategy groups were in drug-free remission 
with a median duration of 23 months. 7
Does DAS-driven therapy result in more drug-free remission than routine non-DAS-
driven treatment? It is known that a proportion of patients treated according to routine 
care, can discontinue their anti-rheumatic medication. 12-14 DAS-driven therapy might have 
a benefit by increasing the proportion of patients who achieve and maintain sustained 
drug-free remission, by inducing remission earlier in the disease course, in patients with 
more severe disease, or all of these alternatives. 
To investigate this, we set out to retrospectively compare the prevalence and predictors 
of sustained drug-free remission in two cohorts of recent-onset RA patients, originating 
from the same region, and treated with either DAS-driven or non-DAS-driven therapy. 
Because anti-citrullinated protein antibodies (ACPA) are known to be an important predic-
tive factor for disease outcome in RA, and current pathophysiological concepts consider 
ACPA-positive and ACPA-negative RA as two distinct disease entities 14, 15, all outcomes 
were investigated separately in ACPA-positive and ACPA-negative patients.




Two cohorts of patients were compared: 
1. the BeSt study (DAS-driven therapy cohort): 508 patients with recent-onset RA ac-
cording to the 1987 American College of Rheumatology (ACR) criteria 16, a symptom 
duration  < 2 years and active disease at baseline (≥ 6/66 swollen joints, ≥ 6/68 tender 
joints, and either an erythrocyte sedimentation rate (ESR) ≥ 28 mm/hr or a global 
health score ≥ 20 mm on a visual analogue scale (VAS) of 0-100 mm), who were 
randomized to four different DAS-driven treatment strategies. The inclusion period was 
2000-2002. 17
2. the Leiden Early Arthritis Clinic (EAC) (non-DAS-driven therapy cohort): 424 patients 
with recent-onset RA according to the 1987 ACR criteria from an observational incep-
tion cohort of consecutive arthritis patients with a symptom duration  < 2 years. The 
inclusion period was 1993-2002. 18 In contrast to a previous report on the EAC 14, 30 
patients who also participated in the BeSt study were excluded. 
The protocols of both cohorts were approved by the local ethics committees and the 
LUMC medical ethics committee, and all participants provided written informed consent.
Treatment
In the BeSt study, patients were randomized to one of four treatment groups: initial metho-
trexate monotherapy subsequently replaced by or extended with other DMARDs (group 
1 and 2), initial combination therapy including conventional DMARDs and prednisone 
(group 3) or initial combination therapy including infliximab (group 4). Every three months, 
the DAS44 was calculated and treatment was adjusted following a strict protocol, aiming 
at a DAS44≤2.4. If the DAS44 was ≤2.4 for at least 6 consecutive months, medication 
was tapered to monotherapy in maintenance dose. Subsequently, from the third year of 
the study, if the DAS44 was <1.6 for at least an additional 6 consecutive months, the last 
DMARD was tapered and discontinued. If the DAS44 increased to >1.6, the last DMARD 
was immediately restarted. Details of the treatment protocol can be found elsewhere.17, 19
Patients in the EAC were treated according to the clinical judgment of their rheumatolo-
gist, via non-DAS-based efficacy evaluations.18 The treatment strategy differed according 
to the inclusion period. Patients included from 1993 to 1996 were initially treated with 
analgesics and subsequently with chloroquine. Between 1996 and 1998, patients were 
initially treated with chloroquine or sulfasalazine, while after 1998 the initial treatment 
strategy consisted of either sulfasalazine or methotrexate.14 The initial treatment of the 
patients described in the current manuscript consisted of non-steroidal anti-inflammatory 
drugs (NSAIDs) in 27% or DMARDs (with or without NSAIDs) in 73% of patients. Of all 
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patients, 37% started with DMARD-combination therapy, and 15% initially (also) used 
corticosteroids. Tapering and discontinuation of the medication was not protocolized.
Definition of remission
In the DAS-driven cohort, sustained drug-free remission was defined as a continued 
DAS44<1.6 after discontinuation of DMARDs. In 85% of the patients in drug-free remis-
sion the swollen joint count (SJC) was zero, as based on systematically performed 66/68 
joint counts at the three-monthly follow-up visits. In the non-DAS-driven cohort patients, 
the DAS was not routinely performed, nor was it calculated post-hoc or imputed. A full 
joint count was registered yearly. In the non-DAS-driven cohort, drug-free remission was 
defined according to the rheumatologist and required the absence of swollen joints after 
cessation of therapy. 
In both cohorts, drug-free remission had to be present for at least one year, and had to 
persist until the end of follow-up, which for the patients in the DAS-driven cohort was the 
5-year follow-up time point. In the non-DAS-driven cohort, patients thus defined as being 
in drug-free remission were discharged from the outpatient clinic after on average 2.5 
years of drug-free remission. After that there was no systematic follow-up, but if patients 
had a recurrence of their arthritis after discharge, they were instructed to return to the 
Leiden University Medical Center. During the period under investigation, one patient was 
re-referred with a relapse and was therefore included in the non-remission group. 
Seventy-two patients (14%) in the DAS-driven cohort dropped out or were lost to follow 
up, and 31 patients (7.3%) in the non-DAS-driven cohort were lost to follow-up before the 
5-year endpoint due to withdrawal, death or moving. An intention to treat analysis with 
last observation carried forward approach was used. 
Statistical analysis
The prevalence of sustained drug-free remission was assessed in both treatment cohorts 
(DAS-driven and non-DAS-driven). Since ACPA has been previously reported as a predic-
tive factor for drug-free remission, results were stratified for ACPA and odds ratios (OR) 
with 95% confidence intervals (CI) for DAS-driven versus non-DAS-driven therapy were 
calculated. 
Baseline variables were assessed for their ability to predict the outcome of sustained 
drug-free remission by univariable logistic regression analysis in both cohorts separately. 
Predictors which had previously been reported and with a p-value<0.10 in univariable 
analysis were taken along in a multivariable analysis with a backward selection procedure 
(removal criterion: p>0.10), yielding independent predictors for sustained drug-free remis-
sion in both cohorts separately. 
Next, we investigated whether DAS-driven treatment was a predictor for sustained drug-
free remission by performing a multivariable logistic regression analysis on a combined 
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dataset of both cohorts. The treatment strategy (DAS-driven versus non-DAS-driven) was 
indicated by a variable (“therapy”) in this combined dataset. To take into account that 
baseline patient characteristics differed between the two cohorts, baseline dissimilari-
ties were corrected for by propensity scores, constructed from the variables age, gender, 
symptom duration, swollen joint count, ESR, rheumatoid factor (RF) and ACPA and all 
significant two-way interactions.20 Via interaction terms we analyzed whether the effect 
of DAS-driven therapy on drug-free remission was different for ACPA-positive or ACPA-
negative patients.
Subsequently, sensitivity analyses were performed to assess whether the early use of 
combination therapy in the DAS-driven cohort or the earlier inclusion period (associated 
with treatment choice) in the non-DAS-driven cohort had influenced the analyses. The sen-
sitivity analysis was performed on the patients who received initial DMARD monotherapy, 
being the patients from arm 1 and 2 in the DAS-driven cohort, and patients included after 
1998 in the non-DAS-driven cohort. 
Table 1. baseline characteristics of patients in the DAs-driven therapy cohort (best) and the non-DAs-








Age, mean ± sD years 54 (13.7) 56 (16.1) 0.06
female gender, no. (%) 346 (68%) 288 (68%) 0.90
symptom duration, median (IQr) weeks 23 (14-53) 20 (11-39) <0.001
bmI, mean (sD) 25.6 (4.0) 25.5 (3.6) 0.62
DAs, mean (sD) 4.4 (0.86) NA -
hAQ, mean (sD) 1.4 (0.67) 1.1 (0.72) <0.001
sJC, median (IQr) 14 (10-19) 8 (5-12) <0.001
CrP, median (IQr) mg/l 21 (9-55) 19 (9-44) 0.41
esr, median (IQr) mm/hr 37 (19-56) 37 (21-59) 0.24
rf-positive, no. (%) 329 (65%) 237 (56%) 0.008
ACPA-positive, no. (%) 294 (62%) 238 (56%) 0.10
se, no. (%) 281 (67%) 270 (67%) 0.98
For dichotomous variables, the number and the percentage of patients are listed, relative to the total number 
of patients for whom information about the characteristic under investigation was available. P-values are 
listed for the comparison between the two cohorts, using t-test for normally distributed variables, Mann-
Whitney for non-Gaussian distributions and Chi-square for dichotomous variables. NA=not applicable.
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resulTs
Cohort characteristics and prevalence of sustained drug-free remission
At baseline, due to the inclusion criteria of the BeSt study, patients in the DAS-driven 
therapy cohort had a longer symptom duration, more active disease characterized by 
worse function measured by the health assessment questionnaire (HAQ) and a higher SJC, 
and were more often RF- or ACPA-positive than patients in the non-DAS-driven cohort 
(Table 1). After 5 years of follow-up, the prevalence of sustained drug-free remission was 
50/508 = 9.8% in the DAS-driven therapy cohort and 45/424 = 10.6% in the non-DAS-
driven cohort (Table 2). All four treatment arms of the DAS-driven study were included in 
the present analysis and there were no significant differences between the treatment arms. 
Stratified for ACPA, the prevalence of sustained drug-free remission was approximately 
20% in ACPA-negative RA patients, irrespective of the therapy cohort. The prevalence of 
drug-free remission was markedly lower in ACPA-positive patients (2-5%). ACPA-positive 
patients treated with DAS-driven therapy had a higher chance of achieving drug-free 
remission compared with non-DAS-driven therapy (OR 2.68, 95%CI 0.97-7.43, p=0.058). 
In the DAS-driven cohort, the discontinuation of antirheumatic therapy was prohibited 
by treatment protocol before two-and-a-half years of follow-up. The mean time (with stan-
dard deviation: SD) to drug-free remission was 3.1 years (SD: 0.5 years) in the DAS-driven 
cohort and 2.6 years (SD: 1.3 years) in the non-DAS-driven therapy cohort.
Predictive factors 
In the DAS-driven cohort, male gender, lower DAS and HAQ at baseline and the absence 
of RF, ACPA and shared epitope (SE) alleles were significantly univariately associated with 
sustained drug-free remission (Table 3). The allocated initial treatment or treatment arm 
(mono- versus combination therapy), was not a predictive factor (data not shown). The 







Total                   DAS-driven therapy 50 (9.8%) 458 (90.2%)
0.92 (0.60-1.41)
                           non-DAS-driven therapy 45 (10.6%) 378 (89.4%)
ACPA-positive     DAS-driven therapy 16 (5.4%) 278 (94.6%)
2.68 (0.97-7.43)
                           non-DAS-driven therapy 5 (2.1%) 233 (97.9%)
ACPA-negative    DAS-driven therapy 34 (18.6%) 149 (81.4%)
0.83 (0.50-1.38)
                           non-DAS-driven therapy 40 (21.6%) 145 (78.4%)
Prevalence of sustained drug-free remission in the DAS-driven and the non-DAS-driven therapy cohort, in 
the total group and stratified for ACPA-positive and ACPA-negative patients. Odds ratios (OR) with 95% 
confidence intervals (CI) represent the chance for drug-free remission with DAS-driven versus non-DAS-
driven therapy.
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multivariate model revealed male gender, short symptom duration, the absence of ACPA 
and lower baseline DAS as independent predictors for sustained drug-free remission in the 
DAS-driven cohort (Table 4 I). If the DAS was replaced with the HAQ, HAQ was also an in-
dependent predictor with borderline significance (OR 0.61, 95% CI: 0.37-1.006, p=0.053). 
RF was a significant independent predictor if put in the model instead of ACPA (OR 0.33, 
95% CI: 0.18-0.60, p=<0.001), but was not significant if included in addition to ACPA.
Also in the non-DAS-driven cohort, absence of RF, ACPA and SE were significant uni-
variate predictors (Table 3). In addition, shorter symptom duration and non-smoking were 
identified as predictors. The inclusion period as surrogate variable for the initial treatment, 
was not predictive for sustained drug-free remission (data not shown). The multivariable 
model revealed a shorter symptom duration and the absence of ACPA as independent 
predictors for sustained drug-free remission in the non-DAS-driven cohort (Table 4 II). 
Table 4. Independent predictors for sustained drug-free remission in the DAs-driven therapy cohort (I) and 
the non-DAs-driven therapy cohort (II).
Predictor or (95% CI) p-value
I DAs-driven cohort  
   Male gender 2.39 (1.26-4.53) 0.008
   Symptom duration (weeks) 0.99 (0.98-1.00) 0.099
   ACPA-positivity 0.20 (0.10-0.39) <0.001
   DAS 0.63 (0.43-0.94) 0.022
II non-DAs-driven cohort
   Symptom duration (weeks) 0.99 (0.97-1.00) 0.108
   ACPA-positivity 0.09 (0.04-0.24) <0.001
Table 5. Independent predictors of sustained drug-free remission from the combined multivariable logistic 
regression analysis.
Predictor or (95% CI) p-value
model I 
    Male gender 1.89 (1.18 - 3.01) 0.01
    Symptom duration (weeks) 0.99 (0.98 – 1.00) 0.06
    ACPA-positivity 0.18 (0.10 – 0.30) <0.01
    DAS-driven vs. non-DAS-driven therapy 1.42 (0.84 – 2.40) 0.19
model II After adding interaction ACPA*therapy
    DAS-driven therapy:
       In ACPA-positive patients 2.95 (1.03 – 8.44) 0.04
       In ACPA-negative patients 1.12 (0.62 – 2.03) 0.72
The analysis was corrected for baseline cohort differences via propensity scores. Model I represents the 
results without interaction terms. Model II shows the effect of DAS-driven therapy separately in ACPA-
positive and negative patients.
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Again, RF was only a significant independent predictor if put in the model instead of ACPA 
(OR 0.25, 95% CI: 0.12-0.51, p=<0.001). 
Looking at the effect of ACPA-positivity, the odds ratio (OR) for sustained drug-free 
remission was two times higher with DAS-driven therapy (OR 0.20) than with non-DAS-
driven therapy (OR 0.09), suggesting that the negative effect of having ACPA on achieving 
sustained drug-free remission may be counterbalanced to some extent by a benefit of 
DAS-driven therapy. 
The multivariable logistic regression analysis with the two datasets combined included 
age, gender, symptom duration, smoking, ESR, C-reactive protein (CRP), RF, ACPA and 
treatment cohort as explanatory variables and was corrected for propensity scores to 
take into account the differences in baseline characteristics between the two cohorts. 
The model revealed male gender, short symptom duration, and the absence of ACPA as 
independent predictors for sustained drug-free remission (Table 5, I). DAS-driven therapy 
was not associated with a significantly higher chance for sustained drug-free remission in 
this multivariable model. However, a significant interaction was present between treat-
ment cohort and ACPA (OR 3.2, 95% CI: 1.04-10.1, p=0.043). We therefore investigated 
the effect of treatment cohort separately for ACPA-positive and ACPA-negative patients. As 
shown in Table 5 II, DAS-driven therapy was associated with a three times higher chance 
for sustained drug-free remission in ACPA-positive patients, but not in ACPA-negative 
patients, confirming our univariable findings. 
Sensitivity analysis
The analyses in the total cohorts did not reveal treatment allocation in the DAS-driven 
cohort nor the inclusion period in the non-DAS-driven cohort as factors associated with 
achieving drug-free remission. Nevertheless, to investigate if the differences in initial treat-
ment and the inclusion period within and between the cohorts influenced our results, we 
performed a sensitivity analysis on the patients who received comparable initial DMARD 
monotherapy in a similar time period. The prevalence of sustained-drug free remission 
was 25/247 (10.1%) in the patients treated with initial methotrexate monotherapy in the 
DAS-driven cohort and 19/199 (9.5%) in the patients included after 1998 in the non-DAS-
driven cohort, treated with either initial methotrexate or sulfasalazine monotherapy. In the 
DAS-driven cohort, independent multivariate predictors for drug-free remission remained 
male gender (OR 2.1, 95% CI: 0.84-5.35, p=0.112), absence of ACPA (OR 0.23, 95% CI: 
0.09-0.59, p=0.002) and short symptom duration (OR 0.98, 95% CI: 0.96-0.99, p=0.038). 
In the non-DAS-driven cohort, only absence of ACPA remained a significant independent 
predictor (OR 0.09, 95% CI: 0.02-0.41, p=0.002).
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DIsCussIon
Although it is clear that tight-control strategies such as DAS-driven therapy result in better 
clinical and radiographic outcomes, and recommendations for ‘treating RA to target’ have 
recently been formulated, it has not yet been investigated whether DAS-driven therapy 
also results in more drug-free remission than non-DAS-driven routine treatment evalu-
ations.9, 10 In this study, we found that in two cohorts of patients with recent-onset RA, 
treated with either DAS-driven or non-DAS-driven therapy, the occurrence of sustained 
drug-free remission was fairly similar, as were predictors of sustained drug-free remission: 
a short symptom duration and the absence of ACPA. 
Since there were significant differences between the two cohorts at baseline, the 
comparison is not straightforward. A randomized controlled trial would be the ideal set-
ting to investigate the effect of DAS-driven versus non-DAS-driven therapy on achieving 
sustained drug-free remission. However, as DAS-driven therapy leads to better functional 
and radiological outcomes than non-DAS-driven therapy 2, 6, 19 such a design may be con-
sidered unethical. In addition, large patient numbers per group would be required, since 
sustained drug-free remission does not occur often. Therefore, we resorted to a retrospec-
tive comparison of two existing large cohorts. 
Patients in the DAS-driven cohort, which started as the BeSt trial, had more severe 
disease and therefore poorer prognosis, based on the inclusion criteria of the trial 17, 
whereas the non-DAS-driven cohort also included less severe patients 18. In addition, the 
definition of sustained drug-free remission and frequency of follow-up differed between 
both cohorts, although it does not appear very likely that this will have had a major impact 
on the results. In the DAS-driven cohort, remission required a sustained DAS<1.6 at three-
monthly intervals and as soon as the DAS rose above 1.6, medication was restarted. In 
15% of patients in remission based on a DAS <1.6, residual joint swelling (based on a 
66/68 joint count) was still present. In the non-DAS driven cohort, remission was based 
on the rheumatologist’s opinion, including absence of swollen joints at yearly evaluations. 
Restart of therapy, duration or frequency of follow-up were not protocolized. 
It is difficult to speculate what the results might have been like if the cohorts had been 
more similar. Considering that the DAS-driven cohort had more disease activity at baseline 
and perhaps a more stringent definition of remission, one could argue that DAS-driven 
therapy leads to more sustained drug-free remission than is reflected by the current study. 
On the other hand, the earlier inclusion period and relative lack of combination therapy 
might have posed a disadvantage for the patients in the non-DAS-driven therapy cohort. 
The inclusion period may have represented different practices in timing and choice of 
prescribing anti-rheumatic drugs.21 Part of the patients in the non-DAS-driven cohort who 
were included at an earlier point in time, were not promptly treated with DMARDs, and a 
delay of DMARD therapy is associated with worse disease outcome.1, 5 Initial combination 
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therapy, used in a subpopulation of the DAS-driven cohort, is associated with early and 
better suppression of disease activity, but was seldom prescribed in the non-DAS-driven 
cohort. It is remarkable in this respect that neither the specific treatment arm in the DAS-
driven cohort (the BeSt study), nor the inclusion period and corresponding treatment 
strategy in the non-DAS-driven cohort (the EAC), were associated with sustained drug-free 
remission, confirming previous reports.14, 19 This suggests that the effect of the differences 
in inclusion period and associated medication use on our results may have been limited. 
It is difficult to separate the effect of using more (novel) DMARDs from the effect of 
DAS-driven strategy, as a tight control strategy with frequent DAS-measurements inher-
ently leads to rapid changes in medication. However, in our sensitivity analysis we partly 
disentangled these effects by excluding all the patients with initial combination therapy, as 
well as the patients included before 1999, which did not result in a change in the observed 
remission rates. 
With, or despite, the differences between the two cohorts, the rate of sustained drug-
free remission did not differ between the DAS-driven and non-DAS-driven cohort. ACPA-
negative patients achieved sustained drug-free remission more easily than ACPA-positive 
patients, whether DAS-driven or not, but ACPA-positive patients, despite having a worse 
prognosis in general 22, had a slightly higher chance for achieving drug-free remission in 
the DAS-driven cohort than in the non-DAS-driven cohort. The more advanced analysis 
methods (employing propensity scores and interaction terms) yielded results compatible 
with the straightforward comparison of the prevalence of sustained drug-free remission: 
more remission in ACPA-positive patients after treatment with DAS-driven therapy (bor-
derline significance). This argues in favor of the robustness of the analysis. We tentatively 
propose that this may indicate that with DAS-driven therapy sustained drug-free remis-
sion can be achieved more readily, even in patients with more unfavorable prognostic 
characteristics. 
The absolute number of patients with sustained drug-free remission in both our cohorts 
is still low and an important question is if and how we can attain more sustained drug-free 
remission in the future. Is sustained drug-free remission intrinsically possible only for cer-
tain patients, or should we be able to induce it in all patients? The similar rates of sustained 
drug-free remission in both cohorts as well as the higher sustained drug-free remission 
rate among ACPA-negative patients support the former, but the fact that with DAS-driven 
treatment drug-free remission was also attainable in more poor prognosis ACPA-positive 
patients support the latter. In addition, the finding of short symptom duration as a predictor 
of sustained drug-free remission may indicate a ‘window of opportunity’. The studied 
DAS-driven cohort aimed at a DAS44≤2.4, a cut-off which allows for some residual inflam-
mation. Thus, actively aiming at even lower levels of disease activity, as well as starting 
treatment earlier and including the use of drug combinations and biologicals might result 
in more patients achieving early and sustained drug-free remission in patients with RA. 
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In summary, in a comparison of a DAS-driven and a non-DAS-driven therapy cohort, the 
occurrence and predictors of sustained drug-free remission appeared similar, but the DAS-
driven cohort had more patients with an unfavorable prognosis. The fact that the presence 
of ACPA at presentation is associated with a significantly lower chance of achieving remis-
sion, calls attention once more to the severe disease course associated with ACPA-positive 
RA. The results of this study suggest that ACPA-positive patients may especially benefit 
from tight disease control strategies. Future trials will hopefully shed more light on the 
optimal treatment strategy for this group of patients with their inherently poor prognosis.
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summary and discussion
The results of the studies presented in this 
dissertation will be summarized and discussed in 
three parts, corresponding to the structure of the 
thesis.
Diana vd Woude BW.indd   237 19-01-12   11:38
Diana vd Woude BW.indd   238 19-01-12   11:38
Summary and discussion 239
PArT 1: rIsk fACTors for AnD herITAbIlITy of rheumAToID 
ArThrITIs
The effect of HLA DRB1 alleles on the risk of rheumatoid arthritis
Rheumatoid arthritis (RA) has a complex, multifaceted etiology, of which many elements 
remain unknown. It is clear that both genetic and environmental risk factors play a role in 
disease development. The field of risk factor investigation in RA has witnessed a paradigm 
shift due to the description of anti-citrullinated protein antibodies (ACPA) several years 
ago 1. ACPA-positive and ACPA-negative disease differ not only in their clinical disease 
phenotype, with ACPA-positive patients having more severe and persistent disease, but 
also with regard to their association with different genetic and environmental risk fac-
tors2, 3. The discovery that the strongest genetic risk factor for RA: the HLA shared epitope 
(SE) alleles specifically predispose to ACPA-positive disease has proven to be crucial for 
the current concepts about the pathophysiological processes underlying the disease 4, 5. 
In addition to the HLA-DRB1 alleles which contribute to RA susceptibility, other HLA-
DRB1 alleles confer protection against disease 6-8. These protective HLA-DRB1 alleles have 
been categorized according to several different classifications usually based on shared 
amino acid sequences among the protective alleles, analogous to the shared epitope clas-
sification of susceptibility alleles. For one of these classifications, the so-called DERAA 
alleles, based on the shared sequence DERAA at position 70-74 of the HLA-DR beta 1 
chain 9, it was shown that their effect was truly protective and not merely the results of the 
absence of predisposing shared epitope alleles 10. Due to limitations of sample size, it was 
unclear whether the protective effect of the various alleles differed among ACPA-positive 
or ACPA-negative RA. In order to obtain a better understanding of which HLA DRB1 
alleles were associated with a consistent protective effect among different populations, 
and to investigate whether these protective effects were specific for ACPA-positive or 
ACPA-negative RA, we performed a meta-analysis as described in chapter 2. 
Unexpectedly, the results revealed that none of the previous classifications of protective 
HLA alleles was completely accurate. Protection was limited to the ACPA-positive subset 
of RA and only conveyed by HLA-DRB1*13 alleles, or more specifically by DRB1*1301. 
The protective effects of the DERAA- and D70-alleles could be explained by DRB1*13, 
which is a part of both of these classifications. Therefore the presence of a DERAA- or 
D70-sequence in itself is not sufficient to confer protection. It should be noted that al-
though our study included over 2700 patients and 3000 controls from large data-sets from 
four different European populations, smaller protective effects which may be present for 
other alleles than DRB1*1301 cannot be excluded.
These findings raise the question what unique feature of the DRB1*1301 alleles may be 
responsible for this protective effect. Intriguingly, the peptide sequence of DRB1*1301 does 
not harbor a particular stretch of amino acids which is truly exclusive to DRB1*1301. On 
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the contrary, there is quite extensive homology between the DRB1*1301 and DRB1*1102 
alleles, despite the fact that no protective effect could be detected for the DRB1*1102 
alleles. Therefore, it is not apparent at the first glance that DRB1*1301 would be capable 
of presenting a unique peptide, although this cannot be ruled out solely on the basis of 
its sequence.
It is noteworthy nonetheless that the difference between DRB1*1301 and the shared 
epitope alleles in the region of the shared epitope defining sequence: position 70 to 74 is 
limited to the two amino acids at position 70 and 71. While the shared epitope alleles as 
well as DRB1*09, which is also associated with predisposition to ACPA-positive RA, all 
harbor a positively charged or neutral amino acid in these two positions, DRB1*1301 car-
ries two negatively charged amino acids in this region which constitutes binding pocket 4 
of the HLA-DRB1 molecule. Despite the fact that this is also the case for all other alleles 
containing the previously described DERAA-sequence, it may nevertheless contribute 
to the protective effect exerted by DRB1*1301, in conjunction with an as yet unknown 
unique feature of the DRB1*1301 molecule or genomic region. 
If one were to assume that the protective effect associated with DRB1*1301 were due 
to antigen-presenting properties of the DRB1*1301 molecule, this would lead to one of 
the following two hypotheses. Hypothesis 1: DRB1*1301 would have to be a very poor 
presenter of a pathogenic peptide, presentation of which by all other HLA-DRB1 mol-
ecules, and especially by the shared epitope (SE) alleles, could lead to the stimulation of 
pathogenic T cells. Despite the fact that there is some evidence that SE alleles can present 
citrullinated antigens 11, 12, one may wonder whether it is plausible that the properties of 
all other DRB1 molecules would be similar in this respect. It is also difficult to envisage 
how DRB1*1301 would confer protection in a heterozygous setting, if there were another 
allele present which could present pathogenic peptides. In this case, the dose of antigen 
presentation would have to be a decisive element in order for there to be a protective 
effect based on the presence of only one DRB1*1301 allele. 
Another possibility is hypothesis 2: DRB1*1301 would have to be a potent presenter of 
a tolerizing peptide. This peptide would have to be practically constitutively present and 
lead to tolerance against the antigens responsible for inciting the autoimmune response in 
RA. In this setting however, one would expect that the presence of a DRB1*13 allele would 
have a dominant protective effect, taking into account that tolerance is considered to be 
an all-or-nothing process. In a heterozygous setting, the effect of the other allele would 
cease to matter, which cannot be reconciled with data showing that patients heterozygous 
for DRB1*1301 and SE still have an increased risk of developing ACPA-positive RA. 
Despite these objections, the advantage of assuming that antigen presentation lies at 
the basis of the protective effect of DRB1*1301, is that it is readily compatible with the 
interesting North-South gradient which was observed in the strength of the associations of 
several HLA-DRB1 alleles. This suggests that environmental factors influence the effect of 
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HLA-DRB1*1301 which is in agreement with the fact that the amount and types of antigen 
available for presentation may vary in different environments. Although this is an attractive 
hypothesis, there are also other conceivable explanations for the geographical differences 
we observed. For example, differences in genetic background might be responsible for the 
variation in the effect of DRB1*13 due to intergenic interactions.
To clarify whether the protective effect associated with DRB1*1301 is due to its antigen 
presenting properties, it would be worthwhile to further characterize its peptide binding 
characteristics, especially with regard to citrullinated peptides. It may also be interesting 
to investigate the characteristics of the ACPA response (as described in part 2 of the thesis) 
in the rare DRB1*1301-positive individuals who do develop ACPA-positive RA. If the fine 
specificity of their ACPA response were to differ from DRB1*1301-negative patients, this 
would argue in favor of a role of DRB1*1301 in the presentation of / induction of tolerance 
to citrullinated peptides.
With regard to HLA-DRB1*1301 it is remarkable that this haplotype / these alleles have 
been described to be associated with protection against several other diseases as well, 
such as narcolepsy 13, chronic hepatitis B 14 and hepatitis C 15. This may suggest the pres-
ence of a more general immunoregulatory factor within the HLA-DRB1*1301 haplotype. 
On the other hand, the fact that HLA-DRB1*1301 alleles have also been reported to be 
associated with an enhanced risk of other diseases such as primary sclerosing cholangitis16 
and type 1 autoimmune hepatitis 17 argues against this hypothesis.
In addition to the possibility that the protective effect may be due to the HLA-DRB1*1301 
molecule itself as elaborated above, it also appears highly probable that the causative gene 
variant is instead located within the extended HLA-DRB1*1301 haplotype. Several studies 
have described that genetic variants and single nucleotide polymorphisms (SNPs) within 
the HLA region can contribute to the genetic risk of ACPA-positive RA, independently of 
the HLA-DRB1 alleles 18, 19. In this area of research, denser mapping of the HLA region 
and ultimately, functional studies of the involved genetic variants will be required to fully 
elucidate the role of HLA-DRB1*1301 or its associated haplotype in rheumatoid arthritis.
The heritability of rheumatoid arthritis
To date, the majority of genetic risk factors, including the HLA shared epitope alleles 
which confer the highest risk of RA of all known genetic risk factors, have been found to 
be associated with ACPA-positive RA. These findings led to the hypothesis that the influ-
ence of genetic factors may be larger in ACPA-positive compared to ACPA-negative RA. 
The study presented in chapter 3 therefore investigated the heritability and the contribu-
tion of the HLA SE alleles to the genetic variance of both disease subsets using data from 
a large RA twin cohort from the United Kingdom. Surprisingly, we discovered that the 
heritability of ACPA-positive and ACPA-negative RA was similar and amounted to approxi-
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mately 66% in both cases. As was to be expected, the HLA SE alleles hardly contributed 
to ACPA-negative RA, but did explain 18% of the genetic variance of ACPA-positive RA. 
As a result of recent genome-wide association studies (GWAS), a large number of new 
single nucleotide polymorphisms (SNPs) have been described to be associated with RA 20, 
21. In a continuation of our first heritability study, we investigated how much of the genetic 
variance could be explained by these new genetic risk factors. In light of the results of 
chapter 2 and the strength of the protective effect associated with DRB1*1301, we also 
wished to take into account to what extent DRB1*1301 contributed to the genetic variance 
of RA. The results of these studies are presented in chapter 4, and unexpectedly, showed 
that the contribution of both the protective HLA DRB1*1301 alleles and the separate 
SNPs to the different subsets of RA was very small. The most likely explanation for the 
limited consequences of the HLA DRB1*1301 alleles with regard to the explained genetic 
variance, is the modest prevalence of these alleles. In case of the SNPs, the contribution 
to the genetic variance is most likely constrained by the low effect sizes with which they 
are associated. These numbers illustrate that largest part of the substantial influence of 
genetic risk factors in RA remains unexplained, and the disease therefore still suffers from 
“missing heritability”, as do many other illnesses 22. Various explanations for this missing 
heritability have been put forward. 
Perhaps many other common variants, tagged by SNPs, remain to be discovered, al-
though it appears likely that they will be associated with increasingly smaller odds ratio’s. 
Thus, the number of SNPs which would be required to explain a reasonable part of the 
genetic variance would seem to be enormous. On the other hand, the true causal genetic 
variants, which are tagged by the SNPs, may be associated with significantly larger effect 
sizes than the SNPs themselves. Thereby, the current figures which are based on the SNP 
effect sizes may prove to be under-estimates of the true contributions of the definitive 
genetic risk factors. 
Another prevalent hypothesis is that so-called rare variants with a low minor allele 
frequency could play a major role 23, 24. If these rare variants are associated with substantial 
odds ratio’s and are inherited in a Mendelian fashion, a small number of families could 
explain a considerable part of the genetic variance of RA 25. In the most extreme form, 
such rare variants could be associated with a very high penetrance and a severe disease 
phenotype, as has been described for mutations in the gene for the interleukin 10-receptor 
in inflammatory bowel disease 26. If milder gene variants in the same gene subsequently 
prove to be present in patients with a normal disease phenotype, rare variants in this 
manner can also provide very valuable information about pathophysiology of the disease 
in general.
Structural genomic variation, including inversions, translocations and copy number 
variants (CNV) may also account for a part of the missing heritability. However, the impact 
of such variation has been called into question by recent data indicating that the SNP 
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genotyping arrays used for the GWAS have captured most of the variability due to this 
trait 27. Interaction between different risk factors may also contribute to the heritability, 
both in the sense of gene-gene (intergenic) interaction and gene-environment interac-
tion. With regard to intergenic interaction, conflicting results have been reported with a 
study in RA describing no such interaction between the known genetic risk factors and a 
number of recently identified SNPs 28. On the other hand, in a study investigating which 
part of the genetic variance in individual height can be explained by genetic risk factors, 
intergenic interaction was found to potentially have a very large impact 29. Finally, it may 
also be worthwhile to reassess the current estimates of heritability, despite the fact that the 
numbers which are currently reported, including those we found, are very much in line 
with previous estimates. 
In conclusion, there are many possible explanations for the current enigma of missing 
heritability. Besides the quest for the solution to this problem which will undoubtedly 
involve the identification of more genetic variants, it is important to be aware of the 
fact that translation of genetic findings to the resulting pathophysiological processes and 
thus to clinically applicable knowledge, is currently lagging behind. It will be equally 
important to conquer the challenges in this area in order to be able to use the data for the 
benefit of RA patients. 
The effect of alcohol consumption on the risk of rheumatoid arthritis
After the preceding studies of genetic risk factors in RA, we also investigated the effect of 
one of the environmental risk factors which has been described in association with RA: 
alcohol consumption. In the past, a possible protective effect of alcohol has been reported 
in several cohorts with relatively limited sample size 30-32, and more recently in two Scandi-
navian cohorts 33. As described in chapter 5, we investigated the association of alcohol not 
only with rheumatoid arthritis, but also with other kinds of inflammatory arthritis (reactive 
arthritis, spondylarthritis, psoriatic arthritis) and osteoarthritis. While alcohol was indeed 
associated with a significantly lower risk of RA, this protective effect was also present 
with regard to the other forms of arthritis. In conjunction with the observation that there 
was a negative correlation between the degree of systemic inflammation, as measured by 
the erythrocyte sedimentation rate (ESR), and alcohol consumption, these results suggest 
that alcohol intake may be inversely associated with systemic inflammatory activity in 
general, rather than with RA in particular. Slightly contradictory to these findings was 
our observation that the protective effect of alcohol consumption was significantly larger 
in patients with ACPA-positive RA as compared to patients with other forms of arthritis. 
This effect persisted after correction for the ESR, indicating that the reduction of alcohol 
consumption in this subgroup was not solely due to the association with an increased 
level of systemic inflammation.
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The inverse correlation between alcohol consumption and systemic inflammation can 
be interpreted in two ways. One hypothesis is that alcohol may suppress both the innate 
and adaptive immune system leading to reduced pro-inflammatory cytokine production 
and in this manner possibly to a decrease or complete absence of joint inflammation where 
it otherwise would have occurred. This theory is supported by immunological studies 
demonstrating reduced dendritic cell and monocyte responses in the presence of alcohol 
34, 35, and by experiments in mice showing that alcohol may prevent the development of 
destructive arthritis 36. Recent results from the prospective Nurses’ Health Study 37 showing 
a U-shaped association between alcohol consumption and markers of inflammation prior 
to the onset of RA, also suggest that alcohol may have an anti-inflammatory effect. 
With regard to our data, it appears that if alcohol were to suppress inflammation, 
one might have expected a dose-response relationship with heavy drinking conferring 
a stronger protective effect than light drinking. The fact that we did not observe a dose-
response relationship is therefore not in line with a dose-dependent suppressive effect of 
alcohol on inflammation. Furthermore, the general immunosuppressive effect of alcohol 
would presumably persist after disease development, yet we did not observe an increase 
in remission, nor a decrease in radiographic joint destruction in RA patients in association 
with alcohol consumption. However, other cohorts have reported an association between 
alcohol consumption and decreased disease severity 38, 39, indicating that a beneficial 
effect of alcohol may also be present after disease onset.
The second possible explanation is that patients with arthritis and a high degree of 
systemic inflammatory activity may drink less alcohol, or report drinking less alcohol, 
due to their illness. The fact that alcohol has also been reported to be inversely associated 
with the risk of other inflammatory diseases 40, 41, could argue in favor of this hypothesis. 
Furthermore, a recent case-control study in systemic lupus erythematosus (SLE) 42 where 
in contrast to our investigation, information on alcohol consumption prior to the mo-
ment of diagnosis was also available, described that there was no association between 
alcohol consumption before SLE diagnosis and the risk of SLE. However, once patients 
had been diagnosed, they reported drinking significantly less alcohol than controls. These 
results suggest that part of the protective association between alcohol consumption and 
the development of arthritis which we and others have described, may be due to recall or 
interviewer bias. 
An observation that cannot be explained by these hypotheses which assume a general 
immunosuppressive effect of alcohol or recall or interviewer bias, is the particularly strong 
negative association between alcohol and ACPA-positive RA. It is remarkable that a previ-
ous Scandinavian study 33 also described this effect, which raises the question whether 
alcohol may specifically interfere with the pathophysiological processes underlying 
ACPA-positive RA. This question was addressed in the Scandinavian study by interaction 
analyses which showed that the effect of alcohol was more pronounced among HLA SE-
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positive patients and smokers. This suggests that alcohol may affect the same pathophysi-
ological pathway in which the HLA SE alleles and smoking are involved.
In summary, it remains difficult at present to draw firm conclusions about the effect of 
alcohol consumption on the risk of developing rheumatoid arthritis. On the basis of our 
results, it appears that an important issue to address is whether the protective association 
may be due to recall bias. This could be achieved by case-control studies using a more 
detailed questionnaire with questions about alcohol ingestion before and after the start 
of symptoms. Alternatively, prospective studies which could record alcohol use prior to 
the onset of disease, might offer even more reliable data in this regard. In addition, inves-
tigations concerning patients with other chronic inflammatory diseases could elucidate 
whether the possible protective effect of alcohol is specific for arthritic conditions or due 
to a more general anti-inflammatory effect. In light of the large interest of the media for 
this topic, a careful communication strategy of the results of further research to a larger 
audience will be key, especially with regard to the large public health risks of excessive 
alcohol consumption.
PArT 2: ChArACTerIsTICs of ACPA
Glycosylation
As described above, the discovery of ACPA has led to a major change in the hypotheses 
about the pathophysiological basis of RA. The fact that the prevalence and titer of ACPA 
increase before disease onset 43-45 could be compatible with a direct pathogenic role for 
these antibodies. Findings from an animal model describing the induction of arthritis by 
citrullinated fibrinogen 46 also support this idea. Because the (patho)physiological effect of 
an antibody response is critically dependent on several specific antibody characteristics, 
we decided to examine various features of the ACPA response in part two of this thesis.
Chapter 6 focuses on carbohydrate structures known as glycans which are linked to the 
Fc part of antibodies. They are crucial for the structural stability of the antibody and influ-
ence its effector functions such as complement activation, antibody-dependent cellular 
cytotoxicity and binding to cellular Fc-receptors. IgG antibodies in the sera of RA patients 
are known to contain mostly G0 glycans, meaning that these glycan chains lack galactose. 
To investigate whether the glycan chains carried by ACPA differ from the glycans carried 
by other antibodies in the sera of RA patients, we developed a technique to analyze 
Fc-linked glycans in an antigen-specific manner 47.
A comparison of serum ACPA IgG1 to total serum IgG1 revealed that ACPA were associ-
ated with a characteristic glycan profile lacking sialic acid residues. ACPA from synovial 
fluid (SF) of RA patients were highly agalactosylated and due to the attachment of sialic 
acid to galactose, thereby also lacked sialic acid. Differences in glycosylation were also 
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detected within RA patients depending on the presence of rheumatoid factor (RF). ACPA 
from RF-positive patients contained significantly more G0 (agalactosylated) glycoforms 
than ACPA from RF-negative patients. 
These results are readily compatible with the functions currently attributed to the various 
glycoforms. The presence of sialic acid residues is thought to mediate anti-inflammatory 
activity of human IgG 48, therefore a lack of sialic acid as was detected in association with 
serum ACPA may increase its pathogenic potential. With regard to the agalactosylated 
glycoforms, it has been previously described that the relative amount of these glycoforms 
in the sera of RA patients correlates with disease activity and decreases during treatment 
49-51. The observation that in comparison to ACPA from serum, ACPA from synovial fluid 
(SF) exhibit a significant reduction in galactose residues therefore suggests that SF ACPA 
may either be closer to, or more intimately involved in inflammation. It is unlikely that 
the inflammatory environment in synovial fluid leads to enzymatic modification of glycan 
residues, since this would affect all antibodies in the SF, while in our experiments the 
glycan profile of total IgG isolated from SF did not differ from the profile of total IgG 
isolated from serum. Together, these results suggest that the glycosylation profile of ACPA 
could facilitate a pathogenic role of these antibodies.
The detected difference in ACPA glycosylation between RF-positive and RF-negative 
patients is intriguing. One possible explanation may be that agalactosylated antibodies 
may lead to the production of RF, because a lack of galactose residues could lead to a 
conformational change in IgG Fc structure revealing new epitopes to which RF could 
bind. On the other hand, if one were to assume that the predominance of G0 glycoforms 
is secondary to inflammation in rheumatoid arthritis, RF-positive individuals may have 
more severe inflammation which could lead to selective agalactosylation of the most 
recently formed antibodies: ACPA. There are however, several findings arguing against 
the hypothesis that the changes in antibody glycosylation in RA are secondary to inflam-
mation, including a recent report describing aberrant IgG glycosylation years before the 
onset of arthritis 52. It is also noteworthy that the RF-positive and RF-negative patients we 
investigated did not differ significantly with regard to measures of inflammation such as 
erythrocyte sedimentation rate and C-reactive protein.
Isotypes and fine specificity
In chapter 7 we investigated the association between disease course and another char-
acteristic of the ACPA response: the antibody isotypes. The different human antibody 
isotypes are known to vary in their ability to recruit effector mechanisms, and are thereby 
key determinants of antibody function. The results described in this chapter can best be 
understood in the light of the findings regarding another antibody characteristic: the fine 
specificity. This designates the exact antigen recognition properties of an antibody. The 
development of ACPA fine specificity was investigated before disease onset and during 
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disease progression as described in chapter 8. Furthermore, the clinical effects of indi-
vidual differences in ACPA fine specificity repertoire were examined in more detail in 
chapter 9. Specifically, we analyzed whether certain ACPA fine specificities were associ-
ated with the extent of radiographic joint damage. Together with a previously published 
article by Verpoort et al 53, these manuscripts provide an overview of the development of 
ACPA fine specificity and isotype use during disease onset and of the predictive value of 
these ACPA characteristics for the future disease course.
In the Leiden Early Arthritis Clinic (EAC), patients who presented with undifferentiated 
arthritis (UA) and whose disease did or did not progress to RA, were used to investigate 
the association of ACPA isotypes and fine specificity with disease outcome. At the time of 
disease onset, ACPA-positive UA patients who later developed RA recognized significantly 
more peptides and had a broader isotype use, than ACPA-positive UA patients whose 
disease did not progress. Thus, despite the same clinical phenotype of UA, the immuno-
logical differences with regard to the ACPA response foretold the future progression of the 
disease. 
Remarkably, after disease onset neither the fine specificity repertoire nor the isotype use 
expanded, despite a progressively worsening of the disease in UA patients who developed 
RA. These findings were corroborated by investigating patients with longstanding RA, in 
whom no differences could be detected between the fine specificity and isotype profiles 
at baseline and after 7 years of follow-up. Despite the fact that we cannot exclude that the 
use of a larger number of citrullinated peptides might have led to different results, these 
findings suggested that the evolution of these ACPA characteristics predominantly occurs 
before disease onset. To further investigate the immunological development of the ACPA 
response prior to disease manifestation, we made use of a unique serum collection from 
blood donors who had donated blood before and shortly after the onset of RA. In line 
with the above hypothesis, the number of recognized citrullinated peptides was found to 
increase in the period preceding disease onset. Although this cohort has not been used 
to study ACPA isotypes before disease manifestation, it seems very probable that most of 
the isotype switching also occurs at that early point in time, in light of the differences in 
isotype use which are already present at presentation among UA patients. 
A graphic depiction of the currently most probable timeline according to which ACPA 
characteristics develop, is shown in Figure 1 in relation to the various clinical stages of RA 
development. An increase prior to disease onset has been reported for both ACPA-levels 
44 and for ACPA fine specificity as presented in this thesis. With regard to ACPA isotype 
use, the development prior to the stage of undifferentiated arthritis is unknown, but seems 
likely to follow a similar pattern. Analogous to the reduction in ACPA levels which has 
been described previously 54, 55, we found a slight decrease in ACPA fine specificity recog-
nition and isotype use during the early disease course. During longer-term follow-up the 
fine specificity and isotype repertoire remained relatively stable.
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In order to examine the clinical consequences of inter-individual differences in fine 
specificity repertoire and isotype distribution, we analyzed the association between 
radiographic joint damage and these ACPA characteristics. This revealed a difference 
between the two antibody properties since a larger number of isotypes was indicative of a 
higher risk of radiographic damage (chapter 7), but no such association was found for an 
expanded ACPA fine specificity repertoire (chapter 9). 
On the whole, one of the most important conclusions of these findings is that the im-
munological development of the ACPA response takes place before disease onset. The 
accumulation of autoantibody reactivities before disease manifestation has also been 
reported in studies of other human diseases, such as SLE 56 and pemphigus 57, as well 
as in animal models such as the collagen-induced arthritis model (CIA) 58. Our observa-
tions with regard to the development of the ACPA fine specificity repertoire have been 
confirmed by a recent study in ACPA-positive arthralgia patients 59, demonstrating that 
differences in citrullinated antigen recognition already exist in the arthralgia phase before 
the development of arthritis. The lack of further broadening of antigen recognition and 
isotype repertoire after the start of the disease, could to some extent be due to the use of 
immunosuppressive medication which was prescribed to RA patients, and sometimes to 
extent to UA patients in the EAC. However, the fact that there was also no change in ACPA 
fine specificity in untreated arthralgia patients who subsequently developed RA 59, sug-
gests that this phenomenon may in fact reflect the natural course of the immune response.
An important implication of the fact that the ACPA response appears to mature so early, 
is that treatment which is initiated once symptoms have developed, may no longer be able 
to influence the characteristics of the ACPA response. Or, from a different point of view, 
one may argue that even if medication would affect the evolution of the ACPA response, it 
is hard to say if this would have any effect considering the advanced state of immunologi-
cal maturation at presentation.
When patients first present with ACPA-positive UA, those among them who recognize 



















figure 1. Development of ACPA characteristics (such as levels and epitope recognition) over time, in 
relationship to the clinical disease stages of rA.
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However, our results suggest that after the development of RA, a broader use of isotypes 
at baseline is associated with more radiographic joint destruction, while an expanded fine 
specificity repertoire at baseline is not. From an immunological perspective this could 
mean that at a later stage in the disease, the antibody effector mechanisms employed by 
the various isotypes are more decisive in determining the extent of tissue destruction than 
the exact peptide recognition properties of the antibody. On the other hand, there are 
several reasons to be cautious in the interpretation of these results.
First of all, the effect of ACPA fine specificity on radiographic joint destruction may 
have been underestimated due to the limited number of citrullinated epitopes under 
investigation. Although this issue was addressed in chapter 9 by using SE alleles as a 
surrogate marker, this likely only represents unmeasured ACPA fine specificities which 
develop under the influence of SE alleles. The impact of the ACPA isotype profile on future 
radiographic progression on the other hand may have been overestimated, and a direct 
comparison of the two studies (chapter 7 and 9) is hampered by the fact that different 
statistical methods were used due to recent advances in statistical techniques. It is also 
worth noting that both the total number of recognized peptides and the overall number 
of isotypes are associated with the total IgG anti-CCP2-level and it is challenging to de-
termine whether these ACPA characteristics are predictive independently from this total 
serum level. The matching approach chosen in chapter 7 suggested that ACPA isotypes do 
supply additional information to the total IgG level, but these results need to be replicated 
in future studies.
Finally, it is interesting to re-examine the role of ACPA in the pathophysiology of RA 
based on the insights acquired from the studies of ACPA characteristics. Although the 
investigations described above were not designed to demonstrate a causal role for ACPA 
in the biological processes underlying RA, the results are compatible with the hypothesis 
that the exact nature and characteristics of the ACPA response may determine disease 
development and progression. The fact that ACPA can be detected years before the clinical 
diagnosis of RA and also in unaffected family members in North American Native popula-
tions with a high prevalence of RA 60, suggests that not all ACPA are pathogenic. Prior to 
the onset of disease, the number of citrullinated epitopes which is recognized increases, 
the isotype usage expands, and perhaps ACPA acquire their specific glycosylation pattern 
associated with inflammation or inflammatory potential. It is possible that these changes 
result in antibodies which can now evoke or contribute to an inflammatory disease pro-
cess. Although this hypothesis cannot be proven by the results described above, it is an 
attractive model for further research.
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The influence of genetic and environmental risk factors on the ACPA fine 
specificity repertoire
The HLA SE alleles not only predispose to ACPA-positive RA, but are also involved in 
shaping the fine specificity of the ACPA response, as was shown in a previous report 
which demonstrated that these alleles predispose to the development of antibodies against 
citrullinated vimentin but not against citrullinated fibrinogen 61. On the basis of these 
results, we decided to investigate whether the combined effect of HLA SE alleles and 
smoking may also be associated with the recognition of distinct citrullinated proteins. 
In the predisposition to ACPA-positive RA, the combined effect of HLA SE alleles and 
smoking has been shown to exceed the sum of their single effects: a phenomenon known 
as biological interaction 62, 63. Linking these epidemiological insights on risk factors for RA 
with biological studies of autoantibody features, chapters 9, 10 and 11 provide a more 
in-depth analysis of the effect of these genetic and environmental risk factors and of their 
possible interaction with regard to the fine specificity repertoire of ACPA.
In chapter 9, the effect of the SE gene dose on ACPA fine specificity was analyzed. 
Reactivity to some citrullinated antigens was found in increased frequency in SE-positive 
patients, while no such effect was observed for other citrullinated antigens. Since patients 
with one or two SE alleles had a similar peptide recognition profile, it appears that one SE 
allele is enough to facilitate the development of certain ACPA fine specificities, and that 
a second SE allele does not enhance this effect. This would be compatible with a role for 
the HLA SE alleles in the presentation of citrullinated peptides, because presentation of 
an “arthritogenic” peptide by a limited number of HLA alleles would be enough to break 
tolerance and result in an autoimmune response. On the other hand, this does not explain 
the higher risk of RA which has been described in association with a double dose of SE in 
previous publications 64, 65.
In addition to the most important genetic risk factor (the HLA SE alleles), chapter 10 and 
11 investigated the influence of the most powerful environmental risk factor for ACPA-
positive RA: smoking. Since a specific interaction between these two risk factors had been 
postulated in association with autoimmunity to citrullinated α-enolase peptide (CEP-1) 
66, we investigated whether the interaction was truly specific for this antigen or might 
also exist for other peptides. In the first analysis (chapter 10), it appeared that this gene-
environment interaction was not specific for citrullinated α-enolase, but rather extended 
to other citrullinated antigens as well, particularly to citrullinated vimentin (cVim). As 
presented in chapter 11 however, the gene-environment interaction was no longer pres-
ent when ACPA-positive cVim-positive patients were compared to ACPA-positive cVim-
negative patients. The interaction between the SE alleles and smoking therefore does not 
affect the development of specific ACPA fine specificities, but rather predisposes to the 
development of ACPA in general. The difference described in chapter 10 between the risk 
factors associated with antibodies to citrullinated vimentin versus citrullinated fibrinogen 
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was not due to a gene-environment interaction, but solely to the effect of the SE alleles, 
which specifically predispose to the development of anti-cVim antibodies as has been 
described previously 61. 
A popular scenario linking the genetic and environmental risk factors of RA consists of 
smoking inducing citrullination of certain proteins in the lungs, presentation of which by 
HLA SE alleles subsequently leads to a break in tolerance and the development of anti-
citrullinated protein immunity. In this setting, association of immunity to certain citrul-
linated antigens with both HLA SE alleles and smoking would imply that the antigen in 
question may play a key role in the pathogenesis of RA and may lie at the basis of autoim-
munity against citrullinated proteins. The contribution of chapter 11 to our understanding 
of the pathophysiology of RA is that it shows that with regard to the specific citrullinated 
proteins investigated thus far, an interaction effect between genetic and environmental 
risk factors cannot be found.
It should be noted that as in the other studies in this thesis concerning ACPA fine specific-
ity, one cannot exclude that different results, in this case entailing a true gene-environment 
interaction between SE alleles and smoking, might be found for other citrullinated antigens. 
Even if this were the case however, the conclusion that the citrullinated antigen associated 
with these specific risk factors may be an antigen of etiologic importance warrants caution 
for several reasons. First of all, in vitro assays may not accurately mimic the way in which 
antigens are presented and recognized in vivo. Furthermore, the etiologic importance 
of a distinct antigen cannot be proven by risk factor association studies, although their 
results may be suggestive. The identification of a likely culprit antigen would require more 
extensive investigations of the in vivo immunologic processes. 
The value of different ACPA tests in clinical practice
In the final chapter of part 2, we investigated the usefulness of the various commercial 
ACPA tests which are currently available for daily clinical practice. In addition to the 
anti-CCP2 test mentioned before, two new tests have been introduced: the anti-CCP3 
test and an assay for anti-modified citrullinated vimentin antibodies (anti-MCV). Chapter 
12 describes the predictive value of these autoantibodies and of the combinations of the 
various tests for three outcome measures: progression from UA to RA, the rate of joint 
destruction and sustained DMARD-free remission in RA. 
The results were similar for all three outcomes. None of the four autoantibody tests 
under investigation (anti-CCP2, anti-CCP3, anti-MCV and RF) had a significantly higher 
positive or negative predictive value than the other tests. Furthermore, there was no ad-
ditive value in performing a second or third autoantibody test compared to performing a 
single assay, especially when the single assay was a CCP2- or CCP3-test. This last conclu-
sion may seem contradictory to the finding that patients with two or three autoantibodies 
had worse outcomes than patients with no or with one autoantibody. Patients with two 
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or three autoantibodies had a higher chance of progression from UA to RA, a higher rate 
of joint destruction and a smaller chance of achieving sustained DMARD-free remission. 
However, it is important to keep in mind when interpreting these results that the single au-
toantibody present in the group of patients with only one autoantibody was almost always 
either anti-MCV or RF. It is therefore very likely that the increased risk of a poor outcome 
in the presence of two autoantibodies as compared to one autoantibody is mainly due to 
the predictive ability of the anti-CCP2-test. It is thus reasonable to conclude that if the 
anti-CCP2-test, or the comparable anti-CCP3-test, is used as the first autoantibody assay 
in arthritis patients, the additive value of an anti-MCV- or RF-assay is limited.
These findings are compatible with the results of chapter 9 which investigated the asso-
ciation of ACPA fine specificity with radiographic progression. Neither the commercially 
available assays using different citrullinated antigens, nor the ACPA fine specificity tests we 
developed in our laboratory, were predictive of a more severe disease course as measured 
by radiographic joint damage. As discussed above, these results do not necessarily mean 
that the ACPA fine specificity does not affect the disease course. It is possible that further 
insights into the recognition of citrullinated antigens in vivo will lead to the development 
of new tests with increased predictive value.
PArT 3: remIssIon
The final part of this thesis consists of two observational studies examining the best possible 
clinical outcome of RA: sustained remission after discontinuation of disease modifying 
anti-rheumatic drugs (DMARDs). While RA was traditionally considered to be a chronic 
life-long disease, the recent improvements in therapeutic options have led to an increase 
in the number of patients that achieve remission 67. Concurrently, this clinical outcome 
has become the focus of more research and discussion within the field of rheumatology 68. 
The studies on remission included in this thesis were performed in order to answer several 
research questions.
Although remission is frequently reported as an outcome in trials of new anti-rheumatic 
drugs, there is a lack of recent data on the number of patients which attain remission with 
more conventional treatment, despite the fact that in daily practice most new RA patients 
are started on a conventional drug such as methotrexate 69. Furthermore, the elucidation 
of which clinical characteristics at baseline are associated with remission can give clues 
about which therapeutic strategy is required to achieve remission in as many patients as 
possible. These data can also lead to an increase in our understanding of the pathophysiol-
ogy of RA, and could lead to new hypotheses about the biological pathways involved in 
disease persistence and resolution.
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In chapter 13, two large independent cohorts of patients treated with conventional ther-
apy were therefore used to determine the prevalence and predictive factors for sustained 
DMARD-free remission. Long-term follow-up data from the Leiden EAC and the British 
Early RA study (ERAS) revealed that sustained DMARD-free remission occurs in 9 to 15% 
of RA patients. Several baseline patient characteristics were found to be independently 
associated with sustained DMARD-free remission in both cohorts: a short symptom dura-
tion before presentation and the absence of IgM rheumatoid factor or anti-CCP antibodies. 
In order to compare these results to remission data from a cohort of patients treated 
with modern goal-steered therapy, we investigated the prevalence and predictive factors 
for sustained drug-free remission in the Leiden EAC and the BeSt (behandelstrategiëen) 
trial, as described in chapter 14. The BeSt trial employed a tight control treatment strategy, 
meaning that the Disease Activity Score (DAS) were measured every 4 months, and treat-
ment was adjusted following a strict protocol aimed at achieving a DAS44≤2.4. Patients 
participating in the BeSt study were randomized among four treatment groups. Since 
there was no significant difference between these groups with regard to the outcome of 
remission, all BeSt-patients were analyzed as part of the DAS-driven cohort in chapter 
14. In comparison to patients treated with conventional treatment in the EAC (the non-
DAS-driven therapy cohort), patients in the DAS-driven cohort had more active disease at 
baseline. Nonetheless, the prevalence of sustained drug-free remission was similar after 
DAS-driven and non-DAS-driven therapy (9.8% versus 10.6%). ACPA-positive patients 
more frequently achieved sustained drug-free remission after DAS-driven than after non-
DAS-driven therapy (5.4% versus 2.1%, OR 2.68, 95% confidence inteval 0.97-7.43). In 
both cohorts, absence of ACPA and short symptom duration were independent predictors 
for sustained drug-free remission.
In the interpretation of the findings of chapter 13 and 14, several points need to be 
taken into account. First of all, the definition of remission used for the EAC in these stud-
ies differs from the definitions employed in other reports 70-72. We aimed to investigate 
sustained DMARD-free remission as the clinical outcome most closely reflecting a cure of 
the disease. This required the absence of swollen joints as observed by a rheumatologist 
for at least one year after discontinuation of DMARD-therapy to ensure that remission was 
long-lasting. In contrast, clinical trials frequently use a DAS-based definition of remission 
which does not require a specified follow-up period but can be fulfilled at one single point 
in time. 
One may argue that the definition of remission used in this thesis also had several draw-
backs. One drawback could be that it was not based on a standardized clinical measure 
such as the DAS or the simplified disease activity index (SDAI) 73. However, considering 
that the diagnosis of synovitis is generally based on the presence of joint swelling, our 
definition requiring the absence of swollen joints could also be deemed a more appropri-
ate measure than compound scores which include inflammatory markers such as CRP 
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or patient-reported outcomes such as visual analogue scales (VAS). Another possible 
weakness of the remission studies in chapter 13 and 14 could be that EAC patients with 
remission were discharged from the outpatient clinic after at least one year of observation. 
This precluded continued observation and indefinite affirmation of the prolonged state 
of remission. On the other hand, most remission patients in the EAC were followed-up 
longer than the minimum requirement of one year with a median time of observation 
of 2.5 years. Furthermore, it seems plausible that most patients who had a recurrence 
of their arthritis after discharge, were referred to the Leiden University Medical Center 
again, the only referral center for Rheumatology in a health care region of approximately 
400.000 inhabitants. Indeed, six patients were found to have experienced a relapse and 
were included in the non-remission group. 
Due to the increased interest in remission and the inconsistencies in the definitions 
of remission used to date as exemplified above, the American College of Rheumatol-
ogy (ACR) and European League Against Rheumatism have recently issued a proposal 
for two possible definitions of remission in RA for clinical trials 70, replacing the 1981 
ACR-definition which was difficult to apply in clinical practice 71. These definitions will 
hopefully be embraced by the field and result in a more uniform approach in the research 
of this important clinical outcome.
In chapter 14, the baseline differences between the DAS-driven and the non-DAS-driven 
cohort posed analytical difficulties and rendered the comparison far from straightforward. 
While acknowledging the differences between the cohorts, several strategies were 
employed to ensure a valid comparison. Taking into account that the inclusion of the 
non-DAS-driven cohort (the EAC) had taken place at an earlier point in time, we per-
formed a sensitivity analysis to specifically assess whether this earlier inclusion period 
had influenced the analyses. This sensitivity analysis showed no differences compared to 
the analysis of the entire cohorts. Furthermore, a multivariable analysis was performed in 
which the differences between the two cohorts were adjusted for by means of propensity 
scores. These adjustments in the statistical analysis do not diminish the fact that a random-
ized controlled trial would be the ideal setting to investigate the effect of DAS-driven 
versus non-DAS-driven therapy on achieving sustained drug-free remission. However, the 
repeated observation that DAS-driven therapy results in better functional and radiological 
outcomes than non-DAS-driven therapy 74, 75 raises the question whether such a random-
ized design would still be considered ethical.
The prevalence of sustained DMARD-free remission of 9-15% reported in chapters 13 
and 14 may be considered surprisingly high, raising the questions whether these patients 
“really” had RA. It is therefore worthwhile to note that these patients not only fulfilled the 
1987 ACR criteria for RA, but also had a median disease duration of 3.5 years before they 
achieved remission, meaning that they had RA disease activity for this lengthy period. 
Furthermore, most of the remission patients had radiological joint destruction albeit less 
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severe than in the non-remission group. Nonetheless, the patient characteristics which 
were identified as being associated with a higher chance of remission (short disease 
duration and absence of autoantibodies), do point to the fact that remission is generally 
achieved by patients who have a milder form of RA from the start. It is not unexpected that 
autoantibody-positive, and especially ACPA-positive patients, have the smallest chances 
of achieving remission, and it is promising that chapter 14 suggests that these patients may 
have the most to gain from tight control treatment strategies such as DAS-driven therapy.
Summarizing our findings with regard to remission, a substantial proportion of RA pa-
tients achieve sustained DMARD-free remission after treatment with conventional therapy. 
The presence of autoantibodies, and in particular ACPA, at presentation is associated 
with a significantly lower chance of achieving remission. Once more this calls attention 
to the severe disease course of ACPA-positive RA and the inherent differences between 
ACPA-positive and ACPA-negative disease. The comparison with the BeSt trial as a DAS-
driven therapy cohort suggests that ACPA-positive patients may especially benefit from 
tight disease control strategies. Future trials will hopefully shed more light on the potential 
usefulness of taking ACPA-status into account in treatment decisions.
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in reumatoïde artritis – 
van erfelijke aanleg tot 
klinische ziekte-uitkomst
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reumAToïDe ArTrITIs en ACPA
Reumatoïde artritis (RA) wordt gekenmerkt door gewrichtsontsteking (artritis) van met 
name de kleine hand- en voetgewrichten. Het is de meest voorkomende vorm van artritis 
met een prevalentie tussen 0.5 en 1% in westerse populaties. De aandoening komt onge-
veer drie keer vaker bij vrouwen dan bij mannen voor en de prevalentie neemt toe met 
de leeftijd. Afgezien van de artritis die tot ernstige gewrichtsdestructie kan leiden, kunnen 
ook ontstekingsreacties in de inwendige organen optreden zoals in het hart, de longen 
en de nieren. Voor patiënten met reumatoïde artritis zijn de behandelmogelijkheden de 
laatste jaren sterk verbeterd. Door de opkomst van tumor necrosis factor (TNF)-blokkers 
en andere zogenoemde “biologicals” is het tegenwoordig mogelijk om bij een groot deel 
van de patiënten een zeer lage ziekte-activiteit te bereiken en zelfs te streven naar remis-
sie. Onderzoek van de afgelopen jaren heeft laten zien dat reumatoïde artritis ingedeeld 
kan worden in twee verschillende vormen op basis van de aan- dan wel afwezigheid van 
antistoffen tegen gecitrullineerde eiwitten: anti-citrullinated protein antibodies (ACPA). 
De ACPA-positieve en ACPA-negatieve patiënten verschillen van elkaar met betrekking tot 
klinische ziekte-uitkomst, en met betrekking tot genetische en omgevingsfactoren die met 
een verhoogd risico op de ziekte gepaard gaan.
ACPA binden aan eiwitten/peptides die citrulline bevatten: een post-translationele mo-
dificatie van het natuurlijk voorkomende aminozuur arginine. Terwijl het voorkomen van 
arginine in menselijke eiwitten dus door de genen is vastgelegd, moet voor het ontstaan 
van citrulline deze arginine door een enzymatisch proces worden veranderd. Dit proces 
heet citrullinatie en wordt gekatalyseerd door enzymen die peptidyl arginine deiminasen 
worden genoemd. De precieze biologische functie van citrullinatie is nog onbekend. Ge-
citrullineerde eiwitten zijn aangetoond in meerdere ontstoken weefsels, zoals ontstoken 
gewichten in verschillende vormen van artritis, in longen en andere organen.
Sinds de ontdekking van ACPA zijn inmiddels verschillende commerciële tests ontwik-
keld die veelal gebruik maken van cyclische gecitrullineerde eiwitten (cyclic citrullinated 
proteins, CCP) als antigen om de aanwezigheid van ACPA aan te tonen. De diagnostische 
eigenschappen van deze bepalingen zijn meermaals onderzocht en vergeleken met het 
klassieke auto-antilichaam dat met RA geassocieerd is: IgM reumafactor (IgM-RF). Het 
belangrijkste verschil tussen beide tests is de toegenomen specificiteit van anti-CCP in 
vergelijking van IgM-RF (95 versus 85%). Voor beide auto-antilichamen is de sensitiviteit 
bij patiënten met vastgestelde RA 67%. ACPA blijken daarnaast van grote voorspellende 
waarde te zijn voor het ziektebeloop van artritis. Niet alleen zijn ACPA de beste voorspeller 
van het voortschrijden van ongedifferentieerde artritis (undifferentiated arthritis, UA) naar 
RA, maar ACPA-positieve RA patiënten hebben ook beduidend meer gewrichtsschade 
dan ACPA-negatieve patiënten. Uit studies die bloeddonoren hebben onderzocht die op 
een later tijdstip RA hebben ontwikkeld, is gebleken dat ACPA reeds voor uitbraak van de 
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ziekte aantoonbaar zijn. Evenals de observatie dat ACPA artritis in muizenmodellen doet 
verergeren, suggereert dit dat de immuunrespons tegen gecitrullineerde eiwitten mogelijk 
een rol speelt bij het ontstaan van RA. Dit heeft geleid tot nader onderzoek naar welke 
factoren geassocieerd zijn met het ontwikkelen van immuniteit tegen gecitrullineerde 
eiwitten. 
rIsICofACToren en PAThofysIologIsCh moDel voor reumAToïDe 
ArTrITIs
Voor het ontstaan van RA zijn zowel genetische risicofactoren als omgevingsfactoren van 
belang. Van de genetische risicofactoren hebben de genen die coderen voor de humane 
leukocyten antigenen (HLA) het grootste effect. Bepaalde HLA DR-allelen die gekenmerkt 
worden door een vergelijkbare aminozuur-volgorde ter plaatse van positie 70-74 van het 
HLA-DRB1 molecuul (de zogenaamde “shared epitope” (SE) allelen) gaan gepaard met 
het grootste risico op RA. Na de ontdekking van ACPA is duidelijk geworden dat de SE 
allelen niet predisponeren voor RA in het algemeen, maar specifiek voor ACPA-positieve 
RA. Dit suggereert dat deze vorm van erfelijke belasting met name leidt tot het ontwik-
kelen van een immuunrespons gericht tegen gecitrullineerde eiwitten. Van vele andere 
genetische factoren is sindsdien ook beschreven dat zij bij voorkeur gepaard gaan met 
ACPA-positieve RA. Daarnaast is een minderheid van genetische risicofactoren mogelijk 
specifiek voor ACPA-negatieve RA. Met betrekking tot omgevingsfactoren is veelvuldig 
een associatie tussen roken en het ontstaan van RA beschreven. Na de opkomst van 
ACPA-bepalingen bleek dat roken eveneens alleen predisponeert voor de ontwikkeling 
van ACPA-positieve RA. Hierbij is opvallend dat het gezamenlijke effect van de SE allelen 
en roken groter is dan de som van de twee individuele effecten, passend bij een interactie 
tussen genetische en omgevings-risicofactoren. 
Deze recente bevindingen hebben grote consequenties gehad voor ons begrip van 
de onderliggende biologische mechanismen die leiden tot het ontstaan van RA. In het 
huidige pathofysiologisch model van RA dat vooral van toepassing is op ACPA-positieve 
ziekte kunnen meerdere fases worden onderscheiden. In de eerste fase vóór het ontstaan 
van de ziekte leidt een erfelijke belasting samen met omgevingsfactoren tot het ontstaan 
van een adaptieve immuunrespons. Zo kunnen mogelijk de SE allelen in combinatie met 
roken aanleiding geven tot het ontstaan van immuniteit tegen gecitrullineerde eiwitten. In 
de tweede fase kan een tot nu toe onbekende prikkel vervolgens leiden tot het ontstaan 
van gewrichtsontsteking wat zich manifesteert als ongedifferentieerde artritis (UA). De 
geactiveerde T cellen, gericht tegen bijvoorbeeld gecitrullineerde eiwitten, kunnen nu 
naar het gewricht migreren en daar inflammatoire cytokines produceren. Daarnaast sti-
muleren de T cellen ook andere cellen in het gewricht, zoals osteoclasten, macrofagen en 
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fibroblasten, wat botresorptie en verdere productie van cytokines zoals TNFα, en matrix 
metalloproteinasen tot gevolg kan hebben. Ook de activatie van B cellen en de productie 
van auto-antilichamen zoals ACPA, kan leiden tot een verergering van het ontstekingspro-
ces. Al deze factoren samen kunnen zorgen voor een voortschrijdend ziekteproces dat 
zich ontwikkelt tot RA en uiteindelijk gewrichtsdestructie veroorzaakt.
Deel 1: erfelIJkheID en AssoCIATIe vAn geneTIsChe rIsICofACToren 
en AlCohol meT ACPA-PosITIeve en ACPA-negATIeve rA
Het onderzoek beschreven in deel 1 van dit proefschrift houdt zich bezig met de erfelijk-
heid van RA, en met de precieze associatie van ACPA-positieve en ACPA-negatieve RA 
met verschillende genetische factoren (de HLA-DRB1 allelen) en de risicofactor alcohol.
Zoals eerder vermeld, is sinds vele jaren bekend dat bepaalde HLA-DRB1 allelen, de 
zogenaamde shared epitope (SE) allelen, de sterkste genetische risicofactor voor het ont-
wikkelen van reumatoïde artritis zijn. Zij zijn specifiek geassocieerd met een groter risico 
op ACPA-positieve RA. Van andere HLA allelen is beschreven dat zij gepaard zouden gaan 
met bescherming tegen RA, maar door enkele tegenstrijdige berichten in de literatuur was 
niet geheel duidelijk welke allelen precies beschermend zouden zijn. De beschermende 
allelen zijn in het verleden samengevat in verschillende classificaties, die analoog aan 
de SE classificatie, berustten op aminozuursequenties die bij alle beschermende allelen 
voorkwamen. Onduidelijk was eveneens of deze beschermende effecten mogelijk ook 
beperkt zijn tot uitsluitend ACPA-positieve of ACPA-negatieve patiënten. Zoals wordt 
beschreven in hoofdstuk 2 hebben wij daarom een meta-analyse uitgevoerd met de 
individuele patiëntengegevens van vier grote Europese cohorten. 
Hieruit bleek dat beschermende effecten alleen aantoonbaar zijn voor de HLA-
DRB1*13 allelen, en in het bijzonder DRB1*1301. Deze allelen beschermen specifiek 
tegen het ontwikkelen van ACPA-positieve RA. Dit betekent ook dat de in het verleden 
geformuleerde classificaties van protectieve allelen allen tot op zekere hoogte onjuist 
zijn. Het beschermende effect dat werd toegeschreven aan deze groepen van allelen, kan 
geheel verklaard worden door het sterke effect van DRB1*1301. Hoe de bescherming 
door DBR1*1301 tegen ACPA-positieve RA precies tot stand komt, zal in toekomstige 
immunologische studies worden onderzocht. Opvallend was dat er geen significante as-
sociaties waren tussen HLA DRB1-allelen en ACPA-negatieve RA.
De meerderheid van de genetische risicofactoren die tot op heden zijn geïdentificeerd, 
is specifiek geassocieerd met ACPA-positieve RA. Dit suggereert dat de erfelijke belasting 
voor ACPA-positieve RA mogelijk groter is dan voor de ACPA-negatieve vorm. Dit was de 
aanleiding voor een studie waarin wij de erfelijkheid van zowel ACPA-positieve als ACPA-
negatieve RA hebben onderzocht. De resultaten hiervan worden behandeld in hoofdstuk 
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3. Met behulp van data van een groot RA-tweelingencohort uit het Verenigd Koninkrijk 
vonden wij dat de erfelijkheid van ACPA-positieve en ACPA-negatieve RA vergelijkbaar 
is en ongeveer 66% bedraagt. Zoals verwacht droegen de HLA SE allelen zeer weinig bij 
aan de genetische variantie van ACPA-negatieve RA, maar verklaarden zij 18% van de 
genetische variantie van ACPA-positieve ziekte. 
Als gevolg van de opkomst van genome-wide association studies (GWAS) bestaat een 
groot deel van de recentelijk beschreven genetische risicofactoren voor RA uit single 
nucleotide polymorphisms (SNPs): veranderingen in het genoom ter grootte van slechts 1 
base. In een voortzetting van hoofdstuk 2 en 3, hebben wij daarom in de studie beschre-
ven in hoofdstuk 4 onderzocht hoe groot de bijdrage van de beschermende DRB1*13 
allelen en verschillende SNPs is, aan de genetische variantie van de verschillende vormen 
van RA. Omdat het unieke RA-tweelingencohort dat voor deze studie noodzakelijk was, 
afkomstig was uit het Verenigd Koninkrijk, hebben wij eveneens data uit het Verenigd 
Koninkrijk gebruikt met betrekking tot het effect van DRB1*13. Hierbij bleek het effect 
van HLA DRB1*13 in het Engelse cohort onverwacht beduidend kleiner te zijn dan in 
de eerdere meta-analyse was gevonden. Logischerwijs leidde dit kleine genetische effect 
slechts tot een kleine bijdrage van HLA DRB1*13 aan de genetische variantie. Zelfs als de 
beschermende invloed van de HLA-DRB1*13 allelen groter zou zijn geweest, zoals werd 
aangenomen in een simulatie met behulp van Nederlandse data, dan nog bleek de bij-
drage van deze allelen aan de genetische variantie zeer beperkt te zijn. Waarschijnlijk ligt 
de relatief lage prevalentie van HLA DRB1*13 ten grondslag aan het beperkte verklarende 
vermogen van deze allelen. De bijdrage van de verschillende SNPs die daarnaast in deze 
studie zijn onderzocht, was eveneens zeer klein. Dit was niet onverwacht gezien de be-
scheiden effecten van deze SNPs op het risico om RA te ontwikkelen. Deze bevindingen 
tonen aan dat het grootste gedeelte van de aanzienlijke invloed van genetische factoren 
op het ontstaan van RA, op dit moment niet verklaard kan worden.
Naast deze verschillende genetische risicofactoren, hebben wij ook het effect van een 
niet-erfelijke risicofactor onderzocht, namelijk alcohol. In het verleden is beschreven 
dat het drinken van alcohol mogelijk zou beschermen tegen de ontwikkeling van RA. 
In hoofdstuk 5 tonen we aan dat alcohol inderdaad geassocieerd is met een significant 
lager risico op het ontstaan van RA, maar dat ditzelfde beschermende effect aanwezig is 
voor andere vormen van artritis. Daarnaast was er een opvallende inverse relatie tussen 
de mate van systemische ontstekingsactiviteit (gemeten door de bezinking) en de hoeveel-
heid geconsumeerde alcohol, wat suggereert dat alcohol mogelijk een effect heeft op, of 
in verband staat met, ontstekingsactiviteit in het algemeen, en niet specifiek met RA. Op 
dit moment is het daarom moeilijk om harde conclusies te trekken over het verband tussen 
alcohol en het ontstaan van RA. Prospectief onderzoek waarin het alcoholgebruik vóór 
het optreden van de klachten wordt onderzocht, en studies in andere aandoeningen die 
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net als RA gepaard gaan met systemische ontstekingsactiviteit zijn noodzakelijk om meer 
licht te werpen op dit mogelijke verband.
Deel 2: eIgensChAPPen vAn ACPA
Glycosylering
De ontdekking van ACPA heeft geleid tot grote veranderingen in de huidige hypotheses 
over de pathofysiologie van RA. Het feit dat zowel de aanwezigheid als de hoeveelheid 
van ACPA toeneemt vlak voordat de ziekte zich manifesteert, suggereert dat ACPA mo-
gelijk pathogeen zouden kunnen zijn. Voor antilichamen in het algemeen geldt dat hun 
precieze eigenschappen bepalen of de binding aan hun antigen leidt tot weefselschade, of 
juist deel uitmaakt van een wenselijke afweerreactie. Om deze reden hebben wij besloten 
meerdere ACPA-karakteristieken nader te bestuderen.
Het eerste kenmerk dat in dit proefschrift in meer detail wordt beschreven, is 
antilichaam-glycosylering. Aan de eiwitstructuur van een antilichaam kunnen meerdere 
verschillende koolhydraatketens verbonden zijn. Deze zogenoemde glycanen zijn zeer 
belangrijk voor de stabiliteit van de antilichaamstructuur en voor de functies die het anti-
lichaam uit kan oefenen. Uit eerder onderzoek was al bekend dat IgG-antilichamen van 
RA patiënten opvallend veel glycanen zonder galactose bevatten, die mogelijk zouden 
kunnen leiden tot meer weefselschade. In hoofdstuk 6 wordt beschreven in hoeverre 
het glycosyleringsprofiel van ACPA verschilt van het profiel van andere antilichamen. In 
vergelijking met totaal serum IgG1 was ACPA IgG1 opvallend arm aan siaalzuur, waarvan 
wordt aangenomen dat het mogelijk een ontstekingsremmend effect heeft. Onderzoek van 
ACPA die waren geïsoleerd uit synoviaalvocht van RA patients toonde aan dat deze zeer 
weinig galactosehoudende glycanen bevatten. Binnen de ACPA-positieve RA patients ver-
schilde de antilichaam-glycosylering afhankelijk van de aanwezigheid van reuma-factor 
(RF): RF-positieve patiënten hadden aanmerkelijk meer galactose-arme ACPA vergeleken 
met RF-negatieve patiënten. Omdat volgens de gangbare hypotheses de afwezigheid van 
galactose- en siaalzuurgroepen kenmerkend is voor antilichamen die veel weefselschade 
kunnen veroorzaken, suggereren deze bevindingen dat ACPA meer schade zouden kun-
nen veroorzaken dan andere antilichamen. Hiermee lijkt het glycosyleringsprofiel van 
ACPA compatibel met een pathogene rol van deze antistoffen.
Isotypes en fijnspecificiteit
Een andere eigenschap van antilichamen die van groot belang is voor hun functie, is 
het antilichaam-isotype. De verschillende humane isotypes (IgM, IgG, IgA, IgD en IgE) 
verschillen sterk in bijvoorbeeld hun binding aan Fc-receptoren of complement. Om te 
onderzoeken of het isotypeprofiel van de ACPA respons verandert in de loop van de tijd en 
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geassocieerd is met gewrichtsschade, wordt in de studie waarvan de resultaten zijn weer-
gegeven in hoofdstuk 7, het isotypegebruik van de ACPA respons op meerdere tijdstippen 
tijdens het ziektebeloop beschreven. De uitkomsten van dit hoofdstuk kunnen het best 
worden geïnterpreteerd samen met de resultaten van het onderzoek naar de antilichaam-
fijnspecificiteit in hoofdstuk 8. De fijnspecificiteit geeft de precieze antigenherkenning 
van een antilichaam weer. Daarnaast is het effect op het klinisch ziektebeloop van indivi-
duele verschillen in de antilichaam-fijnspecificiteit onderzocht in hoofdstuk 9. Deze drie 
hoofdstukken geven samen een overzicht over de ontwikkeling van ACPA-fijnspecificiteit 
en isotypegebruik, en over de voorspellende waarde van deze ACPA-eigenschappen voor 
het verdere ziektebeloop.
Voor deze studies is gebruik gemaakt van materiaal van patiënten die zich met ACPA-
positieve ongedifferentieerde artritis (undifferentiated arthritis, UA) presenteerden bij 
de Leiden Early Arthritis Clinic (EAC). Een deel van deze patiënten heeft in het verdere 
beloop RA ontwikkeld, en een deel niet. Door baseline serummonsters van deze patiënten 
te vergelijken bleek dat de patiënten die later RA ontwikkelden, reeds bij presentatie 
significant meer gecitrullineerde peptiden herkenden en een breder ACPA-isotypegebruik 
hadden. Ondanks eenzelfde klinisch fenotype van UA waren daarmee de immunologische 
karakteristieken van de ACPA respons in dit stadium voorspellend voor het toekomstige 
ziektebeloop. 
Na aanvang van de ziekte was er geen uitbreiding detecteerbaar van fijnspecificiteit- of 
isotype-repertoire, ondanks een toename van de ziekte-activiteit bij UA patiënten die RA 
ontwikkelden. Deze observaties werden bevestigd doordat bij patiënten met langdurige 
RA, geen verschil bleek te zijn in fijnspecificiteit- en isotypeprofiel bij vergelijking van 
serum afgenomen bij presentatie en na 7 jaar follow-up. Dit suggereert dat de evolutie 
van de ACPA-karakteristieken voornamelijk vóór aanvang van de ziekte plaatsvindt. Door 
gebruik te maken van een uniek cohort van bloeddonoren, die vóór en na het ontstaan 
van RA bloed hadden afgestaan, kon deze hypothese verder getoetst worden. Het aantal 
gecitrullineerde peptiden dat herkend werd, steeg inderdaad in de tijd voorafgaand aan 
de manifestatie van de ziekte. Hoewel het isotypeprofiel in dit cohort niet is onderzocht, 
is het aannemelijk dat de uitbreiding van het isotypegebruik eveneens vroeg in het beloop 
plaatsvindt, gezien de verschillen die reeds bij presentatie tussen UA patiënten konden 
worden gevonden. Een belangrijke conclusie die hieruit kan worden getrokken is dat 
de immunologische uitrijping van de ACPA-respons waarschijnlijk plaatsvindt vóór de 
klinische manifestatie van de ziekte. Dit betekent ook dat de behandeling waarmee wordt 
begonnen zodra er klachten zijn ontstaan, vermoedelijk geen invloed meer uit kan oefe-
nen op de karakteristieken van de ACPA-respons.
Om de consequenties van de verschillen in fijnspecificiteit en isotypegebruik voor het 
verdere ziektebeloop te onderzoeken, werd de associatie tussen gewrichtsschade en deze 
twee karakteristieken in kaart gebracht. Hieruit kwam een verschil tussen de twee antili-
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chaamkenmerken naar voren: hoewel een groter aantal isotypes bij presentatie gepaard 
ging met meer gewrichtsschade op de lange termijn, bleek deze associatie niet te bestaan 
met betrekking tot ACPA fijnspecificiteit. 
Het effect van genetische risicofactoren en omgevingsfactoren op het ACPA 
fijnspecificiteitsrepertoire
Van de HLA SE allelen is niet alleen aangetoond dat zij geassocieerd zijn met een hoger 
risico op ACPA-positieve RA, maar ook dat zij een rol spelen bij het vormgeven van de 
ACPA-fijnspecificiteit. Met het oog op de bekende interactie tussen de HLA SE allelen en 
roken in de predispositie voor ACPA-positieve RA, hebben wij onderzocht in hoeverre 
deze interactie ook de herkenning van verschillende gecitrullineerde peptiden beïnvloedt. 
hoofdstukken 9, 10 en 11 bevatten de resultaten van ons onderzoek naar het effect van 
genetische risicofactoren en omgevingsfactoren op het ACPA fijnspecificiteitsrepertoire. 
Het kwantitatieve effect van het aantal aanwezig HLA SE allelen op de herkenning van 
gecitrullineerde peptiden wordt beschreven in hoofdstuk 9. De herkenning van bepaalde, 
maar niet alle, gecitrullineerde peptiden was geassocieerd met het vóórkomen van SE, 
waarbij het aantal aanwezige HLA SE allelen geen verschil maakte. Dit betekent dat de 
aanwezigheid van één HLA SE allel voldoende is om het ACPA fijnspecificiteitsrepertoire 
te vormen. In de hoofdstukken 10 en 11 wordt ook de invloed van de belangrijkste omge-
vingsfactor voor het ontstaan van ACPA-positieve RA onderzocht: roken. In tegenstelling 
tot wat eerder was gepostuleerd, bleek de interactie tussen HLA SE allelen en roken niet 
te leiden tot de specifieke herkenning van een bepaald gecitrullineerd peptide, maar was 
deze interactie voor meerdere gecitrullineerde antigenen aantoonbaar, zoals voor geci-
trullineerd vimentine (cVim) in hoofdstuk 10. Uit verdere analyse in hoofstuk 11 kwam 
echter naar voren dat er geen interactie tussen HLA SE allelen en roken aanwezig was als 
ACPA-positieve cVim-positieve patiënten werden vergeleken met ACPA-positieve cVim-
negatieve patiënten. Hieruit kan worden afgeleid dat de interactie tussen genetische risi-
cofactoren en omgevingsfactoren weliswaar het risico op het ontstaan van ACPA-positieve 
RA verhoogt, maar niet leidt tot herkenning van een bepaald patroon van gecitrullineerde 
eiwitten. De in hoofdstuk 10 beschreven interactie die ook voor gecitrullineerd vimentine 
zou gelden, berustte in feite op enkel het effect van de HLA SE allelen en niet op de 
interactie tussen HLA SE allelen en roken. De belangrijkste bijdrage van deze hoofdstuk-
ken aan ons begrip van de pathofysiologie van RA, is de uitkomst dat de HLA SE allelen 
zeer nauw betrokken zijn bij het ontstaan en de vormgeving van de immuunrespons tegen 
gecitrullineerde antigenen, terwijl voor roken en de interactie tussen deze twee risicofac-
toren geen effect op de karakteristieken van de ACPA respons kon worden aangetoond.
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De waarde van verschillende ACPA-tests in de klinische praktijk
In het laatste hoofdstuk van deel 2 van dit proefschrift worden verschillende ACPA-tests 
vergeleken die allen commercieel verkrijgbaar zijn. Naast de meest gebruikelijke tweede-
generatie-test tegen cyclische gecitrullineerde peptiden (anti-CCP2), is voor dit onderzoek 
gebruik gemaakt van de anti-CCP3 test en de bepaling van antistoffen tegen gemodificeerd 
gecitrullineerd vimentine (anti-MCV). Deze ACPA-tests zijn bovendien ook vergeleken 
met de traditionele reumafactor (RF) IgM-test. De voorspellende waarde van de tests en 
van de combinaties van de verschillende bepalingen is onderzocht met betrekking tot 
drie uitkomstmaten: het voortschrijden van UA naar RA, de mate van gewrichtsschade, 
en aanhoudende medicatie-vrije remissie oftewel remissie zonder gebruik van disease-
modifying antirheumatic drugs (DMARDs). 
In hoofdstuk 12 wordt aangetoond dat de vier bepalingen vergelijkbaar presteerden. 
Geen van de tests had een significant hogere positieve of negatieve voorspellende 
waarde dan de andere bepalingen. Daarnaast had het uitvoeren van twee of meer tests 
geen toegevoegde waarde boven een enkele test, met name als de eerste bepaling een 
CCP2- of CCP3-test was. Patiënten met positieve uitslagen bij twee of meer van deze 
auto-antilichaambepalingen hadden een slechtere prognose dan patiënten bij wie 
slechts één auto-antilichaam aangetoond kon worden. Desondanks bleek het aanvragen 
van meerdere bepalingen niet zinvol, omdat juist de patiënten met twee of meer auto-
antilichamen nagenoeg altijd een positieve uitslag van de anti-CCP2- of anti-CCP3-test 
hadden. Daarom was de voorspellende waarde van een dergelijke test alleen, even groot 
als die van meerdere bepalingen samen.
 
Deel 3: remIssIe
Het laatste deel van dit proefschrift bestaat uit twee studies over de meest gunstige uitkomst 
van RA: aanhoudende DMARD-vrije remissie. Hoewel RA traditioneel werd beschouwd 
als een chronische, levenslang aanhoudende ziekte, hebben recente verbeteringen in de 
therapeutische mogelijkheden ertoe geleid dat remissie voor steeds meer patiënten binnen 
handbereik komt. Tegelijkertijd is remissie als klinische uitkomstmaat het onderwerp van 
talrijke studies geworden. In trials van nieuwe geneesmiddelen wordt remissie vaak als 
maat voor de werkzaamheid genoemd, maar tot nu toe was onbekend hoeveel patiënten 
in remissie komen na behandeling met conventionele medicijnen zoals methotrexaat. 
Een analyse van welke klinische patiëntenkarakteristieken geassocieerd zijn met remissie, 
was bovendien van grote waarde om een beter begrip van de prognose van de individuele 
patiënt en van de mogelijk hieraan ten grondslag liggende biologische mechanismen te 
verwerven.
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In hoofdstuk 13 zijn daarom twee grote, onafhankelijke cohorten van conventioneel 
behandelde patiënten gebruikt om de prevalentie en voorspellende factoren voor aan-
houdende DMARD-vrije remissie vast te stellen. Uit lange termijn data van de Leidse EAC 
en de Britse Early RA Study (ERAS) kwam naar voren dat 9 tot 15% van de RA-patiënten 
deze uitkomst behaalt. Twee factoren waren in beide cohorten geassocieerd met het be-
reiken van aanhoudende DMARD-vrije remissie: een korte klachtenduur voorafgaand aan 
presentatie bij de reumatoloog en de afwezigheid van IgM RF- en anti-CCP-antilichamen.
Om deze data te kunnen vergelijken met gegevens van patiënten die zijn behandeld 
volgens een moderne strategie gericht op het bereiken van een zo laag mogelijke ziekte-
activiteit, zijn in hoofdstuk 14 de EAC en de BeSt (behandelstrategieën) studie naast elkaar 
gelegd. In de BeSt trial werd iedere 4 maanden de ziekte-activiteit met behulp van de 
Disease Activity Score (DAS) gemeten, waarbij de behandeling volgens protocol werd 
aangepast met het doel om een DAS44≤2.4 te bereiken. In vergelijking met de EAC hadden 
de patiënten die deelnamen aan de BeSt een hogere ziekte-activiteit bij aanvang van de 
studie, ten gevolge van de inclusie-criteria van de BeSt die een bepaalde mate van ziekte-
activiteit vereisten. Desalniettemin was de prevalentie van aanhoudende DMARD-vrije 
remissie vergelijkbaar in beide cohorten (9.8% versus 10.6%). ACPA-positieve patiënten 
bereikten vaker remissie als zij waren behandeld met DAS-gestuurde in plaats van met 
niet-DAS-gestuurde therapie (5.4% versus 2.1%, Odds Ratio 2.68, 95%CI 0.97-7.43). In 
beide cohorten waren de afwezigheid van ACPA en een korte klachtenduur voorafgaand 
aan presentatie onafhankelijke voorspellers voor aanhoudende DMARD-vrije remissie.
Uit deze resultaten kan worden afgeleid dat een aanzienlijk deel van RA patiënten na 
behandeling met conventionele therapie, aanhoudende DMARD-vrije remissie bereikt. De 
geringe kans van ACPA-positieve patiënten om remissie te bereiken, vestigt eens te meer 
de aandacht op het ongunstige ziektebeloop bij deze patiëntengroep en de grote verschil-
len tussen ACPA-positieve en ACPA-negatieve patiënten. In de toekomst zal hopelijk meer 
duidelijkheid ontstaan over hoe het best met de ACPA-status van een individuele patiënt 
rekening kan worden gehouden bij het maken van beslissingen omtrent de behandeling.
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